Soluble protein oligomers in neurodegeneration: lesson Î²-peptide

Nature Reviews Molecular Cell Biology

8, 101-112

DOI: 10.1038/nrm2101

Citation Report

#	Article	IF	Citations
1	Electrophysiological Techniques for Studying Synaptic Activity In Vivo. Current Protocols in Pharmacology, 2000, 11, 11.11.1-17.	4.0	1
2	In Vitro and In Vivo Neurotoxicity of Prion Protein Oligomers. PLoS Pathogens, 2007, 3, e125.	2.1	201
3	Self Assembly of Short Aromatic Peptides into Amyloid Fibrils and Related Nanostructures. Prion, 2007, 1, 32-35.	0.9	118
4	Advances on the Understanding of the Origins of Synaptic Pathology in AD. Current Genomics, 2007, 8, 486-508.	0.7	32
5	Structural Reorganisation and Potential Toxicity of Oligomeric Species Formed during the Assembly of Amyloid Fibrils. PLoS Computational Biology, 2007, 3, e173.	1.5	194
6	Molecular Mechanisms of Polypeptide Aggregation in Human Diseases. Current Protein and Peptide Science, 2007, 8, 573-579.	0.7	22
7	New access to Alzheimerâ€™s and other neurodegenerative diseases. Expert Review of Proteomics, 2007, 4, 591-594.	1.3	6
8	Detection of Polyglutamine Protein Oligomers in Cells by Fluorescence Correlation Spectroscopy. Journal of Biological Chemistry, 2007, 282, 24039-24048.	1.6	89
9	Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Human Molecular Genetics, 2007, 16, R115-R123.	1.4	241
10	Familial Alzheimer's disease mutations alter the stability of the amyloid Î²-protein monomer folding nucleus. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16522-16527.	3.3	120
11	Synaptic memory mechanisms: Alzheimer's disease amyloid Î²-peptide-induced dysfunction. Biochemical Society Transactions, 2007, 35, 1219-1223.	1.6	139
12	Amyloid-Î² and synaptic activity in mice and men. NeuroReport, 2007, 18, 1205-1206.	0.6	5
13	The role of intracellular amyloid Î² in Alzheimer's disease. Progress in Neurobiology, 2007, 83, 131-139.	2.8	112
14	Î²-Amyloid pathology in the entorhinal cortex of rats induces memory deficits: Implications for Alzheimerâ€™s disease. Neuroscience, 2007, 147, 28-36.	1.1	84
15	Mitochondrial Dysfunction: The First Domino in Brain Aging and Alzheimer's Disease?. Antioxidants and Redox Signaling, 2007, 9, 1659-1676.	2.5	182
16	Flanking Polyproline Sequences Inhibit Î²-Sheet Structure in Polyglutamine Segments by Inducing PPII-like Helix Structure. Journal of Molecular Biology, 2007, 374, 688-704.	2.0	147
17	Pathways and Intermediates of Amyloid Fibril Formation. Journal of Molecular Biology, 2007, 374, 917-924.	2.0	132
18	Stable insertion of Alzheimer AÎ² peptide into the ER membrane strongly correlates with its length. FEBS Letters, 2007, 581, 3809-3813.	1.3	5

#	Article	IF	Citations
19	Induction of Tau Pathology by Intracerebral Infusion of Amyloid-Î²-Containing Brain Extract and by Amyloid-Î² Deposition in APP Ã— Tau Transgenic Mice. American Journal of Pathology, 2007, 171, 2012-2020.	1.9	239
20	A General Model of Prion Strains and Their Pathogenicity. Science, 2007, 318, 930-936.	6.0	937
21	Loss-of-Function of Human PINK1 Results in Mitochondrial Pathology and Can Be Rescued by Parkin. Journal of Neuroscience, 2007, 27, 12413-12418.	1.7	466
22	Chapter 3 Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease. Annual Reports in Medicinal Chemistry, 2007, 42, 27-47.	0.5	15
23	Reconsidering the Mechanism of Polyglutamine Peptide Aggregation. Biochemistry, 2007, 46, 12810-12820.	1.2	81
24	Models of Î²-Amyloid Ion Channels in the Membrane Suggest That Channel Formation in the Bilayer Is a Dynamic Process. Biophysical Journal, 2007, 93, 1938-1949.	0.2	175
25	Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial functionâ€"role of glucose metabolism and insulin signalling. Archives of Physiology and Biochemistry, 2007, 113, 131-141.	1.0	46
26	Heterologous Amyloid Seeding: Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease. PLoS ONE, 2007, 2, e652.	1.1	29
27	Biochemical Characterization of AÎ² and Tau Pathologies in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 12, 377-390.	1.2	70
28	Molecules that Target betaâ€Amyloid. ChemMedChem, 2007, 2, 1674-1692.	1.6	106
29	Structure of Alzheimer's disease amyloid precursor protein copper-binding domain at atomic resolution. Acta Crystallographica Section F: Structural Biology Communications, 2007, 63, 819-824.	0.7	28
30	Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Molecular Neurodegeneration, 2007, 2, 18.	4.4	655
31	Clinical proteomics in neurodegenerative diseases. Proteomics - Clinical Applications, 2007, 1, 1342-1350.	0.8	21
32	Soluble oligomers from a nonâ€disease related protein mimic AÎ²â€induced tau hyperphosphorylation and neurodegeneration. Journal of Neurochemistry, 2007, 103, 736-748.	2.1	78
33	Neurotoxic species in prion disease: a role for PrP isoforms?. Journal of Neurochemistry, 2007, 103, 1709-1720.	2.1	15
34	Intracellular accumulation of a mild-denatured monomer of the human PrP fragment 90â€"231, as possible mechanism of its neurotoxic effects. Journal of Neurochemistry, 2007, 103, 071018045431007-???.	2.1	27
35	Tollâ€like receptors 2 and 4 mediate AÎ²(1â€"42) activation of the innate immune response in a human monocytic cell line. Journal of Neurochemistry, 2008, 104, 524-533.	2.1	146
36	Pathological activity of familial Alzheimerâ€™s disease-associated mutant presenilin can be executed by six different Î³-secretase complexes. Neurobiology of Disease, 2007, 27, 102-107.	2.1	74

#	Article	IF	Citations
37	Reversibility of prion-induced neurodegeneration. Lancet Neurology, The, 2007, 6, 294-295.	4.9	3
38	Interrogating global gene expression in rat neuronal cultures using SAGE. Neurotoxicity Research, 2007, 12, 209-214.	1.3	0
39	Neuronal disorders: introduction. Cellular and Molecular Life Sciences, 2007, 64, 2191-2193.	2.4	0
40	Mechanistic aspects of Parkinsonâ€™s disease: Î±-synuclein and the biomembrane. Cell Biochemistry and Biophysics, 2007, 47, 285-299.	0.9	95
41	New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's Disease. Neurotherapeutics, 2008, 5, 409-414.	2.1	138
42	A Differential Proteomic Approach Reveals an Evolutionary Conserved Regulation of Nme Proteins by Fe65 in C.Âelegans and Mouse. Neurochemical Research, 2008, 33, 2547-2555.	1.6	5
43	Understanding BACE1: essential protease for amyloid-Î² production in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2008, 65, 3265-3289.	2.4	71
44	Copper binding to the Alzheimerâ€™s disease amyloid precursor protein. European Biophysics Journal, 2008, 37, 269-279.	1.2	62
45	How is protein aggregation in amyloidogenic diseases modulated by biological membranes?. European Biophysics Journal, 2008, 37, 247-255.	1.2	180
46	Acridine derivatives inhibit lysozyme aggregation. European Biophysics Journal, 2008, 37, 1261-1270.	1.2	61
47	In vivo calcium imaging of the aging and diseased brain. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 99-106.	3.3	57
48	Identification of AOSC-binding proteins in neurons. Chinese Journal of Oceanology and Limnology, 2008, 26, 394-399.	0.7	5
49	Disordered Proteins: Biological Membranes as Two-Dimensional Aggregation Matrices. Cell Biochemistry and Biophysics, 2008, 52, 175-189.	0.9	46
50	Dendritic Spine Loss and Synaptic Alterations in Alzheimerâ€™s Disease. Molecular Neurobiology, 2008, 37, 73-82.	1.9	265
51	Calpain-Mediated Signaling Mechanisms in Neuronal Injury and Neurodegeneration. Molecular Neurobiology, 2008, 38, 78-100.	1.9	329
52	Inclusion Body Myositis: A View from the Caenorhabditis elegans Muscle. Molecular Neurobiology, 2008, 38, 178-198.	1.9	15
53	Sequence analyses of presenilin mutations linked to familial Alzheimerâ€™s disease. Cell Stress and Chaperones, 2008, 13, 401-412.	1.2	13
54	Close association of water channel AQP1 with amyloid-Î² deposition in Alzheimer disease brains. Acta Neuropathologica, 2008, 116, 247-260.	3.9	79

#	Article	IF	Citations
55	Recombinant amyloid beta-peptide production by coexpression with an affibody ligand. BMC Biotechnology, 2008, 8, 82.	1.7	37
56	pH Effects on the Conformational Preferences of Amyloid Î²â€Peptide (1â€“40) in HFIP Aqueous Solution by NMR Spectroscopy. ChemMedChem, 2008, 3, 833-843.	1.6	15
57	Frizzledâ€1 is involved in the neuroprotective effect of Wnt3a against AÎ² oligomers. Journal of Cellular Physiology, 2008, 217, 215-227.	2.0	80
58	Simultaneous monitoring of peptide aggregate distributions, structure, and kinetics using amide hydrogen exchange: Application to AÎ²(1â€40) fibrillogenesis. Biotechnology and Bioengineering, 2008, 100, 1214-1227.	1.7	31
59	Î²â€amyloid burden is not associated with rates of brain atrophy. Annals of Neurology, 2008, 63, 204-212.	2.8	187
60	Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease. Neurotherapeutics, 2008, 5, 381-390.	2.1	23
61	Carbamate-appended N-alkylsulfonamides as inhibitors of Î³-secretase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 464-468.	1.0	9
62	Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide. Biophysical Chemistry, 2008, 137, 35-42.	1.5	106
63	Nitrogen-appended N-alkylsulfonamides as inhibitors of Î³-secretase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 175-178.	1.0	10
64	The Zyggregator method for predicting protein aggregation propensities. Chemical Society Reviews, 2008, 37, 1395.	18.7	307
65	Yeast as a model for studying human neurodegenerative disorders. Biotechnology Journal, 2008, 3, 325-338.	1.8	72
66	Secretory Outposts for the Local Processing of Membrane Cargo in Neuronal Dendrites. Traffic, 2008, 9, 1437-1445.	1.3	108
67	Huntingtonâ€™s disease: degradation of mutant huntingtin by autophagy. FEBS Journal, 2008, 275, 4263-4270.	2.2	177
68	Secondary structure conversions of Alzheimerâ€™s AÎ²(1â€“40) peptide induced by membraneâ€mimicking detergents. FEBS Journal, 2008, 275, 5117-5128.	2.2	98
69	Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. FEBS Journal, 2008, 275, 5982-5993.	2.2	55
70	Alzheimer's in real time. Nature, 2008, 451, 638-639.	13.7	20
71	Animal models of Alzheimer's disease and frontotemporal dementia. Nature Reviews Neuroscience, 2008, 9, 532-544.	4.9	604
72	The insulin paradox: aging, proteotoxicity and neurodegeneration. Nature Reviews Neuroscience, 2008, 9, 759-767.	4.9	282

#	Article	IF	Citations
73	Oligomeric amyloid-Î² peptide disrupts phosphatidylinositol-4,5-bisphosphate metabolism. Nature Neuroscience, 2008, 11, 547-554.	7.1	176
74	Lipids revert inert AÎ² amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO Journal, 2008, 27, 224-233.	3.5	303
75	Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells. Journal of Neurochemistry, 2008, 104, 993-1005.	2.1	62
76	Binding of zinc(II) and copper(II) to the fullâ€length Alzheimerâ€™s amyloidâ€Î² peptide. Journal of Neurochemistry, 2008, 104, 1249-1259.	2.1	201
77	Multiple biochemical similarities between infectious and nonâ€infectious aggregates of a prion protein carrying an octapeptide insertion. Journal of Neurochemistry, 2008, 104, 1293-1308.	2.1	34
78	Docosahexaenoic acid disrupts in vitro amyloid Î²_{1â€40} fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimerâ€™s disease model rats. Journal of Neurochemistry, 2008, 107, 1634-1646.	2.1	76
79	Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell, 2008, 7, 824-835.	3.0	87
80	p97 homologs from Caenorhabditis elegans, CDCâ€48.1 and CDCâ€48.2, suppress the aggregate formation of huntingtin exon1 containing expanded polyQ repeat. Genes To Cells, 2008, 13, 827-838.	0.5	33
81	Antiâ€oligomeric single chain variable domain antibody differentially affects huntingtin and Î±â€synuclein aggregates. FEBS Letters, 2008, 582, 517-522.	1.3	12
82	Serpins show structural basis for oligomer toxicity and amyloid ubiquity. FEBS Letters, 2008, 582, 2537-2541.	1.3	21
83	Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radical Biology and Medicine, 2008, 44, 2051-2057.	1.3	304
84	Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Research, 2008, 1230, 273-280.	1.1	164
85	A novel diol-derivative of chalcone produced by bioconversion, 3-(2,3-dihydroxyphenyl)-1-phenylpropan-1-one, activates PKA/MEK/ERK signaling and antagonizes AÎ²-inhibition of the cascade in cultured rat CNS neurons. European Journal of Pharmacology, 2008, 600, 10-17.	1.7	17
86	Biomarkers for early diagnosis of Alzheimer disease: â€˜ALZheimer ASsociated geneâ€™â€“ a new blood biomarker?. Journal of Cellular and Molecular Medicine, 2008, 12, 1094-1117.	1.6	54
87	Amyloidâ€Î² oligomers set fire to inflammasomes and induce Alzheimer's pathology. Journal of Cellular and Molecular Medicine, 2008, 12, 2255-2262.	1.6	149
88	The molecular pathology of Alzheimerâ€™s disease. Psychiatry (Abingdon, England), 2008, 7, 1-5.	0.2	21
89	AÎ²-globulomers are formed independently of the fibril pathway. Neurobiology of Disease, 2008, 30, 212-220.	2.1	103
90	A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiology of Disease, 2008, 31, 46-57.	2.1	92

#	Article	IF	Citations
91	Endogenous secreted amyloid precursor protein-Î± regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiology of Disease, 2008, 31, 250-260.	2.1	163
92	Mechanisms of Protein Fibril Formation: Nucleated Polymerization with Competing Off-Pathway Aggregation. Biophysical Journal, 2008, 94, 379-391.	0.2	182
93	Insights into Stability and Toxicity of Amyloid-Like Oligomers by Replica Exchange Molecular Dynamics Analyses. Biophysical Journal, 2008, 95, 1965-1973.	0.2	51
94	Domain Conformation of Tau Protein Studied by Solution Small-Angle X-ray Scattering. Biochemistry, 2008, 47, 10345-10353.	1.2	187
95	Annular Structures as Intermediates in Fibril Formation of Alzheimer AÎ²_{17â^'42}. Journal of Physical Chemistry B, 2008, 112, 6856-6865.	1.2	70
96	Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease. Science, 2008, 321, 1686-1689.	6.0	882
97	Crosstalk Between Calcium and Redox Signaling: From Molecular Mechanisms to Health Implications. Antioxidants and Redox Signaling, 2008, 10, 1275-1312.	2.5	170
98	Designing Peptide Inhibitors for Oligomerization and Toxicity of Alzheimer's Î²-Amyloid Peptide. Biochemistry, 2008, 47, 1984-1992.	1.2	142
99	Self-Templated Nucleation in Peptide and Protein Aggregation. Physical Review Letters, 2008, 101, 258101.	2.9	89
100	Dimers Initiate and Propagate Serine Protease Inhibitor Polymerisation. Journal of Molecular Biology, 2008, 375, 36-42.	2.0	32
101	Membrane Fusogenic Activity of the Alzheimer's Peptide AÎ²(1â€“42) Demonstrated by Small-Angle Neutron Scattering. Journal of Molecular Biology, 2008, 376, 393-404.	2.0	52
102	Interaction of Alzheimerâ€™s AÎ² Peptide with an Engineered Binding Proteinâ€”Thermodynamics and Kinetics of Coupled Foldingâ€“Binding. Journal of Molecular Biology, 2008, 378, 398-411.	2.0	38
103	Amyloid Î²-Protein Monomer Folding: Free-Energy Surfaces Reveal Alloform-Specific Differences. Journal of Molecular Biology, 2008, 384, 450-464.	2.0	219
104	Calcium imaging in the living brain: prospects for molecular medicine. Trends in Molecular Medicine, 2008, 14, 389-399.	3.5	42
105	Ovariectomy increases neuronal amyloid-Î² binding alcohol dehydrogenase level in the mouse hippocampus. Neurochemistry International, 2008, 52, 1358-1364.	1.9	10
106	Folding versus aggregation: Polypeptide conformations on competing pathways. Archives of Biochemistry and Biophysics, 2008, 469, 100-117.	1.4	352
107	A comparative molecular dynamics analysis of the amyloid Î²-peptide in a lipid bilayer. Archives of Biochemistry and Biophysics, 2008, 470, 54-63.	1.4	62
108	The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron, 2008, 57, 178-201.	3.8	2,712

#	Article	IF	Citations
109	Mechanism of Ca2+ Disruption in Alzheimer's Disease by Presenilin Regulation of InsP3 Receptor Channel Gating. Neuron, 2008, 58, 871-883.	3.8	426
110	Understanding Synapses: Past, Present, and Future. Neuron, 2008, 60, 469-476.	3.8	153
111	Effect on memory of acute administration of naturally secreted fibrils and synthetic amyloid-beta peptides in an invertebrate model. Neurobiology of Learning and Memory, 2008, 89, 407-418.	1.0	10
112	Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends in Neurosciences, 2008, 31, 454-463.	4.2	772
113	Efficient Inhibition of the Alzheimer's Disease Î²-Secretase by Membrane Targeting. Science, 2008, 320, 520-523.	6.0	254
114	Mechanisms of AÎ² mediated neurodegeneration in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2008, 40, 181-198.	1.2	220
115	Prions and the proteasome. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 713-722.	1.8	25
116	Malloryâ€“Denk-bodies: Lessons from keratin-containing hepatic inclusion bodies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 764-774.	1.8	98
117	Form and dimensions of aggregates dictate cytotoxicities of Danish dementia peptides. Biochemical and Biophysical Research Communications, 2008, 372, 62-66.	1.0	6
118	The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO Journal, 2008, 27, 336-349.	3.5	333
119	Picomolar Amyloid-Î² Positively Modulates Synaptic Plasticity and Memory in Hippocampus. Journal of Neuroscience, 2008, 28, 14537-14545.	1.7	627
120	Amyloid Activates GSK-3Î² to Aggravate Neuronal Tauopathy in Bigenic Mice. American Journal of Pathology, 2008, 172, 786-798.	1.9	255
121	The amyloid cascade hypothesis. Alzheimer's and Dementia, 2008, 4, 176-178.	0.4	98
122	Multi-target-Directed Ligands To Combat Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2008, 51, 347-372.	2.9	961
123	BRI2 Inhibits Amyloid Î²-Peptide Precursor Protein Processing by Interfering with the Docking of Secretases to the Substrate. Journal of Neuroscience, 2008, 28, 8668-8676.	1.7	87
124	Alzheimer's AÎ² Peptides Containing an Isostructural Backbone Mutation Afford Distinct Aggregate Morphologies but Analogous Cytotoxicity. Evidence for a Common Low-Abundance Toxic Structure(s)?. Biochemistry, 2008, 47, 50-59.	1.2	37
125	Trifluoromethyldiazirine: an effective photo-induced cross-linking probe for exploring amyloid formation. Chemical Communications, 2008, , 5728.	2.2	19
126	Stabilization of a Î²-hairpin in monomeric Alzheimer's amyloid-Î² peptide inhibits amyloid formation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5099-5104.	3.3	375

#	Article	IF	Citations
127	Structural Classification of Toxic Amyloid Oligomers. Journal of Biological Chemistry, 2008, 283, 29639-29643.	1.6	716
128	Peptides inhibiting specific cleaving activities of presenilins. Expert Opinion on Therapeutic Patents, 2008, 18, 1097-1100.	2.4	0
129	Increasing Solubility of Proteins and Peptides by Site-Specific Modification with Betaine. Bioconjugate Chemistry, 2008, 19, 1113-1118.	1.8	41
130	Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB Journal, 2008, 22, 1296-1305.	0.2	125
131	Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Cmaj, 2008, 178, 548-556.	0.9	201
132	Membraneâ€bound Î²â€amyloid oligomers are recruited into lipid rafts by a fynâ€dependent mechanism. FASEB Journal, 2008, 22, 1552-1559.	0.2	114
133	C-terminal peptides coassemble into AÎ²42 oligomers and protect neurons against AÎ²42-induced neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14175-14180.	3.3	159
134	Intramembrane Proteolysis of GXGD-type Aspartyl Proteases Is Slowed by a Familial Alzheimer Disease-like Mutation. Journal of Biological Chemistry, 2008, 283, 30121-30128.	1.6	34
135	Protein Misfolding and Neurodegeneration. Archives of Neurology, 2008, 65, 184-9.	4.9	286
136	Aberrant molecular properties shared by familial Parkinsonâ€™s disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. Human Molecular Genetics, 2008, 17, 1482-1496.	1.4	87
137	Aggregated, Wild-Type Prion Protein Causes Neurological Dysfunction and Synaptic Abnormalities. Journal of Neuroscience, 2008, 28, 13258-13267.	1.7	60
138	apoE isoformâ€“specific disruption of amyloid Î² peptide clearance from mouse brain. Journal of Clinical Investigation, 2008, 118, 4002-4013.	3.9	623
139	A TAG on to the neurogenic functions of APP. Cell Adhesion and Migration, 2008, 2, 2-8.	1.1	14
140	Emerging and potential therapies for Alzheimer's disease. Expert Opinion on Therapeutic Targets, 2008, 12, 693-704.	1.5	27
141	Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1347-1352.	3.3	290
142	Antibodies to Potato Virus Y Bind the Amyloid Î² Peptide. Journal of Biological Chemistry, 2008, 283, 22550-22556.	1.6	24
143	Amyloid-Î² Binds to the Extracellular Cysteine-rich Domain of Frizzled and Inhibits Wnt/Î²-Catenin Signaling. Journal of Biological Chemistry, 2008, 283, 9359-9368.	1.6	214
144	Site-Specific Blockade of RAGE-V_dPrevents Amyloid-Î² Oligomer Neurotoxicity. Journal of Neuroscience, 2008, 28, 5149-5158.	1.7	120

#	Article	IF	Citations
145	Missense Mutations in the Progranulin Gene Linked to Frontotemporal Lobar Degeneration with Ubiquitin-immunoreactive Inclusions Reduce Progranulin Production and Secretion. Journal of Biological Chemistry, 2008, 283, 1744-1753.	1.6	155
146	A Drosophila Model for Amyotrophic Lateral Sclerosis Reveals Motor Neuron Damage by Human SOD1. Journal of Biological Chemistry, 2008, 283, 24972-24981.	1.6	139
147	Sulfated Polysaccharides Promote the Assembly of Amyloid Î²1â€“42 Peptide into Stable Fibrils of Reduced Cytotoxicity. Journal of Biological Chemistry, 2008, 283, 32471-32483.	1.6	70
148	Altered Function of Factor I Caused by Amyloid Î²: Implication for Pathogenesis of Age-Related Macular Degeneration from Drusen. Journal of Immunology, 2008, 181, 712-720.	0.4	79
149	A Two-Year Study with Fibrillar Â-Amyloid (AÂ) Immunization in Aged Canines: Effects on Cognitive Function and Brain AÂ. Journal of Neuroscience, 2008, 28, 3555-3566.	1.7	113
150	Flotillin-Dependent Clustering of the Amyloid Precursor Protein Regulates Its Endocytosis and Amyloidogenic Processing in Neurons. Journal of Neuroscience, 2008, 28, 2874-2882.	1.7	180
151	Sequestration of Copper from Î²-Amyloid Promotes Selective Lysis by Cyclen-Hybrid Cleavage Agents. Journal of Biological Chemistry, 2008, 283, 31657-31664.	1.6	109
152	Chemical Cross-linking Provides a Model of the Î³-Secretase Complex Subunit Architecture and Evidence for Close Proximity of the C-terminal Fragment of Presenilin with APH-1. Journal of Biological Chemistry, 2008, 283, 34677-34686.	1.6	37
153	Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Human Molecular Genetics, 2008, 17, 345-356.	1.4	219
154	Structure â€“ Function Relationships of Pre-Fibrillar Protein Assemblies in Alzheimers Disease and Related Disorders. Current Alzheimer Research, 2008, 5, 319-341.	0.7	92
155	A Generic Mechanism of Emergence of Amyloid Protofilaments from Disordered Oligomeric Aggregates. PLoS Computational Biology, 2008, 4, e1000222.	1.5	106
156	The Catalytic Core of γ-Secretase: Presenilin Revisited. Current Alzheimer Research, 2008, 5, 147-157.	0.7	33
157	Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17. Current Alzheimer Research, 2008, 5, 187-201.	0.7	87
158	Presenilins: Members of the Î³-Secretase Quartets, But Part-Time Soloists Too. Physiology, 2008, 23, 194-204.	1.6	108
159	Combating Protein Misfolding and Aggregation by Intracellular Antibodies. Current Molecular Medicine, 2008, 8, 2-11.	0.6	12
160	Assembly, Maturation, and Trafficking of the γ-Secretase Complex in Alzheimers Disease. Current Alzheimer Research, 2008, 5, 132-146.	0.7	101
161	An optimized split-ubiquitin cDNA-library screening system to identify novel interactors of the human Frizzled 1 receptor. Nucleic Acids Research, 2008, 36, e37.	6.5	27
162	Alternative pathways for production of Î²-amyloid peptides of Alzheimer's disease. Biological Chemistry, 2008, 389, 993-1006.	1.2	68

#	Article	IF	Citations
163	Intramembrane Proteolysis by Î³-Secretase. Journal of Biological Chemistry, 2008, 283, 29627-29631.	1.6	186
164	Effects of Grape Seed-derived Polyphenols on Amyloid Î²-Protein Self-assembly and Cytotoxicity*. Journal of Biological Chemistry, 2008, 283, 32176-32187.	1.6	177
165	Generation of AÎ²38 and AÎ²42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and Î³-Secretase Modulation. Journal of Biological Chemistry, 2008, 283, 677-683.	1.6	152
166	Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice. Neurodegenerative Diseases, 2008, 5, 157-159.	0.8	134
167	Intrinsic thermal expansivity and hydrational properties of amyloid peptide AÎ²42 in liquid water. Journal of Chemical Physics, 2008, 129, 195101.	1.2	30
168	Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease. Expert Opinion on Biological Therapy, 2008, 8, 633-642.	1.4	3
169	Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7206-7211.	3.3	153
170	Introspective analysis of amyloid as the cause of Alzheimerâ€™s disease: alternative model proposed. Future Neurology, 2008, 3, 527-536.	0.9	0
173	Cell Signaling Pathways and Iron Chelation in the Neurorestorative Activity of Green Tea Polyphenols: Special Reference to Epigallocatechin Gallate (EGCG). Journal of Alzheimer's Disease, 2008, 15, 211-222.	1.2	161
174	A Method for the Detection of Amyloid-Î²1-40, Amyloid-Î²1-42 and Amyloid-Î² Oligomers in Blood Using Magnetic Beads in Combination with Flow Cytometry and its Application in the Diagnostics of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 127-131.	1.2	22
175	Conformational Changes and Aggregation of Expanded Polyglutamine Proteins as Therapeutic Targets of the Polyglutamine Diseases: Exposed β-Sheet Hypothesis. Current Pharmaceutical Design, 2008, 14, 3267-3279.	0.9	60
176	Drosophila Models of Alzheimer's Amyloidosis: The Challenge of Dissecting the Complex Mechanisms of Toxicity of Amyloid-Î² 42. Journal of Alzheimer's Disease, 2008, 15, 523-540.	1.2	57
177	Title is missing!. Kagaku To Seibutsu, 2008, 46, 431-434.	0.0	0
178	The Damage Signals Hypothesis of Alzheimer's Disease Pathogenesis. Journal of Alzheimer's Disease, 2008, 14, 329-333.	1.2	70
179	The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease. Current Pharmaceutical Design, 2008, 14, 1601-1605.	0.9	170
180	N-Methyl-<i>D</i>-Aspartate Receptors Mediate Excitotoxicity in Amyloid Beta-Induced Synaptic Pathology of Alzheimerâ€™s Disease. Neuroembryology and Aging, 2008, 5, 134-143.	0.1	1
181	Is Tau Aggregation Toxic or Protective: A Sensible Question in the Absence of Sensitive Methods?. Journal of Alzheimer's Disease, 2008, 14, 423-429.	1.2	31
182	Peripheral biomarkers of oxidative stress in aging and Alzheimer's disease. Dementia E Neuropsychologia, 2008, 2, 2-8.	0.3	14

#	Article	IF	Citations
183	Contrasting In Vivo Effects of Two Peptide-Based Amyloid-Î² Protein Aggregation Inhibitors in a Transgenic Mouse Model of Amyloid Deposition. Cell Transplantation, 2008, 17, 397-408.	1.2	5
184	Structural Elements Regulating Amyloidogenesis: A Cholinesterase Model System. PLoS ONE, 2008, 3, e1834.	1.1	11
185	Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine â€" A Novel Immunotherapeutic Strategy. PLoS ONE, 2008, 3, e2124.	1.1	100
186	Amyloids: Friend or Foe?. Journal of Alzheimer's Disease, 2008, 13, 407-419.	1.2	85
187	Proteomic 2-D DIGE Profiling of APP23 Transgenic Mice Brain from Pre-plaque and Plaque Phenotypes. Journal of Alzheimer's Disease, 2008, 13, 17-30.	1.2	18
188	AÎ²-Dependent Inhibition of LTP in Different Intracortical Circuits of the Visual Cortex: The Role of RAGE. Journal of Alzheimer's Disease, 2009, 17, 59-68.	1.2	50
189	Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. Pharmaceuticals, 2009, 2, 250-286.	1.7	9
190	Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2009, 8, 16-30.	0.8	453
191	Nucleic acid induced protein aggregation and its role in biology and pathology. Frontiers in Bioscience - Landmark, 2009, 14, 5084.	3.0	14
192	Prion neurodegeneration. Prion, 2009, 3, 195-201.	0.9	55
193	The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biological Chemistry, 2009, 390, 1145-53.	1.2	88
194	Mitochondrial Cholesterol Loading Exacerbates Amyloid Î² Peptide-Induced Inflammation and Neurotoxicity. Journal of Neuroscience, 2009, 29, 6394-6405.	1.7	134
195	Amyloid beta mediates memory formation. Learning and Memory, 2009, 16, 267-272.	0.5	141
196	Glu-333 of Nicastrin Directly Participates in Î³-Secretase Activity. Journal of Biological Chemistry, 2009, 284, 29714-29724.	1.6	54
197	Î³-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimerâ€™s Disease. Science, 2009, 324, 639-642.	6.0	233
198	Amino Acid Position-specific Contributions to Amyloid Î²-Protein Oligomerization. Journal of Biological Chemistry, 2009, 284, 23580-23591.	1.6	79
199	X11Â rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice. Human Molecular Genetics, 2009, 18, 4492-4500.	1.4	30
200	Aggregation and Amyloid Fibril Formation Induced by Chemical Dimerization of Recombinant Prion Protein in Physiological-like Conditions. Journal of Biological Chemistry, 2009, 284, 30907-30916.	1.6	26

#	Article	IF	Citations
201	HLA-DR Alleles in Amyloid Î²-Peptide Autoimmunity: A Highly Immunogenic Role for the DRB1*1501 Allele. Journal of Immunology, 2009, 183, 3522-3530.	0.4	48
202	Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18367-18372.	3.3	225
203	Prion protein and Alzheimer disease. Prion, 2009, 3, 190-194.	0.9	66
204	Establishment of a Cellular Model for Alzheimer's Disease by Overexpressing Swedish-Type Mutated APP695. , 2009, , .		2
205	GluN2B subunit-containing NMDA receptor antagonists prevent AÎ²-mediated synaptic plasticity disruption in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20504-20509.	3.3	142
206	The Type I Hsp40 Ydj1 Utilizes a Farnesyl Moiety and Zinc Finger-like Region to Suppress Prion Toxicity. Journal of Biological Chemistry, 2009, 284, 3628-3639.	1.6	38
207	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12145-12150.	3.3	171
208	Cinnamon Extract Inhibits Tau Aggregation Associated with Alzheimer's Disease In Vitro. Journal of Alzheimer's Disease, 2009, 17, 585-597.	1.2	131
209	Experimental characterization of disordered and ordered aggregates populated during the process of amyloid fibril formation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7828-7833.	3.3	109
210	Distinctive roles of different Î²â€amyloid 42 aggregates in modulation of synaptic functions. FASEB Journal, 2009, 23, 1969-1977.	0.2	23
211	AÎ² Immunotherapy Protects Morphology and Survival of Adult-Born Neurons in Doubly Transgenic APP/PS1 Mice. Journal of Neuroscience, 2009, 29, 14108-14119.	1.7	59
212	Î²-Amyloid Impairs AMPA Receptor Trafficking and Function by Reducing Ca2+/Calmodulin-dependent Protein Kinase II Synaptic Distribution. Journal of Biological Chemistry, 2009, 284, 10639-10649.	1.6	157
213	Amyloid Î²-Protein Assembly and Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 4749-4753.	1.6	564
214	The Cleavage Products of Amyloid-Î² Precursor Protein Are Sorted to Distinct Carrier Vesicles That Are Independently Transported within Neurites. Journal of Neuroscience, 2009, 29, 3565-3578.	1.7	66
215	Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of AÎ² oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1971-1976.	3.3	592
216	Electrochemiluminescence in bioanalysis. Bioanalysis, 2009, 1, 919-935.	0.6	35
217	Searching for MIND: MicroRNAs in Neurodegenerative Diseases. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-8.	3.0	43
218	Cortical Î±7 Nicotinic Acetylcholine Receptor and Î²-Amyloid Levels in Early Alzheimer Disease. Archives of Neurology, 2009, 66, 646-51.	4.9	59

#	Article	IF	Citations
219	Reciprocal Efficiency of RNQ1 and Polyglutamine Detoxification in the Cytosol and Nucleus. Molecular Biology of the Cell, 2009, 20, 4162-4173.	0.9	36
220	Intramembrane Proteolysis by Signal Peptide Peptidases: A Comparative Discussion of GXGD-type Aspartyl Proteases. Journal of Biological Chemistry, 2009, 284, 13975-13979.	1.6	56
221	Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9679-9684.	3.3	201
222	Sulfadiazine Partially Protects the Rat Temporal Cortex from Amyloid Beta Peptide (25â€“35)-Induced Alterations of the Somatostatinergic System. Neuroendocrinology, 2009, 89, 400-410.	1.2	4
223	Recent advance in immunotherapies for Alzheimer disease, with special reference to DNA vaccination. Hum Vaccin, 2009, 5, 373-380.	2.4	12
224	Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimerâ€™s disease?. Future Neurology, 2009, 4, 761-773.	0.9	34
225	Insulin Signaling in Sporadic Alzheimerâ€™s Disease. Science Signaling, 2009, 2, pe36.	1.6	34
226	Humanin; A Defender Against Alzheimers Disease?. Recent Patents on CNS Drug Discovery, 2009, 4, 37-42.	0.9	31
227	Vaccination with AÎ²-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral AÎ² and Lowers Plaque Burden in APP Transgenic Mice. Journal of Immunology, 2009, 182, 7613-7624.	0.4	40
228	A Role for Synaptic Zinc in Activity-Dependent AÎ² Oligomer Formation and Accumulation at Excitatory Synapses. Journal of Neuroscience, 2009, 29, 4004-4015.	1.7	214
229	Cell Adhesion, the Backbone of the Synapse: "Vertebrate" and "Invertebrate" Perspectives. Cold Spring Harbor Perspectives in Biology, 2009, 1, a003079-a003079.	2.3	89
230	A Novel Nicotinic Acetylcholine Receptor Subtype in Basal Forebrain Cholinergic Neurons with High Sensitivity to Amyloid Peptides. Journal of Neuroscience, 2009, 29, 918-929.	1.7	159
231	Bimodal protein solubility distribution revealed by an aggregation analysis of the entire ensemble of Escherichia coli proteins. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4201-4206.	3.3	253
232	Reelin signaling antagonizes Î²-amyloid at the synapse. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15938-15943.	3.3	139
233	Synaptic Activity Reduces Intraneuronal AÎ², Promotes APP Transport to Synapses, and Protects against AÎ²-Related Synaptic Alterations. Journal of Neuroscience, 2009, 29, 9704-9713.	1.7	119
234	Molecular chaperones antagonize proteotoxicity by differentially modulating protein aggregation pathways. Prion, 2009, 3, 51-58.	0.9	51
235	Ca2+ Regulation of Dynamin-Independent Endocytosis in Cortical Astrocytes. Journal of Neuroscience, 2009, 29, 8063-8074.	1.7	43
236	Alzheimerâ€™s Î²-Amyloid-Induced Depolarization of Skeletal Muscle Fibers: Implications for Motor Dysfunctions in Dementia. Cellular Physiology and Biochemistry, 2009, 23, 109-114.	1.1	19

#	Article	IF	Citations
237	Ssd1 Is Required for Thermotolerance and Hsp104-Mediated Protein Disaggregation in Saccharomyces cerevisiae. Molecular and Cellular Biology, 2009, 29, 187-200.	1.1	40
238	Amyloid-Î²₄₂signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20936-20941.	3.3	64
239	Activated Actin-Depolymerizing Factor/Cofilin Sequesters Phosphorylated Microtubule-Associated Protein during the Assembly of Alzheimer-Like Neuritic Cytoskeletal Striations. Journal of Neuroscience, 2009, 29, 12994-13005.	1.7	84
240	Wild-type Cu/Zn superoxide dismutase (SOD1) does not facilitate, but impedes the formation of protein aggregates of amyotrophic lateral sclerosis causing mutant SOD1. Neurobiology of Disease, 2009, 36, 331-342.	2.1	40
241	An amyloid-Î² protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2009, 36, 425-434.	2.1	89
242	Immunodominant epitope and properties of pyroglutamate-modified AÎ²-specific antibodies produced in rabbits. Journal of Neuroimmunology, 2009, 213, 39-46.	1.1	25
243	Protective actions of sex steroid hormones in Alzheimerâ€™s disease. Frontiers in Neuroendocrinology, 2009, 30, 239-258.	2.5	424
244	Fibrinogen, a possible key player in Alzheimerâ€™s disease. Journal of Thrombosis and Haemostasis, 2009, 7, 146-150.	1.9	42
245	From protons to OXPHOS supercomplexes and Alzheimer's disease: Structureâ€“dynamicsâ€“function relationships of energy-transducing membranes. Biochimica Et Biophysica Acta - Bioenergetics, 2009, 1787, 657-671.	0.5	45
246	Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. Brain Research, 2009, 1292, 191-198.	1.1	87
247	Conformationâ€dependent singleâ€chain variable fragment antibodies specifically recognize betaâ€amyloid oligomers. FEBS Letters, 2009, 583, 579-584.	1.3	56
248	A single mutation in an SH3 domain increases amyloid aggregation by accelerating nucleation, but not by destabilizing thermodynamically the native state. FEBS Letters, 2009, 583, 801-806.	1.3	22
249	Bridging the gap: From protein misfolding to protein misfolding diseases. FEBS Letters, 2009, 583, 2581-2586.	1.3	90
250	Membrane injury by pore-forming proteins. Current Opinion in Cell Biology, 2009, 21, 589-595.	2.6	118
251	A Î³â€secretase inhibitor decreases amyloidâ€Î² production in the central nervous system. Annals of Neurology, 2009, 66, 48-54.	2.8	314
254	Modulation of Protein Dimerization by a Supramolecular Hostâ€“Guest System. Chemistry - A European Journal, 2009, 15, 8779-8790.	1.7	34
255	Identification of Physiological and Toxic Conformations in AÎ²42 Aggregates. ChemBioChem, 2009, 10, 287-295.	1.3	100
256	Regulatory role of cytosolic phospholipase A₂Î± in NADPH oxidase activity and in inducible nitric oxide synthase induction by aggregated AÎ²_{1â€“42} in microglia. Glia, 2009, 57, 1727-1740.	2.5	49

#	Article	IF	Citations
257	Retroâ€Enantio Nâ€Methylated Peptides as Î²â€Amyloid Aggregation Inhibitors. ChemMedChem, 2009, 4, 1488-1494.	1.6	38
258	Identifying genes that interact with Drosophila presenilin and amyloid precursor protein. Genesis, 2009, 47, 246-260.	0.8	36
259	Amyloidâ€Î² upâ€regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: Another mechanism of complement activation in ageâ€related macular degeneration. Journal of Cellular Physiology, 2009, 220, 119-128.	2.0	98
260	The small heat shock protein Hsp27 protects cortical neurons against the toxic effects of Î²â€amyloid peptide. Journal of Neuroscience Research, 2009, 87, 3161-3175.	1.3	41
261	Development of Tau Aggregation Inhibitors for Alzheimer's Disease. Angewandte Chemie - International Edition, 2009, 48, 1740-1752.	7.2	249
262	Alzheimer's Disease: From Pathology to Therapeutic Approaches. Angewandte Chemie - International Edition, 2009, 48, 3030-3059.	7.2	544
263	Alzheimer â€“ Mechanismen und therapeutische AnsÃtze. Warum wir im Alter dement werden. Biologie in Unserer Zeit, 2009, 39, 92-100.	0.3	0
264	Promoting Î±â€secretase cleavage of betaâ€amyloid with engineered proteolytic antibody fragments. Biotechnology Progress, 2009, 25, 1054-1063.	1.3	12
265	Recent advances in our understanding of neurodegeneration. Journal of Neural Transmission, 2009, 116, 1111-1162.	1.4	235
266	Synaptic degeneration in Alzheimerâ€™s disease. Acta Neuropathologica, 2009, 118, 167-179.	3.9	446
267	A Comparative Study of Î²-Amyloid Peptides AÎ²1-42 and AÎ²25-35 Toxicity in Organotypic Hippocampal Slice Cultures. Neurochemical Research, 2009, 34, 295-303.	1.6	87
268	Targeting Cdk5 Activity in Neuronal Degeneration and Regeneration. Cellular and Molecular Neurobiology, 2009, 29, 1073-1080.	1.7	53
269	Mitochondria, cholesterol and amyloid Î² peptide: a dangerous trio in Alzheimer disease. Journal of Bioenergetics and Biomembranes, 2009, 41, 417-423.	1.0	50
270	Metal Ion Physiopathology in Neurodegenerative Disorders. NeuroMolecular Medicine, 2009, 11, 223-238.	1.8	131
271	Management and prevention of human prion diseases. Current Neurology and Neuroscience Reports, 2009, 9, 423-429.	2.0	2
272	Interpeptide interactions induce helix to strand structural transition in AÎ² peptides. Proteins: Structure, Function and Bioinformatics, 2009, 77, 1-13.	1.5	141
273	Morphological alterations to neurons of the amygdala and impaired fear conditioning in a transgenic mouse model of Alzheimer's disease. Journal of Pathology, 2009, 219, 41-51.	2.1	54
274	9,10â€Anthraquinone hinders Î²â€aggregation: How does a small molecule interfere with AÎ²â€peptide amyloid fibrillation?. Protein Science, 2009, 18, 792-800.	3.1	91

#	Article	IF	Citations
275	Sequestration of essential proteins causes prion associated toxicity in yeast. Molecular Microbiology, 2009, 73, 1101-1114.	1.2	69
276	Amyloid-Î² causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Molecular Psychiatry, 2009, 14, 206-222.	4.1	188
278	Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death and Differentiation, 2009, 16, 46-56.	5.0	502
279	SRF and myocardin regulate LRP-mediated amyloid-Î² clearance in brain vascular cells. Nature Cell Biology, 2009, 11, 143-153.	4.6	237
280	Perturbation of membranes by the amyloid Î²â€peptide â€“ a molecular dynamics study. FEBS Journal, 2009, 276, 3060-3075.	2.2	65
281	Galantamine protects against oxidative stress induced by amyloidâ€beta peptide in cortical neurons. European Journal of Neuroscience, 2009, 29, 455-464.	1.2	58
282	Proteolytic processing of TAR DNA binding proteinâ€43 by caspases produces Câ€terminal fragments with disease defining properties independent of progranulin. Journal of Neurochemistry, 2009, 110, 1082-1094.	2.1	142
283	Differential effects of Î³â€secretase and BACE1 inhibition on brain AÎ² levels in vitro and in vivo. Journal of Neurochemistry, 2009, 110, 1377-1387.	2.1	24
284	Mechanism of docosahexaenoic acidâ€induced inhibition of in vitro AÎ²_{1â€“42} fibrillation and AÎ²_{1â€“42}â€induced toxicity in SHâ€SY5Y cells. Journal of Neurochemistry, 2009, 111, 568-579.	2.1	62
285	The binding of pullulan modified cholesteryl nanogels to AÎ² oligomers and their suppression of cytotoxicity. Biomaterials, 2009, 30, 5583-5591.	5.7	88
286	The synthesis and structureâ€“activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 654-657.	1.0	45
287	A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-Î². Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4952-4957.	1.0	25
288	Conformational plasticity of DM43, a metalloproteinase inhibitor from Didelphis marsupialis: Chemical and pressure-induced equilibrium (un)folding studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2009, 1794, 1379-1386.	1.1	5
289	An Intramolecular Oâ€“N Migration Reaction on Gold Surfaces: Toward the Preparation of Well-Defined Amyloid Surfaces. ACS Nano, 2009, 3, 3091-3097.	7.3	11
290	Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. American Journal of Alzheimer's Disease and Other Dementias, 2009, 24, 95-121.	0.9	245
291	Genetics and Pathogenesis of Inherited Ataxias and Spastic Paraplegias. Advances in Experimental Medicine and Biology, 2009, 652, 263-296.	0.8	8
292	Animal model of Alzheimerâ€™s disease: characteristics of EEG and memory. Open Life Sciences, 2009, 4, 507-514.	0.6	7
293	Transition from physiological to pathophysiological indices as exemplified by amyloidosis in periodic disease, non-insulin-dependent diabetes mellitus, and Alzheimerâ€™s disease. Human Physiology, 2009, 35, 96-107.	0.1	1

#	Article	IF	Citations
294	Effect of Dehydration on the Aggregation Kinetics of Two Amyloid Peptides. Journal of Physical Chemistry B, 2009, 113, 531-535.	1.2	76
295	Transmembrane Structures of Amyloid Precursor Protein Dimer Predicted by Replica-Exchange Molecular Dynamics Simulations. Journal of the American Chemical Society, 2009, 131, 3438-3439.	6.6	79
296	Myelin Basic Protein Binds to and Inhibits the Fibrillar Assembly of AÎ²42 in Vitro. Biochemistry, 2009, 48, 4720-4727.	1.2	27
297	Molecular Insight into the Inhibition Effect of Trehalose on the Nucleation and Elongation of Amyloid Î²-Peptide Oligomers. Journal of Physical Chemistry B, 2009, 113, 11320-11329.	1.2	68
298	Morphology and Secondary Structure of Stable Î²-Oligomers Formed by Amyloid Peptide PrP(106â^'126). Biochemistry, 2009, 48, 5779-5781.	1.2	29
299	Side Chain Interactions Can Impede Amyloid Fibril Growth: Replica Exchange Simulations of AÎ² Peptide Mutant. Journal of Physical Chemistry B, 2009, 113, 11848-11857.	1.2	23
300	Purification, Pharmacological Modulation, and Biochemical Characterization of Interactors of Endogenous Human Î³-Secretase. Biochemistry, 2009, 48, 1183-1197.	1.2	65
301	Divergent Pathways Mediate Spine Alterations and Cell Death Induced by Amyloid-Î², Wild-Type Tau, and R406W Tau. Journal of Neuroscience, 2009, 29, 14439-14450.	1.7	128
302	Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-Î² peptide. Dalton Transactions, 2009, , 1080-1094.	1.6	464
303	Chapter 3 Small-Molecule Proteinâ€"Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Recent Progress and Future Directions. Annual Reports in Medicinal Chemistry, 2009, , 51-69.	0.5	8
304	Chapter 2 Liveâ€Cell Imaging in the Study of Neurodegeneration. International Review of Cell and Molecular Biology, 2009, 276, 49-103.	1.6	8
305	Structures of Î²-Amyloid Peptide 1â^'40, 1â^'42, and 1â^'55â€"the 672â^'726 Fragment of APPâ€"in a Membrane Environment with Implications for Interactions with Î³-Secretase. Journal of the American Chemical Society, 2009, 131, 17843-17852.	6.6	95
306	Assembly dynamics of two-Î² sheets revealed by molecular dynamics simulations. Journal of Chemical Physics, 2009, 130, 164709.	1.2	28
307	Novel Pentameric Thiophene Derivatives for in Vitro and in Vivo Optical Imaging of a Plethora of Protein Aggregates in Cerebral Amyloidoses. ACS Chemical Biology, 2009, 4, 673-684.	1.6	290
308	Human apolipoprotein Aâ€"I binds amyloid-Î² and prevents AÎ²-induced neurotoxicity. International Journal of Biochemistry and Cell Biology, 2009, 41, 1361-1370.	1.2	114
309	Contribution of neural networks to Alzheimer disease's progression. Brain Research Bulletin, 2009, 80, 309-314.	1.4	53
310	Huntington's disease: The current state of research with peripheral tissues. Experimental Neurology, 2009, 219, 385-397.	2.0	154
311	Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice. Cell, 2009, 139, 1157-1169.	13.5	450

#	Article	IF	Citations
312	Protein aggregation as a paradigm of aging. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 980-996.	1.1	92
313	The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 964-972.	1.4	78
314	Analysis of DNA variations in promoter region of HCNP gene with Alzheimerâ€™s disease. Biochemical and Biophysical Research Communications, 2009, 379, 272-276.	1.0	26
315	Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APPswe/PS1Î”E9 transgenic mouse model of Alzheimerâ€™s disease. Biochemical and Biophysical Research Communications, 2009, 385, 341-345.	1.0	45
316	Ellagic acid promotes AÎ²42 fibrillization and inhibits AÎ²42-induced neurotoxicity. Biochemical and Biophysical Research Communications, 2009, 390, 1250-1254.	1.0	93
317	Synaptic contact number and size in stratum radiatum CA1 of APP/PS1Î”E9 transgenic mice. Neurobiology of Aging, 2009, 30, 1756-1776.	1.5	67
318	AÎ² peptide conformation determines uptake and interleukin-1Î± expression by primary microglial cells. Neurobiology of Aging, 2009, 30, 1792-1804.	1.5	37
319	The Role of Apolipoprotein E in Alzheimer's Disease. Neuron, 2009, 63, 287-303.	3.8	1,251
320	High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-Î² and tau pathologies in the 3xTg-AD model of Alzheimer's disease. Neuroscience, 2009, 159, 296-307.	1.1	52
321	Function, regulation and therapeutic properties of Î²-secretase (BACE1). Seminars in Cell and Developmental Biology, 2009, 20, 175-182.	2.3	73
322	Inflammation in Alzheimer's disease: Amyloid-Î² oligomers trigger innate immunity defence via pattern recognition receptors. Progress in Neurobiology, 2009, 87, 181-194.	2.8	310
323	Alzheimer Î²-amyloid blocks epileptiform activity in hippocampal neurons. Molecular and Cellular Neurosciences, 2009, 41, 420-428.	1.0	18
324	Amyloid-Î² Membrane Binding and Permeabilization are Distinct Processes Influenced Separately by Membrane Charge and Fluidity. Journal of Molecular Biology, 2009, 386, 81-96.	2.0	152
325	Amyloid Aggregation on Lipid Bilayers and Its Impact on Membrane Permeability. Journal of Molecular Biology, 2009, 387, 407-415.	2.0	133
326	Direct in Vivo Intracellular Selection of Conformation-sensitive Antibody Domains Targeting Alzheimer's Amyloid-Î² Oligomers. Journal of Molecular Biology, 2009, 387, 584-606.	2.0	59
327	A possible pathogenesis for Alzheimerâ€™s disease: Craniomaxillofacial dysfunction leading to localized cerebrospinal fluid stasis. Medical Hypotheses, 2009, 72, 199-210.	0.8	5
328	Single-domain antibodies recognize selectively small oligomeric forms of amyloid Î², prevent AÎ²-induced neurotoxicity and inhibit fibril formation. Molecular Immunology, 2009, 46, 695-704.	1.0	87
329	Comparison of AÎ² levels in the brain of familial and sporadic Alzheimer's disease. Neurochemistry International, 2009, 55, 243-252.	1.9	60

#	Article	IF	Citations
330	Secreted amyloid precursor protein-Î± upregulates synaptic protein synthesis by a protein kinase G-dependent mechanism. Neuroscience Letters, 2009, 460, 92-96.	1.0	52
331	Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. NeuroToxicology, 2009, 30, 986-995.	1.4	259
332	Wnt signaling in Alzheimer's disease: Up or down, that is the question. Ageing Research Reviews, 2009, 8, 71-82.	5.0	119
333	Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimerâ€™s disease. Molecular BioSystems, 2009, 5, 134-142.	2.9	30
334	Mitochondrial Glutathione, a Key Survival Antioxidant. Antioxidants and Redox Signaling, 2009, 11, 2685-2700.	2.5	777
335	Biological and Chemical Approaches to Diseases of Proteostasis Deficiency. Annual Review of Biochemistry, 2009, 78, 959-991.	5.0	1,035
336	AÎ² Oligomers and Fibrillar Aggregates Induce Different Apoptotic Pathways in LAN5 Neuroblastoma Cell Cultures. Biophysical Journal, 2009, 96, 4200-4211.	0.2	93
337	Probing Energetics of AÎ² Fibril Elongation by Molecular Dynamics Simulations. Biophysical Journal, 2009, 96, 4428-4437.	0.2	49
338	Molecular Dynamics Simulations of Ibuprofen Binding to AÎ² Peptides. Biophysical Journal, 2009, 97, 2070-2079.	0.2	53
339	The effect of increasing hydrophobicity on the self-assembly of amphipathic Î²-sheet peptides. Molecular BioSystems, 2009, 5, 1058.	2.9	106
340	Progress in the Development of Î²-secretase Inhibitors for Alzheimer's Disease. Progress in Medicinal Chemistry, 2009, 48, 133-161.	4.1	33
341	Structureâ€“neurotoxicity relationships of amyloid Î²-protein oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14745-14750.	3.3	701
342	Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Molecular Brain, 2009, 2, 30.	1.3	114
343	Structural Properties of Pore-Forming Oligomers of Î±-Synuclein. Journal of the American Chemical Society, 2009, 131, 17482-17489.	6.6	191
344	Secretase inhibitors and modulators for Alzheimerâ€™s disease treatment. Expert Review of Neurotherapeutics, 2009, 9, 661-679.	1.4	122
346	The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 33-47.	1.2	64
347	Amyloid-Î²(1â˜’42) Fibrillar Precursors Are Optimal for Inducing Tumor Necrosis Factor-Î± Production in the THP-1 Human Monocytic Cell Line. Biochemistry, 2009, 48, 9011-9021.	1.2	19
348	Probing the Effect of Amino-Terminal Truncation for AÎ²1â˜’40 Peptides. Journal of Physical Chemistry B, 2009, 113, 6692-6702.	1.2	40

#	Article	IF	Citations
349	Quantitative approaches to defining normal and aberrant protein homeostasis. Faraday Discussions, 2009, 143, 277.	1.6	8
350	MAPK, Î²-amyloid and synaptic dysfunction: the role of RAGE. Expert Review of Neurotherapeutics, 2009, 9, 1635-1645.	1.4	60
351	Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions. Alzheimer's and Dementia, 2009, 5, 340-347.	0.4	96
352	Phenolic Compounds Prevent Alzheimerâ€™s Pathology through Different Effects on the Amyloid-Î² Aggregation Pathway. American Journal of Pathology, 2009, 175, 2557-2565.	1.9	359
353	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18809-18814.	3.3	616
354	Modeling of the Zn2+ binding in the 1â€“16 region of the amyloid Î² peptide involved in Alzheimerâ€™s disease. Physical Chemistry Chemical Physics, 2009, 11, 6468.	1.3	31
355	Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer. Journal of Biological Chemistry, 2009, 284, 4230-4237.	1.6	307
356	Chapter 5 Autophagic Clearance of Aggregateâ€Prone Proteins Associated with Neurodegeneration. Methods in Enzymology, 2009, 453, 83-110.	0.4	81
357	ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. Journal of Neuroinflammation, 2009, 6, 41.	3.1	270
362	Coffee â€œBreaksâ€•Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 17, 699-700.	1.2	2
363	Reactive Oxygen Species in Diabetes-induced Vascular Damage, Stroke, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 775-785.	1.2	41
364	Extracellular Amyloid-Î² and Cytotoxic Glial Activation Induce Significant Entorhinal Neuron Loss in Young PS1M146L/APP751SL Mice. Journal of Alzheimer's Disease, 2009, 18, 755-776.	1.2	40
365	Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy. CNS and Neurological Disorders - Drug Targets, 2009, 8, 128-143.	0.8	21
366	St. Johns Wort Components and the Brain: Uptake, Concentrations Reached and the Mechanisms Underlying Pharmacological Effects. Current Drug Metabolism, 2009, 10, 1055-1065.	0.7	26
367	MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders. Current Genomics, 2009, 10, 154-168.	0.7	194
368	Functional Genomics of Brain Aging and Alzheimers Disease: Focus on Selective Neuronal Vulnerability. Current Genomics, 2010, 11, 618-633.	0.7	81
369	Heat Shock Proteins as Suppressors of Accumulation of Toxic Prefibrillar Intermediates and Misfolded Proteins in Neurodegenerative Diseases. Current Pharmaceutical Biotechnology, 2010, 11, 158-166.	0.9	35
370	Amyloid Deposition and Influx Transporter Expression at the Blood-Brain Barrier Increase in Normal Aging. Journal of Neuropathology and Experimental Neurology, 2010, 69, 98-108.	0.9	94

#	Article	IF	Citations
371	Drosophila melanogaster in the Study of Human Neurodegeneration. CNS and Neurological Disorders - Drug Targets, 2010, 9, 504-523.	0.8	165
372	The Cytoprotective Effects of Dantrolene. Anesthesia and Analgesia, 2010, 111, 1400-1410.	1.1	71
373	Traditional used Plants against Cognitive Decline and Alzheimer Disease. Frontiers in Pharmacology, 2010, 1, 138.	1.6	33
374	Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam. Frontiers in Neuroscience, 2010, 1, .	1.4	29
377	Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging. Journal of Alzheimer's Disease, 2010, 20, 843-854.	1.2	230
379	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. Journal of Alzheimer's Disease, 2010, 21, 1119-1128.	1.2	110
380	Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry, 2010, 49, 10039-10041.	1.2	302
381	Amyloidâ€Î² Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 43-49.	1.9	108
382	Destabilizing Alzheimerâ€™s AÎ²₄₂Protofibrils with Morin: Mechanistic Insights from Molecular Dynamics Simulations. Biochemistry, 2010, 49, 3935-3946.	1.2	162
383	Alzheimer's Disease. New England Journal of Medicine, 2010, 362, 329-344.	13.9	4,116
384	Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cellular and Molecular Life Sciences, 2010, 67, 581-600.	2.4	52
385	Mitochondrial dynamics in cell death and neurodegeneration. Cellular and Molecular Life Sciences, 2010, 67, 3435-3447.	2.4	258
386	Î²-amyloid oligomers and cellular prion protein in Alzheimerâ€™s disease. Journal of Molecular Medicine, 2010, 88, 331-338.	1.7	75
387	The implications of gene heterozygosity for protein folding and protein turnover. Journal of Theoretical Biology, 2010, 265, 554-564.	0.8	7
388	Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP. Acta Neuropathologica, 2010, 119, 189-197.	3.9	116
389	Intraneuronal Î²-amyloid accumulation and synapse pathology in Alzheimerâ€™s disease. Acta Neuropathologica, 2010, 119, 523-541.	3.9	341
390	Capillary cerebral amyloid angiopathy identifies a distinct APOE Îµ4-associated subtype of sporadic Alzheimerâ€™s disease. Acta Neuropathologica, 2010, 120, 169-183.	3.9	81
391	Effect of pathogenic mutations on the structure and dynamics of Alzheimerâ€™s AÎ²42-amyloid oligomers. Journal of Molecular Modeling, 2010, 16, 1011-1020.	0.8	30

#	Article	IF	Citations
392	Calcium hypothesis of Alzheimerâ€™s disease. Pflugers Archiv European Journal of Physiology, 2010, 459, 441-449.	1.3	312
393	Transgenic Drosophila models of Alzheimerâ€™s disease and tauopathies. Brain Structure and Function, 2010, 214, 245-262.	1.2	96
394	Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimerâ€™s and Parkinsonâ€™s diseases. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1354-1363.	2.2	89
395	Neurogenesis in the aged and neurodegenerative brain. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1415-1421.	2.2	58
396	Inflammation and Alzheimerâ€™s disease. Archives of Pharmacal Research, 2010, 33, 1539-1556.	2.7	350
397	Alzheimerâ€™s Disease Amyloid Î²-Protein and Synaptic Function. NeuroMolecular Medicine, 2010, 12, 13-26.	1.8	122
398	Nicotinic Receptors, Amyloid-Î², and Synaptic Failure in Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2010, 40, 221-229.	1.1	54
399	Copper Enhances Amyloid-Î² Peptide Neurotoxicity and non Î²-Aggregation: A Series of Experiments Conducted upon Copper-Bound and Copper-Free Amyloid-Î² Peptide. Journal of Molecular Neuroscience, 2010, 41, 66-73.	1.1	39
400	Astrocytes Regulate the Expression of Insulin-Like Growth Factor 1 Receptor (IGF1-R) in Primary Cortical Neurons During In Vitro Senescence. Journal of Molecular Neuroscience, 2010, 40, 342-352.	1.1	14
401	Humanin and the Receptors for Humanin. Molecular Neurobiology, 2010, 41, 22-28.	1.9	51
402	Heteromeric complexes of heat shock protein 70 (HSP70) family members, including Hsp70Bâ€², in differentiated human neuronal cells. Cell Stress and Chaperones, 2010, 15, 545-553.	1.2	22
403	Î±B-Crystallin inhibits the cell toxicity associated with amyloid fibril formation by Î²-casein and the amyloid-Î² peptide. Cell Stress and Chaperones, 2010, 15, 1013-1026.	1.2	57
404	Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example. Journal of Computer-Aided Molecular Design, 2010, 24, 803-817.	1.3	11
405	Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimerâ€™s AÎ² Peptide. International Journal of Peptide Research and Therapeutics, 2010, 16, 23-30.	0.9	5
406	Alzheimer's disease: clinical trials and drug development. Lancet Neurology, The, 2010, 9, 702-716.	4.9	1,033
407	Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. Journal of Neuroimmunology, 2010, 223, 104-114.	1.1	22
408	Anti-11[E]-pyroglutamate-modified amyloid Î² antibodies cross-react with other pathological AÎ² species: Relevance for immunotherapy. Journal of Neuroimmunology, 2010, 229, 248-255.	1.1	12
409	Intraneuronal amyloid Î² accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiology of Disease, 2010, 37, 731-737.	2.1	88

#	Article	IF	Citations
410	Indirubin-3'-monoxime rescues spatial memory deficits and attenuates Î²-amyloid-associated neuropathology in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2010, 39, 156-168.	2.1	56
411	Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiology of Disease, 2010, 39, 265-271.	2.1	73
412	Preclinical Alzheimer disease: Brain oxidative stress, AÎ² peptide and proteomics. Neurobiology of Disease, 2010, 39, 221-228.	2.1	76
413	Icariin inhibits beta-amyloid peptide segment 25â€“35 induced expression of Î²-secretase in rat hippocampus. European Journal of Pharmacology, 2010, 626, 213-218.	1.7	68
414	Different electrophysiological actions of 24- and 72-hour aggregated amyloid-beta oligomers on hippocampal field population spike in both anesthetized and awake rats. Brain Research, 2010, 1354, 227-235.	1.1	20
415	Structural basis for a PABPN1 aggregationâ€preventing antibody fragment in OPMD. FEBS Letters, 2010, 584, 1558-1564.	1.3	5
416	Intracellular calcium signalling in Alzheimerâ€™s disease. Journal of Cellular and Molecular Medicine, 2010, 14, 30-41.	1.6	58
417	Role of the SNKâ€SPAR pathway in the development of Alzheimer's disease. IUBMB Life, 2010, 62, 214-221.	1.5	12
420	Two Functions, One Molecule: A Metalâ€Binding and a Targeting Moiety to Combat Alzheimer's Disease. ChemBioChem, 2010, 11, 950-953.	1.3	47
421	Quantifying Prefibrillar Amyloids in vitro by Using a â€œThioflavinâ€Likeâ€•Spectroscopic Method. ChemBioChem, 2010, 11, 1889-1895.	1.3	23
422	A Strategy for Designing a Peptide Probe for Detection of Î²â€Amyloid Oligomers. ChemBioChem, 2010, 11, 2409-2418.	1.3	41
424	Combining Independent Drug Classes into Superior, Synergistically Acting Hybrid Molecules. Angewandte Chemie - International Edition, 2010, 49, 8743-8746.	7.2	43
425	Detection of AÎ² Plaques by a Novel Specific MRI Probe Precursor CRâ€BSAâ€(Gdâ€DTPA)n in APP/PS1 Transgenic Mice. Anatomical Record, 2010, 293, 2136-2143.	0.8	22
426	Interplay between protein homeostasis networks in protein aggregation and proteotoxicity. Biopolymers, 2010, 93, 229-236.	1.2	25
427	Efficient fourâ€drug cocktail therapy targeting amyloidâ€Î² peptide for Alzheimer's disease. Journal of Neuroscience Research, 2010, 88, 3588-3597.	1.3	13
428	Mass spectrometry and the amyloid problemâ€”How far can we go in the gas phase?. Journal of the American Society for Mass Spectrometry, 2010, 21, 1087-1096.	1.2	61
429	APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks. Neuroscience and Biobehavioral Reviews, 2010, 34, 487-499.	2.9	20
430	The effects of cholesterol on learning and memory. Neuroscience and Biobehavioral Reviews, 2010, 34, 1366-1379.	2.9	87

#	Article	IF	Citations
431	Recombinant GST-I-AÎ²28-induced efficient serum antibody against AÎ²42. Journal of Neuroscience Methods, 2010, 186, 52-59.	1.3	13
432	Lipid-based nanoparticles with high binding affinity for amyloid-Î²1â€“42 peptide. Biomaterials, 2010, 31, 6519-6529.	5.7	190
433	Conformation Sensors that Distinguish Monomeric Proteins from Oligomers in Live Cells. Chemistry and Biology, 2010, 17, 371-379.	6.2	38
434	Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: Structureâ€“activity relationship of P2â€² substituents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4789-4794.	1.0	23
435	Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6231-6236.	1.0	44
436	Phospholipase A2 inhibitors protect against prion and AÎ² mediated synapse degeneration. Molecular Neurodegeneration, 2010, 5, 13.	4.4	36
437	Endocytic pathways mediating oligomeric AÎ²42 neurotoxicity. Molecular Neurodegeneration, 2010, 5, 19.	4.4	48
438	Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain. Molecular Neurodegeneration, 2010, 5, 35.	4.4	30
439	Amyloid-Î²-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the AÎ² peptide. Implications for the pathogenesis of Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 4.	4.4	96
440	Î±-synuclein induced synapse damage is enhanced by amyloid-Î²1-42. Molecular Neurodegeneration, 2010, 5, 55.	4.4	43
441	Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar AÎ² oligomers. Molecular Neurodegeneration, 2010, 5, 57.	4.4	135
442	Amyloidogenic sequences in native protein structures. Protein Science, 2010, 19, 327-348.	3.1	68
443	Discovery and characterization of a mammalian amyloid disaggregation activity. Protein Science, 2010, 19, 836-846.	3.1	29
444	A rapid protein folding assay for the bacterial periplasm. Protein Science, 2010, 19, 1079-1090.	3.1	28
445	Binding of nonsteroidal antiâ€inflammatory drugs to AÎ² fibril. Proteins: Structure, Function and Bioinformatics, 2010, 78, 2849-2860.	1.5	30
447	Blood levels of kynurenines, interleukinâ€23 and soluble human leucocyte antigenâ€G at different stages of Huntingtonâ€™s disease. Journal of Neurochemistry, 2010, 112, 112-122.	2.1	72
448	Diacylglycerol kinases in the regulation of dendritic spines. Journal of Neurochemistry, 2010, 112, 577-587.	2.1	40
449	Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimerâ€™s disease transgenic mice. Journal of Neurochemistry, 2010, 113, 248-261.	2.1	126

#	Article	IF	Citations
450	Abnormal postâ€translational and extracellular processing of brevican in plaqueâ€bearing mice overâ€expressing APPsw. Journal of Neurochemistry, 2010, 113, 784-795.	2.1	33
451	Despite its role in assembly, methionine 35 is not necessary for amyloid Î²â€protein toxicity. Journal of Neurochemistry, 2010, 113, 1252-1262.	2.1	39
452	An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42. Journal of Neurochemistry, 2010, 115, 873-884.	2.1	43
453	Amyloid oligomers: formation and toxicity of AÎ² oligomers. FEBS Journal, 2010, 277, 1348-1358.	2.2	508
454	Amyloid oligomers: dynamics and toxicity in the cytosol and nucleus. FEBS Journal, 2010, 277, 1369-1379.	2.2	22
455	Mysterious oligomerization of the amyloidogenic proteins. FEBS Journal, 2010, 277, 2940-2953.	2.2	178
456	Inhibition of mitochondrial fusion by Î±-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO Journal, 2010, 29, 3571-3589.	3.5	431
457	Differences in prion strain conformations result from non-native interactions in a nucleus. Nature Chemical Biology, 2010, 6, 225-230.	3.9	70
458	Initiation and propagation of neurodegeneration. Nature Medicine, 2010, 16, 1201-1204.	15.2	40
459	In vivo labelling of hippocampal Î²â€amyloid in tripleâ€transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. European Journal of Neuroscience, 2010, 31, 99-109.	1.2	23
460	The turn formation at positions 22 and 23 in the 42â€mer amyloid Î² peptide: The emerging role in the pathogenesis of Alzheimer's disease. Geriatrics and Gerontology International, 2010, 10, S169-79.	0.7	19
462	Severe Motor Neuron Degeneration in the Spinal Cord of the Tg2576 Mouse Model of Alzheimer Disease. Journal of Alzheimer's Disease, 2010, 21, 263-276.	1.2	45
463	Diverse Ecdysterones Show Different Effects on Amyloid-Î²42 Aggregation but All Uniformly Inhibit Amyloid-Î²42-Induced Cytotoxicity. Journal of Alzheimer's Disease, 2010, 22, 107-117.	1.2	13
464	Calcium and Neurogenesis in Alzheimer's Disease. Frontiers in Neuroscience, 2010, 4, 194.	1.4	27
465	Calretinin Interneurons are Early Targets of Extracellular Amyloid-Î² Pathology in PS1/AÎ²PP Alzheimer Mice Hippocampus. Journal of Alzheimer's Disease, 2010, 21, 119-132.	1.2	81
466	A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, S401-S412.	1.2	141
467	Synaptotoxicity of Alzheimer Beta Amyloid Can Be Explained by Its Membrane Perforating Property. PLoS ONE, 2010, 5, e11820.	1.1	134
468	Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2010, 5, e12845.	1.1	219

#	Article	IF	Citations
469	Multiple Events Lead to Dendritic Spine Loss in Triple Transgenic Alzheimer's Disease Mice. PLoS ONE, 2010, 5, e15477.	1.1	145
470	Neuronal Models for Studying Tau Pathology. International Journal of Alzheimer's Disease, 2010, 2010, 1-11.	1.1	3
471	Differential effects of amyloid-beta peptide aggregation status on in vivo retinal neurotoxicity. Eye and Brain, 2010, 2, 121.	3.8	4
472	Anesthetics Promoting in vitro AÎ²PP Metabolism and Amyloid-Î² Toxicity. Journal of Alzheimer's Disease, 2010, 22, S21-S26.	1.2	2
473	GD3 Accumulation in Cell Surface Lipid Rafts Prior to Mitochondrial Targeting Contributes to Amyloid-Î²-induced Apoptosis. Journal of Korean Medical Science, 2010, 25, 1492.	1.1	11
474	Alzheimerâ€™s disease: a molecular mechanism, new hypotheses, and therapeutic strategies. Medicina (Lithuania), 2010, 46, 70.	0.8	5
475	Alzheimer's Disease: A General Introduction and Pathomechanism. Journal of Alzheimer's Disease, 2010, 22, S5-S19.	1.2	143
476	Protein homeostasis and aging in neurodegeneration. Journal of Cell Biology, 2010, 190, 719-729.	2.3	336
477	Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease. Journal of Visualized Experiments, 2010, , .	0.2	23
478	SDS-PAGE/Immunoblot Detection of Aβ Multimers in Human Cortical Tissue Homogenates using Antigen-Epitope Retrieval. Journal of Visualized Experiments, 2010, , .	0.2	25
479	ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12011-12016.	3.3	304
480	Î²-Amyloid Causes Depletion of Synaptic Vesicles Leading to Neurotransmission Failure. Journal of Biological Chemistry, 2010, 285, 2506-2514.	1.6	153
481	Participation of Transmembrane Domain 1 of Presenilin 1 in the Catalytic Pore Structure of the Â-Secretase. Journal of Neuroscience, 2010, 30, 15943-15950.	1.7	56
482	Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimerâ€™s disease mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19014-19019.	3.3	179
483	MicroRNA-101 Regulates Amyloid Precursor Protein Expression in Hippocampal Neurons. Journal of Biological Chemistry, 2010, 285, 18344-18351.	1.6	201
484	Calpain Activation Promotes BACE1 Expression, Amyloid Precursor Protein Processing, and Amyloid Plaque Formation in a Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2010, 285, 27737-27744.	1.6	96
485	Transmembrane Protein 147 (TMEM147) Is a Novel Component of the Nicalin-NOMO Protein Complex. Journal of Biological Chemistry, 2010, 285, 26174-26181.	1.6	37
486	Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs. Human Molecular Genetics, 2010, 19, 3983-3994.	1.4	140

#	Article	IF	Citations
487	Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's diseaseâ€linked APPswe/PS1Î”E9 mice. FASEB Journal, 2010, 24, 1667-1681.	0.2	162
488	Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid Î²₄₂from Isolated Intact Nerve Terminals. Journal of Neuroscience, 2010, 30, 3870-3875.	1.7	78
489	PI3 kinase signaling is involved in AÎ²-induced memory loss in Drosophila. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7060-7065.	3.3	111
490	Gain-of-Function Enhancement of IP ₃ Receptor Modal Gating by Familial Alzheimerâ€™s Diseaseâ€“Linked Presenilin Mutants in Human Cells and Mouse Neurons. Science Signaling, 2010, 3, ra22.	1.6	189
491	Post-transcriptional regulation of amyloid precursor protein by microRNAs and RNA binding proteins. Communicative and Integrative Biology, 2010, 3, 499-503.	0.6	12
492	Inhaled Insulin Forms Toxic Pulmonary Amyloid Aggregates. Endocrinology, 2010, 151, 4717-4724.	1.4	44
493	Fibrillar Oligomers Nucleate the Oligomerization of Monomeric Amyloid Î² but Do Not Seed Fibril Formation. Journal of Biological Chemistry, 2010, 285, 6071-6079.	1.6	143
494	Î³-Secretase Composed of PS1/Pen2/Aph1a Can Cleave Notch and Amyloid Precursor Protein in the Absence of Nicastrin. Journal of Neuroscience, 2010, 30, 1648-1656.	1.7	84
495	Amyloid-Î² Aggregates Cause Alterations of Astrocytic Metabolic Phenotype: Impact on Neuronal Viability. Journal of Neuroscience, 2010, 30, 3326-3338.	1.7	252
496	Alzheimer's Disease: The Quest to Understand Complexity. Journal of Alzheimer's Disease, 2010, 21, 373-383.	1.2	25
497	Single-Particle Detection System for AÎ² Aggregates: Adaptation of Surface-Fluorescence Intensity Distribution Analysis to Laser Scanning Microscopy. Rejuvenation Research, 2010, 13, 206-209.	0.9	17
498	Three-Amino Acid Spacing of Presenilin Endoproteolysis Suggests a General Stepwise Cleavage of Â-Secretase-Mediated Intramembrane Proteolysis. Journal of Neuroscience, 2010, 30, 7853-7862.	1.7	93
499	Amyloid-Î² as a Modulator of Synaptic Plasticity. Journal of Alzheimer's Disease, 2010, 22, 741-763.	1.2	225
500	Olfactory Dysfunction Correlates with Amyloid-Î² Burden in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2010, 30, 505-514.	1.7	258
501	Phospholipase D2 Ablation Ameliorates Alzheimer's Disease-Linked Synaptic Dysfunction and Cognitive Deficits. Journal of Neuroscience, 2010, 30, 16419-16428.	1.7	155
502	Î²-Amyloid Precursor Protein Mutants Respond to Î³-Secretase Modulators. Journal of Biological Chemistry, 2010, 285, 17798-17810.	1.6	64
503	Interaction between Human Prion Protein and Amyloid-Î² (AÎ²) Oligomers. Journal of Biological Chemistry, 2010, 285, 26377-26383.	1.6	244
504	Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13888-13893.	3.3	237

#	Article	IF	Citations
505	TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3858-3863.	3.3	491
506	Beclin 1 Complex in Autophagy and Alzheimer Disease. Archives of Neurology, 2010, 67, 1181-4.	4.9	82
507	Role of biochemical Alzheimerâ€™s disease biomarkers as end points in clinical trials. Biomarkers in Medicine, 2010, 4, 81-89.	0.6	22
508	ADF/Cofilin-Actin Rods in Neurodegenerative Diseases. Current Alzheimer Research, 2010, 7, 241-250.	0.7	141
509	Effects of the English (H6R) and Tottori (D7N) Familial Alzheimer Disease Mutations on Amyloid Î²-Protein Assembly and Toxicity. Journal of Biological Chemistry, 2010, 285, 23186-23197.	1.6	131
510	Sequestration of the AÎ² Peptide Prevents Toxicity and Promotes Degradation In Vivo. PLoS Biology, 2010, 8, e1000334.	2.6	70
511	Diabetes NEP-Like Endopeptidases and Alzheimers Disease. Current Alzheimer Research, 2010, 7, 223-229.	0.7	21
512	Globular state in the oligomers formed by AÎ² peptides. Journal of Chemical Physics, 2010, 132, 225101.	1.2	7
513	Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process. Physiological Reviews, 2010, 90, 465-494.	13.1	389
514	The role of STEP in Alzheimer's disease. Channels, 2010, 4, 347-350.	1.5	27
515	Anesthesia and the Old Brain. Anesthesia and Analgesia, 2010, 110, 421-426.	1.1	59
516	Prion and TNFÎ±: TAC(E)it agreement between the prion protein and cell signaling. Cell Cycle, 2010, 9, 4616-4621.	1.3	6
517	Countering amyloid polymorphism and drug resistance with minimal drug cocktails. Prion, 2010, 4, 244-251.	0.9	18
518	Amyloid Efflux Transporter Expression at the Blood-Brain Barrier Declines in Normal Aging. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1034-1043.	0.9	157
519	Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease. Current Pharmaceutical Design, 2010, 16, 2837-2850.	0.9	34
520	Adeno-associated Virus Gene Therapy With Cholesterol 24-Hydroxylase Reduces the Amyloid Pathology Before or After the Onset of Amyloid Plaques in Mouse Models of Alzheimer's Disease. Molecular Therapy, 2010, 18, 44-53.	3.7	166
521	Neuroinflammation, Oxidative Stress and the Pathogenesis of Alzheimers Disease. Current Pharmaceutical Design, 2010, 16, 2766-2778.	0.9	547
522	Lipid Membranes and β-Amyloid: A Harmful Connection. Current Protein and Peptide Science, 2010, 11, 319-325.	0.7	57

#	Article	IF	Citations
523	Oxygen Sensing: A Common Crossroad in Cancer and Neurodegeneration. Current Topics in Microbiology and Immunology, 2010, 345, 71-103.	0.7	21
524	A STEP forward in neural function and degeneration. Communicative and Integrative Biology, 2010, 3, 419-422.	0.6	16
525	Translational biophysics: the physical sciences in molecular medicine. Future Medicinal Chemistry, 2010, 2, 1633-1639.	1.1	3
526	Nanoimaging for prion related diseases. Prion, 2010, 4, 265-274.	0.9	20
527	Structureâ^'Activity Relationships in Peptide Modulators of Î²-Amyloid Protein Aggregation: Variation in Î±,Î±-Disubstitution Results in Altered Aggregate Size and Morphology. ACS Chemical Neuroscience, 2010, 1, 608-626.	1.7	32
529	AÎ²-Mediated NMDA Receptor Endocytosis in Alzheimer's Disease Involves Ubiquitination of the Tyrosine Phosphatase STEP₆₁. Journal of Neuroscience, 2010, 30, 5948-5957.	1.7	198
530	Is PrPC a Mediator of AÂ Toxicity in Alzheimer's Disease?. Journal of Neuroscience, 2010, 30, 11883-11884.	1.7	2
531	Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease. Neuropsychopharmacology, 2010, 35, 870-880.	2.8	627
532	Oxidative Stress and Amyloid-Beta Pathology in Normal Individuals with A Maternal History of Alzheimer's. Biological Psychiatry, 2010, 68, 913-921.	0.7	44
533	Intrinsic Determinants of Neurotoxic Aggregate Formation by the Amyloid Î² Peptide. Biophysical Journal, 2010, 98, 1677-1684.	0.2	45
534	Molecular Dynamics Simulations of Anti-Aggregation Effect of Ibuprofen. Biophysical Journal, 2010, 98, 2662-2670.	0.2	26
535	Structural Determination of AÎ²25â€“35 Micelles by Molecular Dynamics Simulations. Biophysical Journal, 2010, 99, 666-674.	0.2	23
536	The N-Terminus of the Intrinsically Disordered Protein Î±-Synuclein Triggers Membrane Binding and Helix Folding. Biophysical Journal, 2010, 99, 2116-2124.	0.2	228
537	Designed Fluorescent Probes Reveal Interactions between Amyloid-Î²(1â€“40) Peptides and GM1 Gangliosides in Micelles and Lipid Vesicles. Biophysical Journal, 2010, 99, 1510-1519.	0.2	20
538	Mapping Conformational Ensembles of AÎ² Oligomers in Molecular Dynamics Simulations. Biophysical Journal, 2010, 99, 1949-1958.	0.2	41
539	Measurement of the Attachment and Assembly of Small Amyloid-Î² Oligomers on Live Cell Membranes at Physiological Concentrations UsingÂSingle-Molecule Tools. Biophysical Journal, 2010, 99, 1969-1975.	0.2	62
540	Environmental Conditions Affect the Kinetics of Nucleation of Amyloid Fibrils and Determine Their Morphology. Biophysical Journal, 2010, 99, 3801-3810.	0.2	104
541	Protein Folding in the Cytoplasm and the Heat Shock Response. Cold Spring Harbor Perspectives in Biology, 2010, 2, a004390-a004390.	2.3	335

#	Article	IF	Citations
542	Sex- and brain region-specific acceleration of Î²-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease. Molecular Brain, 2010, 3, 34.	1.3	104
543	Amyloid-Î²1â€“40 Inhibits Amyloid-Î²1â€“42 Induced Activation of Cytoplasmic Phospholipase A2 and Synapse Degeneration. Journal of Alzheimer's Disease, 2010, 21, 985-993.	1.2	19
544	Monoclonal Antibody Against the Turn of the 42-Residue Amyloid Î²-Protein at Positions 22 and 23. ACS Chemical Neuroscience, 2010, 1, 747-756.	1.7	51
545	Development of a Proteolytically Stable Retro-Inverso Peptide Inhibitor of Î²-Amyloid Oligomerization as a Potential Novel Treatment for Alzheimerâ€™s Disease. Biochemistry, 2010, 49, 3261-3272.	1.2	139
546	EGCG remodels mature Î±-synuclein and amyloid-Î² fibrils and reduces cellular toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7710-7715.	3.3	888
547	Silymarin Attenuated the Amyloid Î² Plaque Burden and Improved Behavioral Abnormalities in an Alzheimerâ€™s Disease Mouse Model. Bioscience, Biotechnology and Biochemistry, 2010, 74, 2299-2306.	0.6	70
548	Characterization of the Interaction of Î²-Amyloid with Transthyretin Monomers and Tetramers. Biochemistry, 2010, 49, 8276-8289.	1.2	62
549	Oral Treatment with the <scp>d</scp>-Enantiomeric Peptide D3 Improves the Pathology and Behavior of Alzheimerâ€™s Disease Transgenic Mice. ACS Chemical Neuroscience, 2010, 1, 639-648.	1.7	107
550	The Cu(II)/AÎ²/Human Serum Albumin Model of Control Mechanism for Copper-Related Amyloid Neurotoxicity. Chemical Research in Toxicology, 2010, 23, 298-308.	1.7	49
551	Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase. Journal of Alzheimer's Disease, 2010, 20, S439-S452.	1.2	112
552	Nonsteroidal Anti-inflammatory Drug Naproxen Destabilizes AÎ² Amyloid Fibrils: A Molecular Dynamics Investigation. Journal of Physical Chemistry B, 2010, 114, 15394-15402.	1.2	24
553	Computational Backbone Mutagenesis of AÎ² Peptides: Probing the Role of Backbone Hydrogen Bonds in Aggregation. Journal of Physical Chemistry B, 2010, 114, 4755-4762.	1.2	12
554	fac-{Ru(CO)₃}²⁺ Selectively Targets the Histidine Residues of the Î²-Amyloid Peptide 1-28. Implications for New Alzheimer's Disease Treatments Based on Ruthenium Complexes. Inorganic Chemistry, 2010, 49, 4720-4722.	1.9	76
555	Structural Properties and Dynamic Behavior of Nonfibrillar Oligomers Formed by PrP(106â€“126). Journal of the American Chemical Society, 2010, 132, 7684-7695.	6.6	45
556	Amyloid-Î² Peptide Is a Substrate of the Human 20S Proteasome. ACS Chemical Neuroscience, 2010, 1, 655-660.	1.7	57
557	Amyloid-Î²42 Oligomer Structures from Fibrils: A Systematic Molecular Dynamics Study. Journal of Physical Chemistry B, 2010, 114, 2219-2226.	1.2	49
558	Proteomic analysis of mitochondrial dysfunction in neurodegenerative diseases. Expert Review of Proteomics, 2010, 7, 519-542.	1.3	23
559	AÎ² Oligomers Cause Localized Ca²⁺Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines. Journal of Neuroscience, 2010, 30, 11938-11950.	1.7	566

#	Article	IF	Citations
560	Tubal pregnancy may progress to term if it is converted to abdominal pregnancy by salpingostomy. Medical Hypotheses, 2010, 75, 137-138.	0.8	1
561	APP aggregation caused by abnormal neuronal activity?. Medical Hypotheses, 2010, 75, 138.	0.8	0
562	S-Nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration. Mitochondrion, 2010, 10, 573-578.	1.6	120
563	Neuroprotective effects of cyanidin 3-O-glucopyranoside on amyloid beta (25â€“35) oligomer-induced toxicity. Neuroscience Letters, 2010, 473, 72-76.	1.0	88
564	The Recombinant Amyloid-Î² Peptide AÎ²1â€“42 Aggregates Faster and Is More Neurotoxic than Synthetic AÎ²1â€“42. Journal of Molecular Biology, 2010, 396, 9-18.	2.0	145
565	Vesicle Permeabilization by Purified Soluble Oligomers of Prion Protein: A Comparative Study of the Interaction of Oligomers and Monomers with Lipid Membranes. Journal of Molecular Biology, 2010, 397, 1017-1030.	2.0	18
566	Physicochemical Determinants of Chaperone Requirements. Journal of Molecular Biology, 2010, 400, 579-588.	2.0	52
567	The Non-Core Regions of Human Lysozyme Amyloid Fibrils Influence Cytotoxicity. Journal of Molecular Biology, 2010, 402, 783-796.	2.0	95
568	Amyloid fibrillation and cytotoxicity of insulin are inhibited by the amphiphilic surfactants. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 519-530.	1.8	77
569	ACAT inhibition and amyloid beta reduction. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 960-965.	1.2	56
570	Phospholipase D in brain function and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 799-805.	1.2	77
571	Membrane charge dependent states of the Î²-amyloid fragment AÎ² (16â€“35) with differently charged micelle aggregates. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 660-671.	1.4	24
572	RS-0406 Arrests Amyloid-Î² Oligomer-Induced Behavioural Deterioration In Vivo. Behavioural Brain Research, 2010, 210, 32-37.	1.2	17
573	Triazole-containing BODIPY dyes as novel fluorescent probes for soluble oligomers of amyloid AÎ²1â€“42 peptide. Biochemical and Biophysical Research Communications, 2010, 391, 1455-1458.	1.0	51
574	TAG-1 is an inhibitor of TGFÎ²2-induced neuronal death via amyloid Î² precursor protein. Biochemical and Biophysical Research Communications, 2010, 394, 119-125.	1.0	13
575	Mechanisms Underlying Inflammation in Neurodegeneration. Cell, 2010, 140, 918-934.	13.5	2,860
576	Identification of MOAG-4/SERF as a Regulator of Age-Related Proteotoxicity. Cell, 2010, 142, 601-612.	13.5	120
577	Fyn-Tau-Amyloid: A Toxic Triad. Cell, 2010, 142, 356-358.	13.5	92

#	Article	IF	Citations
578	The putative neurodegenerative links between depression and Alzheimer's disease. Progress in Neurobiology, 2010, 91, 362-375.	2.8	105
579	Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1Î”E9-deleted transgenic mice model of Î²-amyloidosis. Neurobiology of Aging, 2010, 31, 1173-1187.	1.5	144
580	Increased Expression of Î±-Synuclein Reduces Neurotransmitter Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis. Neuron, 2010, 65, 66-79.	3.8	885
581	Emerging roles of nitric oxide in neurodegeneration. Nitric Oxide - Biology and Chemistry, 2010, 22, 290-295.	1.2	52
582	Dysregulated microRNAs in neurodegenerative disorders. Seminars in Cell and Developmental Biology, 2010, 21, 768-773.	2.3	91
583	Mechanism of amyloid plaque formation suggests an intracellular basis of AÎ² pathogenicity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1942-1947.	3.3	262
584	REVIEW: Curcumin and Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2010, 16, 285-297.	1.9	367
585	Molecular recognition of N-protected dipeptides by pseudopeptidic macrocycles: a comparative study of the supramolecular complexes by ESI-MS and NMR. Organic and Biomolecular Chemistry, 2010, 8, 1329.	1.5	28
586	Nuclear Receptors, Inflammation, and Neurodegenerative Diseases. Advances in Immunology, 2010, 106, 21-59.	1.1	32
587	Assessing the Stability of Alzheimerâ€™s Amyloid Protofibrils Using Molecular Dynamics. Journal of Physical Chemistry B, 2010, 114, 1652-1660.	1.2	398
588	Does the term â€˜trophicâ€™ actually mean anti-amyloidogenic? The case of NGF. Cell Death and Differentiation, 2010, 17, 1126-1133.	5.0	33
589	Soluble oligomeric forms of beta-amyloid (AÎ²) peptide stimulate AÎ² production via astrogliosis in the rat brain. Experimental Neurology, 2010, 223, 410-421.	2.0	32
590	Braak Staging in Mouse Models of Alzheimer's Disease. American Journal of Pathology, 2010, 177, 1603-1605.	1.9	7
591	Transgenic Zebrafish as a Novel Animal Model to Study Tauopathies and Other Neurodegenerative Disorders in vivo. Neurodegenerative Diseases, 2010, 7, 99-102.	0.8	29
592	Expression of the Anti-amyloidogenic Secretase ADAM10 Is Suppressed by Its 5â€²-Untranslated Region. Journal of Biological Chemistry, 2010, 285, 15753-15760.	1.6	38
593	NOX Activity Is Increased in Mild Cognitive Impairment. Antioxidants and Redox Signaling, 2010, 12, 1371-1382.	2.5	89
594	Mechanisms of Synapse and Dendrite Maintenance and Their Disruption in Psychiatric and Neurodegenerative Disorders. Annual Review of Neuroscience, 2010, 33, 349-378.	5.0	217
595	A Fluorescent Pentameric Thiophene Derivative Detects in Vitro-Formed Prefibrillar Protein Aggregates. Biochemistry, 2010, 49, 6838-6845.	1.2	88

#	Article	IF	Citations
596	Calcium and Mitochondrial Reactive Oxygen Species Generation: How to Read the Facts. Journal of Alzheimer's Disease, 2010, 20, S413-S426.	1.2	209
597	Discovery of Cyclic Acylguanidines as Highly Potent and Selective Î²-Site Amyloid Cleaving Enzyme (BACE) Inhibitors: Part Iâ€"Inhibitor Design and Validation. Journal of Medicinal Chemistry, 2010, 53, 951-965.	2.9	120
598	LPYFDa Neutralizes Amyloid-Î²-Induced Memory Impairment and Toxicity. Journal of Alzheimer's Disease, 2010, 19, 991-1005.	1.2	29
599	Differently Selected <scp>d</scp>-Enantiomeric Peptides Act on Different AÎ² Species. Rejuvenation Research, 2010, 13, 202-205.	0.9	22
600	Detecting AÎ²*56 Oligomers in Brain Tissues. Methods in Molecular Biology, 2010, 670, 45-56.	0.4	35
602	Structure and Intermolecular Dynamics of Aggregates Populated during Amyloid Fibril Formation Studied by Hydrogen/Deuterium Exchange. Accounts of Chemical Research, 2010, 43, 1072-1079.	7.6	66
603	Novel Research Horizons for Presenilins and Î³-Secretases in Cell Biology and Disease. Annual Review of Cell and Developmental Biology, 2010, 26, 235-260.	4.0	224
604	Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. , 2010, , .		87
605	Design of small molecules that target metal-AÎ² species and regulate metal-induced AÎ² aggregation and neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21990-21995.	3.3	253
606	Applying Hsp104 to protein-misfolding disordersThis paper is one of a selection of papers published in this special issue entitled 8th International Conference on AAA Proteins and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology, 2010, 88, 1-13.	0.9	73
607	Structural factors underlying the species barrier and susceptibility to infection in prion diseaseThis paper is one of a selection of papers published in this special issue entitled â€œCanadian Society of Biochemistry, Molecular & Cellular Biology 52nd Annual Meeting â€" Protein Folding: Principles and Diseasesâ€•and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology, 2010, 88, 195-202.	0.9	23
608	Low Concentrations of Anti-AÎ² Antibodies Generated in Tg2576 Mice by DNA Epitope Vaccine Fused with 3C3d Molecular Adjuvant Do Not Affect AD Pathology. Human Gene Therapy, 2010, 21, 1569-1576.	1.4	8
609	Interactions in the native state of monellin, which play a protective role against aggregation. Molecular BioSystems, 2011, 7, 521-532.	2.9	12
610	Soluble amyloid Î²-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5819-5824.	3.3	770
611	Designed Hairpin Peptides Interfere with Amyloidogenesis Pathways: Fibril Formation and Cytotoxicity Inhibition, Interception of the Preamyloid State. Biochemistry, 2011, 50, 8202-8212.	1.2	50
612	Exploring the Reactions of Î²-Amyloid (AÎ²) Peptide 1â€"28 with AlIIIand FeIIIIons. Inorganic Chemistry, 2011, 50, 6865-6867.	1.9	42
613	The impact of ionic liquids on amyloid fibrilization of AÎ²16-22: tuning the rate of fibrilization using a reverse Hofmeister strategy. Physical Chemistry Chemical Physics, 2011, 13, 16534.	1.3	56
614	Point Mutations in AÎ² Induce Polymorphic Aggregates at Liquid/Solid Interfaces. ACS Chemical Neuroscience, 2011, 2, 294-307.	1.7	20

#	Article	IF	Citations
615	Macrocyclic Î²-Sheet Peptides That Inhibit the Aggregation of a Tau-Protein-Derived Hexapeptide. Journal of the American Chemical Society, 2011, 133, 3144-3157.	6.6	114
616	Curcuminoid Binds to Amyloid-Î²1-42 Oligomer and Fibril. Journal of Alzheimer's Disease, 2011, 24, 33-42.	1.2	80
617	Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006189-a006189.	2.9	2,365
618	Characterizing the Structural Behavior of Selected AÎ²-42 Monomers with Different Solubilities. Journal of Physical Chemistry B, 2011, 115, 4900-4910.	1.2	45
619	AÎ²40 and AÎ²42 Amyloid Fibrils Exhibit Distinct Molecular Recycling Properties. Journal of the American Chemical Society, 2011, 133, 6505-6508.	6.6	93
620	Protein Solubility and Protein Homeostasis: A Generic View of Protein Misfolding Disorders. Cold Spring Harbor Perspectives in Biology, 2011, 3, a010454-a010454.	2.3	83
621	Amyloid Î² Peptides Aggregation in a Mixed Membrane Bilayer: A Molecular Dynamics Study. Journal of Physical Chemistry B, 2011, 115, 12247-12256.	1.2	66
622	Simulation of the Amide I Absorption of Stacked Î²-Sheets. Journal of Physical Chemistry B, 2011, 115, 749-757.	1.2	44
623	Conformer-Specific Hydrogen Exchange Analysis of AÎ²(1â€“42) Oligomers by Top-Down Electron Capture Dissociation Mass Spectrometry. Analytical Chemistry, 2011, 83, 5386-5393.	3.2	62
624	Dense Shell Glycodendrimers as Potential Nontoxic Anti-amyloidogenic Agents in Alzheimerâ€™s Disease. Amyloidâ€“Dendrimer Aggregates Morphology and Cell Toxicity. Biomacromolecules, 2011, 12, 3903-3909.	2.6	99
625	Molecular Engineering of a Secreted, Highly Homogeneous, and Neurotoxic AÎ² Dimer. ACS Chemical Neuroscience, 2011, 2, 242-248.	1.7	27
626	Substantial Contribution of the Two Imidazole Rings of the His13â^'His14 Dyad to Cu(II) Binding in Amyloid-Î²(1â^'16) at Physiological pH and Its Significance. Journal of Physical Chemistry A, 2011, 115, 9590-9602.	1.1	66
627	Hemeâ€“Cu Bound AÎ² Peptides: Spectroscopic Characterization, Reactivity, and Relevance to Alzheimerâ€™s Disease. Journal of the American Chemical Society, 2011, 133, 15545-15552.	6.6	118
628	Distinct Morphologies for Amyloid Beta Protein Monomer: AÎ²_{1â€“40}, AÎ²_{1â€“42}, and AÎ²_{1â€“40}(D23N). Journal of Chemical Theory and Computation, 2011, 7, 2584-2592.	2.3	77
629	Distinct Effects of Zn2+, Cu2+, Fe3+, and Al3+ on Amyloid-Î² Stability, Oligomerization, and Aggregation. Journal of Biological Chemistry, 2011, 286, 9646-9656.	1.6	176
630	In Situ Measurements of the Formation and Morphology of Intracellular Î²-Amyloid Fibrils by Super-Resolution Fluorescence Imaging. Journal of the American Chemical Society, 2011, 133, 12902-12905.	6.6	151
632	Resveratrol Inhibits the Formation of Multiple-Layered Î²-Sheet Oligomers of the Human Islet Amyloid Polypeptide Segment 22â€“27. Biophysical Journal, 2011, 100, 1550-1558.	0.2	76
633	Naproxen Interferes with the Assembly of AÎ² Oligomers Implicated in Alzheimer's Disease. Biophysical Journal, 2011, 100, 2024-2032.	0.2	23

#	Article	IF	Citations
634	Amyloid Oligomer Formation Probed by Water Proton Magnetic ResonanceÂSpectroscopy. Biophysical Journal, 2011, 100, 2302-2308.	0.2	5
635	Phase diagram of polypeptide chains. Journal of Chemical Physics, 2011, 135, 175103.	1.2	16
636	Molecular Insight into Conformational Transition of Amyloid Î²-Peptide 42 Inhibited by (â^')-Epigallocatechin-3-gallate Probed by Molecular Simulations. Journal of Physical Chemistry B, 2011, 115, 11879-11887.	1.2	122
637	Soluble AÎ² Seeds Are Potent Inducers of Cerebral Î²-Amyloid Deposition. Journal of Neuroscience, 2011, 31, 14488-14495.	1.7	203
641	The Nicastrin ectodomain adopts a highly thermostable structure. Biological Chemistry, 2011, 392, 995-1001.	1.2	4
642	Generalization of the Prion Hypothesis to Other Neurodegenerative Diseases: An Imperfect Fit. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2011, 74, 1433-1459.	1.1	63
643	Metal attenuating therapies in neurodegenerative disease. Expert Review of Neurotherapeutics, 2011, 11, 1717-1745.	1.4	22
644	Nucleic acid-mediated protein aggregation and assembly. Advances in Protein Chemistry and Structural Biology, 2011, 84, 1-40.	1.0	33
645	Linking amyloid protein aggregation and yeast survival. Molecular BioSystems, 2011, 7, 1121.	2.9	26
646	Current and Emerging Drug Treatment Options for AlzheimerÊ¼s Disease. Drugs, 2011, 71, 2031-2065.	4.9	196
647	Proteomic research in psychiatry. Journal of Psychopharmacology, 2011, 25, 151-196.	2.0	85
648	Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer's disease model mouse. Molecular Neurodegeneration, 2011, 6, 20.	4.4	32
649	Histone Deacetylases: the Biology and Clinical Implication. Handbook of Experimental Pharmacology, 2011, , .	0.9	7
651	Reduced Mitochondria Cytochrome Oxidase Activity in Adult Children of Mothers with Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 483-490.	1.2	85
652	Role of the Mitochondrial Fission Protein Drp1 in Synaptic Damage and Neurodegeneration. , 2011, , 215-234.		1
653	Resolving controversies on the path to Alzheimer's therapeutics. Nature Medicine, 2011, 17, 1060-1065.	15.2	434
654	Ras and Rap Signaling in Synaptic Plasticity and Mental Disorders. Neuroscientist, 2011, 17, 54-78.	2.6	131
655	A Universal Method for Detection of Amyloidogenic Misfolded Proteins. Biochemistry, 2011, 50, 4322-4329.	1.2	34

#	Article	IF	Citations
656	Alzheimer's Disease and Frontotemporal Dementia. Methods in Molecular Biology, 2011, , .	0.4	5
657	Sirtuins, Aging, and Medicine. New England Journal of Medicine, 2011, 364, 2235-2244.	13.9	490
658	Metastability of Native Proteins and the Phenomenon of Amyloid Formation. Journal of the American Chemical Society, 2011, 133, 14160-14163.	6.6	369
659	Development of Bifunctional Stilbene Derivatives for Targeting and Modulating Metal-Amyloid-Î² Species. Inorganic Chemistry, 2011, 50, 10724-10734.	1.9	75
660	Amyloid-Î²: The seeds of darkness. International Journal of Biochemistry and Cell Biology, 2011, 43, 1247-1251.	1.2	26
661	Neuroprotective action of proline-rich polypeptide-1 in Î²-amyloid induced neurodegeneration in rats. Brain Research Bulletin, 2011, 86, 262-271.	1.4	24
662	Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1584-1590.	1.8	114
663	Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 236-243.	1.4	75
664	Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1380-1399.	1.4	361
665	Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 1703-1712.	1.1	24
666	Î³-Secretase-mediated growth hormone receptor proteolysis: Mapping of the intramembranous cleavage site. Biochemical and Biophysical Research Communications, 2011, 408, 432-436.	1.0	4
667	Insulin receptor mutation results in insulin resistance and hyperinsulinemia but does not exacerbate Alzheimerâ€™s-like phenotypes in mice. Biochemical and Biophysical Research Communications, 2011, 409, 34-39.	1.0	21
668	Endoplasmic reticulum stress enhances Î³-secretase activity. Biochemical and Biophysical Research Communications, 2011, 416, 362-366.	1.0	45
669	Combining NMR and X-ray Crystallography in Fragment-Based Drug Discovery: Discovery of Highly Potent and Selective BACE-1 Inhibitors. Topics in Current Chemistry, 2011, 317, 83-114.	4.0	49
670	Nanomechanics of functional and pathological amyloid materials. Nature Nanotechnology, 2011, 6, 469-479.	15.6	703
671	Suppression of Amyloid Î² A11 Antibody Immunoreactivity by Vitamin C. Journal of Biological Chemistry, 2011, 286, 27559-27572.	1.6	34
672	The Postsynaptic Organization of Synapses. Cold Spring Harbor Perspectives in Biology, 2011, 3, a005678-a005678.	2.3	455
673	Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. Vaccine, 2011, 29, 4043-4050.	1.7	14

#	Article	IF	Citations
674	Use of yeast as a system to study amyloid toxicity. Methods, 2011, 53, 226-231.	1.9	12
675	Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones. Methods, 2011, 53, 267-274.	1.9	13
676	Presenilin mouse and zebrafish models for dementia: Focus on neurogenesis. Progress in Neurobiology, 2011, 93, 149-164.	2.8	34
677	The future of Alzheimer's disease: The next 10 years. Progress in Neurobiology, 2011, 95, 718-728.	2.8	190
678	Protection against AÎ²-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiology of Aging, 2011, 32, 614-623.	1.5	65
679	Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. Neurobiology of Aging, 2011, 32, 1400-1408.	1.5	79
680	Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiology of Aging, 2011, 32, 1-14.	1.5	211
681	Mechanisms and Function of Dendritic Exocytosis. Neuron, 2011, 69, 856-875.	3.8	111
682	Timing-Dependent Septal Cholinergic Induction of Dynamic Hippocampal Synaptic Plasticity. Neuron, 2011, 71, 155-165.	3.8	251
683	Selective Neuronal Vulnerability in Neurodegenerative Diseases: from Stressor Thresholds to Degeneration. Neuron, 2011, 71, 35-48.	3.8	465
684	Rich Regulates Target Specificity of Photoreceptor Cells and N-Cadherin Trafficking in the Drosophila Visual System via Rab6. Neuron, 2011, 71, 447-459.	3.8	29
685	Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimerâ€™s-like changes. Neuropharmacology, 2011, 60, 910-920.	2.0	241
686	The role of histone acetylation in age-associated memory impairment and Alzheimerâ€™s disease. Neurobiology of Learning and Memory, 2011, 96, 19-26.	1.0	122
687	Amyloid in neurodegenerative diseases: Friend or foe?. Seminars in Cell and Developmental Biology, 2011, 22, 476-481.	2.3	73
688	The synapse and brain function. Seminars in Cell and Developmental Biology, 2011, 22, 488-491.	2.3	1
689	Prions and manganese: A maddening beast. Metallomics, 2011, 3, 229-238.	1.0	40
690	Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-Î² aggregation. Metallomics, 2011, 3, 284.	1.0	36
691	Î³-Secretase Modulators as Potential Disease Modifying Anti-Alzheimerâ€™s Drugs. Journal of Medicinal Chemistry, 2011, 54, 669-698.	2.9	149

#	Article	IF	Citations
692	Insight into Amyloid Structure Using Chemical Probes. Chemical Biology and Drug Design, 2011, 77, 399-411.	1.5	139
693	Lysozyme. Advances in Protein Chemistry and Structural Biology, 2011, 84, 63-111.	1.0	205
694	Amyloid Î²-Peptide Oligomers Stimulate RyR-Mediated Ca²⁺ Release Inducing Mitochondrial Fragmentation in Hippocampal Neurons and Prevent RyR-Mediated Dendritic Spine Remodeling Produced by BDNF. Antioxidants and Redox Signaling, 2011, 14, 1209-1223.	2.5	118
695	Enhanced ROS Generation Mediated by Alzheimer's Disease Presenilin Regulation of InsP₃R Ca²⁺ Signaling. Antioxidants and Redox Signaling, 2011, 14, 1225-1235.	2.5	50
696	Amyloid-Î² Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain. Journal of Biological Chemistry, 2011, 286, 22122-22130.	1.6	127
697	The Role of Mammalian Sirtuins in the Regulation of Metabolism, Aging, and Longevity. Handbook of Experimental Pharmacology, 2011, 206, 125-162.	0.9	140
698	Folding stability of amyloidâ€Î² 40 monomer is an important determinant of the nucleation kinetics in fibrillization. FASEB Journal, 2011, 25, 1390-1401.	0.2	41
699	Effects of sex hormones on Alzheimer's disease-associated Î²-amyloid oligomer formation in vitro. Experimental Neurology, 2011, 228, 298-302.	2.0	29
701	The Role of Glycogen Synthase Kinase-3 (GSK-3) in Alzheimerâ€™s Disease. , 0, , .		4
702	A multi nutrient concept to enhance synapse formation and function: science behind a medical food for Alzheimerâ€™s disease. Oleagineux Corps Gras Lipides, 2011, 18, 267-270.	0.2	4
706	Formation of the 42-mer Amyloid Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease. Journal of Amino Acids, 2011, 2011, 1-10.	5.8	13
707	Docosahexaenoic acid (DHA) in stroke, Alzheimerâ€™s disease, and blinding retinal degenerations: coping with neuroinflammation and sustaining cell survival. Oleagineux Corps Gras Lipides, 2011, 18, 208-213.	0.2	0
708	Tau Oligomers as Potential Drug Target for Alzheimer Disease (AD) Treatment. , 2011, , .		0
709	Modeling Amyloid Diseases in Fruit Fly Drosophila Melanogaster. , 0, , .		0
710	Glucose Metabolism and Insulin Action in Alzheimerâ€™s Disease Pathogenesis. , 0, , .		0
711	Amyloid Hypothesis and Alzheimer's Disease. , 2011, , .		3
712	Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders. International Journal of Alzheimer's Disease, 2011, 2011, 1-18.	1.1	7
713	E22Î" Mutation in AmyloidÎ²-Protein PromotesÎ²-Sheet Transformation, Radical Production, and Synaptotoxicity, But Not Neurotoxicity. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	1.1	15

#	Article	IF	Citations
714	Soluble AÎ²1-40 Peptide Increases Excitatory Neurotransmission and Induces Epileptiform Activity in Hippocampal Neurons. Journal of Alzheimer's Disease, 2011, 23, 673-687.	1.2	30
715	Detection of Soluble Amyloid-Î²Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-8.	1.1	17
716	Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-Î² Species in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	1.1	35
717	Angiotensin II, a neuropeptide at the frontier between endocrinology and neuroscience: is there a link between the angiotensin II type 2 receptor and Alzheimerâ€™s disease?. Frontiers in Endocrinology, 2011, 2, 17.	1.5	31
718	Crowding Alone Cannot Account for Cosolute Effect on Amyloid Aggregation. PLoS ONE, 2011, 6, e15608.	1.1	62
719	Docosahexaenoic Acid-Derived Neuroprotectin D1 Induces Neuronal Survival via Secretase- and PPARÎ³-Mediated Mechanisms in Alzheimer's Disease Models. PLoS ONE, 2011, 6, e15816.	1.1	203
720	Point Mutations in AÎ² Result in the Formation of Distinct Polymorphic Aggregates in the Presence of Lipid Bilayers. PLoS ONE, 2011, 6, e16248.	1.1	36
721	The Intracellular Threonine of Amyloid Precursor Protein That Is Essential for Docking of Pin1 Is Dispensable for Developmental Function. PLoS ONE, 2011, 6, e18006.	1.1	22
722	Polymorphic Structures of Alzheimer's Î²-Amyloid Globulomers. PLoS ONE, 2011, 6, e20575.	1.1	47
723	Rationally Designed Turn Promoting Mutation in the Amyloid-Î² Peptide Sequence Stabilizes Oligomers in Solution. PLoS ONE, 2011, 6, e21776.	1.1	19
724	Intracellular Trafficking of the Amyloid Î²-Protein Precursor (APP) Regulated by Novel Function of X11-Like. PLoS ONE, 2011, 6, e22108.	1.1	29
725	Secreted Human Amyloid Precursor Protein Binds Semaphorin 3a and Prevents Semaphorin-Induced Growth Cone Collapse. PLoS ONE, 2011, 6, e22857.	1.1	14
726	WNT5A Signaling Contributes to AÎ²-Induced Neuroinflammation and Neurotoxicity. PLoS ONE, 2011, 6, e22920.	1.1	64
727	Effects of Heparin and Enoxaparin on APP Processing and AÎ² Production in Primary Cortical Neurons from Tg2576 Mice. PLoS ONE, 2011, 6, e23007.	1.1	23
728	A Peptide That Binds Specifically to the Î²-Amyloid of Alzheimer's Disease: Selection and Assessment of Anti-Î²-Amyloid Neurotoxic Effects. PLoS ONE, 2011, 6, e27649.	1.1	24
729	Grape Seed Polyphenolic Extract Specifically Decreases AÎ²*56 in the Brains of Tg2576 Mice. Journal of Alzheimer's Disease, 2011, 26, 657-666.	1.2	49
730	Cotinine Reduces Amyloid-Î² Aggregation and Improves Memory in Alzheimer's Disease Mice. Journal of Alzheimer's Disease, 2011, 24, 817-835.	1.2	77
731	Alzheimers Disease: Review of Emerging Treatment Role for Intravenous Immunoglobulins. Journal of Central Nervous System Disease, 2011, 3, JCNSD.S5018.	0.7	9

#	Article	IF	Citations
732	ADAM10: potential â€˜molecular scissorsâ€™ for the treatment of Alzheimerâ€™s disease. Future Neurology, 2011, 6, 1-4.	0.9	0
733	Recent Developments in Tau-Based Therapeutics for Neurodegenerative Diseases. Recent Patents on CNS Drug Discovery, 2011, 6, 20-30.	0.9	25
734	Pharmacological Treatment of Alzheimer Disease. Canadian Journal of Psychiatry, 2011, 56, 579-588.	0.9	96
735	Tyrosol and Hydroxytyrosol Two Main Components of Olive Oil, Protect N2a Cells Against Amyloid-β-Induced Toxicity. Involvement of the NF-κB Signaling. Current Alzheimer Research, 2011, 8, 543-551.	0.7	121
736	Solution NMR Studies of Aβ Monomer Dynamics. Protein and Peptide Letters, 2011, 18, 354-361.	0.4	8
737	Modulators of Nucleoside Metabolism in the Therapy of Brain Diseases. Current Topics in Medicinal Chemistry, 2011, 11, 1068-1086.	1.0	47
738	Structures Behind the Amyloid Aggregation of α-Synuclein: An NMR based Approach. Current Protein and Peptide Science, 2011, 12, 188-205.	0.7	12
739	Mitophagy in Neurodegeneration: An Opportunity for Therapy?. Current Drug Targets, 2011, 12, 790-799.	1.0	26
740	â€¦ ALZHEIMER DISEASE. JAAPA: Official Journal of the American Academy of Physician Assistants, 2011, 24, 56-57.	0.1	6
741	GULP1 is a novel APP-interacting protein that alters APP processing. Biochemical Journal, 2011, 436, 631-639.	1.7	17
742	Hippocampal synaptic activity, pattern separation and episodic-like memory: implications for mouse models of Alzheimer's disease pathology. Biochemical Society Transactions, 2011, 39, 902-909.	1.6	23
744	Targeting the Kynurenine Pathway-Related Alterations in Alzheimer's Disease: A Future Therapeutic Strategy. Journal of Alzheimer's Disease, 2011, 24, 199-209.	1.2	26
745	Humanin Signal for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 27-32.	1.2	13
746	Statins: The Role in the Treatment and Prevention of Alzheimer's Neurodegeneration. Journal of Alzheimer's Disease, 2011, 27, 1-10.	1.2	41
747	Dendritic Cells Regulate Amyloid-Î²-Specific T-Cell Entry into the Brain: The Role of Perivascular Amyloid-Î². Journal of Alzheimer's Disease, 2011, 27, 99-111.	1.2	25
748	Î²-Secretase activity in rat astrocytes: translational block of BACE1 and modulation of BACE2 expression. European Journal of Neuroscience, 2011, 33, 236-243.	1.2	30
749	Aging causes distinct characteristics of polyglutamine amyloids in vivo. Genes To Cells, 2011, 16, 557-564.	0.5	11
750	Alpha-secretase in Alzheimerâ€™s disease: molecular identity, regulation and therapeutic potential. Journal of Neurochemistry, 2011, 116, 10-21.	2.1	169

#	Article	IF	Citations
751	Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid Î²-peptide. Journal of Neurochemistry, 2011, 116, 522-529.	2.1	41
752	Lowâ€n oligomers as therapeutic targets of Alzheimerâ€™s disease. Journal of Neurochemistry, 2011, 117, 19-28.	2.1	80
753	The memory enhancing effect of the APPâ€derived tripeptide Acâ€rER is mediated through CRMP2. Journal of Neurochemistry, 2011, 118, 616-625.	2.1	10
754	Amyloid-beta oligomers increase the localization of prion protein at the cell surface. Journal of Neurochemistry, 2011, 117, 538-553.	2.1	60
755	Proteomic study of the toxic effect of oligomeric AÎ²1-42 in situ prepared from â€˜iso-AÎ²1-42â€™. Journal of Neurochemistry, 2011, 117, no-no.	2.1	18
756	Regulated intramembrane proteolysis - lessons from amyloid precursor protein processing. Journal of Neurochemistry, 2011, 117, 779-796.	2.1	213
757	Effects of rapamycin and TOR on aging and memory: implications for Alzheimerâ€™s disease. Journal of Neurochemistry, 2011, 117, 927-936.	2.1	38
758	Chronic psychosocial stress enhances longâ€term depression in a subthreshold amyloidâ€beta rat model of Alzheimerâ€™s disease. Journal of Neurochemistry, 2011, 119, 408-416.	2.1	21
759	Dysregulated phosphorylation of Ca²⁺/calmodulinâ€dependent protein kinase IIâ€Î± in the hippocampus of subjects with mild cognitive impairment and Alzheimerâ€™s disease. Journal of Neurochemistry, 2011, 119, 791-804.	2.1	91
760	Membrane cholesterol content plays a key role in the neurotoxicity of Î²â€amyloid: implications for Alzheimerâ€™s disease. Aging Cell, 2011, 10, 595-603.	3.0	81
761	GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. British Journal of Pharmacology, 2011, 164, 2054-2063.	2.7	128
762	Ion mobilityâ€“mass spectrometry reveals a conformational conversion from random assembly to Î²-sheet in amyloid fibril formation. Nature Chemistry, 2011, 3, 172-177.	6.6	315
763	Amyloid-Î² and tau â€” a toxic pas de deux in Alzheimer's disease. Nature Reviews Neuroscience, 2011, 12, 67-72.	4.9	1,147
764	Linking lipids to Alzheimer's disease: cholesterol and beyond. Nature Reviews Neuroscience, 2011, 12, 284-296.	4.9	751
765	Extracellular phosphorylation of the amyloid Î²-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO Journal, 2011, 30, 2255-2265.	3.5	160
766	The cellular prion protein mediates neurotoxic signalling of Î²-sheet-rich conformers independent of prion replication. EMBO Journal, 2011, 30, 2057-2070.	3.5	209
767	Correlation of Polydispersed Prion Protein and Characteristic Pathology in the Thalamus in Variant Creutzfeldtâ€Jakob Disease: Implication of Small Oligomeric Species. Brain Pathology, 2011, 21, 298-307.	2.1	10
768	Possible implications of insulin resistance and glucose metabolism in Alzheimerâ€™s disease pathogenesis. Journal of Cellular and Molecular Medicine, 2011, 15, 1807-1821.	1.6	223

#	Article	IF	Citations
769	Recent progress in understanding Alzheimer's Î²-amyloid structures. Trends in Biochemical Sciences, 2011, 36, 338-345.	3.7	146
770	Liposomes functionalized with acidic lipids rescue AÎ²-induced toxicity in murine neuroblastoma cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 560-571.	1.7	27
771	Mechanism mediating oligomeric AÎ² clearance by naÃ¯ve primary microglia. Neurobiology of Disease, 2011, 42, 221-230.	2.1	110
772	Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms. Neurobiology of Disease, 2011, 42, 530-538.	2.1	50
773	Inflammation in the early stages of neurodegenerative pathology. Journal of Neuroimmunology, 2011, 238, 1-11.	1.1	181
774	Coarse-grained models for protein aggregation. Current Opinion in Structural Biology, 2011, 21, 209-220.	2.6	170
775	Parallel findings in age-related macular degeneration and Alzheimerâ€™s disease. Progress in Retinal and Eye Research, 2011, 30, 217-238.	7.3	236
776	Cerebral amyloid-Î² PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurology, The, 2011, 10, 424-435.	4.9	491
777	CSF Î±-synuclein, tau, and amyloid Î² in Parkinson's disease. Lancet Neurology, The, 2011, 10, 681.	4.9	15
778	Utility of imaging for nutritional intervention studies in Alzheimer's disease. European Journal of Pharmacology, 2011, 668, S59-S69.	1.7	16
779	Countering neurodegeneration by reducing the activity of the insulin/IGF signaling pathway: Current knowledge and future prospects. Experimental Gerontology, 2011, 46, 124-128.	1.2	11
780	Astrocytes contain amyloid-Î² annular protofibrils in Alzheimer's disease brains. FEBS Letters, 2011, 585, 3052-3057.	1.3	32
781	Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 965-973.	1.9	105
782	Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid Î²-protein fibrils. Bioorganic and Medicinal Chemistry, 2011, 19, 5967-5974.	1.4	83
783	Regulation of matrix metalloproteinase 2 by oligomeric amyloid Î² protein. Brain Research, 2011, 1387, 141-148.	1.1	51
784	Protein folding stress in neurodegenerative diseases: a glimpse into the ER. Current Opinion in Cell Biology, 2011, 23, 239-252.	2.6	200
785	Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis. Cell Calcium, 2011, 50, 222-233.	1.1	455
786	Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases. Metallomics, 2011, 3, 1163.	1.0	108

#	Article	IF	Citations
787	Does amino acid sequence determine the properties of AÎ² dimer?. Journal of Chemical Physics, 2011, 135, 035103.	1.2	3
788	Docosahexaenoic Acid Signalolipidomics in Nutrition: Significance in Aging, Neuroinflammation, Macular Degeneration, Alzheimer's, and Other Neurodegenerative Diseases. Annual Review of Nutrition, 2011, 31, 321-351.	4.3	358
789	Testing the Therapeutic Potential of Doxycycline in a Drosophila melanogaster Model of Alzheimer Disease. Journal of Biological Chemistry, 2011, 286, 41647-41655.	1.6	63
790	The Synaptic Protein Neuroligin-1 Interacts with the Amyloid Î²-Peptide. Is There a Role in Alzheimerâ€™s Disease?. Biochemistry, 2011, 50, 8127-8137.	1.2	49
791	Ca2+ dysfunction in neurodegenerative disorders: Alzheimer's disease. BioFactors, 2011, 37, 189-196.	2.6	37
792	Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nature Reviews Drug Discovery, 2011, 10, 930-944.	21.5	249
793	Vitamin C Restores Behavioral Deficits and Amyloid-Î² Oligomerization without Affecting Plaque Formation in a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 7-18.	1.2	85
794	In vivo injected mitochondria-targeted plastoquinone antioxidant SkQR1 prevents Î²-amyloid-induced decay of long-term potentiation in rat hippocampal slices. Biochemistry (Moscow), 2011, 76, 1367-1370.	0.7	34
795	Functional Interactions of Fibrillar and Oligomeric Amyloid-Î² with Alpha7 Nicotinic Receptors in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 23, 335-347.	1.2	51
796	Cerebrovascular disorders: molecular insights and therapeutic opportunities. Nature Neuroscience, 2011, 14, 1390-1397.	7.1	82
797	Detoxified Extract of Rhus verniciflua Stokes Inhibits Rotenone-Induced Apoptosis in Human Dopaminergic Cells, SH-SY5Y. Cellular and Molecular Neurobiology, 2011, 31, 213-223.	1.7	46
798	AÎ² Oligomer-Induced Synapse Degeneration in Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2011, 31, 939-948.	1.7	144
799	Amyloid-Î² Decreases Nitric Oxide Production in Cultured Retinal Neurons: A Possible Mechanism for Synaptic Dysfunction in Alzheimerâ€™s Disease?. Neurochemical Research, 2011, 36, 163-169.	1.6	23
800	Tau, prions and AÎ²: the triad of neurodegeneration. Acta Neuropathologica, 2011, 121, 5-20.	3.9	84
801	Alzheimerâ€™s disease: ageing-related or age-related? New hypotheses from an old debate. Neurological Sciences, 2011, 32, 1241-1247.	0.9	7
802	Curcumin-decorated nanoliposomes with very high affinity for amyloid-Î²1-42 peptide. Biomaterials, 2011, 32, 1635-1645.	5.7	198
803	APP Transgenic Mice: Their Use and Limitations. NeuroMolecular Medicine, 2011, 13, 117-137.	1.8	69
804	Occlusal Disharmony Increases Amyloid-Î² in the Rat Hippocampus. NeuroMolecular Medicine, 2011, 13, 197-203.	1.8	27

#	Article	IF	Citations
805	Comparison of Pharmacological Modulation of APP Metabolism in Primary Chicken Telencephalic Neurons and in a Human Neuroglioma Cell Line. Journal of Molecular Neuroscience, 2011, 43, 257-267.	1.1	14
806	Neuroprotectin D1 Induces Neuronal Survival and Downregulation of Amyloidogenic Processing in Alzheimerâ€™s Disease Cellular Models. Molecular Neurobiology, 2011, 43, 131-138.	1.9	40
807	Expression of human amyloid precursor protein in the skeletal muscles of Drosophila results in age- and activity-dependent muscle weakness. BMC Physiology, 2011, 11, 7.	3.6	7
808	The CCAAT/enhancer binding protein (C/EBP) Î´ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-Î² peptide. Journal of Neuroinflammation, 2011, 8, 34.	3.1	28
809	IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. Journal of Neuroinflammation, 2011, 8, 52.	3.1	263
810	Anchored FRET sensors detect local caspase activation prior to neuronal degeneration. Molecular Neurodegeneration, 2011, 6, 35.	4.4	13
811	Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Molecular Neurodegeneration, 2011, 6, 39.	4.4	462
812	Coordinated increase of Î³-secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: quantitative analysis of p3-AlcÎ± with a new ELISA system. Molecular Neurodegeneration, 2011, 6, 76.	4.4	10
813	Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids and Barriers of the CNS, 2011, 8, 21.	2.4	104
814	Next-generation DNA sequencing-based assay for measuring allelic expression imbalance (AEI) of candidate neuropsychiatric disorder genes in human brain. BMC Genomics, 2011, 12, 518.	1.2	15
815	Structural memory of natively unfolded tau protein detected by smallâ€angle Xâ€ray scattering. Proteins: Structure, Function and Bioinformatics, 2011, 79, 2122-2131.	1.5	52
816	Dissociation of Î²-amyloid from lipoprotein in cerebrospinal fluid from Alzheimer's disease accelerates Î²-amyloid-42 assembly. Journal of Neuroscience Research, 2011, 89, 815-821.	1.3	10
817	Î³â€Secretase component presenilin is important for microglia Î²â€amyloid clearance. Annals of Neurology, 2011, 69, 170-180.	2.8	45
818	Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders. Annals of Neurology, 2011, 70, 532-540.	2.8	536
821	Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles: Functional Similarities with Proteins. Angewandte Chemie - International Edition, 2011, 50, 5110-5115.	7.2	248
822	The Dynamic Structure of Filamentous Tau. Angewandte Chemie - International Edition, 2011, 50, 11520-11524.	7.2	74
823	Salting-in characteristics of globular proteins. Biophysical Chemistry, 2011, 156, 72-78.	1.5	28
824	Binding studies of truncated variants of the AÎ² peptide to the V-domain of the RAGE receptor reveal AÎ² residues responsible for binding. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 592-609.	1.1	30

#	Article	IF	Citations
825	Ligand - based virtual screening procedure for the prediction and the identification of novel Î²-amyloid aggregation inhibitors using Kohonen maps and Counterpropagation Artificial Neural Networks. European Journal of Medicinal Chemistry, 2011, 46, 497-508.	2.6	93
826	The binding affinity of anti-AÎ²1-42ÂMAb-decorated nanoliposomes to AÎ²1-42Âpeptides inÂvitro and to amyloid deposits in post-mortem tissue. Biomaterials, 2011, 32, 5489-5497.	5.7	76
827	Autophagy in different flavors: Dysregulated protein degradation in neurological diseases. Neurobiology of Disease, 2011, 43, 1-3.	2.1	5
828	ABri peptide aggregation quantification by fluorescamine and alpha imager assay. Journal of Industrial and Engineering Chemistry, 2011, 17, 427-429.	2.9	1
829	Physiological cholesterol concentration is a neuroprotective factor against Î²-amyloid and Î²-amyloidâ€“metal complexes toxicity. Journal of Inorganic Biochemistry, 2011, 105, 1066-1072.	1.5	13
830	Macroautophagy-generated increase of lysosomal amyloid Î²-protein mediates oxidant-induced apoptosis of cultured neuroblastoma cells. Autophagy, 2011, 7, 1528-1545.	4.3	72
831	Amyloid Î² Enhances Migration of Endothelial Progenitor Cells by Upregulating CX3CR1 in Response to Fractalkine, Which May Be Associated With Development of Choroidal Neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, e11-8.	1.1	10
832	Chemical Biology, Molecular Mechanism and Clinical Perspective of Î³ - Secretase Modulators in Alzheimers Disease. Current Neuropharmacology, 2011, 9, 598-622.	1.4	38
833	Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease. Recent Patents on CNS Drug Discovery, 2011, 6, 222-233.	0.9	19
834	Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases. Current Drug Therapy, 2011, 6, 197-206.	0.2	2
835	Aβ Oligomers Induce Glutamate Release from Hippocampal Neurons. Current Alzheimer Research, 2011, 8, 552-562.	0.7	88
836	Age-dependent Accumulation of Soluble Amyloid Î² (AÎ²) Oligomers Reverses the Neuroprotective Effect of Soluble Amyloid Precursor Protein-Î± (sAPPÎ±) by Modulating Phosphatidylinositol 3-Kinase (PI3K)/Akt-GSK-3Î² Pathway in Alzheimer Mouse Model. Journal of Biological Chemistry, 2011, 286, 18414-18425.	1.6	164
837	Ageing and protein aggregation-mediated disorders: from invertebrates to mammals. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 94-98.	1.8	54
838	CC Chemokine Receptor 2 Deficiency Aggravates Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2011, 31, 6208-6220.	1.7	151
839	Targeting Oligomers in Neurodegenerative Disorders: Lessons from Î±-Synuclein, Tau, and Amyloid-Î² Peptide. Journal of Alzheimer's Disease, 2011, 24, 223-232.	1.2	95
840	The ER stress factor XBP1s prevents amyloid-Î² neurotoxicity. Human Molecular Genetics, 2011, 20, 2144-2160.	1.4	258
841	RNA polymerase III drives alternative splicing of the potassium channelâ€“interacting protein contributing to brain complexity and neurodegeneration. Journal of Cell Biology, 2011, 193, 851-866.	2.3	35
842	Amyloid Î²-Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation. Journal of Biological Chemistry, 2011, 286, 20797-20811.	1.6	72

#	Article	IF	Citations
843	Islet amyloid polypeptide demonstrates a persistent capacity to disrupt membrane integrity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9460-9465.	3.3	127
844	Translational Repression of the Disintegrin and Metalloprotease ADAM10 by a Stable G-quadruplex Secondary Structure in Its 5â€²-Untranslated Region. Journal of Biological Chemistry, 2011, 286, 45063-45072.	1.6	68
845	Neurodegenerative processes in Huntington's disease. Cell Death and Disease, 2011, 2, e228-e228.	2.7	128
846	AÎ²42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete AÎ²42 Species. Journal of Biological Chemistry, 2011, 286, 8585-8596.	1.6	168
847	Membrane Anchored and Lipid Raft Targeted Î²-Secretase Inhibitors for Alzheimer's Disease Therapy. Journal of Alzheimer's Disease, 2011, 24, 143-152.	1.2	18
848	Presenilin-2 Mutation Causes Early Amyloid Accumulation and Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-12.	3.0	42
849	Blood-Brain Barrier Breakdown and Blood-Brain Communication in Neurological and Psychiatric Diseases. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-2.	0.8	13
850	The Blood-Brain Barrier and Microvascular Water Exchange in Alzheimer's Disease. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-9.	0.8	23
851	Therapeutic Approaches to Delay the Onset of Alzheimer's Disease. Journal of Aging Research, 2011, 2011, 1-11.	0.4	8
852	Amyloid Î²-Induced Impairments in Hippocampal Synaptic Plasticity Are Rescued by Decreasing Mitochondrial Superoxide. Journal of Neuroscience, 2011, 31, 5589-5595.	1.7	132
853	Neurotoxicity Induced by Okadaic Acid in the Human Neuroblastoma SH-SY5Y Line Can Be Differentially Prevented by Î±7 and Î²2* Nicotinic Stimulation. Toxicological Sciences, 2011, 123, 193-205.	1.4	44
854	High ability of apolipoprotein E4 to stabilize amyloidâ€Î² peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB Journal, 2011, 25, 1585-1595.	0.2	83
855	Characterization of Oligomer Formation of Amyloid-Î² Peptide Using a Split-luciferase Complementation Assay. Journal of Biological Chemistry, 2011, 286, 27081-27091.	1.6	65
856	â€˜Alzheimer-likeâ€™ pathology in a murine model of arterial hypertension. Biochemical Society Transactions, 2011, 39, 939-944.	1.6	30
857	Glaucoma and Alzheimerâ€™s disease in the elderly. Aging Health, 2011, 7, 719-733.	0.3	12
858	Fyn, a Potential Target for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 243-252.	1.2	50
859	SOD1 (Copper/Zinc Superoxide Dismutase) Deficiency Drives Amyloid Î² Protein Oligomerization and Memory Loss in Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2011, 286, 44557-44568.	1.6	202
860	Recovery of Small Infectious PrPres Aggregates from Prion-infected Cultured Cells. Journal of Biological Chemistry, 2011, 286, 8141-8148.	1.6	16

#	Article	IF	Citations
861	Activation of D1/D5 Dopamine Receptors Protects Neurons from Synapse Dysfunction Induced by Amyloid-Î² Oligomers. Journal of Biological Chemistry, 2011, 286, 3270-3276.	1.6	77
862	The Molecular Basis of Distinct Aggregation Pathways of Islet Amyloid Polypeptide. Journal of Biological Chemistry, 2011, 286, 6291-6300.	1.6	104
863	Amyloid-Î²-induced Synapse Damage Is Mediated via Cross-linkage of Cellular Prion Proteins. Journal of Biological Chemistry, 2011, 286, 37955-37963.	1.6	82
864	Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO Journal, 2011, 30, 3065-3077.	3.5	104
865	A Single Tyrosine Residue in the Amyloid Precursor Protein Intracellular Domain Is Essential for Developmental Function. Journal of Biological Chemistry, 2011, 286, 8717-8721.	1.6	45
866	Novel Î³-Secretase Enzyme Modulators Directly Target Presenilin Protein. Journal of Biological Chemistry, 2011, 286, 37181-37186.	1.6	82
867	Tracking a toxic polyQ epitope. Nature Chemical Biology, 2011, 7, 861-862.	3.9	0
868	Microglial P2X₇receptor expression is accompanied by neuronal damage in the cerebral cortex of the APP_{swe}/PS1dE9 mouse model of Alzheimer's disease. Experimental and Molecular Medicine, 2011, 43, 7.	3.2	83
869	Tetrahydrohyperforin prevents cognitive deficit, AÎ² deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1Î”E9 model of Alzheimer's disease: a possible effect on APP processing. Translational Psychiatry, 2011, 1, e20-e20.	2.4	62
870	Disordered Binding of Small Molecules to AÎ²(12â€“28). Journal of Biological Chemistry, 2011, 286, 41578-41588.	1.6	46
871	microRNA-34c is a novel target to treat dementias. EMBO Journal, 2011, 30, 4299-4308.	3.5	302
872	In Silico Theoretical Molecular Modeling for Alzheimerâ€™s Disease: The Nicotine-Curcumin Paradigm in Neuroprotection and Neurotherapy. International Journal of Molecular Sciences, 2011, 12, 694-724.	1.8	47
873	Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO Journal, 2011, 30, 4825-4837.	3.5	171
874	Suppression of Alzheimer's Disease-Related Phenotypes by Expression of Heat Shock Protein 70 in Mice. Journal of Neuroscience, 2011, 31, 5225-5234.	1.7	148
875	Entrapment of AÎ²1â^'40peptide in unstructured aggregates. Journal of Physics Condensed Matter, 2012, 24, 244103.	0.7	7
876	Retromer Binds the FANSHY Sorting Motif in SorLA to Regulate Amyloid Precursor Protein Sorting and Processing. Journal of Neuroscience, 2012, 32, 1467-1480.	1.7	225
877	Early Amyloidogenic Oligomerization Studied through Fluorescence Lifetime Correlation Spectroscopy. International Journal of Molecular Sciences, 2012, 13, 9400-9418.	1.8	22
878	Natural Biomolecules and Protein Aggregation: Emerging Strategies against Amyloidogenesis. International Journal of Molecular Sciences, 2012, 13, 17121-17137.	1.8	48

#	Article	IF	Citations
879	Therapeutic Effect of Yi-Chi-Tsung-Ming-Tang on AmyloidÎ²1â^'40-Induced Alzheimer's Disease-Like Phenotype via an Increase of Acetylcholine and Decrease of AmyloidÎ². Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-10.	0.5	3
880	Generation of Alzheimer Disease-associated Amyloid Î²42/43 Peptide by Î³-Secretase Can Be Inhibited Directly by Modulation of Membrane Thickness. Journal of Biological Chemistry, 2012, 287, 21326-21334.	1.6	89
881	Kinetics of Amyloid Aggregation: A Study of the GNNQQNY Prion Sequence. PLoS Computational Biology, 2012, 8, e1002782.	1.5	41
882	BACE1 Dependent Neuregulin Processing: Review. Current Alzheimer Research, 2012, 9, 178-183.	0.7	62
883	Time of Day Regulates Subcellular Trafficking, Tripartite Synaptic Localization, and Polyadenylation of the Astrocytic Fabp7 mRNA. Journal of Neuroscience, 2012, 32, 1383-1394.	1.7	52
884	Connecting Macroscopic Observables and Microscopic Assembly Events in Amyloid Formation Using Coarse Grained Simulations. PLoS Computational Biology, 2012, 8, e1002692.	1.5	63
885	Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer's disease. EMBO Journal, 2012, 31, 187-200.	3.5	67
886	Lipid Rafts and Alzheimerâ€™s Disease: Protein-Lipid Interactions and Perturbation of Signaling. Frontiers in Physiology, 2012, 3, 189.	1.3	161
887	Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?. Biochemical Journal, 2012, 446, 165-177.	1.7	89
888	Synapses and Alzheimer's Disease. Cold Spring Harbor Perspectives in Biology, 2012, 4, a005777-a005777.	2.3	340
889	Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006312-a006312.	2.9	637
890	Biochemistry of Amyloid Â-Protein and Amyloid Deposits in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006262-a006262.	2.9	451
891	Combined Effects of Agitation, Macromolecular Crowding, and Interfaces on Amyloidogenesis. Journal of Biological Chemistry, 2012, 287, 38006-38019.	1.6	71
892	Trafficking and Proteolytic Processing of APP. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006270-a006270.	2.9	847
893	Intra-membrane Oligomerization and Extra-membrane Oligomerization of Amyloid-Î² Peptide Are Competing Processes as a Result of Distinct Patterns of Motif Interplay. Journal of Biological Chemistry, 2012, 287, 748-756.	1.6	38
894	Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2012, 32, 127-138.	1.2	18
895	Postsynaptic Receptors for Amyloid-Î² Oligomers as Mediators of Neuronal Damage in Alzheimerâ€™s Disease. Frontiers in Physiology, 2012, 3, 464.	1.3	84
896	Structural heterogeneities of self-assembled peptide nanomaterials. , 2012, , .		2

#	Article	IF	Citations
897	Cell-Permeable, Small-Molecule Activators of the Insulin-Degrading Enzyme. Journal of Biomolecular Screening, 2012, 17, 1348-1361.	2.6	13
898	FBL2 Regulates Amyloid Precursor Protein (APP) Metabolism by Promoting Ubiquitination-Dependent APP Degradation and Inhibition of APP Endocytosis. Journal of Neuroscience, 2012, 32, 3352-3365.	1.7	55
899	Small Amphipathic Molecules Modulate Secondary Structure and Amyloid Fibril-forming Kinetics of Alzheimer Disease Peptide AÎ²1â€“42. Journal of Biological Chemistry, 2012, 287, 16947-16954.	1.6	41
900	Resting state brain networks and their implications in neurodegenerative disease. Proceedings of SPIE, 2012, , .	0.8	0
901	C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-Î². Brain, 2012, 135, 2140-2154.	3.7	45
902	Molecular Pathology in Neurodegenerative Diseases. Current Drug Targets, 2012, 13, 1548-1559.	1.0	31
903	An Effector-Reduced Anti-Â-Amyloid (AÂ) Antibody with Unique AÂ Binding Properties Promotes Neuroprotection and Glial Engulfment of AÂ. Journal of Neuroscience, 2012, 32, 9677-9689.	1.7	266
904	Stimulation of the Amyloidogenic Pathway by Cytoplasmic Superoxide Radicals in an Alzheimer's Disease Mouse Model. Bioscience, Biotechnology and Biochemistry, 2012, 76, 1098-1103.	0.6	21
905	Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB Journal, 2012, 26, 1946-1959.	0.2	420
906	Exploring the inter-molecular interactions in amyloid-Î² protofibril with molecular dynamics simulations and molecular mechanics Poisson-Boltzmann surface area free energy calculations. Journal of Chemical Physics, 2012, 136, 145101.	1.2	31
907	A graph theoretic mathematical model for Alzheimer's disease: Using a systems biology approach. , 2012, , .		6
908	Striatal-Enriched Protein Tyrosine Phosphatase in Alzheimerâ€™s Disease. Advances in Pharmacology, 2012, 64, 303-325.	1.2	20
909	Visualizing Amyloid Assembly. Science, 2012, 336, 308-309.	6.0	4
910	Expression of the plant viral protease NIa in the brain of a mouse model of Alzheimer's disease mitigates AÎ² pathology and improves cognitive function. Experimental and Molecular Medicine, 2012, 44, 740.	3.2	16
911	Phosphorylation of Amyloid-Î² Peptide at Serine 8 Attenuates Its Clearance via Insulin-degrading and Angiotensin-converting Enzymes. Journal of Biological Chemistry, 2012, 287, 8641-8651.	1.6	64
912	Amyloid Î² (AÎ²) Peptide Directly Activates Amylin-3 Receptor Subtype by Triggering Multiple Intracellular Signaling Pathways. Journal of Biological Chemistry, 2012, 287, 18820-18830.	1.6	80
913	Glucagon-Like Peptide-1 Cleavage Product GLP-1(9-36) Amide Rescues Synaptic Plasticity and Memory Deficits in Alzheimer's Disease Model Mice. Journal of Neuroscience, 2012, 32, 13701-13708.	1.7	97
914	Loss of PAFAH1B2 Reduces Amyloid-Î² Generation by Promoting the Degradation of Amyloid Precursor Protein C-Terminal Fragments. Journal of Neuroscience, 2012, 32, 18204-18214.	1.7	23

#	Article	IF	Citations
915	Membrane-Microdomain Localization of Amyloid Î²-Precursor Protein (APP) C-terminal Fragments Is Regulated by Phosphorylation of the Cytoplasmic Thr668 Residue. Journal of Biological Chemistry, 2012, 287, 19715-19724.	1.6	27
916	Immunotherapy for Alzheimerâ€™s disease: from anti-Î²-amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4, 213-238.	1.0	121
917	Extracting Î²-amyloid from Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3199-3200.	3.3	14
918	Epidermal growth factor receptor is a preferred target for treating Amyloid-Î²â€“induced memory loss. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16743-16748.	3.3	154
919	Identification of Novel Potentially Toxic Oligomers Formed in Vitro from Mammalian-derived Expanded huntingtin Exon-1 Protein. Journal of Biological Chemistry, 2012, 287, 16017-16028.	1.6	95
920	Preparation of Stable Amyloid Î²-Protein Oligomers of Defined Assembly Order. Methods in Molecular Biology, 2012, 849, 23-31.	0.4	19
921	Sphingolipid-modulated Exosome Secretion Promotes Clearance of Amyloid-Î² by Microglia. Journal of Biological Chemistry, 2012, 287, 10977-10989.	1.6	473
923	Prion protein facilitates uptake of zinc into neuronal cells. Nature Communications, 2012, 3, 1134.	5.8	119
924	Cerebrospinal fluid amyloid Î² and tau in LRRK2 mutation carriers. Neurology, 2012, 78, 55-61.	1.5	39
925	Aging, Protein Aggregation, Chaperones and Neurodegenerative Disorders: Mechanisms of Coupling and Therapeutic Opportunities. Rambam Maimonides Medical Journal, 2012, 3, e0021.	0.4	13
926	Environmental Factors Preceding A40 Monomer to Oligomers and the Detection of Oligomers in Alzheimer's Disease Patient Serum. Journal of Amino Acids, 2012, 2012, 1-8.	5.8	1
927	Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome. International Journal of Proteomics, 2012, 2012, 1-14.	2.0	394
928	The Role of Tau in Neurodegenerative Diseases and Its Potential as a Therapeutic Target. Scientifica, 2012, 2012, 1-20.	0.6	55
929	Molecular basis of Î²-amyloid oligomer recognition with a conformational antibody fragment. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12503-12508.	3.3	76
930	Sublethal Doses of Î²-Amyloid Peptide Abrogate DNA-dependent Protein Kinase Activity. Journal of Biological Chemistry, 2012, 287, 2618-2631.	1.6	49
931	Can anaesthetic technique effect postoperative outcome?. Current Opinion in Anaesthesiology, 2012, 25, 185-198.	0.9	56
932	Highly neurotoxic monomeric Î±-helical prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3113-3118.	3.3	48
933	Binding with Nucleic Acids or Glycosaminoglycans Converts Soluble Protein Oligomers to Amyloid. Journal of Biological Chemistry, 2012, 287, 736-747.	1.6	49

#	Article	IF	Citations
934	Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease. Current Pharmaceutical Design, 2012, 18, 27-33.	0.9	203
935	Calsyntenin-1 shelters APP from proteolytic processing during anterograde axonal transport. Biology Open, 2012, 1, 761-774.	0.6	48
936	Newly defined toxic Î±-helical prion protein monomer: implications for other neurodegenerative diseases?. Expert Review of Proteomics, 2012, 9, 233-235.	1.3	2
937	The ?7 Nicotinic Acetylcholine Receptor Complex: One, Two or Multiple Drug Targets?. Current Drug Targets, 2012, 13, 707-720.	1.0	30
938	Peptides for Therapy and Diagnosis of Alzheimer's Disease. Current Pharmaceutical Design, 2012, 18, 755-767.	0.9	102
939	Drosophila Models of Proteinopathies: the Little Fly that Could. Current Pharmaceutical Design, 2012, 18, 1108-1122.	0.9	48
940	Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease. Current Alzheimer Research, 2012, 9, 110-119.	0.7	30
941	Natural Animal Models of Neurodegenerative Protein Misfolding Diseases. Current Pharmaceutical Design, 2012, 18, 1148-1158.	0.9	17
942	Granular Non-Fibrillar Aggregates and Toxicity in Alzheimerâ€™s Disease. Current Alzheimer Research, 2012, 9, 962-971.	0.7	17
943	PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 211-219.	0.9	57
945	Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-Î² in a Fraction of Amyloid-Î² Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates. Journal of Alzheimer's Disease, 2012, 29, 361-371.	1.2	17
946	Role of Aluminum and Other Metal Ions in the Pathogenesis of Alzheimerâ€™s Disease. , 2012, , 233-260.		0
947	Prion Diseases, Metals and Antioxidants. , 2012, , 261-306.		1
948	A Possible Key Role for Redox-Active Metal Ions and Soluble Oligomers in Neurodegenerative Disease. , 2012, , 23-44.		0
949	Longitudinal Characterization of the Brain Proteomes for the Tg2576 Amyloid Mouse Model Using Shotgun Based Mass Spectrometry. Journal of Proteome Research, 2012, 11, 6159-6174.	1.8	24
950	Synthesis of a New Class of Bis(thiourea)hydrazide Pseudopeptides as Potential Inhibitors of Î²-Sheet Aggregation. Organic Letters, 2012, 14, 330-333.	2.4	10
951	Safety and biomarker effects of solanezumab in patients withÂAlzheimer's disease. Alzheimer's and Dementia, 2012, 8, 261-271.	0.4	240
952	Design of Î²-Amyloid Aggregation Inhibitors from a Predicted Structural Motif. Journal of Medicinal Chemistry, 2012, 55, 3002-3010.	2.9	53

#	Article	IF	Citations
953	AÎ² oligomer toxicity inhibitor protects memory in models of synaptic toxicity. British Journal of Pharmacology, 2012, 167, 383-392.	2.7	15
954	Nicotinic ACh Receptors in the Hippocampus: Role in Excitability and Plasticity. Nicotine and Tobacco Research, 2012, 14, 1249-1257.	1.4	56
955	Size and sulfation are critical for the effect of heparin on <scp>APP</scp> processing and AÎ² production. Journal of Neurochemistry, 2012, 123, 447-457.	2.1	14
956	Conformational Analysis of Thioflavin T Bound to the Surface of Amyloid Fibrils. Langmuir, 2012, 28, 16490-16495.	1.6	50
957	Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3Î² by Tideglusib. Journal of Biological Chemistry, 2012, 287, 893-904.	1.6	190
958	Hyperamylinemia Contributes to Cardiac Dysfunction in Obesity and Diabetes. Circulation Research, 2012, 110, 598-608.	2.0	113
959	Alzheimer's Disease and Amyloid: Culprit or Coincidence?. International Review of Neurobiology, 2012, 102, 277-316.	0.9	67
960	In vitroOligomerization and Fibrillogenesis of Amyloid-beta Peptides. Sub-Cellular Biochemistry, 2012, 65, 53-74.	1.0	25
961	Optimisation of BACE1 inhibition of tripartite structures by modification of membrane anchors, spacers and pharmacophores â€“ development of potential agents for the treatment of Alzheimer's disease. Organic and Biomolecular Chemistry, 2012, 10, 8216.	1.5	18
962	Out-of-register Î²-sheets suggest a pathway to toxic amyloid aggregates. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20913-20918.	3.3	184
963	Î±-Synuclein phosphorylation as a therapeutic target in Parkinsonâ€™s disease. Reviews in the Neurosciences, 2012, 23, 191-8.	1.4	48
964	Role of Elongation and Secondary Pathways in S6 Amyloid Fibril Growth. Biophysical Journal, 2012, 102, 2167-2175.	0.2	36
965	Pittsburgh compound B and the postmortem diagnosis of alzheimer disease. Annals of Neurology, 2012, 72, 564-570.	2.8	31
966	Direct Observation of Internalization and ROS Generation of Amyloid Î²â€Peptide in Neuronal Cells at Subcellular Resolution. ChemBioChem, 2012, 13, 2335-2338.	1.3	18
967	A Bioinorganic View of Alzheimerâ€™s Disease: When Misplaced Metal Ions (Re)direct the Electrons to the Wrong Target. Chemistry - A European Journal, 2012, 18, 15910-15920.	1.7	84
968	Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-Î² in murine brain. Acta Neuropathologica, 2012, 124, 465-478.	3.9	57
969	Functional and Structural Effects of Amyloid-Î² Aggregate on Xenopus laevis Oocytes. Molecules and Cells, 2012, 34, 349-356.	1.0	5
970	Effect of Mid-infrared Free-Electron Laser Irradiation on Refolding of Amyloid-Like Fibrils of Lysozyme into Native Form. Protein Journal, 2012, 31, 710-716.	0.7	32

#	Article	IF	Citations
971	BACE1 in Alzheimer's disease. Clinica Chimica Acta, 2012, 414, 171-178.	0.5	70
972	Protein disulfide isomerases in neurodegeneration: From disease mechanisms to biomedical applications. FEBS Letters, 2012, 586, 2826-2834.	1.3	87
973	Transient small molecule interactions kinetically modulate amyloid Î² peptide selfâ€assembly. FEBS Letters, 2012, 586, 3991-3995.	1.3	21
974	A plant cell-based system that predicts aÎ²42 misfolding: Potential as a drug discovery tool for Alzheimer's disease. Molecular Genetics and Metabolism, 2012, 107, 571-579.	0.5	15
975	Traumatic Brain Injury: Risk Factors and Biomarkers of Alzheimer's Disease and Chronic Traumatic Encephalopathy. Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1, 143-148.	0.7	7
976	Helix-Dipole Effects in Peptide Self-Assembly to Amyloid. Biochemistry, 2012, 51, 4167-4174.	1.2	5
977	Identification and Characterization of an AÎ² Oligomer Precipitating Peptide That May Be Useful to Explore Gene Therapeutic Approaches to Alzheimer Disease. Rejuvenation Research, 2012, 15, 144-147.	0.9	8
979	JNK3 Perpetuates Metabolic Stress Induced by AÎ² Peptides. Neuron, 2012, 75, 824-837.	3.8	197
980	Artificial Analogs of Naturally Occurring Tumor Promoters as Biochemical Tools and Therapeutic Leads. Bioscience, Biotechnology and Biochemistry, 2012, 76, 1262-1274.	0.6	19
981	A covalently reactive group-modified peptide that specifically reacts with lysine16 in amyloid Î². Chemical Communications, 2012, 48, 10565.	2.2	10
982	Dynamics of Zn^{II} Binding as a Key Feature in the Formation of Amyloid Fibrils by AÎ²11-28. Inorganic Chemistry, 2012, 51, 701-708.	1.9	23
983	Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease. Journal of Biological Chemistry, 2012, 287, 2678-2688.	1.6	457
984	2D amyloid aggregation of human islet amyloid polypeptide at the solidâ€“liquid interface. Soft Matter, 2012, 8, 1616-1622.	1.2	19
985	A peptide probe for detection of various beta-amyloid oligomers. Molecular BioSystems, 2012, 8, 2741.	2.9	16
986	Dendrimers antiamyloidogenic potential in neurodegenerative diseases. New Journal of Chemistry, 2012, 36, 211-216.	1.4	21
987	Protein Phosphatases and Alzheimer's Disease. Progress in Molecular Biology and Translational Science, 2012, 106, 343-379.	0.9	89
988	Hybrid Compounds. BioDrugs, 2012, 26, 21-31.	2.2	39
989	Explicit Solvent Molecular Dynamics Simulations of AÎ² Peptide Interacting with Ibuprofen Ligands. Journal of Physical Chemistry B, 2012, 116, 12922-12932.	1.2	33

#	Article	IF	Citations
990	Animal Models of Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006320-a006320.	2.9	336
991	Selenium-Enhanced Electron Microscopic Imaging of Different Aggregate Forms of a Segment of the Amyloid Î² Peptide in Cells. ACS Nano, 2012, 6, 4740-4747.	7.3	4
992	Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aî²₄₂ Peptide. Journal of the American Chemical Society, 2012, 134, 6625-6636.	6.6	187
993	Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006247-a006247.	2.9	608
994	Reactivity of Diphenylpropynone Derivatives Toward Metal-Associated Amyloid-Î² Species. Inorganic Chemistry, 2012, 51, 12959-12967.	1.9	36
995	Formation of Two Different Types of Oligomers in the Early Phase of pH-Induced Aggregation of the Alzheimer Aî²(12-28) Peptide. Journal of Physical Chemistry B, 2012, 116, 12389-12397.	1.2	7
996	Copper Coordination to Native N-Terminally Modified versus Full-Length Amyloid-Î²: Second-Sphere Effects Determine the Species Present at Physiological pH. Inorganic Chemistry, 2012, 51, 12988-13000.	1.9	40
997	Î³-Synuclein: Seeding of Î±-Synuclein Aggregation and Transmission between Cells. Biochemistry, 2012, 51, 4743-4754.	1.2	79
998	Characterization of Heparin-induced Glyceraldehyde-3-phosphate Dehydrogenase Early Amyloid-like Oligomers and Their Implication in Î±-Synuclein Aggregation. Journal of Biological Chemistry, 2012, 287, 2398-2409.	1.6	24
999	Identification of an Aggregation-Prone Structure of Tau. Journal of the American Chemical Society, 2012, 134, 16607-16613.	6.6	127
1000	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 215-225.	1.5	122
1001	MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiology of Aging, 2012, 33, 522-534.	1.5	164
1002	Amyloid Î²1â€“42 oligomer inhibits myelin sheet formation in vitro. Neurobiology of Aging, 2012, 33, 499-509.	1.5	64
1003	Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form. Neurobiology of Aging, 2012, 33, 1320-1328.	1.5	32
1004	An amyloid Î²42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1522-1532.	1.5	97
1005	Different Î²-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiology of Aging, 2012, 33, 825.e1-825.e13.	1.5	86
1006	Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiology of Aging, 2012, 33, 831.e11-831.e19.	1.5	40
1007	Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiology of Aging, 2012, 33, 2291-2305.	1.5	241

#	Article	IF	Citations
1008	Î±-Mangostin, a polyphenolic xanthone derivative from mangosteen, attenuates Î²-amyloid oligomers-induced neurotoxicity by inhibiting amyloid aggregation. Neuropharmacology, 2012, 62, 871-881.	2.0	104
1009	An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines. Neuroscience, 2012, 210, 21-32.	1.1	27
1010	Overexpression of cellular prion protein (PrPC) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-Î² (AÎ²1â€“40) administration in mice. Neuroscience, 2012, 215, 79-89.	1.1	23
1011	Effects of Polyphenols on Brain Ageing and Alzheimerâ€™s Disease: Focus on Mitochondria. Molecular Neurobiology, 2012, 46, 161-178.	1.9	107
1012	Structure and Dynamics of Small Soluble AÎ²(1â€“40) Oligomers Studied by Top-Down Hydrogen Exchange Mass Spectrometry. Biochemistry, 2012, 51, 3694-3703.	1.2	64
1013	Morin Inhibits the Early Stages of Amyloid Î²-Peptide Aggregation by Altering Tertiary and Quaternary Interactions to Produce â€œOff-Pathwayâ€•Structures. Biochemistry, 2012, 51, 5990-6009.	1.2	64
1014	Preventing Alzheimerâ€™s Disease. Science, 2012, 337, 1488-1492.	6.0	328
1015	Endoplasmic reticulum stress occurs downstream of GluN2B subunit of Nâ€methylâ€Dâ€aspartate receptor in mature hippocampal cultures treated with amyloidâ€Î² oligomers. Aging Cell, 2012, 11, 823-833.	3.0	100
1016	Toxicity in Rat Primary Neurons through the Cellular Oxidative Stress Induced by the Turn Formation at Positions 22 and 23 of AÎ²42. ACS Chemical Neuroscience, 2012, 3, 674-681.	1.7	31
1017	Soluble Prion Protein Inhibits Amyloid-Î² (AÎ²) Fibrillization and Toxicity. Journal of Biological Chemistry, 2012, 287, 33104-33108.	1.6	79
1018	Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation. Journal of Medicinal Chemistry, 2012, 55, 9331-9345.	2.9	55
1019	Cognitive Decline Typical of Frontotemporal Lobar Degeneration in Transgenic Mice Expressing the 25-kDa C-Terminal Fragment of TDP-43. American Journal of Pathology, 2012, 180, 293-302.	1.9	41
1020	Presenilin-1 L166P Mutant Human Pluripotent Stem Cellâ€“Derived Neurons Exhibit Partial Loss of Î³-Secretase Activity in Endogenous Amyloid-Î² Generation. American Journal of Pathology, 2012, 180, 2404-2416.	1.9	104
1021	Label-free electrochemical detection of Amyloid beta aggregation in the presence of iron, copper and zinc. Journal of Electroanalytical Chemistry, 2012, 681, 89-95.	1.9	49
1022	The inorganic perspectives of neurotrophins and Alzheimer's disease. Journal of Inorganic Biochemistry, 2012, 111, 130-137.	1.5	27
1023	Sequence-Based Prediction of Protein Solubility. Journal of Molecular Biology, 2012, 421, 237-241.	2.0	85
1024	Metal Binding Dictates Conformation and Function of the Amyloid Precursor Protein (APP) E2 Domain. Journal of Molecular Biology, 2012, 416, 438-452.	2.0	88
1025	Molecular Interactions of Alzheimer's AÎ² Protofilaments with Lipid Membranes. Journal of Molecular Biology, 2012, 421, 572-586.	2.0	64

#	Article	IF	Citations
1026	Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity. Journal of Molecular Biology, 2012, 421, 427-440.	2.0	301
1027	Chemical Strategies for Controlling Protein Folding and Elucidating the Molecular Mechanisms of Amyloid Formation and Toxicity. Journal of Molecular Biology, 2012, 421, 204-236.	2.0	27
1028	From Macroscopic Measurements to Microscopic Mechanisms of Protein Aggregation. Journal of Molecular Biology, 2012, 421, 160-171.	2.0	407
1029	Kinin-mediated inflammation in neurodegenerative disorders. Neurochemistry International, 2012, 61, 72-78.	1.9	26
1030	Anti-amyloidogenic and fibril-destabilizing effects of two manganeseâ€“salen derivatives against hen egg-white lysozyme aggregation. International Journal of Biological Macromolecules, 2012, 50, 187-197.	3.6	25
1031	Thermal disaggregation of type B yeast hexokinase by indole derivatives: A mechanistic study. International Journal of Biological Macromolecules, 2012, 50, 1260-1266.	3.6	2
1032	Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimerâ€™s disease. Journal of Clinical Neuroscience, 2012, 19, 946-949.	0.8	80
1033	Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1070-1078.	1.8	37
1034	Inhibitory effect of curcumin on the Al(III)-induced AÎ²42 aggregation and neurotoxicity in vitro. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1207-1215.	1.8	51
1035	Anti-amyloidogenic effects of soybean isoflavones in vitro: Fluorescence spectroscopy demonstrating direct binding to AÎ² monomers, oligomers and fibrils. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1316-1324.	1.8	32
1036	Inhibiting effect of Î±s1-casein on AÎ²1â€“40 fibrillogenesis. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 124-132.	1.1	49
1037	Peptideâ€“surfactant interactions: Consequences for the amyloid-beta structure. Biochemical and Biophysical Research Communications, 2012, 420, 136-140.	1.0	21
1038	Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for AÎ² oligomers. Biochemical and Biophysical Research Communications, 2012, 422, 375-380.	1.0	10
1039	Fucoidan, a sulfated polysaccharide from brown algae, improves cognitive impairment induced by infusion of AÎ² peptide in rats. Environmental Toxicology and Pharmacology, 2012, 33, 304-311.	2.0	93
1040	Temperature profoundly affects ataxin-3 fibrillogenesis. Biochimie, 2012, 94, 1026-1031.	1.3	8
1041	MicroRNA-195 downregulates Alzheimer's disease amyloid-Î² production by targeting BACE1. Brain Research Bulletin, 2012, 88, 596-601.	1.4	169
1042	Affinity of copper and zinc ions to proteins and peptides related to neurodegenerative conditions (AÎ²,) Tj ETQq0 0 0 rgBT /Overlock 10	9.5	120
1043	Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases). Coordination Chemistry Reviews, 2012, 256, 2129-2141.	9.5	354

#	Article	IF	Citations
1044	Coordination of redox active metal ions to the amyloid precursor protein and to amyloid-Î² peptides involved in Alzheimer disease. Part 2: Dependence of Cu(II) binding sites with AÎ² sequences. Coordination Chemistry Reviews, 2012, 256, 2175-2187.	9.5	129
1045	Coordination of redox active metal ions to the amyloid precursor protein and to amyloid-Î² peptides involved in Alzheimer disease. Part 1: An overview. Coordination Chemistry Reviews, 2012, 256, 2164-2174.	9.5	149
1046	Metal ions as modulators of protein conformation and misfolding in neurodegeneration. Coordination Chemistry Reviews, 2012, 256, 2253-2270.	9.5	147
1047	Neurodegenerative diseases and exposure to the environmental metals Mn, Pb, and Hg. Coordination Chemistry Reviews, 2012, 256, 2147-2163.	9.5	78
1048	The Amyloid State of Proteins in Human Diseases. Cell, 2012, 148, 1188-1203.	13.5	1,496
1049	Identification of beta-amyloid-binding sites on transthyretin. Protein Engineering, Design and Selection, 2012, 25, 337-345.	1.0	56
1050	2-(N-Benzyl-N-phenylsulfonamido)alkyl amide derivatives as Î³-secretase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6828-6831.	1.0	5
1051	Î²â€Amyloid induced effects on cholinergic, serotonergic, and dopaminergic neurons is differentially counteracted by antiâ€inflammatory drugs. Journal of Neuroscience Research, 2013, 91, 83-94.	1.3	23
1052	Negatively Charged Gold Nanoparticles Inhibit Alzheimer's Amyloidâ€Î² Fibrillization, Induce Fibril Dissociation, and Mitigate Neurotoxicity. Small, 2012, 8, 3631-3639.	5.2	281
1053	Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregates. Journal of Biomedical Science, 2012, 19, 104.	2.6	52
1054	Multi-compartmental modeling of SORLAâ€™s influence on amyloidogenic processing in Alzheimerâ€™s disease. BMC Systems Biology, 2012, 6, 74.	3.0	12
1055	Alzheimerâ€™s disease AÎ² assemblies mediating rapid disruption of synaptic plasticity and memory. Molecular Brain, 2012, 5, 25.	1.3	82
1056	Phospho-dependent ubiquitination and degradation of PAR-1 regulates synaptic morphology and tau-mediated AÎ² toxicity in Drosophila. Nature Communications, 2012, 3, 1312.	5.8	49
1057	APOE4-specific Changes in AÎ² Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2012, 287, 41774-41786.	1.6	213
1058	From Sirtuin Biology to Human Diseases: An Update. Journal of Biological Chemistry, 2012, 287, 42444-42452.	1.6	218
1059	Linking Amyloid-ÃŸ and Tau: Amyloid-ÃŸ Induced Synaptic Dysfunction via Local Wreckage of the Neuronal Cytoskeleton. Neurodegenerative Diseases, 2012, 10, 64-72.	0.8	78
1060	Altered neurochemical profile in the <scp>M</scp>cGillâ€<scp>R</scp>â€<scp>T</scp>hy1â€<scp>APP</scp> rat model of <scp>A</scp>lzheimer's disease: a longitudinal in vivo¹H <scp>MRS</scp> study. Journal of Neurochemistry, 2012, 123, 532-541.	2.1	34
1061	Experimental Inhibition of Peptide Fibrillogenesis by Synthetic Peptides, Carbohydrates and Drugs. Sub-Cellular Biochemistry, 2012, 65, 271-294.	1.0	0

#	Article	IF	Citations
1062	A protective mutation. Nature, 2012, 488, 38-39.	13.7	20
1063	Dynamics of Metastable Î²-Hairpin Structures in the Folding Nucleus of Amyloid Î²-Protein. Journal of Physical Chemistry B, 2012, 116, 6311-6325.	1.2	28
1064	Large Aggregates Are the Major Soluble AÎ² Species in AD Brain Fractionated with Density Gradient Ultracentrifugation. PLoS ONE, 2012, 7, e32014.	1.1	85
1065	Fibrillation precursor of superoxide dismutase 1 revealed by gradual tuning of the protein-folding equilibrium. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17868-17873.	3.3	65
1066	Mitochondrion-Derived Reactive Oxygen Species Lead to Enhanced Amyloid Beta Formation. Antioxidants and Redox Signaling, 2012, 16, 1421-1433.	2.5	273
1068	Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity. International Immunopharmacology, 2012, 14, 550-557.	1.7	12
1069	Crystal structure of a conformation-dependent rabbit IgG Fab specific for amyloid prefibrillar oligomers. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1908-1914.	1.1	22
1070	Modulation of beta-amyloid aggregation by engineering the sequence connecting beta-strand forming domains. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2012, 1824, 1069-1079.	1.1	7
1071	Solid-state NMR analysis of the Î²-strand orientation of the protofibrils of amyloid Î²-protein. Biochemical and Biophysical Research Communications, 2012, 428, 458-462.	1.0	18
1072	Protective effects of caffeoylquinic acids on the aggregation and neurotoxicity of the 42-residue amyloid Î²-protein. Bioorganic and Medicinal Chemistry, 2012, 20, 5844-5849.	1.4	76
1073	Two Different Binding Modes of Î±-Synuclein to Lipid Vesicles Depending on its Aggregation State. Biophysical Journal, 2012, 102, 1646-1655.	0.2	39
1074	Charge Effects on the Fibril-Forming Peptide KTVIIE: A Two-Dimensional Replica Exchange Simulation Study. Biophysical Journal, 2012, 102, 1952-1960.	0.2	14
1075	Adsorption Mechanism and Collapse Propensities of the Full-Length, Monomeric AÎ²1-42 on the Surface of a Single-Walled Carbon Nanotube: A Molecular Dynamics Simulation Study. Biophysical Journal, 2012, 102, 1889-1896.	0.2	51
1076	Binding of Î²-Amyloid (1â€“42) Peptide to Negatively Charged Phospholipid Membranes in the Liquid-Ordered State: Modeling and Experimental Studies. Biophysical Journal, 2012, 103, 453-463.	0.2	65
1077	Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid Î²1â€“40. European Journal of Pharmacology, 2012, 692, 38-45.	1.7	23
1078	Theoretical studies on the spectroscopic properties of a series of halide Zinc (II) complexes with pyridinylimine and pyridinylmethylamine derivatives. Synthetic Metals, 2012, 162, 2138-2148.	2.1	7
1079	In vitro characterization of [18F]-florbetaben, an AÎ² imaging radiotracer. Nuclear Medicine and Biology, 2012, 39, 1042-1048.	0.3	54
1080	Microbial manipulation of the amyloid fold. Research in Microbiology, 2012, 163, 592-606.	1.0	63

#	Article	IF	Citations
1081	Retromers in Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2012, 10, 116-121.	0.8	26
1082	New and emerging treatments for Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2012, 12, 535-543.	1.4	50
1083	Modeling the Polyglutamine Aggregation Pathway in Huntingtonâ€™s Disease: From Basic Studies to Clinical Applications. Sub-Cellular Biochemistry, 2012, 65, 353-388.	1.0	1
1084	DENN/MADD/IG20 Alternative Splicing Changes and Cell Death in Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2012, 48, 97-110.	1.1	5
1085	From Mitochondrial Dysfunction to Amyloid Beta Formation: Novel Insights into the Pathogenesis of Alzheimerâ€™s Disease. Molecular Neurobiology, 2012, 46, 186-193.	1.9	125
1086	Molecular Interactions of Alzheimer's Biomarker FDDNP with AÎ² Peptide. Biophysical Journal, 2012, 103, 2341-2351.	0.2	15
1087	The Amyloid Precursor Protein Has a Flexible Transmembrane Domain and Binds Cholesterol. Science, 2012, 336, 1168-1171.	6.0	438
1088	Specific Binding of a Î²-Cyclodextrin Dimer to the Amyloid Î² Peptide Modulates the Peptide Aggregation Process. Biochemistry, 2012, 51, 4280-4289.	1.2	49
1089	Amyloid-Î² and Tau Pathology of Alzheimer's Disease Induced by Diabetes in a Rabbit Animal Model. Journal of Alzheimer's Disease, 2012, 32, 291-305.	1.2	81
1090	Methods for Analysis of Amyloid-Î² Aggregates. Journal of Alzheimer's Disease, 2012, 28, 735-758.	1.2	62
1091	The N-Methylated Peptide SEN304 Powerfully Inhibits AÎ²(1â€“42) Toxicity by Perturbing Oligomer Formation. Biochemistry, 2012, 51, 8338-8352.	1.2	61
1092	Dye-Binding Assays for Evaluation of the Effects of Small Molecule Inhibitors on Amyloid (AÎ²) Self-Assembly. ACS Chemical Neuroscience, 2012, 3, 807-819.	1.7	120
1093	Isolated Amyloid-Î²(1â€“42) Protofibrils, But Not Isolated Fibrils, Are Robust Stimulators of Microglia. ACS Chemical Neuroscience, 2012, 3, 302-311.	1.7	62
1094	Fungal Prions. Progress in Molecular Biology and Translational Science, 2012, 107, 417-456.	0.9	7
1095	Modulating metals as a therapeutic strategy for Alzheimerâ€™s disease. Future Medicinal Chemistry, 2012, 4, 955-969.	1.1	16
1096	Laser-Induced Liquid Bead Ion Desorption Mass Spectrometry: An Approach to Precisely Monitor the Oligomerization of the Î²-Amyloid Peptide. Analytical Chemistry, 2012, 84, 5276-5284.	3.2	30
1097	Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Scientific Reports, 2012, 2, 700.	1.6	396
1098	Misfolded proteins in Alzheimer's disease and type II diabetes. Chemical Society Reviews, 2012, 41, 608-621.	18.7	335

#	Article	IF	Citations
1099	Quantitative connection between polyglutamine aggregation kinetics and neurodegenerative process in patients with Huntingtonâ€™s disease. Molecular Neurodegeneration, 2012, 7, 20.	4.4	4
1100	Intraneuronal AÎ² detection in 5xFAD mice by a new AÎ²-specific antibody. Molecular Neurodegeneration, 2012, 7, 8.	4.4	144
1101	Development of a Small D-Enantiomeric Alzheimerâ€™s Amyloid-Î² Binding Peptide Ligand for Future In Vivo Imaging Applications. PLoS ONE, 2012, 7, e41457.	1.1	23
1102	Amyloid-Î² Peptide Binds to Cytochrome C Oxidase Subunit 1. PLoS ONE, 2012, 7, e42344.	1.1	73
1103	Copper Chelator Induced Efficient Episodic Memory Recovery in a Non-Transgenic Alzheimerâ€™s Mouse Model. PLoS ONE, 2012, 7, e43105.	1.1	75
1104	Amyloid-Mediated Sequestration of Essential Proteins Contributes to Mutant Huntingtin Toxicity in Yeast. PLoS ONE, 2012, 7, e29832.	1.1	29
1105	Characterization of Oligomers of Heterogeneous Size as Precursors of Amyloid Fibril Nucleation of an SH3 Domain: An Experimental Kinetics Study. PLoS ONE, 2012, 7, e49690.	1.1	30
1106	The Relationship between Aggregation and Toxicity of Polyglutamine-Containing Ataxin-3 in the Intracellular Environment of Escherichia coli. PLoS ONE, 2012, 7, e51890.	1.1	20
1107	The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimerâ€™s Disease and Beyond. Frontiers in Physiology, 2012, 3, 8.	1.3	69
1108	A Peephole into the Brain: Neuropathological Features of Alzheimerâ€™s Disease Revealed by in vivo Two-Photon Imaging. Frontiers in Psychiatry, 2012, 3, 26.	1.3	29
1109	Parkin Null Cortical Neuronal/Glial Cultures are Resistant to Amyloid-Î²1-42 Toxicity: A Role for Autophagy?. Journal of Alzheimer's Disease, 2012, 32, 57-76.	1.2	13
1111	Traditional and Modern Medicine Harmonizing the Two Approaches in the Treatment of Neurodegeneration (Alzheimerâ€™s Disease â€“ AD). , 0, , .		4
1112	Age-related changes in synaptic markers and monocyte subsets link the cognitive decline of APPSwe/PS1 mice. Frontiers in Cellular Neuroscience, 2012, 6, 51.	1.8	33
1113	The Activity and mRNA Expression of Î²-Secretase, Cathepsin D, and Cathepsin B in the Brain of Senescence-Accelerated Mouse. Journal of Alzheimer's Disease, 2012, 28, 471-480.	1.2	12
1114	Hematopoietic CC-Chemokine Receptor 2 (CCR2) Competent Cells Are Protective for the Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Medicine, 2012, 18, 297-313.	1.9	61
1115	Lipoproteins and Apolipoproteins in Alzheimer's Disease. , 0, , .		1
1116	Measurement of beta-amyloid peptides in specific cells using a photo thin-film transistor. Nanoscale Research Letters, 2012, 7, 72.	3.1	1
1117	Structural transitions and oligomerization along polyalanine fibril formation pathways from computer simulations. Proteins: Structure, Function and Bioinformatics, 2012, 80, 1582-1597.	1.5	10

#	Article	IF	Citations
1118	Hexafluoroisopropanol induces selfâ€assembly of Î²â€amyloid peptides into highly ordered nanostructures. Journal of Peptide Science, 2012, 18, 233-241.	0.8	26
1119	Inhibitory Effect of Ethanol Extract of Magnolia officinalis on Memory Impairment and Amyloidogenesis in a Transgenic Mouse Model of Alzheimer's Disease via Regulating Î²â€Secretase Activity. Phytotherapy Research, 2012, 26, 1884-1892.	2.8	30
1120	Molecular Mechanisms of Amyloid Oligomers Toxicity. Journal of Alzheimer's Disease, 2012, 33, S67-S78.	1.2	294
1121	Phenolic Compounds Prevent Amyloid Î²-Protein Oligomerization and Synaptic Dysfunction by Site-specific Binding. Journal of Biological Chemistry, 2012, 287, 14631-14643.	1.6	208
1122	Inhibition of Microglial Activation Protects Hippocampal Neurogenesis and Improves Cognitive Deficits in a Transgenic Mouse Model for Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2012, 9, 187-198.	0.8	141
1123	Neuropathogenic role of adenylate kinase-1 in AÎ²-mediated tau phosphorylation via AMPK and GSK3Î². Human Molecular Genetics, 2012, 21, 2725-2737.	1.4	67
1124	Bioinorganic Chemistry of Alzheimerâ€™s Disease. Chemical Reviews, 2012, 112, 5193-5239.	23.0	581
1125	Impairment of protein synthesis is an early effect of amyloid-Î² in neurons. Neurochemical Journal, 2012, 6, 121-131.	0.2	3
1126	Axon injury and stress trigger a microtubule-based neuroprotective pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11842-11847.	3.3	62
1127	Distinct Dimerization for Various Alloforms of the Amyloid-Beta Protein: AÎ²_{1â€“40}, AÎ²_{1â€“42}, and AÎ²_{1â€“40} (D23N). Journal of Physical Chemistry B, 2012, 116, 4043-4055.	3.2	102
1128	The Amyloid Beta Peptide: A Chemistâ€™s Perspective. Role in Alzheimerâ€™s and Fibrillization. Chemical Reviews, 2012, 112, 5147-5192.	23.0	785
1129	Insights into the Mechanisms of Amyloid Formation of Zn^{II}-Ab11-28: pH-Dependent Zinc Coordination and Overall Charge as Key Parameters for Kinetics and the Structure of Zn^{II}-Ab11-28 Aggregates. Inorganic Chemistry, 2012, 51, 7897-7902.	1.9	10
1130	Peripheral Mitochondrial Dysfunction in Alzheimerâ€™s Disease: Focus on Lymphocytes. Molecular Neurobiology, 2012, 46, 194-204.	1.9	107
1131	A novel approach for addressing Alzheimer's disease: The chemoâ€optical synergism. Journal of Neuroscience Research, 2012, 90, 1297-1298.	1.3	4
1132	Amyloid-Î² Oligomers Induce Differential Gene Expression in Adult Human Brain Slices. Journal of Biological Chemistry, 2012, 287, 7436-7445.	1.6	80
1133	Endogenous prion protein conversion is required for prionâ€induced neuritic alterations and neuronal death. FASEB Journal, 2012, 26, 3854-3861.	0.2	21
1134	Structure of an Intermediate State in Protein Folding and Aggregation. Science, 2012, 336, 362-366.	6.0	339
1135	Mitochondria-Targeted Antioxidants as Promising Drugs for Treatment of Age-Related Brain Diseases. Journal of Alzheimer's Disease, 2012, 28, 283-289.	1.2	78

#	Article	IF	Citations
1136	The Butter Flavorant, Diacetyl, Exacerbates Î²-Amyloid Cytotoxicity. Chemical Research in Toxicology, 2012, 25, 2083-2091.	1.7	32
1139	Molecular Composition of Subâ€stoichiometrically Labeled Î±â€Synuclein Oligomers Determined by Singleâ€Molecule Photobleaching. Angewandte Chemie - International Edition, 2012, 51, 8821-8824.	7.2	74
1140	Towards Alzheimer's root cause: ECSIT as an integrating hub between oxidative stress, inflammation and mitochondrial dysfunction. BioEssays, 2012, 34, 532-541.	1.2	43
1141	Inhibition of Cuâ€Amyloidâ€Î² by using Bifunctional Peptides with Î²â€Sheet Breaker and Chelator Moieties. Chemistry - A European Journal, 2012, 18, 4836-4839.	1.7	29
1142	Î²â€amyloid peptide is internalized into chick retinal neurons and alters the distribution of myosin Vb. Cytoskeleton, 2012, 69, 166-178.	1.0	1
1143	Effect of the surface charge of artificial model membranes on the aggregation of amyloid Î²-peptide. Biochimie, 2012, 94, 1730-1738.	1.3	40
1144	New and emerging treatments for Alzheimer's disease. Expert Opinion on Emerging Drugs, 2012, 17, 147-156.	1.0	25
1145	Small-molecule BACE1 inhibitors: a patent literature review (2006 â€“ 2011). Expert Opinion on Therapeutic Patents, 2012, 22, 511-540.	2.4	77
1146	Conserved features of intermediates in amyloid assembly determine their benign or toxic states. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11172-11177.	3.3	115
1147	Spectral Unmixing Imaging of Wavelength-Responsive Fluorescent Probes: An Application for the Real-Time Report of Amyloid Beta Species in Alzheimerâ€™s Disease. Molecular Imaging and Biology, 2012, 14, 293-300.	1.3	36
1148	Modeling Parkinsonâ€™s Disease Using Induced Pluripotent Stem Cells. Current Neurology and Neuroscience Reports, 2012, 12, 237-242.	2.0	62
1149	Sortilin and SorLA Regulate Neuronal Sorting of Trophic and Dementia-Linked Proteins. Molecular Neurobiology, 2012, 45, 379-387.	1.9	27
1150	AÎ² Toxicity in Alzheimer's Disease. Molecular Neurobiology, 2012, 45, 366-378.	1.9	134
1151	Reactive oxidative species enhance amyloid toxicity in APP/PS1 mouse neurons. Neuroscience Bulletin, 2012, 28, 233-239.	1.5	6
1152	Cerebrospinal fluid levels of AÎ²42 relationship with cholinergic cortical activity in Alzheimerâ€™s disease patients. Journal of Neural Transmission, 2012, 119, 771-778.	1.4	31
1153	A novel ARC gene polymorphism is associated with reduced risk of Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 833-842.	1.4	27
1154	Amyloid Î²: linking synaptic plasticity failure to memory disruption in Alzheimerâ€™s disease. Journal of Neurochemistry, 2012, 120, 140-148.	2.1	110
1155	Improvement of cognitive function in Alzheimerâ€™s disease model mice by genetic and pharmacological inhibition of the EP₄ receptor. Journal of Neurochemistry, 2012, 120, 795-805.	2.1	34

#	Article	IF	Citations
1156	Crossâ€functional E3 ligases Parkin and Câ€terminus Hsp70â€interacting protein in neurodegenerative disorders. Journal of Neurochemistry, 2012, 120, 350-370.	2.1	52
1157	Autoreactiveâ€AÎ² antibodies promote APP Î²â€secretase processing. Journal of Neurochemistry, 2012, 120, 732-740.	2.1	25
1158	Alterations in phosphatidylethanolamine levels affect the generation of AÎ². Aging Cell, 2012, 11, 63-72.	3.0	31
1159	A Î²â€amyloid oligomer directly modulates P/Qâ€type calcium currents in Xenopus oocytes. British Journal of Pharmacology, 2012, 165, 1572-1583.	2.7	36
1160	Metal-associated amyloid-Î² species in Alzheimer's disease. Current Opinion in Chemical Biology, 2012, 16, 67-73.	2.8	230
1161	Copper(II) interaction with amyloid-Î²: Affinity and speciation. Coordination Chemistry Reviews, 2012, 256, 3-12.	9.5	66
1162	Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid Î² peptide in mice. Experimental Neurology, 2012, 233, 767-775.	2.0	70
1163	Oligomers of beta-amyloid protein (AÎ²1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain. Experimental Neurology, 2012, 236, 215-227.	2.0	107
1164	Effect of Nâ€homocysteinylation on physicochemical and cytotoxic properties of amyloid Î²â€peptide. FEBS Letters, 2012, 586, 127-131.	1.3	29
1165	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral Î³-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers. Clinical Therapeutics, 2012, 34, 654-667.	1.1	62
1166	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. European Journal of Medicinal Chemistry, 2012, 48, 206-213.	2.6	27
1167	Quality Control Compartments Coming of Age. Traffic, 2012, 13, 635-642.	1.3	30
1168	Early and Selective Impairments in Axonal Transport Kinetics of Synaptic Cargoes Induced by Soluble Amyloid Î²â€Protein Oligomers. Traffic, 2012, 13, 681-693.	1.3	50
1169	Role of Î±â€synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS Journal, 2012, 279, 1000-1013.	2.2	146
1170	Cotinine: A Potential New Therapeutic Agent against Alzheimer's disease. CNS Neuroscience and Therapeutics, 2012, 18, 517-523.	1.9	72
1171	Syntheses and Structureâ€“Activity Relationships of Seven Manganeseâ€“Salen Derivatives as Antiâ€amyloidogenic and Fibrilâ€destabilizing Agents Against Hen Eggâ€white Lysozyme Aggregation. Chemical Biology and Drug Design, 2012, 80, 227-236.	1.5	14
1172	Proteome folding and aggregation. Current Opinion in Structural Biology, 2012, 22, 138-143.	2.6	39
1173	Herpes simplex virus type 1-based amplicon vectors for fundamental research in neurosciences and gene therapy of neurological diseases. Journal of Physiology (Paris), 2012, 106, 2-11.	2.1	18

#	Article	IF	Citations
1174	A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting AÎ²42-induced cytotoxicity and increasing microglial phagocytosis. Neurobiology of Disease, 2012, 46, 701-709.	2.1	32
1175	The role of Î±-synuclein in neurodegeneration â€" An update. Translational Neuroscience, 2012, 3, .	0.7	16
1176	Vitamin A and Alzheimer's disease. Geriatrics and Gerontology International, 2012, 12, 180-188.	0.7	99
1177	Distinctive H-(RLDL)4-OH peptide complexes potentiate nanostructure self-assembling in water. Doklady Biochemistry and Biophysics, 2012, 443, 96-99.	0.3	7
1178	Cell Interaction Study of Amyloid by Using Luminescent Conjugated Polythiophene: Implication that Amyloid Cytotoxicity Is Correlated with Prolonged Cellular Binding. ChemBioChem, 2012, 13, 358-363.	1.3	12
1179	Huperzine a alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice. Journal of Neuroscience Research, 2012, 90, 508-517.	1.3	47
1180	Structural Basis of Î²â€Amyloidâ€Dependent Synaptic Dysfunctions. Angewandte Chemie - International Edition, 2012, 51, 1576-1579.	7.2	57
1181	The Role of Pro, Gly Lys, and Arg Containing Peptides on Amyloid-Beta Aggregation. International Journal of Peptide Research and Therapeutics, 2012, 18, 53-61.	0.9	7
1182	Involvement of kynurenines in Huntingtonâ€™s disease and stroke-induced brain damage. Journal of Neural Transmission, 2012, 119, 261-274.	1.4	51
1183	The role of amyloidogenic protein oligomerization in neurodegenerative disease. Journal of Molecular Medicine, 2013, 91, 653-664.	1.7	35
1184	Effects of antiparkinsonian agents on Î²-amyloid and Î±-synuclein oligomer formation in vitro. Journal of Neuroscience Research, 2013, 91, 1371-1381.	1.3	22
1185	Is the novel amyloid-Î² tetramer fold a stable conformation?. Journal of Cheminformatics, 2013, 5, .	2.8	0
1186	Stability of single and double layer fibrillar amyloid-Î² oligomers. Journal of Cheminformatics, 2013, 5, .	2.8	0
1187	Membrane trafficking in neuronal maintenance and degeneration. Cellular and Molecular Life Sciences, 2013, 70, 2919-2934.	2.4	62
1188	(â^')-Epigallocatechin-3-gallate alleviates spatial memory impairment in APP/PS1 mice by restoring IRS-1 signaling defects in the hippocampus. Molecular and Cellular Biochemistry, 2013, 380, 211-218.	1.4	47
1189	Ionic and Molecular Mechanisms of Î²-Amyloid-Induced Depolarization in Mouse Skeletal Muscle Fibers. Neuroscience and Behavioral Physiology, 2013, 43, 479-484.	0.2	3
1190	SnapShot: Pathobiology of Alzheimer's Disease. Cell, 2013, 154, 468-468.e1.	13.5	42
1191	Aggregation of Alzheimerâ€™s Amyloid Î²-Peptide in Biological Membranes: A Molecular Dynamics Study. Biochemistry, 2013, 52, 4971-4980.	1.2	51

#	Article	IF	Citations
1192	Picomolar Amyloid-Î² Peptides Enhance Spontaneous Astrocyte Calcium Transients. Journal of Alzheimer's Disease, 2013, 38, 49-62.	1.2	59
1193	Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nature Communications, 2013, 4, 2250.	5.8	184
1194	Understanding the relationship between GSK-3 and Alzheimerâ€™s disease: a focus on how GSK-3 can modulate synaptic plasticity processes. Expert Review of Neurotherapeutics, 2013, 13, 495-503.	1.4	28
1195	Novel disease-modifying therapeutics for the treatment of Alzheimerâ€™s disease. Expert Review of Clinical Pharmacology, 2013, 6, 423-442.	1.3	7
1196	Molecular mechanisms of dendrite stability. Nature Reviews Neuroscience, 2013, 14, 536-550.	4.9	314
1197	Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes. Journal of Neurochemistry, 2013, 127, 471-481.	2.1	56
1198	Synthetic AÎ² oligomers (AÎ²1â€“42 globulomer) modulate presynaptic calcium currents: Prevention of AÎ²-induced synaptic deficits by calcium channel blockers. European Journal of Pharmacology, 2013, 702, 44-55.	1.7	32
1199	Progress towards a consensus on biomarkers for Alzheimerâ€™s disease: a review of peripheral analytes. Biomarkers in Medicine, 2013, 7, 641-662.	0.6	30
1200	Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant. Clinical Immunology, 2013, 149, 11-24.	1.4	12
1201	Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathologica, 2013, 126, 671-682.	3.9	76
1202	Structures of Oligomers of a Peptide from Î²-Amyloid. Journal of the American Chemical Society, 2013, 135, 12460-12467.	6.6	50
1203	Molecular Mechanism of Prion Protein Oligomerization at Atomic Resolution. Angewandte Chemie - International Edition, 2013, 52, 10002-10005.	7.2	21
1204	Neurotoxic Saboteurs: Straws that Break the Hippoâ€™s (Hippocampus) Back Drive Cognitive Impairment and Alzheimerâ€™s Disease. Neurotoxicity Research, 2013, 24, 407-459.	1.3	47
1205	AÎ²P1-42 incorporation and channel formation in planar lipid membranes: the role of cholesterol and its oxidation products. Journal of Bioenergetics and Biomembranes, 2013, 45, 369-381.	1.0	14
1206	AÎ² Monomers Transiently Sample Oligomer and Fibril-Like Configurations: Ensemble Characterization Using a Combined MD/NMR Approach. Journal of Molecular Biology, 2013, 425, 3338-3359.	2.0	198
1207	A novel hybrid of 6-chlorotacrine and metalâ€“amyloid-Î² modulator for inhibition of acetylcholinesterase and metal-induced amyloid-Î² aggregation. Chemical Science, 2013, 4, 4137.	3.7	48
1208	Antioxidant role of amyloid Î² protein in cell-free and biological systems: implication for the pathogenesis of Alzheimerdisease. Free Radical Biology and Medicine, 2013, 56, 184-192.	1.3	34
1209	The effect of Cu2+ and Zn2+ on the AÎ²42 peptide aggregation and cellular toxicity. Metallomics, 2013, 5, 1529.	1.0	114

#	Article	IF	Citations
1210	Upexpression of Beclin-1-Dependent Autophagy Protects Against Beta-amyloid-Induced Cell Injury in PC12 Cells. Journal of Molecular Neuroscience, 2013, 51, 180-186.	1.1	28
1211	Function and Dysfunction of Î±-Synuclein: Probing Conformational Changes and Aggregation by Single Molecule Fluorescence. Molecular Neurobiology, 2013, 47, 622-631.	1.9	24
1212	Contributions of Degradation and Brain-to-blood Elimination Across the Bloodâ€"Brain Barrier to Cerebral Clearance of Human Amyloid-Î² Peptide(1-40) in Mouse Brain. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1770-1777.	2.4	16
1213	Microvascular cerebral blood volume changes in aging APPswe/PS1dE9 AD mouse model: a voxel-wise approach. Brain Structure and Function, 2013, 218, 1085-1098.	1.2	23
1214	Induction of heat shock proteins in cerebral cortical cultures by celastrol. Cell Stress and Chaperones, 2013, 18, 155-160.	1.2	35
1216	Curcumin and neurodegenerative diseases. BioFactors, 2013, 39, 122-132.	2.6	131
1217	Identification of small-molecule binding pockets in the soluble monomeric form of the AÎ²42 peptide. Journal of Chemical Physics, 2013, 139, 035101.	1.2	72
1218	Mitochondria-Targeted Plastoquinone Antioxidant SkQ1 Prevents Amyloid-Î²-Induced Impairment of Long-Term Potentiation in Rat Hippocampal Slices. Journal of Alzheimer's Disease, 2013, 36, 377-383.	1.2	27
1219	A canine model of human aging and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1384-1389.	1.8	98
1220	Crystal Structure of a Human Prion Protein Fragment Reveals a Motif for Oligomer Formation. Journal of the American Chemical Society, 2013, 135, 10202-10205.	6.6	55
1221	Amyloid-Î²(1â€"42) Protofibrils Formed in Modified Artificial Cerebrospinal Fluid Bind and Activate Microglia. Journal of NeuroImmune Pharmacology, 2013, 8, 312-322.	2.1	32
1222	Higher-Order Structure and Protein Aggregate Characterization of Protein Therapeutics: Perspectives from Good Manufacturing Practices and Regulatory Guidance. , 2013, , 261-281.		1
1223	A qualitative model for aggregation and diffusion of $$eta $$ -amyloid in Alzheimerâ€™s disease. Journal of Mathematical Biology, 2013, 67, 1369-1392.	0.8	34
1224	Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and AÎ² pathology at the lysosome. Age, 2013, 35, 673-687.	3.0	50
1225	N-truncated amyloid Î² (AÎ²) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathologica, 2013, 126, 189-205.	3.9	153
1226	Suppression of eIF2Î± kinases alleviates Alzheimer's diseaseâ€"related plasticity and memory deficits. Nature Neuroscience, 2013, 16, 1299-1305.	7.1	486
1227	Revealing Hidden Helix Propensity in AÎ² Peptides by Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2013, 117, 12030-12038.	1.2	7
1228	Binding to the lipid monolayer induces conformational transition in AÎ² monomer. Journal of Molecular Modeling, 2013, 19, 737-750.	0.8	9

#	Article	IF	Citations
1229	Glucose metabolism in normal aging and Alzheimerâ€™s disease: methodological and physiological considerations for PET studies. Clinical and Translational Imaging, 2013, 1, 217-233.	1.1	211
1230	Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice. Cell Stress and Chaperones, 2013, 18, 759-771.	1.2	74
1231	Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for Î²-amyloid peptide-induced toxicity. Drug Discovery Today: Technologies, 2013, 10, e115-e119.	4.0	95
1232	Constitutive Î±- and Î²-secretase cleavages of the amyloid precursor protein are partially coupled in neurons, but not in frequently used cell lines. Neurobiology of Disease, 2013, 49, 137-147.	2.1	58
1233	Exploring the accessible conformations of Nâ€terminal acetylated Î±â€synuclein. FEBS Letters, 2013, 587, 1128-1138.	1.3	29
1234	Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress. Nature Communications, 2013, 4, 2753.	5.8	182
1235	Identification of BACE1 inhibitors from Panax ginseng saponinsâ€”An Insilco approach. Computers in Biology and Medicine, 2013, 43, 1037-1044.	3.9	51
1236	Inhibition of amyloid beta-induced synaptotoxicity by a pentapeptide derived from the glycine zipper region of the neurotoxic peptide. Neurobiology of Aging, 2013, 34, 2805-2814.	1.5	41
1237	Probing into the interaction of Î²-amyloid peptides with bilayer lipid membrane by electrochemical techniques. Electrochemistry Communications, 2013, 30, 26-28.	2.3	15
1238	Native ion mobility-mass spectrometry and related methods in structural biology. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1239-1256.	1.1	201
1239	Fibrillar seeds alleviate amyloid-Î² cytotoxicity by omitting formation of higher-molecular-weight oligomers. Biochemical and Biophysical Research Communications, 2013, 439, 321-326.	1.0	13
1240	Atomic structure and hierarchical assembly of a cross-Î² amyloid fibril. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5468-5473.	3.3	479
1241	Proliferation of amyloid-Î²42 aggregates occurs through a secondary nucleation mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9758-9763.	3.3	1,162
1242	Specific Domains of AÎ² Facilitate Aggregation on and Association with Lipid Bilayers. Journal of Molecular Biology, 2013, 425, 1915-1933.	2.0	36
1243	The Amyloid Precursor Protein Represses Expression of Acetylcholinesterase in Neuronal Cell Lines. Journal of Biological Chemistry, 2013, 288, 26039-26051.	1.6	19
1244	The effects of ferulic acid on Î²-amyloid fibrillar structures investigated through experimental and computational techniques. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2924-2937.	1.1	23
1245	Design and Synthesis of Curcumin Analogues for in Vivo Fluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimerâ€™s Disease. Journal of the American Chemical Society, 2013, 135, 16397-16409.	6.6	286
1246	Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes. Neurobiology of Aging, 2013, 34, 1680-1686.	1.5	14

#	Article	IF	Citations
1247	Alzheimer disease therapyâ€"moving from amyloid-Î² to tau. Nature Reviews Neurology, 2013, 9, 677-686.	4.9	421
1248	Alzheimerâ€™s Amyloid-Î² Oligomers Rescue Cellular Prion Protein Induced Tau Reduction via the Fyn Pathway. ACS Chemical Neuroscience, 2013, 4, 1287-1296.	1.7	26
1249	The Off-rate of Monomers Dissociating from Amyloid-Î² Protofibrils. Journal of Biological Chemistry, 2013, 288, 37104-37111.	1.6	26
1250	Heme prevents amyloid beta peptide aggregation through hydrophobic interaction based on molecular dynamics simulation. Physical Chemistry Chemical Physics, 2013, 15, 14098-14106.	1.3	18
1251	Proteopathic Seeds and Neurodegenerative Diseases. Research and Perspectives in Alzheimer's Disease, 2013, , .	0.1	4
1252	Formation of Dynamic Soluble Surfactant-induced Amyloid Î² Peptide Aggregation Intermediates. Journal of Biological Chemistry, 2013, 288, 23518-23528.	1.6	43
1253	Widespread Aggregation and Neurodegenerative Diseases Are Associated with Supersaturated Proteins. Cell Reports, 2013, 5, 781-790.	2.9	245
1254	Openâ€"closed motion of Mint2 regulates APP metabolism. Journal of Molecular Cell Biology, 2013, 5, 48-56.	1.5	15
1255	The inhibitory effects of Escherichia coli maltose binding protein on Î²-amyloid aggregation and cytotoxicity. Archives of Biochemistry and Biophysics, 2013, 538, 41-48.	1.4	8
1256	<scp>CD</scp>4 <scp>T</scp> cells in immunity and immunotherapy of <scp>A</scp>lzheimer's disease. Immunology, 2013, 139, 438-446.	2.0	56
1257	Site-specific Inhibitory Mechanism for Amyloid Î²42 Aggregation by Catechol-type Flavonoids Targeting the Lys Residues. Journal of Biological Chemistry, 2013, 288, 23212-23224.	1.6	192
1258	Modulation of the stability of amyloidogenic precursors by anion binding strongly influences the rate of amyloid nucleation. Physical Chemistry Chemical Physics, 2013, 15, 15508.	1.3	17
1259	Amyloid-Î²25â€"35 induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2. Neuroscience Research, 2013, 77, 180-185.	1.0	37
1260	Orally bioavailable small molecule drug protects memory in Alzheimer's disease models. Neurobiology of Aging, 2013, 34, 1116-1125.	1.5	16
1261	Soluble oligomers are sufficient for transmission of a yeast prion but do not confer phenotype. Journal of Cell Biology, 2013, 203, 197-204.	2.3	16
1262	Functional regulation of Alu element of human angiotensin-converting enzyme gene in neuron cells. Neurobiology of Aging, 2013, 34, 1921.e1-1921.e7.	1.5	25
1263	N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathologica Communications, 2013, 1, 56.	2.4	36
1265	Cysteine-rich domain of scavenger receptor AI modulates the efficacy of surface targeting and mediates oligomeric AÎ² internalization. Journal of Biomedical Science, 2013, 20, 54.	2.6	14

#	Article	IF	Citations
1266	Change of dynamics of raft-model membrane induced by amyloid-Î² protein binding. European Physical Journal E, 2013, 36, 74.	0.7	18
1267	Brains from non-Alzheimerâ€™s individuals containing amyloid deposits accelerate AÎ² deposition in vivo. Acta Neuropathologica Communications, 2013, 1, 76.	2.4	30
1268	Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation. Acta Neuropathologica Communications, 2013, 1, 75.	2.4	58
1269	The absence of myelin basic protein promotes neuroinflammation and reduces amyloid Î²-protein accumulation in Tg-5xFAD mice. Journal of Neuroinflammation, 2013, 10, 134.	3.1	30
1270	SUMO and Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2013, 15, 720-736.	1.8	82
1271	Interplay between Folding and Assembly of Fibril-Forming Polypeptides. Physical Review Letters, 2013, 111, 058101.	2.9	30
1273	Modulating Ca2+release by the IP3R/Ca2+channel as a potential therapeutic treatment for neurological diseases. Pharmaceutical Patent Analyst, 2013, 2, 629-636.	0.4	3
1274	Vascular Aspects of Cognitive Impairment and Dementia. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1696-1706.	2.4	124
1275	Biophysical Studies of the Amyloid Î²â€Peptide: Interactions with Metal Ions and Small Molecules. ChemBioChem, 2013, 14, 1692-1704.	1.3	89
1276	Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of Drosophila ameliorates AÎ²42-induced Alzheimer's diseaseâ€“like symptoms. Neurobiology of Aging, 2013, 34, 2604-2612.	1.5	39
1277	Two Î²-strands of RAGE participate in the recognition and transport of amyloid-Î² peptide across the blood brain barrier. Biochemical and Biophysical Research Communications, 2013, 439, 252-257.	1.0	16
1278	Alzheimerâ€™s Disease: Pathophysiology and Applications of Magnetic Nanoparticles as MRI Theranostic Agents. ACS Chemical Neuroscience, 2013, 4, 1417-1429.	1.7	95
1279	Cytosolic phospholipase A2Î± upregulation mediates apoptotic neuronal death induced by aggregated amyloid-Î² peptide1â€“42. Neurochemistry International, 2013, 63, 541-550.	1.9	28
1280	Amyloid-Î² oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO Journal, 2013, 32, 2920-2937.	3.5	222
1281	Statistical Mechanical Treatments of Protein Amyloid Formation. International Journal of Molecular Sciences, 2013, 14, 17420-17452.	1.8	4
1282	Ibuprofen Inhibits the Synaptic Failure Induced by the Amyloid-Î² Peptide in Hippocampal Neurons. Journal of Alzheimer's Disease, 2013, 35, 463-473.	1.2	16
1283	A Relationship between the Aggregation Rates of Î±-Synuclein Variants and the Î²-Sheet Populations in Their Monomeric Forms. Journal of Physical Chemistry B, 2013, 117, 10737-10741.	1.2	13
1284	Copperâ€“Î²-amyloid peptides exhibit neither monooxygenase nor superoxide dismutase activities. Chemical Communications, 2013, 49, 4027.	2.2	14

#	Article	IF	Citations
1285	Intrahippocampal injection of AÎ²₁₋₄₂inhibits neurogenesis and down-regulates IFN-Î³ and NF-Î²B expression in hippocampus of adult mouse brain. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 13-20.	1.4	51
1286	Immunoliposomes for Alzheimer's disease therapy. , 2013, , .		1
1287	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. Alzheimer's Research and Therapy, 2013, 5, S8.	3.0	17
1288	Slow Excitotoxicity in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 643-668.	1.2	82
1289	Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiology of Aging, 2013, 34, 22-34.	1.5	58
1290	Alzheimer's Disease Modeling: Ups, Downs, and Perspectives for Human Induced Pluripotent Stem Cells. Journal of Alzheimer's Disease, 2013, 34, 563-588.	1.2	34
1291	Aliphatic peptides show similar self-assembly to amyloid core sequences, challenging the importance of aromatic interactions in amyloidosis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 519-524.	3.3	119
1292	Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease. Pflugers Archiv European Journal of Physiology, 2013, 465, 441-450.	1.3	69
1293	Î±-Synuclein Oligomers: an Amyloid Pore?. Molecular Neurobiology, 2013, 47, 613-621.	1.9	87
1294	The Backbone Dynamics of the Amyloid Precursor Protein Transmembrane Helix Provides a Rationale for the Sequential Cleavage Mechanism of Î³-Secretase. Journal of the American Chemical Society, 2013, 135, 1317-1329.	6.6	71
1295	Critical roles of key domains in complete adsorption of AÎ² peptide on single-walled carbon nanotubes: insights with point mutations and MD simulations. Physical Chemistry Chemical Physics, 2013, 15, 837-844.	1.3	31
1296	Longâ€term <scp>A</scp>Î² exposure augments m<scp>C</scp>a²⁺â€independent m<scp>ROS</scp>â€mediated depletion of cardiolipin for the shift of a lethal transient mitochondrial permeability transition to its permanent mode in <scp>NARP</scp> cybrids: a protective targeting of melatonin. Journal of Pineal Research, 2013, 54, 107-125.	3.4	22
1297	Amyloid-Î² oligomers link depressive-like behavior and cognitive deficits in mice. Molecular Psychiatry, 2013, 18, 1053-1054.	4.1	136
1298	Mitochondrial glutathione: Features, regulation and role in disease. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 3317-3328.	1.1	160
1299	Avoiding the oligomeric state: Î±Bâ€crystallin inhibits fragmentation and induces dissociation of apolipoprotein Câ€I amyloid fibrils. FASEB Journal, 2013, 27, 1214-1222.	0.2	47
1300	Different effects of soluble and aggregated amyloid Î²42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. Journal of Neural Transmission, 2013, 120, 113-120.	1.4	15
1301	Cu(II) Affinity for the Alzheimerâ€™s Peptide: Tyrosine Fluorescence Studies Revisited. Analytical Chemistry, 2013, 85, 1501-1508.	3.2	148
1302	Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Molecular Medicine, 2013, 5, 52-63.	3.3	270

#	Article	IF	Citations
1303	Cyclic adenosine monophosphate as an endogenous modulator of the amyloidâ€Î²2 precursor protein metabolism. IUBMB Life, 2013, 65, 127-133.	1.5	21
1304	Ethanol Reduces Amyloid Aggregation In Vitro and Prevents Toxicity in Cell Lines. Archives of Medical Research, 2013, 44, 1-7.	1.5	24
1305	Amyloid beta(1â€“42) in aqueous environments: Effects of ionic strength and E22Q (Dutch) mutation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2486-2493.	1.1	22
1306	Formation of non-toxic AÎ² fibrils by small heat shock protein under heat-stress conditions. Biochemical and Biophysical Research Communications, 2013, 430, 1259-1264.	1.0	5
1307	Presenilin 2 mutation accelerates the onset of impairment in trace eyeblink conditioning in a mouse model of Alzheimer's disease overexpressing human mutant amyloid precursor protein. Neuroscience Letters, 2013, 538, 15-19.	1.0	12
1308	The role of Î³-secretase in hippocampal synaptic transmission and activity-dependent synaptic plasticity. Neuroscience Letters, 2013, 554, 16-21.	1.0	6
1309	Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Neurobiology of Aging, 2013, 34, 2574-2584.	1.5	44
1310	Drain of the brain: low-affinity p75 neurotrophin receptor affords a molecular sink for clearance of cortical amyloid Î² by the cholinergic modulator system. Neurobiology of Aging, 2013, 34, 2517-2524.	1.5	17
1311	Monoclonal antibodies against large oval aggregates of AÎ²1â€“42. Journal of Bioscience and Bioengineering, 2013, 115, 216-220.	1.1	5
1312	Amyloid beta 25â€“35 impairs reconsolidation of object recognition memory in rats and this effect is prevented by lithium carbonate. Neuroscience Letters, 2013, 548, 79-83.	1.0	10
1313	Anesthesia and tau pathology. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 47, 147-155.	2.5	88
1314	Non-toxic conformer of amyloid Î² may suppress amyloid Î²-induced toxicity in rat primary neurons: Implications for a novel therapeutic strategy for Alzheimerâ€™s disease. Biochemical and Biophysical Research Communications, 2013, 438, 1-5.	1.0	17
1315	Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-Î² (AÎ²1â€“40) administration in mice. Behavioural Brain Research, 2013, 244, 107-115.	1.2	78
1316	Lipid interaction triggering Septin2 to assembly into Î²-sheet structures investigated by Langmuir monolayers and PM-IRRAS. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1441-1448.	1.4	13
1317	The effect of fulvic acid on preâ€•and postaggregation state of AÎ²17â€“42: Molecular dynamics simulation studies, S. Verma, A. Singh and A. Mishra, Biochim Biophys Acta 1834 (2013) 24â€“33. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2867-2868.	1.1	1
1318	Role of Cholesterol in APP Metabolism and Its Significance in Alzheimerâ€™s Disease Pathogenesis. Molecular Neurobiology, 2013, 47, 37-63.	1.9	102
1319	In Vitro and Mechanistic Studies of an Antiamyloidogenic Self-Assembled Cyclic <scp>d</scp>,<scp>l</scp>-Î±-Peptide Architecture. Journal of the American Chemical Society, 2013, 135, 3474-3484.	6.6	95
1320	Modeling Alzheimerâ€™s Disease with iPSCs Reveals Stress Phenotypes Associated with Intracellular AÎ² and Differential Drug Responsiveness. Cell Stem Cell, 2013, 12, 487-496.	5.2	652

#	Article	IF	Citations
1321	Î²-Amyloid-aluminum complex alters cytoskeletal stability and increases ROS production in cortical neurons. Neurochemistry International, 2013, 62, 566-574.	1.9	20
1322	A Crossâ€Sectional Study on Cerebrospinal Fluid Biomarker Levels in Cognitively Normal Elderly Subjects With or Without a Family History of Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2013, 19, 38-42.	1.9	15
1323	Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. Journal of Neuroscience, 2013, 33, 4923-4934.	1.7	100
1324	Carnosine Inhibits AÎ²₄₂ Aggregation by Perturbing the Hâ€Bond Network in and around the Central Hydrophobic Cluster. ChemBioChem, 2013, 14, 583-592.	1.3	76
1325	Advances with RNA interference in Alzheimer’s disease research. Drug Design, Development and Therapy, 2013, 7, 117.	2.0	20
1326	Positron Emission Tomography in Alzheimer Disease. , 2013, , 131-174.		3
1327	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathologica, 2013, 125, 413-423.	3.9	302
1328	Aggregation and neurotoxicity of recombinant Î±-synuclein aggregates initiated by dimerization. Molecular Neurodegeneration, 2013, 8, 5.	4.4	71
1329	Levels of Soluble Apolipoprotein E/Amyloid-Î² (AÎ²) Complex Are Reduced and Oligomeric AÎ² Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*. Journal of Biological Chemistry, 2013, 288, 5914-5926.	1.6	136
1330	The missing link in the amyloid cascade of Alzheimerâ€™s disease â€“ Metal ions. Neurochemistry International, 2013, 62, 367-378.	1.9	72
1331	The Supramolecular Chemistry of Î²-Sheets. Journal of the American Chemical Society, 2013, 135, 5477-5492.	6.6	160
1332	ProNGFNGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice. Cell Death and Differentiation, 2013, 20, 1017-1030.	5.0	62
1333	Spike bursts increase amyloid-Î² 40/42 ratio by inducing a presenilin-1 conformational change. Nature Neuroscience, 2013, 16, 587-595.	7.1	77
1334	Exercise counteracts declining hippocampal function in aging and Alzheimer's disease. Neurobiology of Disease, 2013, 57, 47-55.	2.1	238
1335	The unfolded protein response in Alzheimerâ€™s disease. Seminars in Immunopathology, 2013, 35, 277-292.	2.8	102
1336	Inhibitor Design Against Cytotoxic Î²-Amyloid Species. Modecular Medicine and Medicinal, 2013, , 187-206.	0.4	0
1338	Splice variants of the Alzheimerâ€™s disease beta-secretase, BACE1. Neurogenetics, 2013, 14, 1-9.	0.7	7
1339	In silico investigation and targeting of amyloid Î² oligomers of different size. Molecular BioSystems, 2013, 9, 2118.	2.9	19

#	Article	IF	Citations
1343	Analytical model and multiscale simulations of AÎ² peptide aggregation in lipid membranes: towards a unifying description of conformational transitions, oligomerization and membrane damage. Physical Chemistry Chemical Physics, 2013, 15, 8940.	1.3	45
1344	Extolling the benefits of molecular therapeutic lipidation. Molecular BioSystems, 2013, 9, 2179.	2.9	21
1345	Revealing the secondary structural changes of amyloid Î² peptide by probing the spectral fingerprint characters. Journal of Raman Spectroscopy, 2013, 44, 670-674.	1.2	29
1346	Peroxisome Proliferator-Activated Receptor (PPAR) Î³ and PPARÎ± Agonists Modulate Mitochondrial Fusion-Fission Dynamics: Relevance to Reactive Oxygen Species (ROS)-Related Neurodegenerative Disorders?. PLoS ONE, 2013, 8, e64019.	1.1	84
1347	sym-Triazines for Directed Multitarget Modulation of Cholinesterases and Amyloid-Î² in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2013, 4, 339-349.	1.7	22
1348	Restoring long-term potentiation impaired by amyloid-beta oligomers: Comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists. Brain Research Bulletin, 2013, 96, 28-38.	1.4	24
1349	Natural Compounds May Open New Routes to Treatment of Amyloid Diseases. Neurotherapeutics, 2013, 10, 429-439.	2.1	75
1350	Deleterious effects of soluble amyloid-Î² oligomers on multiple steps of synaptic vesicle trafficking. Neurobiology of Disease, 2013, 55, 129-139.	2.1	50
1351	Effect of Ionic Aqueous Environments on the Structure and Dynamics of the AÎ²_{21â€“30} Fragment: A Molecular-Dynamics Study. Journal of Physical Chemistry B, 2013, 117, 6614-6624.	1.2	18
1352	RASâ€“MAPKâ€“MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature, 2013, 498, 325-331.	13.7	119
1353	Binding and Aggregation Mechanism of Amyloid Î²-Peptides onto the GM1 Ganglioside-Containing Lipid Membrane. Journal of Physical Chemistry B, 2013, 117, 8085-8094.	1.2	75
1354	Molecular dynamics simulation studies of the structural response of an isolated AÎ²1â€“42 monomer localized in the vicinity of the hydrophilic TiO2 surface. European Biophysics Journal, 2013, 42, 487-494.	1.2	11
1355	Effects of membrane interaction and aggregation of amyloid Î²-peptide on lipid mobility and membrane domain structure. Physical Chemistry Chemical Physics, 2013, 15, 8929.	1.3	73
1356	Fused in sarcoma (FUS): An oncogene goes awry in neurodegeneration. Molecular and Cellular Neurosciences, 2013, 56, 475-486.	1.0	116
1357	Conjugated Polyelectrolyte-Based Imaging and Monitoring of Protein Aggregation. , 2013, , 295-314.		1
1358	Peripherally Applied Synthetic Peptide isoAsp7-AÎ²(1-42) Triggers Cerebral Î²-Amyloidosis. Neurotoxicity Research, 2013, 24, 370-376.	1.3	71
1359	Astrocyte signaling and neurodegeneration. Prion, 2013, 7, 28-36.	0.9	56
1360	Binding Mechanism of Inositol Stereoisomers to Monomers and Aggregates of AÎ²(16-22). Journal of Physical Chemistry B, 2013, 117, 6603-6613.	1.2	24

#	Article	IF	Citations
1361	The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease. , 2013, 54, 871.		176
1362	Nanoparticulates. , 2013, , 1373-1419.		5
1363	A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses. Journal of Medicinal Chemistry, 2013, 56, 5987-6006.	2.9	76
1364	Aza-BODIPY: Improved synthesis and interaction with soluble AÎ²1â€“42 oligomers. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1732-1735.	1.0	36
1365	Mechanistic Studies Unravel the Complexity Inherent in Tau Aggregation Leading to Alzheimerâ€™s Disease and the Tauopathies. Biochemistry, 2013, 52, 4107-4126.	1.2	51
1366	Proteotoxicity and Cardiac Dysfunction â€” Alzheimer's Disease of the Heart?. New England Journal of Medicine, 2013, 368, 455-464.	13.9	260
1367	What does make an amyloid toxic: Morphology, structure or interaction with membrane?. Biochimie, 2013, 95, 12-19.	1.3	65
1368	A new controlled concept of immune-sensing platform for specific detection of Alzheimer's biomarkers. Biosensors and Bioelectronics, 2013, 40, 329-335.	5.3	40
1369	Apomyoglobin Sequesters Heme from Heme Bound AÎ² Peptides. Inorganic Chemistry, 2013, 52, 10929-10935.	1.9	13
1370	Single Molecule Characterization of the Interactions between Amyloid-Î² Peptides and the Membranes of Hippocampal Cells. Journal of the American Chemical Society, 2013, 135, 1491-1498.	6.6	75
1371	Design of Metastable Î²-Sheet Oligomers from Natively Unstructured Peptide. ACS Chemical Neuroscience, 2013, 4, 1520-1523.	1.7	15
1372	Amyloid Î²-protein oligomers and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2013, 5, 60.	3.0	209
1373	Factors That Drive Peptide Assembly and Fibril Formation: Experimental and Theoretical Analysis of Sup35 NNQQNY Mutants. Journal of Physical Chemistry B, 2013, 117, 8436-8446.	1.2	24
1374	Tracking the Mechanism of Fibril Assembly by Simulated Two-Dimensional Ultraviolet Spectroscopy. Journal of Physical Chemistry A, 2013, 117, 342-350.	1.1	12
1375	Structureâ€“Activity Relationship for (+)-Taxifolin Isolated from Silymarin as an Inhibitor of Amyloid Î² Aggregation. Bioscience, Biotechnology and Biochemistry, 2013, 77, 1100-1103.	0.6	45
1376	Dimerization of Chirally Mutated Enkephalin Neurotransmitters: Implications for Peptide and Protein Aggregation Mechanisms. Journal of Physical Chemistry B, 2013, 117, 1770-1779.	1.2	10
1377	Human Prefoldin Inhibits Amyloid-Î² (AÎ²) Fibrillation and Contributes to Formation of Nontoxic AÎ² Aggregates. Biochemistry, 2013, 52, 3532-3542.	1.2	43
1378	Impaired Transcription in Alzheimer's Disease: Key Role in Mitochondrial Dysfunction and Oxidative Stress. Journal of Alzheimer's Disease, 2013, 34, 115-131.	1.2	61

#	Article	IF	Citations
1379	The role of amyloid Î² in the pathogenesis of Alzheimer's disease. Journal of Clinical Pathology, 2013, 66, 362-366.	1.0	97
1380	Ion Mobility Spectrometry Reveals the Mechanism of Amyloid Formation of AÎ²(25â€“35) and Its Modulation by Inhibitors at the Molecular Level: Epigallocatechin Gallate and Scyllo-inositol. Journal of the American Chemical Society, 2013, 135, 16926-16937.	6.6	83
1381	Axonal Transport and Mitochondrial Dysfunction in Alzheimer's Disease. Neurodegenerative Diseases, 2013, 12, 111-124.	0.8	32
1382	Overlapped Metabolic and Therapeutic Links between Alzheimer and Diabetes. Molecular Neurobiology, 2013, 47, 399-424.	1.9	71
1383	Identification of PrP sequences essential for the interaction between the PrP polymers and AÎ² peptide in a yeast-based assay. Prion, 2013, 7, 469-476.	0.9	21
1384	Amyloid-Î² oligomers regulate the properties of human neural stem cells through GSK-3Î² signaling. Experimental and Molecular Medicine, 2013, 45, e60-e60.	3.2	58
1385	Prion Protein Misfolding, Strains, and Neurotoxicity: An Update from Studies on Mammalian Prions. International Journal of Cell Biology, 2013, 2013, 1-24.	1.0	49
1386	Targeting Synaptic Dysfunction in Alzheimer's Disease by Administering a Specific Nutrient Combination. Journal of Alzheimer's Disease, 2013, 38, 459-479.	1.2	96
1387	Conformational Stability of Fibrillar Amyloid-Beta Oligomers via Protofilament Pair Formation â€“ A Systematic Computational Study. PLoS ONE, 2013, 8, e70521.	1.1	64
1388	Trimeric Tau Is Toxic to Human Neuronal Cells at Low Nanomolar Concentrations. International Journal of Cell Biology, 2013, 2013, 1-9.	1.0	70
1389	Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?. ImmunoTargets and Therapy, 2014, 3, 19.	2.7	11
1390	The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. Frontiers in Physiology, 2013, 4, 45.	1.3	77
1391	Impaired Glutathione Synthesis in Neurodegeneration. International Journal of Molecular Sciences, 2013, 14, 21021-21044.	1.8	172
1392	Degradation of Misfolded Proteins by Autophagy: Is it a Strategy for Huntington's Disease Treatment?. Journal of Huntington's Disease, 2013, 2, 149-157.	0.9	21
1393	Is Alzheimer's a disease of the white matter?. Current Opinion in Psychiatry, 2013, 26, 244-251.	3.1	110
1394	Palmitoylation of Amyloid Precursor Protein Regulates Amyloidogenic Processing in Lipid Rafts. Journal of Neuroscience, 2013, 33, 11169-11183.	1.7	130
1395	Prion protein: structural features and related toxicity. Acta Biochimica Et Biophysica Sinica, 2013, 45, 435-441.	0.9	10
1396	The Selective BACE1 Inhibitor VIa Reduces Amyloid-Î² Production in Cell and Mouse Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 823-834.	1.2	11

#	Article	IF	Citations
1397	Using optical profilometry to characterize cell membrane roughness influenced by amyloid-beta 42 aggregates and electric fields. Journal of Biomedical Optics, 2013, 19, 011009.	1.4	8
1398	Detection of Î²-amyloid oligomers as a predictor of neurological outcome after brain injury. Journal of Neurosurgery, 2013, 118, 1336-1342.	0.9	52
1399	Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Scientific Reports, 2013, 3, 1472.	1.6	83
1400	Amyloid-like fibrils labeled with magnetic nanoparticles. Biomolecular Concepts, 2013, 4, 425-432.	1.0	3
1402	NeuroAiDÂ® (MLC601) and Amyloid Precursor Protein Processing. Cerebrovascular Diseases, 2013, 35, 30-37.	0.8	10
1403	QARIP: a web server for quantitative proteomic analysis of regulated intramembrane proteolysis. Nucleic Acids Research, 2013, 41, W459-W464.	6.5	20
1404	Prion Propagation and Toxicity Occur In Vitro with Two-Phase Kinetics Specific to Strain and Neuronal Type. Journal of Virology, 2013, 87, 2535-2548.	1.5	35
1405	High Expression and Purification of Amino-Terminal Fragment of Human Amyloid Precursor Protein inPichia pastorisand Partial Analysis of Its Properties. BioMed Research International, 2013, 2013, 1-9.	0.9	3
1406	Disease Modifying Therapies for Alzheimer's Disease Targeting AÎ²Oligomers: Implications for Therapeutic Mechanisms. BioMed Research International, 2013, 2013, 1-6.	0.9	9
1407	Quantitative Proteomic Analysis of the Hippocampus in the 5XFAD Mouse Model at Early Stages of Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2013, 36, 321-334.	1.2	39
1408	The Hsp70/90 cochaperone, Sti1, suppresses proteotoxicity by regulating spatial quality control of amyloid-like proteins. Molecular Biology of the Cell, 2013, 24, 3588-3602.	0.9	60
1409	Targeting nascent soluble AÎ²42 for potential Alzheimer drug development. Journal of Neurochemistry, 2013, 125, 329-331.	2.1	2
1410	Inhibition of Amyloid Î² Aggregation by Acteoside, a Phenylethanoid Glycoside. Bioscience, Biotechnology and Biochemistry, 2013, 77, 1329-1332.	0.6	61
1411	Important functional role of residue x of the presenilin Gx<scp>GD</scp> protease active site motif for <scp>APP</scp> substrate cleavage specificity and substrate selectivity of Î³â€secretase. Journal of Neurochemistry, 2013, 125, 144-156.	2.1	18
1412	Operational dissection of Î²â€amyloid cytopathic effects on cultured neurons. Journal of Neuroscience Research, 2013, 91, 706-716.	1.3	22
1413	Val⁸â€GLPâ€1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid Î² peptide in rats. Journal of Neuroscience Research, 2013, 91, 568-577.	1.3	24
1414	Implication of novel bis-imidazopyridines for management of Alzheimer's disease and establishment of its role on protein phosphatase 2A activity in brain*. Journal of Pharmacy and Pharmacology, 2013, 65, 1785-1795.	1.2	23
1415	Stress granules in neurodegeneration â€“ lessons learnt from <scp>TAR DNA</scp> binding protein of 43ÂkDa and fused in sarcoma. FEBS Journal, 2013, 280, 4348-4370.	2.2	151

#	Article	IF	Citations
1416	Î±-Synuclein Oligomers Impair Neuronal Microtubule-Kinesin Interplay. Journal of Biological Chemistry, 2013, 288, 21742-21754.	1.6	117
1417	Common mechanism unites membrane poration by amyloid and antimicrobial peptides. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6382-6387.	3.3	157
1418	Characterizing affinity epitopes between prion protein and Î²-amyloid using an epitope mapping immunoassay. Experimental and Molecular Medicine, 2013, 45, e34-e34.	3.2	26
1419	Pathogenic prions deviate PrPC signaling in neuronal cells and impair A-beta clearance. Cell Death and Disease, 2013, 4, e456-e456.	2.7	25
1420	Amylin deposition in the brain: A second amyloid in Alzheimer disease?. Annals of Neurology, 2013, 74, 517-526.	2.8	272
1421	Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight AÂ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers. Journal of Neuroscience, 2013, 33, 9626-9634.	1.7	160
1422	Improved Spatial Learning Strategy and Memory in Aged Alzheimer AÎ²PPswe/PS1dE9 Mice on a Multi-Nutrient Diet. Journal of Alzheimer's Disease, 2013, 37, 233-245.	1.2	31
1423	Genomic background-related activation of microglia and reduced Î²-amyloidosis in a mouse model of Alzheimer's disease. European Journal of Microbiology and Immunology, 2013, 3, 21-27.	1.5	14
1424	The ABCA7 transporter, brain lipids and Alzheimerâ€™s disease. Clinical Lipidology, 2013, 8, 97-108.	0.4	1
1425	The Amyloid-Î² Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 985-994.	1.2	60
1426	Seeded strainâ€like transmission of Î²â€amyloid morphotypes in APP transgenic mice. EMBO Reports, 2013, 14, 1017-1022.	2.0	118
1428	Distinct Conformational States of the Alzheimer Î²â€Amyloid Peptide Can Be Detected by Highâ€Pressure NMR Spectroscopy. Angewandte Chemie - International Edition, 2013, 52, 8943-8947.	7.2	30
1429	Nano-Chaperones: Nanoparticles Acting as Artificial Chaperones. Regenerative Medicine, Artificial Cells and Nanomedicine, 2013, , 449-480.	0.7	1
1431	Realâ€time Amyloid Aggregation Monitoring with a Photonic Crystalâ€based Approach. ChemPhysChem, 2013, 14, 3476-3482.	1.0	23
1433	The antibody-based magnetic microparticle immunoassay using p-FET sensing platform for Alzheimer's disease pathogenic factor. , 2013, , .		0
1434	Involvement of Insulin-Degrading Enzyme in Insulin- and Atrial Natriuretic Peptide-Sensitive Internalization of Amyloid-Î² Peptide in Mouse Brain Capillary Endothelial Cells. Journal of Alzheimer's Disease, 2013, 38, 185-200.	1.2	29
1435	Intracellular Localization of Amyloid-Î² Peptide in SH-SY5Y Neuroblastoma Cells. Journal of Alzheimer's Disease, 2013, 37, 713-733.	1.2	28
1436	Comparing Brain Amyloid Deposition, Glucose Metabolism, and Atrophy in Mild Cognitive Impairment with and without a Family History of Dementia. Journal of Alzheimer's Disease, 2013, 35, 509-524.	1.2	36

#	Article	IF	Citations
1437	Increased Glutaminyl Cyclase Expression in Peripheral Blood of Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2013, 34, 263-271.	1.2	23
1438	Increased Apolipoprotein D Dimer Formation in Alzheimer's Disease Hippocampus is Associated with Lipid Conjugated Diene Levels. Journal of Alzheimer's Disease, 2013, 35, 475-486.	1.2	22
1439	A Novel Drug Candidate for Alzheimer's Disease Treatment: gx-50 Derived from Zanthoxylum Bungeanum. Journal of Alzheimer's Disease, 2013, 34, 203-213.	1.2	52
1440	Medicine, 2013, 102, 112b-113a.	0.0	0
1442	Disease-modifying drugs in Alzheimer's disease. Drug Design, Development and Therapy, 2013, 7, 1471.	2.0	55
1443	Prion Chemical Biology: On the Road to Therapeutics?. Current Topics in Medicinal Chemistry, 2013, 13, 2441-2464.	1.0	4
1445	Alzheimerâ€™s disease and insulin resistance: translating basic science into clinical applications. Journal of Clinical Investigation, 2013, 123, 531-539.	3.9	285
1447	The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production. PLoS ONE, 2013, 8, e58837.	1.1	122
1448	A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1Î”E9 Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e54769.	1.1	76
1449	Brain Region Specific Pre-Synaptic and Post-Synaptic Degeneration Are Early Components of Neuropathology in Prion Disease. PLoS ONE, 2013, 8, e55004.	1.1	24
1450	Neuroinflammation and Neuronal Loss Precede AÎ² Plaque Deposition in the hAPP-J20 Mouse Model of Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e59586.	1.1	262
1451	Characterization of a Single-Chain Variable Fragment Recognizing a Linear Epitope of AÎ²: A Biotechnical Tool for Studies on Alzheimerâ€™s Disease?. PLoS ONE, 2013, 8, e59820.	1.1	6
1452	Intravenous Immunglobulin Binds Beta Amyloid and Modifies Its Aggregation, Neurotoxicity and Microglial Phagocytosis In Vitro. PLoS ONE, 2013, 8, e63162.	1.1	10
1453	Stability of Transmembrane Amyloid Î²-Peptide and Membrane Integrity Tested by Molecular Modeling of Site-Specific AÎ²42 Mutations. PLoS ONE, 2013, 8, e78399.	1.1	27
1454	A Structure-Toxicity Study of AÃŸ42 Reveals a New Anti-Parallel Aggregation Pathway. PLoS ONE, 2013, 8, e80262.	1.1	41
1455	Carnosine's Effect on Amyloid Fibril Formation and Induced Cytotoxicity of Lysozyme. PLoS ONE, 2013, 8, e81982.	1.1	45
1456	Selective Injection System into Hippocampus CA1 via Monitored Theta Oscillation. PLoS ONE, 2013, 8, e83129.	1.1	6
1457	Generation of Amyloid-Î² Is Reduced by the Interaction of Calreticulin with Amyloid Precursor Protein, Presenilin and Nicastrin. PLoS ONE, 2013, 8, e61299.	1.1	16

#	Article	IF	Citations
1458	Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease. Current Pharmaceutical Design, 2013, 19, 6773-6790.	0.9	47
1459	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. Frontiers in Aging Neuroscience, 2013, 5, 25.	1.7	12
1460	Neprilysin and AÎ² Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2013, 5, 98.	1.7	129
1461	Canonical Wnt signaling protects hippocampal neurons from AÎ² oligomers: role of non-canonical Wnt-5a/Ca2+ in mitochondrial dynamics. Frontiers in Cellular Neuroscience, 2013, 7, 97.	1.8	77
1462	Microglia and Synapse: Interactions in Health and Neurodegeneration. Neural Plasticity, 2013, 2013, 1-10.	1.0	67
1463	Neuroinflammation and Copper in Alzheimerâ€™s Disease. International Journal of Alzheimer's Disease, 2013, 2013, 1-12.	1.1	47
1464	Antibody-conjugated, dual-modal, near-infrared fluorescent iron oxide nanoparticles for antiamyloidgenic activity and specific detection of amyloid-β fibrils. International Journal of Nanomedicine, 2013, 8, 4063.	3.3	26
1465	Trisubstituted Phenolic Compounds as Inhibitors of Acetylcholinesterase and Amyloid Beta Aggregate Formation. Current Enzyme Inhibition, 2013, 9, 67-74.	0.3	5
1467	Intravenous immunoglobulin for the treatment of Alzheimer's disease: current evidence and considerations. Degenerative Neurological and Neuromuscular Disease, 2014, 4, 121.	0.7	1
1468	Pan-Amyloid Oligomer Specific scFv Antibody Attenuates Memory Deficits and Brain Amyloid Burden in Mice with Alzheimerâ€™s Disease. Current Alzheimer Research, 2014, 11, 69-78.	0.7	22
1469	Triptolide Preserves Cognitive Function and Reduces Neuropathology in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2014, 9, e108845.	1.1	32
1470	Aggregate-Depleted Brain Fails to Induce AÎ² Deposition in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2014, 9, e89014.	1.1	36
1471	Molecular Investigations of Protriptyline as a Multi-Target Directed Ligand in Alzheimer's Disease. PLoS ONE, 2014, 9, e105196.	1.1	26
1472	Biochemical Assessment of Precuneus and Posterior Cingulate Gyrus in the Context of Brain Aging and Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e105784.	1.1	16
1473	Neprilysin Is Poorly Expressed in the Prefrontal Cortex of Aged Dogs with Cognitive Dysfunction Syndrome. International Journal of Alzheimer's Disease, 2014, 2014, 1-7.	1.1	5
1474	Hijacking PrPc-dependent signal transduction: when prions impair AÎ² clearance. Frontiers in Aging Neuroscience, 2014, 6, 25.	1.7	20
1475	Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for AlzheimerÃ¢â‚¬â„¢s Disease by Deep Sequencing. Frontiers in Aging Neuroscience, 2014, 6, 75.	1.7	78
1476	Metals and cholesterol: two sides of the same coin in AlzheimerÃ¢â‚¬â„¢s disease pathology. Frontiers in Aging Neuroscience, 2014, 6, 91.	1.7	36

#	Article	IF	Citations
1477	AlzheimerÃ¢â‚¬â„¢s disease: relevant molecular and physiopathological events affecting amyloid-ÃŽÂ² brain balance and the putative role of PPARs. Frontiers in Aging Neuroscience, 2014, 6, 176.	1.7	46
1478	Reciprocal modulation of AÃŽÂ²42 aggregation by copper and homocysteine. Frontiers in Aging Neuroscience, 2014, 6, 237.	1.7	7
1479	Histone-acetylation: a link between Alzheimer's disease and post-traumatic stress disorder?. Frontiers in Neuroscience, 2014, 8, 160.	1.4	35
1480	Polyglutamine-Rich Suppressors of Huntingtin Toxicity Act Upstream of Hsp70 and Sti1 in Spatial Quality Control of Amyloid-Like Proteins. PLoS ONE, 2014, 9, e95914.	1.1	20
1481	Alzheim(i)R: MicroRNAs in Alzheimerâ€™s Disease. Journal of Cytology & Histology, 2014, 05, .	0.1	1
1482	Activation of Heat Shock Proteins by Nanocurcumin to Prevent Neurodegenerative Diseases. Brain Disorders & Therapy, 2014, 03, .	0.1	4
1483	Assessment of the Effect of Macromolecular Crowding on Aggregation Behaviour of a Model Amyloidogenic Peptide. Protein and Peptide Letters, 2014, 22, 87-93.	0.4	8
1484	Exploring the role of hydration and confinement in the aggregation of amyloidogenic peptides AÎ²16â^'22 and Sup357â^'13 in AOT reverse micelles. Journal of Chemical Physics, 2014, 141, 22D530.	1.2	13
1486	Prion-like activity of Cu/Zn superoxide dismutase. Prion, 2014, 8, 33-41.	0.9	57
1487	Stages and Conformations of the Tau Repeat Domain during Aggregation and Its Effect on Neuronal Toxicity. Journal of Biological Chemistry, 2014, 289, 20318-20332.	1.6	77
1488	Altered synaptic structure in the hippocampus in a mouse model of Alzheimerâ€™s disease with soluble amyloid-Î² oligomers and no plaque pathology. Molecular Neurodegeneration, 2014, 9, 41.	4.4	60
1489	Oligomeric AÎ²-induced synaptic dysfunction in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 48.	4.4	424
1490	Role of BRI2 in Dementia. Journal of Alzheimer's Disease, 2014, 40, 481-494.	1.2	21
1491	Chronic Î³-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures. Molecular Psychiatry, 2014, 19, 937-946.	4.1	38
1492	Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Review of Clinical Immunology, 2014, 10, 405-419.	1.3	86
1493	Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. Current Medical Research and Opinion, 2014, 30, 2021-2032.	0.9	68
1494	The translocator protein as a drug target in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2014, 14, 439-448.	1.4	20
1495	Neurodegenerative disorders: Dysregulation of a carefully maintained balance?. Experimental Gerontology, 2014, 58, 279-291.	1.2	17

#	Article	IF	Citations
1496	Silibinin ameliorates LPS-induced memory deficits in experimental animals. Neurobiology of Learning and Memory, 2014, 116, 117-131.	1.0	43
1497	Interactions between Tau and Î±-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Human Molecular Genetics, 2014, 23, 3008-3023.	1.4	63
1498	Apolipoprotein E in Synaptic Plasticity and Alzheimerâ€™s Disease: Potential Cellular and Molecular Mechanisms. Molecules and Cells, 2014, 37, 767-776.	1.0	113
1499	Intrinsically Disordered Proteins: Where Computation Meets Experiment. Polymers, 2014, 6, 2684-2719.	2.0	50
1500	Challenges in Designing Therapeutic Agents for Treating Alzheimerâ€™s Disease-from Serendipity to Rationality. , 2014, , 40-141.		10
1501	Combining BACE1 Inhibition with Metal Chelation as Possible Therapy for Alzheimerâ€™s Disease. , 2014, , 547-565.		0
1502	Matrix Metalloproteinases and Their Multiple Roles in Alzheimerâ€™s Disease. BioMed Research International, 2014, 2014, 1-8.	0.9	79
1503	Alzheimerâ€™s Diseaseâ€”A Panorama Glimpse. International Journal of Molecular Sciences, 2014, 15, 12631-12650.	1.8	14
1504	Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. PLoS Computational Biology, 2014, 10, e1003956.	1.5	151
1505	Differential roles of the ubiquitin proteasome system (UPS) and autophagy in the clearance of soluble and aggregated TDP-43 species. Journal of Cell Science, 2014, 127, 1263-78.	1.2	216
1506	Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin. BioMed Research International, 2014, 2014, 1-14.	0.9	94
1507	Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology, 2014, 82, 752-760.	1.5	44
1508	Scaling and alpha-helix regulation of protein relaxation in a lipid bilayer. Journal of Chemical Physics, 2014, 141, 225101.	1.2	4
1509	Sequestration of a Î²â€Hairpin for Control of Î±â€Synuclein Aggregation. Angewandte Chemie - International Edition, 2014, 53, 4227-4230.	7.2	101
1510	Preparation Protocols of AÎ²(1â€“40) Promote the Formation of Polymorphic Aggregates and Altered Interactions with Lipid Bilayers. Biochemistry, 2014, 53, 7038-7050.	1.2	21
1511	AÎ² Selectively Impairs mGluR7 Modulation of NMDA Signaling in Basal Forebrain Cholinergic Neurons: Implication in Alzheimer's Disease. Journal of Neuroscience, 2014, 34, 13614-13628.	1.7	37
1512	Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on <scp>GABA_A</scp> receptor potentiation. British Journal of Pharmacology, 2014, 171, 389-402.	2.7	16
1513	Engineered aggregation inhibitor fusion for production of highly amyloidogenic human islet amyloid polypeptide. Journal of Biotechnology, 2014, 191, 221-227.	1.9	21

#	Article	IF	Citations
1514	Epigenetic memory: the Lamarckian brain. EMBO Journal, 2014, 33, 945-967.	3.5	85
1515	Crucial role of nonspecific interactions in amyloid nucleation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17869-17874.	3.3	157
1516	Structure activity relationship study of curcumin analogues toward the amyloid-beta aggregation inhibitor. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5621-5626.	1.0	41
1517	A Hexameric Peptide Barrel as Building Block of Amyloidâ€Î² Protofibrils. Angewandte Chemie - International Edition, 2014, 53, 12756-12760.	7.2	128
1518	Synaptic Change in the Posterior Cingulate Gyrus in the Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1073-1090.	1.2	112
1519	Apolipoprotein E receptor pathways in Alzheimer disease. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2014, 6, 255-270.	6.6	9
1520	Capping of AÎ²42 Oligomers by Small Molecule Inhibitors. Biochemistry, 2014, 53, 7893-7903.	1.2	70
1521	Lessons Learned from Major Clinical Trials Conducted Over the Past Decades. , 2014, , 77-97.		3
1522	Mitochondrial Dysfunction. Progress in Molecular Biology and Translational Science, 2014, 127, 183-210.	0.9	73
1523	Conversion of AÎ²43 to AÎ²40 by the successive action of angiotensinâ€converting enzyme 2 and angiotensinâ€converting enzyme. Journal of Neuroscience Research, 2014, 92, 1178-1186.	1.3	45
1524	p38 MAP kinase-mediated NMDA receptor-dependent suppression of hippocampal hypersynchronicity in a mouse model of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 149.	2.4	65
1525	Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study. BMJ Open, 2014, 4, e004850-e004850.	0.8	66
1526	Conformational targeting of intracellular AÎ² oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nature Communications, 2014, 5, 3867.	5.8	49
1527	The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathologica Communications, 2014, 2, 56.	2.4	62
1528	Structureâ€“Function Studies of Amyloid Pores in Alzheimerâ€™s Disease as a Case Example of Neurodegenerative Diseases. , 2014, , 397-408.		0
1529	Combined Treatment with a BACE Inhibitor and Anti-AÎ² Antibody Gantenerumab Enhances Amyloid Reduction in APP_{London}Mice. Journal of Neuroscience, 2014, 34, 11621-11630.	1.7	82
1530	FDG-PET and amyloid-PET imaging. Current Opinion in Neurology, 2014, 27, 405-413.	1.8	55
1531	Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. Aids, 2014, 28, 1579-1591.	1.0	109

#	Article	IF	Citations
1532	Mild Cognitive Impairment and Asymptomatic Alzheimer Disease Subjects. Journal of Neuropathology and Experimental Neurology, 2014, 73, 295-304.	0.9	55
1533	Genome-wide analysis ofSaccharomyces cerevisiaeidentifies cellular processes affecting intracellular aggregation of Alzheimer's amyloid-Î²42: importance of lipid homeostasis. Molecular Biology of the Cell, 2014, 25, 2235-2249.	0.9	27
1534	Real-Time Monitoring of Inclusion Formation in Living Zebrafish. , 2014, , 157-165.		0
1535	AÎ² Fibril Polymorphism and Alzheimerâ€™s Disease. , 2014, , 189-196.		0
1536	Interactions between gold nanoparticles and amyloid Î² 25â€“35 peptide. IET Nanobiotechnology, 2014, 8, 295-303.	1.9	6
1537	Nutritional Approaches for Healthy Aging of the Brain and the Prevention of Neurodegenerative Diseases. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 457-479.	0.2	4
1538	The structured core domain of Î±B-crystallin can prevent amyloid fibrillation and associated toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1562-70.	3.3	181
1539	Insulin resistance, neuroinflammation, and Alzheimerâ€™s disease. Reviews in the Neurosciences, 2014, 25, 509-25.	1.4	51
1540	Structural Diversity of Alzheimer's Disease Amyloid-Î² Dimers and Their Role in Oligomerization and Fibril Formation. Journal of Alzheimer's Disease, 2014, 39, 583-600.	1.2	26
1541	Differential regulation of amyloid precursor protein sorting with pathological mutations results in a distinct effect on amyloidâ€Î² production. Journal of Neurochemistry, 2014, 131, 407-412.	2.1	8
1542	Comparing atomistic molecular mechanics force fields for a difficult target: a case study on the Alzheimerâ€™s amyloid Î²-peptide. Journal of Biomolecular Structure and Dynamics, 2014, 32, 1817-1832.	2.0	74
1543	Structural Interactions between Inhibitor and Substrate Docking Sites Give Insight into Mechanisms of Human PS1 Complexes. Structure, 2014, 22, 125-135.	1.6	56
1544	Detection of Misfolded AÎ² Oligomers for Sensitive Biochemical Diagnosis of Alzheimerâ€™s Disease. Cell Reports, 2014, 7, 261-268.	2.9	154
1545	Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer's disease. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1680-1692.	1.4	50
1546	Beta-Amyloid Associated Differential Effects of APOE Îµ4 on Brain Metabolism in Cognitively Normal Elderly. American Journal of Geriatric Psychiatry, 2014, 22, 961-970.	0.6	34
1547	Epitopeâ€based DNA vaccine for Alzheimer's disease: Translational study in macaques. Alzheimer's and Dementia, 2014, 10, 284-295.	0.4	41
1548	Taurine and central nervous system disorders. Amino Acids, 2014, 46, 31-46.	1.2	121
1549	Prospective atom-based 3D-QSAR model prediction, pharmacophore generation, and molecular docking study of carbamate derivatives as dual inhibitors of AChE and MAO-B for Alzheimerâ€™s disease. Medicinal Chemistry Research, 2014, 23, 1114-1122.	1.1	17

#	Article	IF	Citations
1550	Inflammation and Programmed Cell Death in Alzheimerâ€™s Disease: Comparison of the Central Nervous System and Peripheral Blood. Molecular Neurobiology, 2014, 50, 463-472.	1.9	16
1551	Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases. Biophysical Reviews, 2014, 6, 97-110.	1.5	30
1552	Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimerâ€™s disease. Nature Communications, 2014, 5, 3422.	5.8	204
1553	Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nature Reviews Neuroscience, 2014, 15, 233-249.	4.9	599
1554	Monomeric AÎ²1â€“42 and RAGE: key players in neuronal differentiation. Neurobiology of Aging, 2014, 35, 1301-1308.	1.5	28
1555	Role of Sirt1 During the Ageing Process: Relevance to Protection of Synapses in the Brain. Molecular Neurobiology, 2014, 50, 744-756.	1.9	44
1556	Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?. Neuropharmacology, 2014, 80, 95-102.	2.0	98
1557	Targeted studies on the interaction of nicotine and morin molecules with amyloid Î²-protein. Journal of Molecular Modeling, 2014, 20, 2109.	0.8	12
1558	Zinc and its effects on oxidative stress in Alzheimerâ€™s disease. Neurological Sciences, 2014, 35, 923-928.	0.9	32
1559	Monitoring of Neuronal Loss in the Hippocampus of AÎ²-Injected Rat: Autophagy, Mitophagy, and Mitochondrial Biogenesis Stand Against Apoptosis. NeuroMolecular Medicine, 2014, 16, 175-190.	1.8	47
1560	Role of P2X7 purinoceptors in neuroprotective mechanism of ischemic postconditioning in mice. Molecular and Cellular Biochemistry, 2014, 390, 161-173.	1.4	16
1561	Soluble apoE/AÎ² complex: mechanism and therapeutic target for APOE4-induced AD risk. Molecular Neurodegeneration, 2014, 9, 2.	4.4	98
1562	Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochemical Pharmacology, 2014, 88, 468-478.	2.0	93
1563	Republished: The role of amyloid Î² in the pathogenesis of Alzheimerâ€™s disease. Postgraduate Medical Journal, 2014, 90, 113-117.	0.9	15
1564	Mitochondrial import and degradation of amyloid-Î² peptide. Biochimica Et Biophysica Acta - Bioenergetics, 2014, 1837, 1069-1074.	0.5	117
1565	Side-Chain to Main-Chain Hydrogen Bonding Controls the Intrinsic Backbone Dynamics of the Amyloid Precursor Protein Transmembrane Helix. Biophysical Journal, 2014, 106, 1318-1326.	0.2	33
1566	Brain metabolite clearance: impact on Alzheimerâ€™s disease. Metabolic Brain Disease, 2014, 29, 553-561.	1.4	10
1567	Hsp90-Tau Complex Reveals Molecular Basis for Specificity in Chaperone Action. Cell, 2014, 156, 963-974.	13.5	269

#	Article	IF	Citations
1568	Structureâ€Activity Relationships for a Series of Compounds that Inhibit Aggregation of the Alzheimer's Peptide, AÎ²42. Chemical Biology and Drug Design, 2014, 84, 505-512.	1.5	18
1569	Evaluation of nanoparticle tracking for characterization of fibrillar protein aggregates. AICHE Journal, 2014, 60, 1236-1244.	1.8	26
1570	Î²-Amyloid Fibrils in Alzheimer Disease Are Not Inert When Bound to Copper Ions but Can Degrade Hydrogen Peroxide and Generate Reactive Oxygen Species. Journal of Biological Chemistry, 2014, 289, 12052-12062.	1.6	93
1571	Location and Conformation of Amyloid Î²(25â€“35) Peptide and its Sequenceâ€Shuffled Peptides within Membranes: Implications for Aggregation and Toxicity in PC12 Cells. ChemMedChem, 2014, 9, 1002-1011.	1.6	19
1572	Electrochemical impedance spectroscopy analysis of A-beta (1-42) peptide using a nanostructured biochip. Electrochimica Acta, 2014, 134, 249-257.	2.6	47
1573	Defining the limits: Protein aggregation and toxicityin vivo. Critical Reviews in Biochemistry and Molecular Biology, 2014, 49, 294-303.	2.3	34
1574	Tau acts as a mediator for <scp>A</scp>lzheimer's diseaseâ€related synaptic deficits. European Journal of Neuroscience, 2014, 39, 1202-1213.	1.2	43
1575	The amyloid state and its association with protein misfolding diseases. Nature Reviews Molecular Cell Biology, 2014, 15, 384-396.	16.1	1,894
1576	Protein Electrochemistry: Application in Medicine. A Review. Electrochimica Acta, 2014, 140, 72-82.	2.6	53
1577	The novel vaccine peptide GV1001 effectively blocks Î²-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiology of Aging, 2014, 35, 1255-1274.	1.5	55
1578	Differential effects of the ApoE4 genotype on brain structure and function. NeuroImage, 2014, 89, 81-91.	2.1	57
1579	New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. Biochemical Pharmacology, 2014, 88, 540-547.	2.0	101
1580	Rational Design of a Structural Framework with Potential Use to Develop Chemical Reagents That Target and Modulate Multiple Facets of Alzheimerâ€™s Disease. Journal of the American Chemical Society, 2014, 136, 299-310.	6.6	166
1581	Accelerated clinical course of prion disease in mice compromised in repair of oxidative DNA damage. Free Radical Biology and Medicine, 2014, 68, 1-7.	1.3	11
1582	Structure-Specific Intrinsic Fluorescence of Protein Amyloids Used to Study their Kinetics of Aggregation. , 2014, , 147-155.		24
1583	Golgi-Associated plant Pathogenesis Related protein 1 (GAPR-1) forms amyloid-like fibrils by interaction with acidic phospholipids and inhibits AÎ² aggregation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 88-96.	1.4	18
1584	A Chaperome Subnetwork Safeguards Proteostasis in Aging and Neurodegenerative Disease. Cell Reports, 2014, 9, 1135-1150.	2.9	476
1585	2â€Methoxyâ€4â€methylsulfinylbenzyl: A Backbone Amide Safetyâ€Catch Protecting Group for the Synthesis and Purification of Difficult Peptide Sequences. Chemistry - A European Journal, 2014, 20, 15031-15039.	1.7	20

#	Article	IF	Citations
1586	Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2014, 71, 4803-4813.	2.4	42
1587	Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimerâ€™s disease mouse model. Nature Communications, 2014, 5, 5422.	5.8	237
1588	Structureâ€“activity relationships of sugar-based peptidomimetics as modulators of amyloid Î²-peptide early oligomerization and fibrillization. European Journal of Medicinal Chemistry, 2014, 86, 752-758.	2.6	24
1589	NDP52 associates with phosphorylated tau in brains of an Alzheimer disease mouse model. Biochemical and Biophysical Research Communications, 2014, 454, 196-201.	1.0	34
1590	CD47 does not mediate amyloid-Î²(1â€“42) protofibril-stimulated microglial cytokine release. Biochemical and Biophysical Research Communications, 2014, 454, 239-244.	1.0	9
1591	Monoclonal Antibodies against AÎ²42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain. Journal of Biological Chemistry, 2014, 289, 32131-32143.	1.6	103
1592	Estimation of phosphorylation level of amyloid-beta isolated from human blood plasma: Ultrahigh-resolution mass spectrometry. Molecular Biology, 2014, 48, 607-614.	0.4	8
1593	Atorvastatin prevents amyloid-Î² peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. Acta Pharmacologica Sinica, 2014, 35, 716-726.	2.8	32
1594	Emerging Roles of Extracellular Vesicles in the Nervous System. Journal of Neuroscience, 2014, 34, 15482-15489.	1.7	219
1595	Global CNS Transduction of Adult Mice by Intravenously Delivered rAAVrh.8 and rAAVrh.10 and Nonhuman Primates by rAAVrh.10. Molecular Therapy, 2014, 22, 1299-1309.	3.7	179
1596	Small Bifunctional Chelators That Do Not Disaggregate Amyloid Î² Fibrils Exhibit Reduced Cellular Toxicity. Inorganic Chemistry, 2014, 53, 11367-11376.	1.9	43
1597	Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2457-2467.	1.8	14
1598	Fluorinated beta-sheet breaker peptides. Journal of Materials Chemistry B, 2014, 2, 2259-2264.	2.9	44
1599	Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors. MedChemComm, 2014, 5, 474-488.	3.5	6
1600	Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nature Communications, 2014, 5, 4824.	5.8	153
1601	Structure and Biomedical Applications of Amyloid Oligomer Nanoparticles. ACS Nano, 2014, 8, 11042-11052.	7.3	27
1602	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics, 2014, 6, 1216-1219.	1.0	34
1603	Self-assembly of Cu(ii) with amyloid Î²19â€“20 peptide: relevant to Alzheimer's disease. RSC Advances, 2014, 4, 21840.	1.7	2

#	Article	IF	Citations
1604	Mechanism of Amyloid-Î² Fibril Elongation. Biochemistry, 2014, 53, 6981-6991.	1.2	76
1605	Designing BODIPY-based probes for fluorescence imaging of Î²-amyloid plaques. RSC Advances, 2014, 4, 51032-51037.	1.7	37
1606	Protein postâ€translational modifications and misfolding: New concepts in heart failure. Proteomics - Clinical Applications, 2014, 8, 534-542.	0.8	45
1607	Toxicity of Protein Oligomers Is Rationalized by a Function Combining Size and Surface Hydrophobicity. ACS Chemical Biology, 2014, 9, 2309-2317.	1.6	166
1608	Beta-Amyloid Oligomers Activate Apoptotic BAK Pore for Cytochrome c Release. Biophysical Journal, 2014, 107, 1601-1608.	0.2	29
1609	Nicotinic ACh receptors in the hippocampal circuit; functional expression and role in synaptic plasticity. Journal of Physiology, 2014, 592, 4147-4153.	1.3	49
1610	Non-native Soluble Oligomers of Cu/Zn Superoxide Dismutase (SOD1) Contain a Conformational Epitope Linked to Cytotoxicity in Amyotrophic Lateral Sclerosis (ALS). Biochemistry, 2014, 53, 2423-2432.	1.2	41
1611	Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nature Medicine, 2014, 20, 130-138.	15.2	547
1612	Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease. Diabetes, 2014, 63, 2262-2272.	0.3	462
1613	Self-assembly of stable oligomeric and fibrillar aggregates of AÎ² peptides relevant to Alzheimer's disease: morphology dependent Cu/heme toxicity and inhibition of PROS generation. Dalton Transactions, 2014, 43, 13377.	1.6	23
1614	Targeting autophagy in neurodegenerative diseases. Trends in Pharmacological Sciences, 2014, 35, 583-591.	4.0	130
1615	Beta-asarone attenuates amyloid beta-induced autophagy via Akt/mTOR pathway in PC12 cells. European Journal of Pharmacology, 2014, 741, 195-204.	1.7	61
1616	Role of water in protein folding, oligomerization, amyloidosis and miniprotein. Journal of Peptide Science, 2014, 20, 747-759.	0.8	22
1617	Microscopic Hydration Properties of the AÎ²_{1â€“42} Peptide Monomer and the Globular Protein Ubiquitin: A Comparative Molecular Dynamics Study. Journal of Physical Chemistry B, 2014, 118, 11591-11604.	1.2	15
1618	Single Point Mutations Induce a Switch in the Molecular Mechanism of the Aggregation of the Alzheimerâ€™s Disease Associated AÎ²₄₂ Peptide. ACS Chemical Biology, 2014, 9, 378-382.	1.6	25
1619	Design, synthesis and evaluation of multifunctional salphen derivatives for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2014, 87, 540-551.	2.6	36
1620	X-ray Crystallographic Structures of Trimers and Higher-Order Oligomeric Assemblies of a Peptide Derived from AÎ²_{17â€“36}. Journal of the American Chemical Society, 2014, 136, 5595-5598.	6.6	85
1621	Hydrogen/Deuterium Exchange-Protected Oligomers Populated during AÎ² Fibril Formation Correlate with Neuronal Cell Death. ACS Chemical Biology, 2014, 9, 2678-2685.	1.6	19

#	Article	IF	Citations
1622	Investigating the Structural Impact of the Glutamine Repeat in Huntingtin Assembly. Biophysical Journal, 2014, 107, 411-421.	0.2	16
1623	Interaction between Prion Protein and AÎ² Amyloid Fibrils Revisited. ACS Chemical Neuroscience, 2014, 5, 340-345.	1.7	28
1624	Alzheimerâ€™s AÎ²10â€“40 Peptide Binds and Penetrates DMPC Bilayer: An Isobaricâ€“Isothermal Replica Exchange Molecular Dynamics Study. Journal of Physical Chemistry B, 2014, 118, 2638-2648.	1.2	45
1625	Valproic acid attenuates the suppression of acetyl histone H3 and CREB activity in an inducible cell model of Machadoâ€“Joseph disease. International Journal of Developmental Neuroscience, 2014, 38, 17-22.	0.7	22
1626	Amyloid-Î² oligomers as a template for secondary amyloidosis in Alzheimer's disease. Neurobiology of Disease, 2014, 71, 14-23.	2.1	55
1627	Binding of AÎ² peptide creates lipid density depression in DMPC bilayer. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 2678-2688.	1.4	22
1628	Nanoliposomes presenting on surface a cis-glycofused benzopyran compound display binding affinity and aggregation inhibition ability towards Amyloid Î²1-42 peptide. European Journal of Medicinal Chemistry, 2014, 85, 43-50.	2.6	23
1629	PrPC signalling in neurons: From basics to clinical challenges. Biochimie, 2014, 104, 2-11.	1.3	25
1630	The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology. ACS Chemical Neuroscience, 2014, 5, 1178-1191.	1.7	85
1631	Truncated and modified amyloid-beta species. Alzheimer's Research and Therapy, 2014, 6, 28.	3.0	233
1632	Soluble amyloid beta levels are elevated in the white matter of Alzheimerâ€™s patients, independent of cortical plaque severity. Acta Neuropathologica Communications, 2014, 2, 83.	2.4	39
1633	Soluble Î³-Secretase Modulators Selectively Inhibit the Production of the 42-Amino Acid Amyloid Î² Peptide Variant and Augment the Production of Multiple Carboxy-Truncated Amyloid Î² Species. Biochemistry, 2014, 53, 702-713.	1.2	49
1634	Metal complexes designed to bind to amyloid-Î² for the diagnosis and treatment of Alzheimer's disease. Chemical Society Reviews, 2014, 43, 6701-6715.	18.7	142
1635	Dimerization Process of Amyloid-Î²(29â€“42) Studied by the Hamiltonian Replica-Permutation Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2014, 118, 11428-11436.	1.2	44
1636	Transient dynamics of AÎ² contribute to toxicity in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2014, 71, 3507-3521.	2.4	76
1637	Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 127, 787-801.	3.9	129
1638	Insights into the molecular interactions between aminopeptidase and amyloid beta peptide using molecular modeling techniques. Amino Acids, 2014, 46, 1853-1866.	1.2	34
1639	The hairpin conformation of the amyloid Î² peptide is an important structural motif along the aggregation pathway. Journal of Biological Inorganic Chemistry, 2014, 19, 623-634.	1.1	88

#	Article	IF	Citations
1640	Mid-infrared free-electron laser tuned to the amide I band for converting insoluble amyloid-like protein fibrils into the soluble monomeric form. Lasers in Medical Science, 2014, 29, 1701-1707.	1.0	32
1641	Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Molecular Brain, 2014, 7, 40.	1.3	107
1642	Oligomer-targeting with a conformational antibody fragment promotes toxicity in AÎ²-expressing flies. Acta Neuropathologica Communications, 2014, 2, 43.	2.4	10
1643	Retro-inversal of Intracellular Selected Î²-Amyloid-Interacting Peptides: Implications for a Novel Alzheimerâ€™s Disease Treatment. Biochemistry, 2014, 53, 2101-2111.	1.2	17
1644	A role for the neurexinâ€“neuroligin complex in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 746-756.	1.5	42
1645	The coexistence of an equal amount of Alzheimer's amyloidâ€Î² 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway. FEBS Journal, 2014, 281, 2674-2687.	2.2	43
1646	Mechanistic effects of protein palmitoylation and the cellular consequences thereof. Chemistry and Physics of Lipids, 2014, 180, 44-52.	1.5	44
1647	The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 372-380.	0.4	189
1648	Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimerâ€™s disease. Nature Communications, 2014, 5, 3443.	5.8	108
1649	Spatial Propagation of Protein Polymerization. Physical Review Letters, 2014, 112, 098101.	2.9	20
1650	Increased Susceptibility to Amyloid-Î²-Induced Neurotoxicity in Mice Lacking the Low-Density Lipoprotein Receptor. Journal of Alzheimer's Disease, 2014, 41, 43-60.	1.2	48
1651	Pharma-Nutrition. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , .	0.2	0
1652	Is Amyloid-Î² an Innocent Bystander and Marker in Alzheimer's Disease? Is the Liability of Multivalent Cation Homeostasis and its Influence on Amyloid-Î² Function the Real Mechanism?. Journal of Alzheimer's Disease, 2014, 42, 69-85.	1.2	12
1653	The Flavonoid Derivative 2-(4â€² Benzyloxyphenyl)-3-hydroxy-chromen-4-one Protects Against AÎ²42-Induced Neurodegeneration in Transgenic Drosophila: Insights from In Silico and In Vivo Studies. Neurotoxicity Research, 2014, 26, 331-350.	1.3	34
1654	Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs. Chemical Society Reviews, 2014, 43, 6750-6764.	18.7	80
1655	Physicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs). Chemical Reviews, 2014, 114, 6661-6714.	23.0	391
1656	Detection of AÎ²-interacting proteins via a novel AÎ²-adsorbents that use immobilized regular comb polymer. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 971, 94-98.	1.2	0
1657	Microglia in Health and Disease. , 2014, , .		19

#	Article	IF	Citations
1658	Surface Effects Mediate Self-Assembly of Amyloid-Î² Peptides. ACS Nano, 2014, 8, 10178-10186.	7.3	46
1659	Activation of TRPML1 Clears Intraneuronal AÎ² in Preclinical Models of HIV Infection. Journal of Neuroscience, 2014, 34, 11485-11503.	1.7	91
1660	Guilt by Association: The Physical Chemistry and Biology of Protein Aggregation. Journal of Physical Chemistry Letters, 2014, 5, 2012-2014.	2.1	7
1661	NMR structure of the Arctic mutation of the Alzheimerâ€™s AÎ²(1â€“40) peptide docked to SDS micelles. Journal of Molecular Structure, 2014, 1076, 518-523.	1.8	17
1662	Amyloid-Î²(1-42) protofibrils stimulate a quantum of secreted IL-1Î² despite significant intracellular IL-1Î² accumulation in microglia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2276-2285.	1.8	32
1663	Intracellular selection of peptide inhibitors that target disulphideâ€bridged AÎ²₄₂ oligomers. Protein Science, 2014, 23, 1262-1274.	3.1	8
1664	Supersaturation-limited Amyloid Fibrillation of Insulin Revealed by Ultrasonication. Journal of Biological Chemistry, 2014, 289, 18228-18238.	1.6	45
1665	Role of Bilayer Characteristics on the Structural Fate of AÎ²(1â€“40) and AÎ²(25â€“40). Biochemistry, 2014, 53, 3004-3011.	1.2	8
1666	A Kinetic Approach to the Sequenceâ€“Aggregation Relationship in Disease-Related Protein Assembly. Journal of Physical Chemistry B, 2014, 118, 1003-1011.	1.2	65
1667	8-Hydroxyquinoline Schiff-base compounds as antioxidants and modulators of copper-mediated AÎ² peptide aggregation. Journal of Inorganic Biochemistry, 2014, 139, 106-116.	1.5	76
1668	How does brain insulin resistance develop in Alzheimer's disease?. Alzheimer's and Dementia, 2014, 10, S26-32.	0.4	261
1669	The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. , 2014, 10, 271-283.		23
1670	Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2249-2262.	1.5	123
1671	PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiology of Aging, 2014, 35, 2072-2078.	1.5	54
1672	Photophysical study of Thioflavin T as fluorescence marker of amyloid fibrils. Dyes and Pigments, 2014, 110, 97-105.	2.0	91
1673	Insulin growth factor binding protein 7 is a novel target to treat dementia. Neurobiology of Disease, 2014, 62, 135-143.	2.1	40
1674	Polymorphism of Oligomers of a Peptide from Î²-Amyloid. Journal of the American Chemical Society, 2014, 136, 5432-5442.	6.6	24
1675	The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: It's time for reconciliation. Neurobiology of Disease, 2014, 62, 144-159.	2.1	109

#	Article	IF	Citations
1676	Naturally occurring polyphenolic inhibitors of amyloid beta aggregation. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3108-3112.	1.0	76
1677	Brain Iron Homeostasis: From Molecular Mechanisms To Clinical Significance and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2014, 20, 1324-1363.	2.5	165
1678	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.4	114
1679	Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease. Scientific Reports, 2014, 4, 7190.	1.6	84
1680	Camptothecin and its Analogs Reduce Amyloid-Î² Production and Amyloid-Î²42-Induced IL-1Î² Production. Journal of Alzheimer's Disease, 2014, 43, 465-477.	1.2	11
1681	Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. Frontiers in Behavioral Neuroscience, 2014, 8, 332.	1.0	38
1682	Strikingly Reduced Amyloid Burden and Improved Behavioral Performance in Alzheimer's Disease Mice Immunized with Recombinant Chimeric Vaccines by Hexavalent Foldable AÎ²1-15 Fused to Toxin-Derived Carrier Proteins. Journal of Alzheimer's Disease, 2014, 41, 243-260.	1.2	13
1683	Age-Dependent Alterations of the Hippocampal Cell Composition and Proliferative Potential in the hAÎ²PPSwInd-J20 Mouse. Journal of Alzheimer's Disease, 2014, 41, 1177-1192.	1.2	13
1684	Metallothioneins and the Central Nervous System: From a Deregulation in Neurodegenerative Diseases to the Development of New Therapeutic Approaches. Journal of Alzheimer's Disease, 2014, 41, 29-42.	1.2	20
1685	Andrographolide reduces cognitive impairment in young and mature AÎ²PPswe/PS-1 mice. Molecular Neurodegeneration, 2014, 9, 61.	4.4	95
1686	3,3â€²,4â€²,5â€²-Tetrahydroxyflavone Induces Formation of Large Aggregates of Amyloid Î² Protein. Biological and Pharmaceutical Bulletin, 2014, 37, 748-754.	0.6	11
1687	Synthesis and in Vitro Evaluation of 1,3,4-Thiadiazol-2-yl Urea Derivatives as Novel AChE Inhibitors. Chemical and Pharmaceutical Bulletin, 2014, 62, 524-527.	0.6	7
1688	Effects of Alzheimer's Disease-Associated Risk Loci on Cerebrospinal Fluid Biomarkers and Disease Progression: A Polygenic Risk Score Approach. Journal of Alzheimer's Disease, 2014, 43, 565-573.	1.2	49
1689	Clinical Trials and Drug Development. Cancer Control, 2014, 21, 188-189.	0.7	1
1691	A Hexameric Peptide Barrel as Building Block of Amyloidâ€Î²2 Protofibrils. Angewandte Chemie, 2014, 126, 12970-12974.	1.6	8
1692	Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease. International Journal of Neuropsychopharmacology, 2014, 17, 117-126.	1.0	13
1693	Caspase-dependent degradation of MDMx/MDM4 cell cycle regulatory protein in amyloid Î²-induced neuronal damage. Neuroscience Letters, 2015, 609, 182-188.	1.0	5
1694	Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimerâ€™s disease (Review). Molecular Medicine Reports, 2015, 12, 3-12.	1.1	77

#	Article	IF	Citations
1695	Novel curcumin derivatives as potent inhibitors of amyloid Î² aggregation. Biochemistry and Biophysics Reports, 2015, 4, 357-368.	0.7	28
1696	Î¼â€Opioid Receptor Attenuates AÎ² Oligomersâ€Induced Neurotoxicity Through <scp>mTOR</scp> Signaling. CNS Neuroscience and Therapeutics, 2015, 21, 8-14.	1.9	37
1697	The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration. Aging Cell, 2015, 14, 715-724.	3.0	61
1698	New Targets of Molecular Imaging in Atherosclerosis: Prehension of Current Status. Analytical Sciences, 2015, 31, 245-255.	0.8	2
1699	Loss of Polo ameliorates APP-induced Alzheimerâ€™s disease-like symptoms in Drosophila. Scientific Reports, 2015, 5, 16816.	1.6	15
1700	SDS-PAGE analysis of AÎ² oligomers is disserving research into AlzheimerÂ´s disease: appealing for ESI-IM-MS. Scientific Reports, 2015, 5, 14809.	1.6	88
1701	Protection against Î²-amyloid-induced synaptic and memory impairments via altering Î²-amyloid assembly by bis(heptyl)-cognitin. Scientific Reports, 2015, 5, 10256.	1.6	29
1702	Chronic Noise Exposure Acts Cumulatively to Exacerbate Alzheimerâ€™s Disease-Like Amyloid-Î² Pathology and Neuroinflammation in the Rat Hippocampus. Scientific Reports, 2015, 5, 12943.	1.6	43
1703	Bv8/prokineticin 2 is involved in AÎ²-induced neurotoxicity. Scientific Reports, 2015, 5, 15301.	1.6	40
1704	Potential Therapeutic Implications of Gelsolin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 13-25.	1.2	12
1705	QIAD assay for quantitating a compoundâ€™s efficacy in elimination of toxic AÎ² oligomers. Scientific Reports, 2015, 5, 13222.	1.6	39
1706	Oxidative Stress and Aberrant Cell Cycle in Alzheimerâ€™s Disease Lymphocytes: Diagnostic Prospects. Journal of Alzheimer's Disease, 2015, 46, 329-350.	1.2	45
1707	Tau and Amyloid-Î² Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 965-975.	1.2	18
1708	MicroRNA-34c Downregulation Ameliorates Amyloid-Î²-Induced Synaptic Failure and Memory Deficits by Targeting VAMP2. Journal of Alzheimer's Disease, 2015, 48, 673-686.	1.2	37
1709	Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X. Scientific Reports, 2015, 5, 17338.	1.6	34
1710	The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 373-383.	1.2	19
1712	Ortho-methylated 3-hydroxypyridines hinder hen egg-white lysozyme fibrillogenesis. Scientific Reports, 2015, 5, 12052.	1.6	18
1713	Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 50, 335-352.	1.2	42

#	Article	IF	Citations
1714	The physical basis of protein misfolding disorders. Physics Today, 2015, 68, 36-41.	0.3	22
1715	Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus. Journal of Visualized Experiments, 2015, , e52805.	0.2	21
1716	Synthesis and characterization of the amyloid Î²40 dimer model with a linker at position 30 adjacent to the intermolecular Î²-sheet region. Biochemical and Biophysical Research Communications, 2015, 466, 463-467.	1.0	6
1717	A review on protein oligomerization process. International Journal of Precision Engineering and Manufacturing, 2015, 16, 2731-2760.	1.1	16
1718	Solvent exposure of Tyr10 as a probe of structural differences between monomeric and aggregated forms of the amyloid-Î² peptide. Biochemical and Biophysical Research Communications, 2015, 468, 696-701.	1.0	11
1719	Melatonin ameliorates amyloid betaâ€induced memory deficits, tau hyperphosphorylation and neurodegeneration via <scp>PI</scp>3/Akt/<scp>GS</scp>k3Î² pathway in the mouse hippocampus. Journal of Pineal Research, 2015, 59, 47-59.	3.4	180
1720	Structure-Free Validation of Residual Dipolar Coupling and Paramagnetic Relaxation Enhancement Measurements of Disordered Proteins. Biochemistry, 2015, 54, 6876-6886.	1.2	19
1721	STIM2 protects hippocampal mushroom spines from amyloid synaptotoxicity. Molecular Neurodegeneration, 2015, 10, 37.	4.4	62
1722	Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2015, 7, 74.	3.0	109
1723	Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out. IUBMB Life, 2015, 67, 404-413.	1.5	22
1724	Arachidonic or Docosahexaenoic Acid Diet Prevents Memory Impairment in Tg2576 Mice. Journal of Alzheimer's Disease, 2015, 48, 149-162.	1.2	29
1725	Aggregation process of AÎ²₁₋₄₀with non-AÎ²amyloid component ofÎ±-synuclein. Journal of Physics: Conference Series, 2015, 640, 012008.	0.3	0
1726	Targeted Magnetic Nanoparticles for Remote Magnetothermal Disruption of Amyloidâ€Î² Aggregates. Advanced Healthcare Materials, 2015, 4, 2100-2109.	3.9	23
1727	The protein arginine methyltransferase <scp>PRMT</scp>5 regulates AÎ²â€induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease. Journal of Neurochemistry, 2015, 134, 969-977.	2.1	30
1728	Aggregationâ€Prone Amyloidâ€Î²â‹…Cu^{II} Species Formed on the Millisecond Timescale under Mildly Acidic Conditions. ChemBioChem, 2015, 16, 1293-1297.	1.3	26
1729	Influence of Aromatic Residues on the Material Characteristics of AÎ² Amyloid Protofibrils at the Atomic Scale. ChemPhysChem, 2015, 16, 2403-2414.	1.0	15
1730	Perspectives on Inhibiting Î²â€Amyloid Aggregation through Structureâ€Based Drug Design. ChemMedChem, 2015, 10, 1467-1474.	1.6	25
1731	Expression of human amyloid precursor protein in Drosophila melanogaster nerve cells causes a decrease in presynaptic gene mRNA levels. Genetics and Molecular Research, 2015, 14, 9225-9232.	0.3	4

#	Article	IF	Citations
1732	The Biology of the Escherichia coli Extracellular Matrix. Microbiology Spectrum, 2015, 3, .	1.2	66
1733	The Biology of the Escherichia coli Extracellular Matrixs. , 2015, , 249-267.		5
1734	The elusive nature and diagnostics of misfolded AÎ² oligomers. Frontiers in Chemistry, 2015, 3, 17.	1.8	24
1735	Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases. Antibodies, 2015, 4, 170-196.	1.2	5
1736	cAMP-Inhibits Cytoplasmic Phospholipase A2 and Protects Neurons against Amyloid-Î²-Induced Synapse Damage. Biology, 2015, 4, 591-606.	1.3	17
1737	Can insulin signaling pathways be targeted to transport AÃŽÂ² out of the brain?. Frontiers in Aging Neuroscience, 2015, 7, 114.	1.7	27
1738	Connectivity of Pathology: The Olfactory System as a Model for Network-Driven Mechanisms of Alzheimerâ€™s Disease Pathogenesis. Frontiers in Aging Neuroscience, 2015, 7, 234.	1.7	37
1739	How the Wnt signaling pathway protects from neurodegeneration: the mitochondrial scenario. Frontiers in Cellular Neuroscience, 2015, 9, 166.	1.8	61
1740	The prion protein constitutively controls neuronal store-operated Ca2+ entry through Fyn kinase. Frontiers in Cellular Neuroscience, 2015, 9, 416.	1.8	24
1741	Tau Oligomers: The Toxic Player at Synapses in Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2015, 9, 464.	1.8	127
1742	Fluid Biomarkers in Clinical Trials of Alzheimerâ€™s Disease Therapeutics. Frontiers in Neurology, 2015, 6, 186.	1.1	22
1743	Neurobiology of Alzheimerâ€™s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research, 2015, 12, 712-722.	0.7	134
1744	Preventing Effect of L-Type Calcium Channel Blockade on Electrophysiological Alterations in Dentate Gyrus Granule Cells Induced by Entorhinal Amyloid Pathology. PLoS ONE, 2015, 10, e0117555.	1.1	21
1745	Pharmacokinetics, Safety and Tolerability of Melissa officinalis Extract which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial. PLoS ONE, 2015, 10, e0126422.	1.1	70
1746	Conformational Dynamics and Binding Free Energies of Inhibitors of BACE-1: From the Perspective of Protonation Equilibria. PLoS Computational Biology, 2015, 11, e1004341.	1.5	31
1747	Structure-Based Peptide Design to Modulate Amyloid Beta Aggregation and Reduce Cytotoxicity. PLoS ONE, 2015, 10, e0129087.	1.1	37
1748	Self-Assembly of AÎ²40, AÎ²42 and AÎ²43 Peptides in Aqueous Mixtures of Fluorinated Alcohols. PLoS ONE, 2015, 10, e0136567.	1.1	16
1749	Modeling the Role of the Glymphatic Pathway and Cerebral Blood Vessel Properties in Alzheimerâ€™s Disease Pathogenesis. PLoS ONE, 2015, 10, e0139574.	1.1	67

#	Article	IF	Citations
1750	Amyloid Precursor Protein Translation Is Regulated by a 3â€™UTR Guanine Quadruplex. PLoS ONE, 2015, 10, e0143160.	1.1	42
1751	Lysosomal Enzyme Glucocerebrosidase Protects against AÎ²1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854.	1.1	12
1752	NLRP3 Inflammasome: Activation and Regulation in Age-Related Macular Degeneration. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	79
1753	Axonal Terminals Exposed to Amyloid-Î² May Not Lead to Pre-Synaptic Axonal Damage. Journal of Alzheimer's Disease, 2015, 45, 1139-1148.	1.2	8
1754	Zinc as chaperone-mimicking agent for retardation of amyloid Î² peptide fibril formation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 5407-5412.	3.3	102
1755	Prion-Protein-interacting Amyloid-Î² Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. Journal of Biological Chemistry, 2015, 290, 17415-17438.	1.6	104
1756	Tong Luo Jiu Nao ameliorates AÎ²1â€“40-induced cognitive impairment on adaptive behavior learning by modulating ERK/CaMKII/CREB signaling in the hippocampus. BMC Complementary and Alternative Medicine, 2015, 15, 55.	3.7	8
1757	Alzheimer Disease. , 2015, , 753-768.		6
1758	A novel nicotinic mechanism underlies Î²-amyloid-induced neurotoxicity. Neuropharmacology, 2015, 97, 457-463.	2.0	24
1759	Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2260-2271.	1.5	128
1760	Inhibition of amyloid fibril formation and cytotoxicity by a chemical analog of Curcumin as a stable inhibitor. International Journal of Biological Macromolecules, 2015, 78, 396-404.	3.6	28
1761	In Vitro Neuroprotective Activities of Compounds from Angelica shikokiana Makino. Molecules, 2015, 20, 4813-4832.	1.7	30
1762	Preparation and biological evaluation of conformationally constrained BACE1 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 3260-3268.	1.4	16
1763	Compounds for imaging amyloid-Î² deposits in an Alzheimerâ€™s brain: a patent review. Expert Opinion on Therapeutic Patents, 2015, 25, 413-423.	2.4	18
1764	Characterization of Aldh2 -/- mice as an age-related model of cognitive impairment and Alzheimerâ€™s disease. Molecular Brain, 2015, 8, 27.	1.3	67
1765	Real-time investigation of cytochrome c release profiles in living neuronal cells undergoing amyloid beta oligomer-induced apoptosis. Nanoscale, 2015, 7, 10340-10343.	2.8	14
1766	High Resolution Structural Characterization of AÎ²₄₂ Amyloid Fibrils by Magic Angle Spinning NMR. Journal of the American Chemical Society, 2015, 137, 7509-7518.	6.6	103
1767	Yeast red pigment modifies Amyloid beta growth in Alzheimer disease models in bothSaccharomyces cerevisiaeandDrosophila melanogaster. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 100-111.	1.4	8

#	Article	IF	Citations
1768	Effects of dipole modifiers on channel-forming activity of amyloid and amyloid-like peptides in lipid bilayers. Cell and Tissue Biology, 2015, 9, 250-259.	0.2	4
1769	The Voltage-dependent Anion Channel 1 Mediates Amyloid Î² Toxicity and Represents a Potential Target for Alzheimer Disease Therapy. Journal of Biological Chemistry, 2015, 290, 30670-30683.	1.6	109
1770	EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-Î² oligomers and plaques. Nature Communications, 2015, 6, 8997.	5.8	96
1771	Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimerâ€™s disease. Nature Communications, 2015, 6, 8762.	5.8	210
1772	Molecular regulation of dendritic spine dynamics and their potential impact on synaptic plasticity and neurological diseases. Neuroscience and Biobehavioral Reviews, 2015, 59, 208-237.	2.9	100
1773	Combined Experimental and Simulation Studies Suggest a Revised Mode of Action of the Antiâ€Alzheimer Disease Drug NQâ€Trp. Chemistry - A European Journal, 2015, 21, 12657-12666.	1.7	20
1774	Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia. Molecular Neurodegeneration, 2015, 10, 68.	4.4	69
1775	Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2015, 40, 54-62.	0.7	21
1776	Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory. Neuropathology and Applied Neurobiology, 2015, 41, 414-427.	1.8	75
1777	Potential Role of Vitamin C in the Prevention of Alzheimerâ€™s Disease. , 2015, , 663-668.		0
1778	The Roles of Cellular and Organismal Aging in the Development of Late-Onset Maladies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 1-23.	9.6	31
1779	Strong Inhibition of Betaâ€Amyloid Peptide Aggregation Realized by Twoâ€Steps Evolved Peptides. Chemical Biology and Drug Design, 2015, 85, 356-368.	1.5	6
1780	The <scp><scp>Ca</scp></scp>²⁺ channel inhibitor 2â€<scp>APB</scp> reverses <scp>Î²</scp>â€amyloidâ€induced <scp>LTP</scp> deficit in hippocampus by blocking <scp>BAX</scp> and caspaseâ€3 hyperactivation. British Journal of Pharmacology, 2015, 172, 2273-2285.	2.7	16
1781	The N-terminal region of myelin basic protein reduces fibrillar amyloid-Î² deposition in Tg-5xFAD mice. Neurobiology of Aging, 2015, 36, 801-811.	1.5	10
1782	MRZ-99030 â€“ A novel modulator of AÎ² aggregation: II â€“ Reversal ofÂAÎ² oligomer-induced deficits in long-term potentiation (LTP) andÂcognitive performance in rats and mice. Neuropharmacology, 2015, 92, 170-182.	2.0	23
1783	Neurotoxicity and synaptic plasticity impairment of N-acetylglucosamine polymers: implications for Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1780-1791.	1.5	17
1784	Caffeolyquinic Acid Protects against Alzheimerâ€™s Disease through Inhibition of Amyloid Beta-Induced Toxicity. , 2015, , 729-735.		0
1785	Interaction of apoNeuroglobin with hemeâ€“AÎ² complexes relevant to Alzheimerâ€™s disease. Journal of Biological Inorganic Chemistry, 2015, 20, 563-574.	1.1	9

#	Article	IF	Citations
1786	A molecular chaperone breaks the catalytic cycle that generates toxic AÎ² oligomers. Nature Structural and Molecular Biology, 2015, 22, 207-213.	3.6	373
1787	Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment. Brain, 2015, 138, 992-1008.	3.7	67
1788	Amyloids, melanins and oxidative stress in melanomagenesis. Experimental Dermatology, 2015, 24, 171-174.	1.4	20
1789	Pullulan and pullulan derivatives as promising biomolecules for drug and gene targeting. Carbohydrate Polymers, 2015, 123, 190-207.	5.1	213
1790	Substitution of Proline32 by Î±-Methylproline Preorganizes Î²2-Microglobulin for Oligomerization but Not for Aggregation into Amyloids. Journal of the American Chemical Society, 2015, 137, 2524-2535.	6.6	17
1791	Probing the Sources of the Apparent Irreproducibility of Amyloid Formation: Drastic Changes in Kinetics and a Switch in Mechanism Due to Micellelike Oligomer Formation at Critical Concentrations of IAPP. Journal of Physical Chemistry B, 2015, 119, 2886-2896.	1.2	85
1792	<scp>APOE</scp>â€modulated AÎ²â€induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. Journal of Neurochemistry, 2015, 133, 465-488.	2.1	123
1793	Orientations of Residues along the Î²-Arch of Self-Assembled Amylin Fibril-Like Structures Lead to Polymorphism. Biomacromolecules, 2015, 16, 156-165.	2.6	46
1794	Interaction of AÎ²_{1â€“42} Amyloids with Lipids Promotes â€œOff-Pathwayâ€•Oligomerization and Membrane Damage. Biomacromolecules, 2015, 16, 944-950.	2.6	44
1795	Modulation of Alzheimerâ€™s AÎ² Protofilament-Membrane Interactions by Lipid Headgroups. ACS Chemical Neuroscience, 2015, 6, 446-455.	1.7	55
1796	Protective Effects of Baicalin on AÎ²1â€“42-Induced Learning and Memory Deficit, Oxidative Stress, and Apoptosis in Rat. Cellular and Molecular Neurobiology, 2015, 35, 623-632.	1.7	51
1797	Cognitive recovery by chronic activation of the large-conductance calcium-activated potassium channel in a mouse model of Alzheimer's disease. Neuropharmacology, 2015, 92, 8-15.	2.0	46
1798	Atomic-Level Study of the Effects of O4 Molecules on the Structural Properties of Protofibrillar AÎ² Trimer: Î²-Sheet Stabilization, Salt Bridge Protection, and Binding Mechanism. Journal of Physical Chemistry B, 2015, 119, 2786-2794.	1.2	40
1799	Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases. Trends in Pharmacological Sciences, 2015, 36, 72-77.	4.0	147
1800	Tauâ€targeting passive immunization modulates aspects of pathology in tau transgenic mice. Journal of Neurochemistry, 2015, 132, 135-145.	2.1	70
1801	Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nature Reviews Neuroscience, 2015, 16, 109-120.	4.9	611
1802	Influence of the Î²â€Sheet Content on the Mechanical Properties of Aggregates during Amyloid Fibrillization. Angewandte Chemie, 2015, 127, 2492-2496.	1.6	22
1803	Assembly of AÎ² Proceeds via Monomeric Nuclei. Journal of Molecular Biology, 2015, 427, 287-290.	2.0	32

#	Article	IF	Citations
1804	Concluding the Amyloid Formation Pathway of a Coiledâ€Coilâ€Based Peptide from the Size of the Critical Nucleus. ChemPhysChem, 2015, 16, 108-114.	1.0	2
1805	Towards Ratiometric Sensing of Amyloid Fibrils In Vitro. Chemistry - A European Journal, 2015, 21, 3425-3434.	1.7	23
1806	Label-free detection of Alzheimerâ€™s disease through the ADP3 peptoid recognizing the serum amyloid-beta42 peptide. Chemical Communications, 2015, 51, 718-721.	2.2	38
1807	Chemical Cross-Linking/Mass Spectrometry Maps the Amyloid Î² Peptide Binding Region on Both Apolipoprotein E Domains. ACS Chemical Biology, 2015, 10, 1010-1016.	1.6	34
1808	Influence of the Î²â€Sheet Content on the Mechanical Properties of Aggregates during Amyloid Fibrillization. Angewandte Chemie - International Edition, 2015, 54, 2462-2466.	7.2	129
1809	Viral capsid assembly as a model for protein aggregation diseases: Active processes catalyzed by cellular assembly machines comprising novel drug targets. Virus Research, 2015, 207, 155-164.	1.1	16
1810	Luteolin Reduces BACE1 Expression through NF-Î¹B and Estrogen Receptor Mediated Pathways in HEK293 and SH-SY5Y Cells. Journal of Alzheimer's Disease, 2015, 45, 659-671.	1.2	32
1811	Hybridization of an AÎ²-specific antibody fragment with aminopyrazole-based Î²-sheet ligands displays striking enhancement of target affinity. Organic and Biomolecular Chemistry, 2015, 13, 2974-2979.	1.5	5
1812	Protein misfolding cyclic amplification (PMCA): Current status and future directions. Virus Research, 2015, 207, 47-61.	1.1	33
1813	Cyclinâ€Dependent kinase 5 targeting prevents Î²â€Amyloid aggregation involving glycogen synthase kinase 3Î² and phosphatases. Journal of Neuroscience Research, 2015, 93, 1258-1266.	1.3	20
1814	A Cyclic Peptide Mimic of the Î²-Amyloid Binding Domain on Transthyretin. ACS Chemical Neuroscience, 2015, 6, 778-789.	1.7	23
1815	Localization and Trafficking of Amyloid-Î² Protein Precursor and Secretases: Impact on Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 329-347.	1.2	64
1816	Teneurins and Alzheimerâ€™s disease: A suggestive role for a unique family of proteins. Medical Hypotheses, 2015, 84, 402-407.	0.8	13
1817	The proteasome gets a grip on protein complexity. Nature Structural and Molecular Biology, 2015, 22, 181-183.	3.6	1
1818	Secondary nucleation wears the BRICHOS in this family. Nature Structural and Molecular Biology, 2015, 22, 180-181.	3.6	3
1819	Silibinin inhibits acetylcholinesterase activity and amyloid Î² peptide aggregation: a dual-target drug for the treatment of Alzheimerâ€™s disease. Neurobiology of Aging, 2015, 36, 1792-1807.	1.5	89
1820	COB231 targets amyloid plaques in postâ€mortem human brain tissue and in an Alzheimer mouse model. Journal of Neurochemistry, 2015, 132, 609-618.	2.1	4
1821	Evidence against a role of P-glycoprotein in the clearance of the Alzheimerâ€™s disease AÎ²1â€“42 peptides. Cell Stress and Chaperones, 2015, 20, 421-430.	1.2	11

#	Article	IF	Citations
1822	Pumilio1 Haploinsufficiency Leads to SCA1-like Neurodegeneration by Increasing Wild-Type Ataxin1 Levels. Cell, 2015, 160, 1087-1098.	13.5	139
1823	Reversible redox modifications in the microglial proteome challenged by beta amyloid. Molecular BioSystems, 2015, 11, 1584-1593.	2.9	15
1824	From molecule to molecule and cell to cell: Prion-like mechanisms in amyotrophic lateral sclerosis. Neurobiology of Disease, 2015, 77, 257-265.	2.1	74
1825	Scanning ultrasound removes amyloid-Î² and restores memory in an Alzheimerâ€™s disease mouse model. Science Translational Medicine, 2015, 7, 278ra33.	5.8	409
1826	Engineering of a peptide probe for Î²-amyloid aggregates. Molecular BioSystems, 2015, 11, 2281-2289.	2.9	14
1827	Chemical Fluorescent Probe for Detection of AÎ² Oligomers. Journal of the American Chemical Society, 2015, 137, 13503-13509.	6.6	163
1828	Regulation of protein homeostasis in neurodegenerative diseases: the role of coding and non-coding genes. Cellular and Molecular Life Sciences, 2015, 72, 4027-4047.	2.4	29
1829	Destabilization of Alzheimerâ€™s AÎ²42 Protofibrils with a Novel Drug Candidate wgx-50 by Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2015, 119, 11196-11202.	1.2	69
1830	Improvement of spatial learning by facilitating large-conductance calcium-activated potassium channel with transcranial magnetic stimulation in Alzheimer's disease model mice. Neuropharmacology, 2015, 97, 210-219.	2.0	63
1831	Supramolecular Glycosylation Accelerates Proteolytic Degradation of Peptide Nanofibrils. Journal of the American Chemical Society, 2015, 137, 10092-10095.	6.6	32
1832	Design and Characterization of Chemically Stabilized AÎ²42 Oligomers. Biochemistry, 2015, 54, 5315-5321.	1.2	13
1833	Molecular Mechanisms of Alzheimerâ€™s Biomarker FDDNP Binding to AÎ² Amyloid Fibril. Journal of Physical Chemistry B, 2015, 119, 11568-11580.	1.2	14
1834	Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus. Scientific Reports, 2015, 5, 11708.	1.6	116
1835	Identification and characterization of PKCÎ³, a kinase associated with SCA14, as an amyloidogenic protein. Human Molecular Genetics, 2015, 24, 525-539.	1.4	22
1836	Biophysical insight into the anti-amyloidogenic behavior of taurine. International Journal of Biological Macromolecules, 2015, 80, 375-384.	3.6	78
1837	Analyzing dendritic spine pathology in Alzheimerâ€™s disease: problems and opportunities. Acta Neuropathologica, 2015, 130, 1-19.	3.9	154
1838	How to Stabilize Both the Proteins and the Membranes: Diverse Effects of sHsps in Neuroprotection. Heat Shock Proteins, 2015, , 527-562.	0.2	4
1839	CALHM1 ion channel elicits amyloid-Î² clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain. Journal of Cell Science, 2015, 128, 2330-2338.	1.2	32

#	Article	IF	Citations
1840	Lipids in Amyloid-Î² Processing, Aggregation, and Toxicity. Advances in Experimental Medicine and Biology, 2015, 855, 67-94.	0.8	56
1841	Prion Protein Modulates Monoaminergic Systems and Depressive-like Behavior in Mice. Journal of Biological Chemistry, 2015, 290, 20488-20498.	1.6	22
1842	The Effect of (â^')-Epigallo-catechin-(3)-gallate on Amyloidogenic Proteins Suggests a Common Mechanism. Advances in Experimental Medicine and Biology, 2015, 863, 139-161.	0.8	56
1843	Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye, 2015, 29, 1013-1026.	1.1	133
1844	Mechanism of Nucleated Conformational Conversion of AÎ²42. Biochemistry, 2015, 54, 4197-4207.	1.2	68
1845	A theoretical study on the molecular determinants of the affibody protein Z_{AÎ²3}bound to an amyloid Î² peptide. Physical Chemistry Chemical Physics, 2015, 17, 16886-16893.	1.3	4
1846	Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases. Advances in Experimental Medicine and Biology, 2015, , .	0.8	7
1847	Binding interactions of agents that alter Î±-synuclein aggregation. RSC Advances, 2015, 5, 11577-11590.	1.7	22
1848	Competition between surface adsorption and folding of fibril-forming polypeptides. Physical Review E, 2015, 91, 022711.	0.8	7
1849	Neuronal hyperactivity â€“ A key defect in Alzheimer's disease?. BioEssays, 2015, 37, 624-632.	1.2	182
1850	Modulation of bovine serum albumin fibrillation by ester bonded and conventional gemini surfactants. RSC Advances, 2015, 5, 58616-58624.	1.7	22
1851	Exogenous Î²-amyloid peptide interferes with GLUT4 localization in neurons. Brain Research, 2015, 1615, 42-50.	1.1	12
1852	Discovery of Small Molecules for Up-Regulating the Translation of Antiamyloidogenic Secretase, a Disintegrin and Metalloproteinase 10 (ADAM10), by Binding to the G-Quadruplex-Forming Sequence in the 5â€² Untranslated Region (UTR) of Its mRNA. Journal of Medicinal Chemistry, 2015, 58, 3875-3891.	2.9	54
1853	<scp>TDP</scp>â€43 in amyotrophic lateral sclerosis â€“ is it a prion disease?. European Journal of Neurology, 2015, 22, 753-761.	1.7	38
1854	X-ray Crystallographic Structures of Oligomers of Peptides Derived from Î²₂-Microglobulin. Journal of the American Chemical Society, 2015, 137, 6304-6311.	6.6	36
1855	Dissociation of a BRICHOS trimer into monomers leads to increased inhibitory effect on AÎ²42 fibril formation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 835-843.	1.1	20
1856	New insights into Alzheimer's disease pathogenesis: the involvement of neuroligins in synaptic malfunction. Neurodegenerative Disease Management, 2015, 5, 137-145.	1.2	17
1857	Alzheimer's disease-related amyloid-Î² induces synaptotoxicity in human iPS cell-derived neurons. Cell Death and Disease, 2015, 6, e1709-e1709.	2.7	86

#	Article	IF	Citations
1858	The role of positron emission tomography imaging in understanding Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2015, 15, 395-406.	1.4	27
1859	Exploring the Alzheimer amyloid-Î² peptide conformational ensemble: A review of molecular dynamics approaches. Peptides, 2015, 69, 86-91.	1.2	69
1860	Mechanisms of the self-assembly of EAK16-family peptides into fibrillar and globular structures: molecular dynamics simulations from nano- to micro-seconds. European Biophysics Journal, 2015, 44, 263-276.	1.2	19
1861	Specific Amyloid Î² Clearance by a Catalytic Antibody Construct. Journal of Biological Chemistry, 2015, 290, 10229-10241.	1.6	26
1862	Amyloid Î² oligomers induce interleukin-1Î² production in primary microglia in a cathepsin B- and reactive oxygen species-dependent manner. Biochemical and Biophysical Research Communications, 2015, 458, 561-567.	1.0	20
1863	1H- and 13C-NMR spectroscopy of Thy-1-APPSL mice brain extracts indicates metabolic changes in Alzheimerâ€™s disease. Journal of Neural Transmission, 2015, 122, 541-550.	1.4	10
1864	Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-Î²1â€“40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems. Neurotoxicity Research, 2015, 28, 32-42.	1.3	25
1865	Dementia and Insulin Resistance. , 2015, , 403-412.		0
1866	Roles of zinc ions and structural polymorphism of Î²-amyloid in the development of Alzheimerâ€™s disease. Molecular Biology, 2015, 49, 217-230.	0.4	27
1867	Advances in Alzheimerâ€™s Disease Drug Development. BMC Medicine, 2015, 13, 62.	2.3	78
1868	APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. Molecular Neurodegeneration, 2015, 10, 7.	4.4	79
1869	Glutamate receptors function as scaffolds for the regulation of Î²-amyloid and cellular prion protein signaling complexes. Molecular Brain, 2015, 8, 18.	1.3	59
1870	A combination Alzheimerâ€™s therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice. Molecular Brain, 2015, 8, 19.	1.3	26
1871	The Role of Oxidative Stress in Neurodegenerative Diseases. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 151-167.	0.4	2
1872	Biomarkers of Alzheimer Disease, Insulin Resistance, and Obesity in Childhood. Pediatrics, 2015, 135, 1074-1081.	1.0	30
1873	Immune attack: the role of inflammation in Alzheimer disease. Nature Reviews Neuroscience, 2015, 16, 358-372.	4.9	1,677
1874	Semaphorins. , 2015, , .		6
1875	Nodulisporiviridins Aâ€“H, Bioactive Viridins from Nodulisporium sp.. Journal of Natural Products, 2015, 78, 1221-1230.	1.5	51

#	Article	IF	Citations
1876	Layers of structure and function in protein aggregation. Nature Chemical Biology, 2015, 11, 373-377.	3.9	35
1877	Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model. Journal of Neuroscience, 2015, 35, 4857-4868.	1.7	122
1878	The unfolded protein response in the therapeutic effect of hydroxy-DHA against Alzheimerâ€™s disease. Apoptosis: an International Journal on Programmed Cell Death, 2015, 20, 712-724.	2.2	17
1879	CYP2J2 rs890293 polymorphism is associated with susceptibility to Alzheimerâ€™s disease in the Chinese Han population. Neuroscience Letters, 2015, 593, 56-60.	1.0	28
1880	Is interaction of amyloid Î²-peptides with metals involved in cognitive activity?. Metallomics, 2015, 7, 1205-1212.	1.0	18
1881	Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Experimental and Molecular Medicine, 2015, 47, e147-e147.	3.2	650
1882	â€œBoomerang Neuropathologyâ€•of Late-Onset Alzheimerâ€™s Disease is Shrouded in Harmful â€œBDDSâ€• Breathing, Diet, Drinking, and Sleep During Aging. Neurotoxicity Research, 2015, 28, 55-93.	1.3	11
1883	An Early Folding Contact between Phe19 and Leu34 is Critical for Amyloid-Î² Oligomer Toxicity. ACS Chemical Neuroscience, 2015, 6, 1290-1295.	1.7	52
1884	Uptake of raft components into amyloid Î²-peptide aggregates and membrane damage. Analytical Biochemistry, 2015, 481, 18-26.	1.1	8
1885	Ligand Binding Thermodynamics in Drug Discovery: Still a Hot Tip?. Journal of Medicinal Chemistry, 2015, 58, 6321-6335.	2.9	94
1886	Nanomedicine for the treatment of Alzheimer's disease. Nanomedicine, 2015, 10, 1203-1218.	1.7	72
1887	Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 319-344.	0.9	105
1888	Multiple Structural States Exist Throughout the Helical Nucleation Sequence of the Intrinsically Disordered Protein Stathmin, As Reported by Electron Paramagnetic Resonance Spectroscopy. Biochemistry, 2015, 54, 1717-1728.	1.2	8
1889	Alzheimerâ€™s Disease and Mechanism-Based Attempts to Enhance Cognition. , 2015, , 193-231.		0
1890	High Calorie Diet and the Human Brain. , 2015, , .		10
1891	Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals. Journal of Nutrition, Health and Aging, 2015, 19, 413-423.	1.5	124
1892	Biophysical Comparison of Soluble Amyloid-Î²(1â€“42) Protofibrils, Oligomers, and Protofilaments. Biochemistry, 2015, 54, 2193-2204.	1.2	41
1893	Calcium Enhances Binding of A Î² Monomer to DMPC Lipid Bilayer. Biophysical Journal, 2015, 108, 1807-1818.	0.2	16

#	Article	IF	Citations
1894	Prediction of a stable associated liquid of short amyloidogenic peptides. Physical Chemistry Chemical Physics, 2015, 17, 10556-10567.	1.3	18
1895	Apolipoprotein E Regulates Amyloid Formation within Endosomes of Pigment Cells. Cell Reports, 2015, 13, 43-51.	2.9	109
1896	Druggability of Intrinsically Disordered Proteins. Advances in Experimental Medicine and Biology, 2015, 870, 383-400.	0.8	52
1897	Effects of lysine residues on structural characteristics and stability of tau proteins. Biochemical and Biophysical Research Communications, 2015, 466, 486-492.	1.0	12
1898	Primary Nucleation Kinetics of Short Fibril-Forming Amyloidogenic Peptides. Journal of Physical Chemistry B, 2015, 119, 12568-12579.	1.2	37
1899	The increased potassium intake improves cognitive performance and attenuates histopathological markers in a model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2630-2644.	1.8	26
1900	Beta Amyloid Hallmarks: From Intrinsically Disordered Proteins to Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2015, 870, 401-421.	0.8	23
1901	Peptide dimer structure in an AÎ²(1â€“42) fibril visualized with cryo-EM. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11858-11863.	3.3	196
1902	Amyloid-PET predicts inhibition of de novo plaque formation upon chronic Î³-secretase modulator treatment. Molecular Psychiatry, 2015, 20, 1179-1187.	4.1	46
1903	Tau Aggregation Propensity Engrained in Its Solution State. Journal of Physical Chemistry B, 2015, 119, 14421-14432.	1.2	30
1904	Investigation of low amyloid level toxicity effects on the function of hippocampal neurons. Open Life Sciences, 2014, 10, .	0.6	0
1905	Review of Amyotrophic Lateral Sclerosis, Parkinsonâ€™s and Alzheimerâ€™s diseases helps further define pathology of the novel paradigm for Alzheimerâ€™s with heavy metals as primary disease cause. Medical Hypotheses, 2015, 85, 779-790.	0.8	25
1906	Neurodegenerative Disorders as Systemic Diseases. , 2015, , .		2
1907	Nanoscale assemblies of small molecules control the fate of cells. Nano Today, 2015, 10, 615-630.	6.2	49
1908	Synaptotagmins interact with APP and promote AÎ² generation. Molecular Neurodegeneration, 2015, 10, 31.	4.4	34
1909	Linking insulin with Alzheimerâ€™s disease: emergence as type III diabetes. Neurological Sciences, 2015, 36, 1763-1769.	0.9	49
1910	Biodegradable Polymer Nanogels for Drug/Nucleic Acid Delivery. Chemical Reviews, 2015, 115, 8564-8608.	23.0	401
1911	Site-specific dynamics of amyloid formation and fibrillar configuration of AÎ²_{1â€“23} using an unnatural amino acid. Chemical Communications, 2015, 51, 7000-7003.	2.2	20

#	Article	IF	Citations
1912	Two macrocyclic polyamines as modulators of metal-mediated AÎ²40aggregation. Integrative Biology (United Kingdom), 2015, 7, 655-662.	0.6	21
1913	Effects of structural modifications on the metal binding, anti-amyloid activity, and cholinesterase inhibitory activity of chalcones. Organic and Biomolecular Chemistry, 2015, 13, 9418-9426.	1.5	29
1914	Targeting disordered proteins with small molecules using entropy. Trends in Biochemical Sciences, 2015, 40, 491-496.	3.7	87
1915	Label-free Quantitative Proteomics of Mouse Cerebrospinal Fluid Detects Î²-Site APP Cleaving Enzyme (BACE1) Protease Substrates In Vivo. Molecular and Cellular Proteomics, 2015, 14, 2550-2563.	2.5	70
1916	Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathologica, 2015, 130, 713-729.	3.9	53
1917	Myeloid Cells in Alzheimer's Disease: Culprits, Victims or Innocent Bystanders?. Trends in Neurosciences, 2015, 38, 659-668.	4.2	60
1918	Physico-chemical methods for studying amyloid-Î² aggregation. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2015, 9, 258-274.	0.2	12
1919	A Kinetic Model for Cell Damage Caused by Oligomer Formation. Biophysical Journal, 2015, 109, 1338-1346.	0.2	1
1920	Structural differences of amyloid-Î² fibrils revealed by antibodies from phage display. BMC Biotechnology, 2015, 15, 57.	1.7	12
1921	Genetic markers of cholesterol transport and gray matter diffusion: a preliminary study of the CETP I405V polymorphism. Journal of Neural Transmission, 2015, 122, 1581-1592.	1.4	3
1922	Effects of BACE1 haploinsufficiency on APP processing and AÎ² concentrations in male and female 5XFAD Alzheimer mice at different disease stages. Neuroscience, 2015, 307, 128-137.	1.1	23
1923	Amyloid-Î² Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a. Cell Reports, 2015, 12, 1244-1251.	2.9	54
1924	Human Hsp70 Disaggregase Reverses Parkinsonâ€™s-Linked Î±-Synuclein Amyloid Fibrils. Molecular Cell, 2015, 59, 781-793.	4.5	336
1925	A Rational Design Strategy for the Selective Activity Enhancement of a Molecular Chaperone toward a Target Substrate. Biochemistry, 2015, 54, 5103-5112.	1.2	25
1926	Î-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature, 2015, 526, 443-447.	13.7	308
1927	The Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology. Physiological Reviews, 2015, 95, 1111-1155.	13.1	481
1928	Association between variant amyloid deposits and motor deficits in FAD-associated presenilin-1 mutations: A systematic review. Neuroscience and Biobehavioral Reviews, 2015, 56, 180-192.	2.9	11
1929	Lipid insertion domain unfolding regulates protein orientational transition behavior in a lipid bilayer. Biophysical Chemistry, 2015, 206, 22-39.	1.5	7

#	Article	IF	Citations
1930	What can lipidomics tell us about the pathogenesis of Alzheimer disease?. Biological Chemistry, 2015, 396, 1281-1291.	1.2	21
1931	Characterization of the interactions between Î²â€amyloid peptide and the membranes of human SKâ€Nâ€SH cells. FEBS Letters, 2015, 589, 1929-1934.	1.3	4
1932	Oleocanthal Enhances Amyloid-Î² Clearance from the Brains of TgSwDI Mice and in Vitro across a Human Blood-Brain Barrier Model. ACS Chemical Neuroscience, 2015, 6, 1849-1859.	1.7	123
1933	Modified screen printed electrode for development of a highly sensitive label-free impedimetric immunosensor to detect amyloid beta peptides. Analytica Chimica Acta, 2015, 892, 69-76.	2.6	69
1934	Protein N-homocysteinylation: From cellular toxicity to neurodegeneration. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 2239-2245.	1.1	63
1935	In vitro validation of effects of BDNF-expressing mesenchymal stem cells on neurodegeneration in primary cultured neurons of APP/PS1 mice. Neuroscience, 2015, 307, 37-50.	1.1	29
1936	A model for non-obligate oligomer formation in protein aggregration. Biochemical and Biophysical Research Communications, 2015, 465, 523-527.	1.0	5
1937	Histone H3 Ser57 and Thr58 phosphorylation in the brain of 5XFAD mice. FEBS Open Bio, 2015, 5, 550-556.	1.0	25
1938	Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. Journal of Immunological Methods, 2015, 424, 64-79.	0.6	15
1939	Aging Mechanisms. , 2015, , .		4
1940	microRNA-33 Regulates ApoE Lipidation and Amyloid-Î² Metabolism in the Brain. Journal of Neuroscience, 2015, 35, 14717-14726.	1.7	104
1941	The soluble extracellular fragment of neuroligin-1 targets AÎ² oligomers to the postsynaptic region of excitatory synapses. Biochemical and Biophysical Research Communications, 2015, 466, 66-71.	1.0	23
1942	Advances in the therapy of Alzheimerâ€™s disease: targeting amyloid beta and tau and perspectives for the future. Expert Review of Neurotherapeutics, 2015, 15, 83-105.	1.4	64
1943	Neuropathology and biochemistry of AÎ² and its aggregates in Alzheimerâ€™s disease. Acta Neuropathologica, 2015, 129, 167-182.	3.9	224
1944	Rescue of impaired lateâ€“phase long-term depression in a tau transgenic mouse model. Neurobiology of Aging, 2015, 36, 730-739.	1.5	37
1945	Modulation of adenosine signaling prevents scopolamine-induced cognitive impairment in zebrafish. Neurobiology of Learning and Memory, 2015, 118, 113-119.	1.0	40
1946	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. Advances in Anatomy, Embryology and Cell Biology, 2015, , .	1.0	81
1947	Effect of amyloid Î²-peptide on the fluidity of phosphatidylcholine membranes: Uses and limitations of diphenylhexatriene fluorescence anisotropy. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 753-759.	1.4	22

#	Article	IF	Citations
1948	AÎ² self-association and adsorption on a hydrophobic nanosurface: competitive effects and the detection of small oligomers via electrical response. Soft Matter, 2015, 11, 269-279.	1.2	15
1949	The neuroprotective effects of Î²-hydroxybutyrate on AÎ²-injected rat hippocampus in vivo and in AÎ²-treated PC-12 cells in vitro. Free Radical Research, 2015, 49, 139-150.	1.5	47
1950	The green tea polyphenol (â^')â€epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Letters, 2015, 589, 77-83.	1.3	172
1951	Double Negative (IgG+IgDâ^'CD27â^') B Cells are Increased in a Cohort of Moderate-Severe Alzheimer's Disease Patients and Show a Pro-Inflammatory Trafficking Receptor Phenotype. Journal of Alzheimer's Disease, 2015, 44, 1241-1251.	1.2	49
1952	P2Y receptors in Alzheimer's disease. Biology of the Cell, 2015, 107, 1-21.	0.7	38
1953	Statistically quantified measurement of an Alzheimer's marker by surface-enhanced Raman scattering. Journal of Biophotonics, 2015, 8, 567-574.	1.1	40
1954	The Role of Cholesterol Metabolism in Alzheimerâ€™s Disease. Molecular Neurobiology, 2015, 51, 947-965.	1.9	62
1955	Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?. European Neuropsychopharmacology, 2015, 25, 713-724.	0.3	78
1956	Deregulation of purine metabolism in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 68-80.	1.5	108
1957	Age Progression of Neuropathological Markers in the Brain of the Chilean Rodent Octodon degus, a Natural Model of <scp>A</scp>lzheimer's Disease. Brain Pathology, 2015, 25, 679-691.	2.1	42
1958	Goldâ€Nanoparticleâ€Based Multifunctional Amyloidâ€Î² Inhibitor against Alzheimerâ€™s Disease. Chemistry - A European Journal, 2015, 21, 829-835.	1.7	127
1959	AA Amyloidosis: Pathogenesis and Targeted Therapy. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 321-344.	9.6	201
1960	Functional Characteristics and Molecular Mechanism of a New scFv Antibody Against AÎ²42 Oligomers and Immature Protofibrils. Molecular Neurobiology, 2015, 52, 1269-1281.	1.9	13
1961	Unfolded protein responseâ€induced <scp>ER</scp> dj3 secretion links <scp>ER</scp> stress to extracellular proteostasis. EMBO Journal, 2015, 34, 4-19.	3.5	110
1962	Modulation of the AÎ² peptide aggregation pathway by KP1019 limits AÎ²-associated neurotoxicity. Metallomics, 2015, 7, 129-135.	1.0	37
1963	Electrical signaling of enzyme-linked immunosorbent assays with an ion-sensitive field-effect transistor. Biosensors and Bioelectronics, 2015, 64, 318-323.	5.3	49
1964	Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. Neurobiology of Aging, 2015, 36, 201-210.	1.5	65
1965	Fibrillation of Î² amyloid peptides in the presence of phospholipid bilayers and the consequent membrane disruption. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 266-276.	1.4	52

#	Article	IF	Citations
1966	AÎ² and NMDAR activation cause mitochondrial dysfunction involving ER calcium release. Neurobiology of Aging, 2015, 36, 680-692.	1.5	74
1967	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. Colombia Medica, 2016, , 203-212.	0.7	55
1968	Selenoergothionein as a Potential Inhibitor against Amyloid Î²-Protein (AÎ²): Docking and Molecular Dynamics Studies. International Journal of Biomedical Data Mining, 2016, 5, .	0.1	0
1969	Stress and Cognitive Reserve as independent factors of neuropsychological performance in healthy elderly. Ciencia E Saude Coletiva, 2016, 21, 3499-3508.	0.1	14
1970	Histone Deacetylases as Therapeutic Targets in Neurodegenerative Diseases. , 2016, , 33-45.		1
1971	AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species. Current Pharmaceutical Design, 2016, 22, 3950-3970.	0.9	75
1972	Acceleration of Amyloidosis byÂInflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 101-113.	1.2	62
1973	Dendrobium alkaloids prevent AÎ²_{25â€“35}-induced neuronal and synaptic loss via promoting neurotrophic factors expression in mice. PeerJ, 2016, 4, e2739.	0.9	67
1974	Brain Lipids in the Pathophysiology and Treatment of Alzheimerâ€™s Disease. , 2016, , .		4
1975	Soluble Amyloid-Î²42 Stimulates Glutamate Release through Activation of the Î±7 Nicotinic Acetylcholine Receptor. Journal of Alzheimer's Disease, 2016, 53, 337-347.	1.2	40
1976	Nutritional and Methodological Perspectives of Zinc Ions and Complexes - Physiological and Pathological States. International Journal of Electrochemical Science, 2016, , 4470-4496.	0.5	4
1977	Oxidative Stress, Inflammation, and Formation of Betaâ€•Amyloid 1â€42 in Brain. , 2016, , .		2
1978	The Dual Function of Reactive Oxygen/Nitrogen Species in Bioenergetics and Cell Death: The Role of ATP Synthase. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-17.	1.9	66
1979	Nanomechanical Characterization of Amyloid Fibrils Using Single-Molecule Experiments and Computational Simulations. Journal of Nanomaterials, 2016, 2016, 1-16.	1.5	10
1980	Overview of Alzheimerâ€™s Disease and Some Therapeutic Approaches Targeting AÎ²by Using Several Synthetic and Herbal Compounds. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-22.	1.9	126
1981	Effects of End-Terminal Capping on Transthyretin (105â€“115) Amyloid Protofibrils Using Steered Molecular Dynamics. Journal of Nanomaterials, 2016, 2016, 1-10.	1.5	4
1982	Amyloid-Î²-Induced Dysregulation of AMPA Receptor Trafficking. Neural Plasticity, 2016, 2016, 1-12.	1.0	83
1983	Astaxanthin Protects Primary Hippocampal Neurons against Noxious Effects of AÎ²-Oligomers. Neural Plasticity, 2016, 2016, 1-13.	1.0	52

#	Article	IF	Citations
1984	FcÎ³RIIb-SHIP2 axis links AÎ² to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. ELife, 2016, 5, .	2.8	36
1985	The Unfolded Protein Response and the Role of Protein Disulfide Isomerase in Neurodegeneration. Frontiers in Cell and Developmental Biology, 2015, 3, 80.	1.8	125
1986	Magnetic Resonance Q Mapping Reveals a Decrease in Microvessel Density in the arcAÎ² Mouse Model of Cerebral Amyloidosis. Frontiers in Aging Neuroscience, 2015, 7, 241.	1.7	16
1987	Hippocampal Injections of Oligomeric Amyloid Î²-peptide (1â€“42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway. Frontiers in Aging Neuroscience, 2015, 7, 245.	1.7	84
1988	In Vivo Detection of Amyloid Plaques by Gadolinium-Stained MRI Can Be Used to Demonstrate the Efficacy of an Anti-amyloid Immunotherapy. Frontiers in Aging Neuroscience, 2016, 8, 55.	1.7	15
1989	In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's AÎ² protein. Frontiers in Aging Neuroscience, 2016, 8, 223.	1.7	34
1990	Amyloidosis in Retinal Neurodegenerative Diseases. Frontiers in Neurology, 2016, 7, 127.	1.1	34
1991	Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay. Frontiers in Neuroscience, 2016, 10, 8.	1.4	22
1992	Proteomic Substrate Identification for Membrane Proteases in the Brain. Frontiers in Molecular Neuroscience, 2016, 9, 96.	1.4	26
1993	PMEL Amyloid Fibril Formation: The Bright Steps of Pigmentation. International Journal of Molecular Sciences, 2016, 17, 1438.	1.8	76
1994	Tethered and Polymer Supported Bilayer Lipid Membranes: Structure and Function. Membranes, 2016, 6, 30.	1.4	78
1995	Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps. Journal of Visualized Experiments, 2016, , .	0.2	4
1996	Predictive Big Data Analytics: A Study of Parkinsonâ€™s Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations. PLoS ONE, 2016, 11, e0157077.	1.1	94
1997	Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity. PLoS ONE, 2016, 11, e0147470.	1.1	12
1998	Assessing the Effects of Acute Amyloid Î² Oligomer Exposure in the Rat. International Journal of Molecular Sciences, 2016, 17, 1390.	1.8	13
1999	Drug Development in Alzheimerâ€™s Disease: The Contribution of PET and SPECT. Frontiers in Pharmacology, 2016, 7, 88.	1.6	22
2000	Methods for the Specific Detection and Quantitation of Amyloid-Î² Oligomers in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 53, 53-67.	1.2	26
2001	AMPK in the central nervous system: physiological roles and pathological implications. Research and Reports in Biology, 0, , 1.	0.2	12

#	Article	IF	Citations
2002	Modulating Role of TTR in AÎ² Toxicity, from Health to Disease. , 0, , .		1
2003	The amyloid cascade hypothesis: are we poised for success or failure?. Journal of Neurochemistry, 2016, 139, 237-252.	2.1	308
2004	Neuroprotective Effect of Osthole on Neuron Synapses in an Alzheimerâ€™s Disease Cell Model via Upregulation of MicroRNA-9. Journal of Molecular Neuroscience, 2016, 60, 71-81.	1.1	45
2005	Proteolytic processing of Neuregulin-1. Brain Research Bulletin, 2016, 126, 178-182.	1.4	37
2006	Waterâ€Soluble Conjugated Polymers for the Detection and Inhibition of Protein Aggregation. Advanced Functional Materials, 2016, 26, 9026-9031.	7.8	34
2007	Intracellular soluble Î±â€synuclein oligomers reduce pyramidal cell excitability. Journal of Physiology, 2016, 594, 2751-2772.	1.3	41
2008	Substrate recruitment of Î³â€secretase and mechanism of clinical presenilin mutations revealed by photoaffinity mapping. EMBO Journal, 2016, 35, 1628-1643.	3.5	104
2009	Remodeling of the conformational ensemble of the repeat domain of tau by an aggregation enhancer. Protein Science, 2016, 25, 1010-1020.	3.1	27
2011	Introduction of <scp>d</scp>â€Glutamate at a Critical Residue of AÎ²42 Stabilizes a Prefibrillary Aggregate with Enhanced Toxicity. Chemistry - A European Journal, 2016, 22, 11967-11970.	1.7	31
2012	Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy. Synapse, 2016, 70, 408-417.	0.6	17
2013	Bacoside-A, an anti-amyloid natural substance, inhibits membrane disruption by the amyloidogenic determinant of prion protein through accelerating fibril formation. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 2208-2214.	1.4	18
2014	Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-Î² B-cell epitope chimeric protein as subunit vaccine. Human Vaccines and Immunotherapeutics, 2016, 12, 2801-2804.	1.4	8
2015	A General Strategy for Facile Synthesis and In Situ Screening of Selfâ€Assembled Polymerâ€Peptide Nanomaterials. Advanced Materials, 2016, 28, 1859-1867.	11.1	45
2016	miRâ€186 is decreased in aged brain and suppresses <scp>BACE</scp>1 expression. Journal of Neurochemistry, 2016, 137, 436-445.	2.1	78
2017	Quercetin and quercetin-3-Î²-d-glucoside improve cognitive and memory function in Alzheimerâ€™s disease mouse. Applied Biological Chemistry, 2016, 59, 721-728.	0.7	26
2018	Ten Challenges of the Amyloid Hypothesis of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 447-457.	1.2	71
2019	Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. Annual Review of Genetics, 2016, 50, 329-346.	3.2	53
2020	Overexpression of Metallothionein-1 Modulates the Phenotype of the Tg2576 Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 81-95.	1.2	17

#	Article	IF	Citations
2021	Comparing generalized ensemble methods for sampling of systems with many degrees of freedom. Journal of Chemical Physics, 2016, 145, 174107.	1.2	11
2022	The Calpain Proteolytic System. , 2016, , 670-680.		4
2023	Alpha-1-Antitrypsin Deficiency: A Misfolded Secretory Glycoprotein Damages the Liver by Proteotoxicity and Its Reduced Secretion Predisposes to Emphysematous Lung Disease Because of Protease-Inhibitor Imbalance. , 2016, , 789-800.		0
2024	Zinc-induced interactions of the metal-binding domain of beta-amyloid with nucleic acids and glycosaminoglycans. Molecular Biology, 2016, 50, 927-929.	0.4	3
2025	Structural analysis of F20L oligomeric and protofibrillar amyloid pair structures using molecular dynamics simulations. , 2016, , .		0
2026	Interrelationship between Miniâ€Mental State Examination scores and biochemical parameters in patients with mild cognitive impairment and Alzheimer's disease. Geriatrics and Gerontology International, 2017, 17, 1737-1745.	0.7	18
2027	Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms. Scientific Reports, 2016, 6, 28658.	1.6	45
2028	Field amplified sample stacking of amyloid beta (1-42) oligomers using capillary electrophoresis. Biomicrofluidics, 2016, 10, 033105.	1.2	9
2029	Amyloid-Î² Increases Activity of Proteasomes Capped with 19S and 11S Regulators. Journal of Alzheimer's Disease, 2016, 54, 763-776.	1.2	12
2030	Neutron Scattering Studies of the Interplay of Amyloid Î² Peptide(1â€“40) and An Anionic Lipid 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol. Scientific Reports, 2016, 6, 30983.	1.6	27
2031	Measuring discrimination- and reversal learning in mouse models within 4 days and without prior food deprivation. Learning and Memory, 2016, 23, 660-667.	0.5	29
2032	Dynamics of proteins aggregation. I. Universal scaling in unbounded media. Journal of Chemical Physics, 2016, 145, 134306.	1.2	9
2033	Structure of Crenezumab Complex with AÎ² Shows Loss of Î²-Hairpin. Scientific Reports, 2016, 6, 39374.	1.6	84
2034	Improved Neuroprotection Provided by Drug Combination in Neurons Exposed to Cell-Derived Soluble Amyloid-Î² Peptide. Journal of Alzheimer's Disease, 2016, 52, 975-987.	1.2	8
2035	Neutrophil Gelatinase-Associated Lipocalin and its Receptors in Alzheimerâ€™s Disease (AD) Brain Regions: Differential Findings in AD with and without Depression. Journal of Alzheimer's Disease, 2016, 55, 763-776.	1.2	39
2036	Understanding structural characteristics of out-of-register hIAPP amyloid proteins via molecular dynamics. RSC Advances, 2016, 6, 77666-77672.	1.7	3
2037	Biofunctionalized Silica Nanoparticles: Standards in Amyloid-Î² Oligomer-Based Diagnosis of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 54, 79-88.	1.2	30
2038	Electrostatically-guided inhibition of Curli amyloid nucleation by the CsgC-like family of chaperones. Scientific Reports, 2016, 6, 24656.	1.6	51

#	Article	IF	Citations
2039	Scutellaria barbata flavonoids alleviate memory deficits and neuronal injuries induced by composited AÎ² in rats. Behavioral and Brain Functions, 2016, 12, 33.	1.4	16
2040	Intraneuronal Amylin Deposition, Peroxidative Membrane Injury and Increased IL-1Î² Synthesis in Brains of Alzheimerâ€™s Disease Patients with Type-2 Diabetes and in Diabetic HIP Rats. Journal of Alzheimer's Disease, 2016, 53, 259-272.	1.2	56
2041	Immunization with Small Amyloid-Î²-derived Cyclopeptide Conjugates Diminishes Amyloid-Î²-Induced Neurodegeneration in Mice. Journal of Alzheimer's Disease, 2016, 52, 1111-1123.	1.2	5
2042	Study of Exosomes Shed New Light on Physiology of Amyloidogenesis. Cellular and Molecular Neurobiology, 2016, 36, 327-342.	1.7	13
2043	Future Therapeutics in Alzheimerâ€™s Disease: Development Status of BACE Inhibitors. BioDrugs, 2016, 30, 173-194.	2.2	36
2044	AÎ²40 has a subtle effect on AÎ²42 protofibril formation, but to a lesser degree than AÎ²42 concentration, in AÎ²42/AÎ²40 mixtures. Archives of Biochemistry and Biophysics, 2016, 597, 1-11.	1.4	17
2045	The inhibitory mechanism of a fullerene derivative against amyloid-Î² peptide aggregation: an atomistic simulation study. Physical Chemistry Chemical Physics, 2016, 18, 12582-12591.	1.3	67
2046	Coordination of Zn2+ and Cu2+ to the membrane disrupting fragment of amylin. Dalton Transactions, 2016, 45, 8099-8106.	1.6	30
2047	Selective Persistence of Sensorimotor Mismatch Signals in Visual Cortex of Behaving Alzheimerâ€™s Disease Mice. Current Biology, 2016, 26, 956-964.	1.8	49
2048	Deposition of C-terminally truncated AÎ² species AÎ²37 and AÎ²39 in Alzheimerâ€™s disease and transgenic mouse models. Acta Neuropathologica Communications, 2016, 4, 24.	2.4	29
2049	Alzheimerâ€™s Amyloid-Î² Sequesters Caspase-3 in Vitro via Its C-Terminal Tail. ACS Chemical Neuroscience, 2016, 7, 1097-1106.	1.7	17
2050	The effect of structural heterogeneity on the conformation and stability of AÎ²â€“tau mixtures. RSC Advances, 2016, 6, 52236-52247.	1.7	13
2051	Single-Molecule Sequencing. , 2016, , 217-235.		1
2052	Mechanisms of prion-induced neurodegeneration. Expert Reviews in Molecular Medicine, 2016, 18, e5.	1.6	36
2053	Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimerâ€™s disease. British Journal of Nutrition, 2016, 115, 449-465.	1.2	186
2054	Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased AÎ² generation in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 235-256.	3.9	193
2055	Efficient synthesis of longer AÎ² peptides via removable backbone modification. Organic and Biomolecular Chemistry, 2016, 14, 5012-5018.	1.5	25
2056	AÎ²-Induced Insulin Resistance and the Effects of Insulin on the Cholesterol Synthesis Pathway and AÎ² Secretion in Neural Cells. Neuroscience Bulletin, 2016, 32, 227-238.	1.5	24

#	Article	IF	Citations
2058	Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimerâ€™s disease. Neuroscience and Biobehavioral Reviews, 2016, 65, 326-340.	2.9	58
2059	Oleanolic Acid Inhibiting the Differentiation of Neural Stem Cells into Astrocyte by Down-Regulating JAK/STAT Signaling Pathway. The American Journal of Chinese Medicine, 2016, 44, 103-117.	1.5	16
2060	Neurochemical Aspects of Alzheimer Disease. , 2016, , 1-76.		1
2061	Characterization of insulin-degrading enzyme-mediated cleavage of AÎ² in distinct aggregation states. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1281-1290.	1.1	12
2062	Identification of approved drugs that inhibit the binding of amyloid Î² oligomers to ephrin typeâ€B receptor 2. FEBS Open Bio, 2016, 6, 461-468.	1.0	13
2063	Phosphorylation of the amyloid Î²-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. Acta Neuropathologica, 2016, 131, 525-537.	3.9	84
2064	Alzheimer's disease: a mathematical model for onset and progression. Mathematical Medicine and Biology, 2017, 34, 193-214.	0.8	45
2065	Intracerebral Injection of Metal-Binding Domain of AÎ² Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice. Neurotoxicity Research, 2016, 29, 551-557.	1.3	28
2066	RAN translationâ€"What makes it run?. Brain Research, 2016, 1647, 30-42.	1.1	89
2067	Proteostasis impairment in ALS. Brain Research, 2016, 1648, 571-579.	1.1	73
2068	Multifunctional quinoline-triazole derivatives as potential modulators of amyloid-Î² peptide aggregation. Journal of Inorganic Biochemistry, 2016, 158, 131-138.	1.5	25
2069	Biological evaluation of synthetic Î±,Î²-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-Î² aggregation. Bioorganic and Medicinal Chemistry, 2016, 24, 2352-2359.	1.4	31
2071	A Novel AÎ² B-Cell Epitope Vaccine (rCV01) for Alzheimerâ€™s Disease Improved Synaptic and Cognitive Functions in 3ÂÃ—ÂTg-AD Mice. Journal of NeuroImmune Pharmacology, 2016, 11, 657-668.	2.1	12
2072	The Alzheimer's disease A Î² peptide binds to the anionic DMPS lipid bilayer. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 1118-1128.	1.4	15
2073	Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimerâ€™s disease treatment. Colloids and Surfaces B: Biointerfaces, 2016, 145, 8-13.	2.5	140
2074	The Dynamics and Turnover of Tau Aggregates in Cultured Cells. Journal of Biological Chemistry, 2016, 291, 13175-13193.	1.6	59
2075	Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation. Accounts of Chemical Research, 2016, 49, 801-808.	7.6	33
2076	Aggregation of the Inflammatory S100A8 Precedes AÎ² Plaque Formation in Transgenic APP Mice: Positive Feedback for S100A8 and AÎ² Productions. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw073.	1.7	34

#	Article	IF	Citations
2077	Importance of the Dimethylamino Functionality on a Multifunctional Framework for Regulating Metals, Amyloid-Î², and Oxidative Stress in Alzheimerâ€™s Disease. Inorganic Chemistry, 2016, 55, 5000-5013.	1.9	19
2078	Antibody modified-silver nanoparticles for colorimetric immuno sensing of AÎ²(1â€“40/1â€“42) based on the interaction between Î²-amyloid and Cu2+. Sensors and Actuators B: Chemical, 2016, 234, 63-69.	4.0	32
2079	Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-d-sedoheptulose derived from Corni fructus as cholinesterase and Î²-secretase 1 inhibitors. Archives of Pharmacal Research, 2016, 39, 794-805.	2.7	32
2080	Evidence for Inhibition of Lysozyme Amyloid Fibrillization by Peptide Fragments from Human Lysozyme: A Combined Spectroscopy, Microscopy, and Docking Study. Biomacromolecules, 2016, 17, 1998-2009.	2.6	35
2081	The fine-tuning of proteolytic pathways in Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2016, 73, 3433-3451.	2.4	16
2082	Impaired protein degradation in FTLD and related disorders. Ageing Research Reviews, 2016, 32, 122-139.	5.0	58
2083	Ionic Strength Modulation of the Free Energy Landscape of AÎ²₄₀ Peptide Fibril Formation. Journal of the American Chemical Society, 2016, 138, 6893-6902.	6.6	80
2084	Synthesis and structureâ€“activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of Î²-amyloid-42 aggregation. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3330-3335.	1.0	14
2085	Letter: Mass Spectrometric Evidence for Iron Binding to the Neuroprotective Peptide NAP and its Cys5 Mutant. European Journal of Mass Spectrometry, 2016, 22, 97-104.	0.5	5
2086	Effects of grape seed proanthocyanidin on Alzheimer's disease in vitro and in vivo. Experimental and Therapeutic Medicine, 2016, 12, 1681-1692.	0.8	28
2087	Overview of the potent cyanobacterial neurotoxin Î²-methylamino-L-alanine (BMAA) and its analytical determination. Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment, 2016, 33, 1570-1586.	1.1	9
2088	Computational Modeling of Î²-Secretase 1 (BACE-1) Inhibitors Using Ligand Based Approaches. Journal of Chemical Information and Modeling, 2016, 56, 1936-1949.	2.5	166
2089	Exploring the aggregation free energy landscape of the amyloid-Î² protein (1â€“40). Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11835-11840.	3.3	113
2090	Î±7-Nicotinic Acetylcholine Receptors and Î²-Amyloid Peptides in Alzheimerâ€™s Disease. Neuromethods, 2016, , 171-205.	0.2	2
2091	Amyloid Î²â€induced astrogliosis is mediated by Î²1â€integrin via NADPH oxidase 2 in Alzheimer's disease. Aging Cell, 2016, 15, 1140-1152.	3.0	53
2092	Semisynthesis and Structureâ€“Activity Studies of Uncarinic Acid C Isolated from Uncaria rhynchophylla as a Specific Inhibitor of the Nucleation Phase in Amyloid Î²42 Aggregation. Journal of Natural Products, 2016, 79, 2521-2529.	1.5	28
2093	A Phosphomimetic Mutation Stabilizes SOD1 and Rescues Cell Viability in the Context of an ALS-Associated Mutation. Structure, 2016, 24, 1898-1906.	1.6	41
2094	Assembly of Peptides Derived from Î²-Sheet Regions of Î²-Amyloid. Journal of the American Chemical Society, 2016, 138, 13882-13890.	6.6	34

#	Article	IF	Citations
2095	Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of <scp>d</scp>-Enantiomeric Peptides Designed to Eliminate Cytotoxic AÎ² Species. ACS Chemical Neuroscience, 2016, 7, 1088-1096.	1.7	24
2096	Application of Nanomedicine to the CNS Diseases. International Review of Neurobiology, 2016, 130, 73-113.	0.9	17
2097	Back to the oligomeric state: pH-induced dissolution of concanavalin A amyloid-like fibrils into non-native oligomers. RSC Advances, 2016, 6, 75082-75091.	1.7	10
2098	Neurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review. European Journal of Medicinal Chemistry, 2016, 124, 1121-1141.	2.6	58
2099	An in silico study of the effect of SOD1 electrostatic loop dynamics on amyloidâ€like filament formation. European Biophysics Journal, 2016, 45, 853-859.	1.2	6
2100	Detecting Alzheimer's disease biomarkers: From antibodies to new bio-mimetic receptors and their application to established and emerging bioanalytical platforms â€“ A critical review. Analytica Chimica Acta, 2016, 940, 21-37.	2.6	47
2101	Amyloid-like Self-Assembly of a Cellular Compartment. Cell, 2016, 166, 637-650.	13.5	294
2102	Translational control by eIF2Î± in neurons: Beyond the stress response. Cytoskeleton, 2016, 73, 551-565.	1.0	38
2103	Specific protein homeostatic functions of small heatâ€shock proteins increase lifespan. Aging Cell, 2016, 15, 217-226.	3.0	45
2104	Neurological dysfunctions associated with altered <scp>BACE</scp>1â€dependent Neuregulinâ€1 signaling. Journal of Neurochemistry, 2016, 136, 234-249.	2.1	40
2105	Current and future treatment of amyloid diseases. Journal of Internal Medicine, 2016, 280, 177-202.	2.7	73
2106	Molecular pathogenesis of human amyloidosis: Lessons from Î²₂â€microglobulinâ€related amyloidosis. Pathology International, 2016, 66, 193-201.	0.6	35
2107	Phosphorylation Interferes with Maturation of Amyloid-Î² Fibrillar Structure in the N Terminus. Journal of Biological Chemistry, 2016, 291, 16059-16067.	1.6	22
2108	Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine Î²-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 8593-8600.	2.9	11
2109	Beneficial effects of increased lysozyme levels in Alzheimer's disease modelled in Drosophila melanogaster. FEBS Journal, 2016, 283, 3508-3522.	2.2	15
2110	Attack on amyloid-Î² protein. Nature, 2016, 537, 36-37.	13.7	42
2111	The antibody aducanumab reduces AÎ² plaques in Alzheimerâ€™s disease. Nature, 2016, 537, 50-56.	13.7	2,179
2112	Asp32 and Asp228 determine the selective inhibition of BACE1 as shown by docking and molecular dynamics simulations. European Journal of Medicinal Chemistry, 2016, 124, 1142-1154.	2.6	42

#	Article	IF	Citations
2113	Early effects of AÎ² 1-42 oligomers injection in mice: Involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways. Behavioural Brain Research, 2016, 314, 106-115.	1.2	57
2114	Holdase activity of secreted Hsp70 masks amyloid-Î²42 neurotoxicity in Drosophila. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5212-21.	3.3	60
2115	Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. Scientific Reports, 2016, 6, 23349.	1.6	37
2116	Amyloid Î² oligomers elicit mitochondrial transport defects and fragmentation in a time-dependent and pathway-specific manner. Molecular Brain, 2016, 9, 79.	1.3	45
2117	Epigenetic regulation of cognition: A circumscribed review of the field. Development and Psychopathology, 2016, 28, 1285-1304.	1.4	33
2118	Feâ€“oxy adducts of hemeâ€“AÎ² and hemeâ€“hIAPP complexes: intermediates in ROS generation. Metallomics, 2016, 8, 1266-1272.	1.0	12
2119	Phosphatidylethanolamine Metabolism in Health and Disease. International Review of Cell and Molecular Biology, 2016, 321, 29-88.	1.6	269
2120	A mechanism for propagated SOD1 misfolding from frustration analysis of a G85R mutant protein assembly. Biochemical and Biophysical Research Communications, 2016, 478, 1634-1639.	1.0	3
2121	Functional modulation of strychnine-sensitive glycine receptors in rat hippocampal pyramidal neurons by amyloid-Î² protein (1-42). Brain Research, 2016, 1651, 61-72.	1.1	6
2122	In vitro prion-like behaviour of TDP-43 in ALS. Neurobiology of Disease, 2016, 96, 236-247.	2.1	118
2123	Cell Damage in Light Chain Amyloidosis. Journal of Biological Chemistry, 2016, 291, 19813-19825.	1.6	58
2124	Amyloid Î²-peptides interfere with mitochondrial preprotein import competence by a coaggregation process. Molecular Biology of the Cell, 2016, 27, 3257-3272.	0.9	87
2125	Coassembly of Peptides Derived from Î²-Sheet Regions of Î²-Amyloid. Journal of the American Chemical Society, 2016, 138, 13891-13900.	6.6	23
2126	Î²-Amyloid-acetylcholine molecular interaction: new role of cholinergic mediators in anti-Alzheimer therapy?. Future Medicinal Chemistry, 2016, 8, 1179-1189.	1.1	32
2127	Physical determinants of the self-replication of protein fibrils. Nature Physics, 2016, 12, 874-880.	6.5	90
2128	Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease. Chemical Biology and Drug Design, 2016, 88, 889-898.	1.5	22
2129	Trifluoroethanol modulates Î±-synuclein amyloid-like aggregate formation, stability and dissolution. Biophysical Chemistry, 2016, 216, 23-30.	1.5	9
2130	Alzheimerâ€™s disease like pathology induced six weeks after aggregated amyloid-beta injection in rats: increased oxidative stress and impaired long-term memory with anxiety-like behavior. Neurological Research, 2016, 38, 838-850.	0.6	71

#	Article	IF	Citations
2131	The endocytic pathway in microglia during health, aging and Alzheimerâ€™s disease. Ageing Research Reviews, 2016, 32, 89-103.	5.0	93
2132	A Study of AÎ² Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls. Neurodegenerative Diseases, 2016, 16, 398-406.	0.8	14
2133	When, where and how? Focus on neuronal calcium dysfunctions in Alzheimerâ€™s Disease. Cell Calcium, 2016, 60, 289-298.	1.1	31
2134	Three-Dimensional Study of Alzheimerâ€™s Disease Hallmarks Using the iDISCO Clearing Method. Cell Reports, 2016, 16, 1138-1152.	2.9	156
2135	Influence of membrane environments and copper ions on the structural features of amyloidogenic proteins correlated to neurodegeneration. Coordination Chemistry Reviews, 2016, 327-328, 8-19.	9.5	8
2136	Copperâ€AÎ² Peptides and Oxidation of Catecholic Substrates: Reactivity and Endogenous Peptide Damage. Chemistry - A European Journal, 2016, 22, 16964-16973.	1.7	18
2137	Combined Solutionâ€•and Magic Angle Spinning NMR Reveals Regions of Distinct Dynamics in Amyloid Î² Protofibrils. ChemistrySelect, 2016, 1, 5850-5853.	0.7	4
2138	Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)â€“A Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2016, 59, 10435-10450.	2.9	126
2139	Curcumin inhibits the Al(<scp>iii</scp>) and Zn(<scp>ii</scp>) induced amyloid fibrillation of Î²-lactoglobulin in vitro. RSC Advances, 2016, 6, 111299-111307.	1.7	6
2140	Site-specific phosphorylation of tau inhibits amyloid-Î² toxicity in Alzheimerâ€™s mice. Science, 2016, 354, 904-908.	6.0	241
2141	Mathematical model on Alzheimerâ€™s disease. BMC Systems Biology, 2016, 10, 108.	3.0	86
2142	Common molecular mechanism of amyloid pore formation by Alzheimerâ€™s Î²-amyloid peptide and Î±-synuclein. Scientific Reports, 2016, 6, 28781.	1.6	137
2143	Iowa Mutant Apolipoprotein A-I (ApoA-IIowa) Fibrils Target Lysosomes. Scientific Reports, 2016, 6, 30391.	1.6	14
2144	Monoclonal antibody with conformational specificity for a toxic conformer of amyloid Î²42 and its application toward the Alzheimerâ€™s disease diagnosis. Scientific Reports, 2016, 6, 29038.	1.6	50
2145	An Atomistic View of Amyloidogenic Self-assembly: Structure and Dynamics of Heterogeneous Conformational States in the Pre-nucleation Phase. Scientific Reports, 2016, 6, 33156.	1.6	25
2146	BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimerâ€™s disease models. Scientific Reports, 2016, 6, 33427.	1.6	22
2147	Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloidâ€Î² (AÎ²)₄₂ peptides. Journal of Neurochemistry, 2016, 139, 1175-1191.	2.1	62
2148	HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimerâ€™s disease. Scientific Reports, 2016, 6, 31895.	1.6	111

#	Article	IF	Citations
2149	Novel insights into multitargeted potential of Nâ€²-(4-benzylpiperidin-1-yl)alkylamine derivatives in the management of Alzheimer's disease associated pathogenesis. RSC Advances, 2016, 6, 104847-104867.	1.7	7
2150	Conformational features of the AÎ²₄₂ peptide monomer and its interaction with the surrounding solvent. Physical Chemistry Chemical Physics, 2016, 18, 30144-30159.	1.3	25
2151	Alzheimerâ€™s disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and AÎ² pathological molecules. Scientific Reports, 2016, 6, 28912.	1.6	37
2152	Systemic study of a natural feedback loop in Huntingtonâ€™s disease at the onset of neurodegeneration. BioSystems, 2016, 150, 46-51.	0.9	3
2153	Mechanism of Nucleation and Growth of AÎ²40 Fibrils from All-Atom and Coarse-Grained Simulations. Journal of Physical Chemistry B, 2016, 120, 12088-12097.	1.2	25
2154	Discovery of furo[2,3- d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5729-5731.	1.0	14
2155	Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid Î²-Peptide(1â€“40). Journal of Physical Chemistry B, 2016, 120, 11405-11411.	1.2	36
2156	Dendrite Maintenance. , 2016, , 317-355.		0
2157	IL4/STAT6 Signaling Activates Neural Stem Cell Proliferation and Neurogenesis upon Amyloid-Î²42 Aggregation in Adult Zebrafish Brain. Cell Reports, 2016, 17, 941-948.	2.9	136
2158	Strain-dependent profile of misfolded prion protein aggregates. Scientific Reports, 2016, 6, 20526.	1.6	35
2159	Citrullination and deamidation affect aggregation properties of amyloidÎ²-proteins. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 234-241.	1.4	16
2160	A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimerâ€™s disease. Science Advances, 2016, 2, e1600947.	4.7	84
2161	Glycation induces conformational changes in the amyloid-Î² peptide and enhances its aggregation propensity: molecular insights. Physical Chemistry Chemical Physics, 2016, 18, 31446-31458.	1.3	23
2162	Bioenergetic Impairment in Animal and Cellular Models of Alzheimerâ€™s Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions. Journal of Alzheimer's Disease, 2016, 54, 307-324.	1.2	62
2163	Agmatine, A Metabolite of Arginine, Improves Learning and Memory in Streptozotocin-Induced Alzheimer's Disease Model in Rats. Journal of Microbiology and Biotechnology, 2016, 26, 342-354.	0.9	8
2164	Genetic and Biochemical Approaches for In Vivo and In Vitro Assessment of Protein Oligomerization: The Ryanodine Receptor Case Study. Journal of Visualized Experiments, 2016, , .	0.2	3
2165	Generation and deposition of AÎ²43 by the virtually inactive presenilinâ€1 L435F mutant contradicts the presenilin lossâ€ofâ€function hypothesis of Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 458-465.	3.3	60
2166	Hydrophobic tail length plays a pivotal role in amyloid beta (25-35) fibril-surfactant interactions. Proteins: Structure, Function and Bioinformatics, 2016, 84, 1213-1223.	1.5	20

#	Article	IF	Citations
2167	Quantitative Aspects of Electrochemical Detection of Amyloidâ€Î² Aggregation. Electroanalysis, 2016, 28, 1977-1983.	1.5	21
2168	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging, 2016, 44, 159-172.	1.5	59
2169	Common therapeutic strategies for prion and Alzheimerâ€™s diseases. Biological Chemistry, 2016, 397, 1115-1124.	1.2	5
2170	Molecular Imaging in Alzheimer Clinical Trials. , 2016, , 523-563.		0
2171	The Prion-Like Properties of Amyloid-Î² Assemblies: Implications for Alzheimer's Disease. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a024398.	2.9	71
2172	Generation of aggregation prone N-terminally truncated amyloid Î² peptides by meprin Î² depends on the sequence specificity at the cleavage site. Molecular Neurodegeneration, 2016, 11, 19.	4.4	65
2173	Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. Neuroscience and Biobehavioral Reviews, 2016, 68, 547-562.	2.9	114
2174	Mechanisms of protein misfolding: Novel therapeutic approaches to protein-misfolding diseases. Journal of Molecular Structure, 2016, 1123, 311-326.	1.8	14
2175	Modulation of Amyloid Î²-Protein (AÎ²) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting AÎ² Toxicity. ACS Chemical Neuroscience, 2016, 7, 845-856.	1.7	35
2176	Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms. Methods in Pharmacology and Toxicology, 2016, , 121-138.	0.1	0
2177	On the possible structural role of single chain sphingolipids Sphingosine and Sphingosine 1-phosphate in the amyloid-Î² peptide interactions with membranes. Consequences for Alzheimerâ€™s disease development. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2016, 510, 317-327.	2.3	3
2178	Cyanidin 3- O -Î²-glucopyranoside activates peroxisome proliferator-activated receptor-Î³ and alleviates cognitive impairment in the APP swe /PS1 Î”E9 mouse model. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1786-1800.	1.8	31
2179	The modeling of Alzheimer's disease by the overexpression of mutant Presenilin 1 in human embryonic stem cells. Biochemical and Biophysical Research Communications, 2016, 469, 587-592.	1.0	14
2180	Identification of common therapeutic targets for selected neurodegenerative disorders: An in silico approach. Journal of Computational Science, 2016, 17, 292-306.	1.5	11
2181	Role of transient receptor potential ankyrin 1 channels in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2016, 13, 92.	3.1	77
2182	Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans Tauopathy model. Molecular Neurodegeneration, 2016, 11, 33.	4.4	38
2183	Liver X receptor-Î² improves autism symptoms via downregulation of Î²-amyloid expression in cortical neurons. Italian Journal of Pediatrics, 2016, 42, 46.	1.0	4
2184	Palmitoylation in Alzheimerâ¿¿s disease and other neurodegenerative diseases. Pharmacological Research, 2016, 111, 133-151.	3.1	102

#	Article	IF	Citations
2185	Oligomer Formation of Amyloid-Î²(29â€“42) from Its Monomers Using the Hamiltonian Replica-Permutation Molecular Dynamics Simulation. Journal of Physical Chemistry B, 2016, 120, 6555-6561.	1.2	36
2186	End Capping Alters the Structural Characteristics and Mechanical Properties of Transthyretin (105â€“115) Amyloid Protofibrils. ChemPhysChem, 2016, 17, 425-432.	1.0	14
2187	Membraneâ€bound tetramer and trimer AÎ² oligomeric species correlate with toxicity towards cultured neurons. Journal of Neurochemistry, 2016, 136, 594-608.	2.1	67
2188	Alzheimerâ€™s disease due to loss of function: A new synthesis of the available data. Progress in Neurobiology, 2016, 143, 36-60.	2.8	111
2189	High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer Î²-amyloid peptide. Biochemical Journal, 2016, 473, 1563-1578.	1.7	29
2190	Endogenous Docosahexaenoic Acid (DHA) Prevents AÎ²1â€“42 Oligomer-Induced Neuronal Injury. Molecular Neurobiology, 2016, 53, 3146-3153.	1.9	25
2191	Solvent Removal Induces a Reversible Î²-to-Î± Switch in Oligomeric AÎ² Peptide. Journal of Molecular Biology, 2016, 428, 268-273.	2.0	19
2192	Polyglutamine aggregates impair lipid membrane integrity and enhance lipid membrane rigidity. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 661-670.	1.4	20
2193	Microtubule Dynamics in Neuronal Development, Plasticity, and Neurodegeneration. International Review of Cell and Molecular Biology, 2016, 321, 89-169.	1.6	79
2194	Inhibitory effects of antioxidant vitamins against thiyl radical-induced trans fatty acid formation in PC-12 cells. Journal of Functional Foods, 2016, 21, 212-222.	1.6	8
2195	Effects of an amyloid-beta 1-42 oligomers antibody screened from a phage display library in APP/PS1 transgenic mice. Brain Research, 2016, 1635, 169-179.	1.1	15
2196	Cognitive-enhancing activities of the polyprenol preparation RoprenÂ® in gonadectomized Î²-amyloid (25â€“35) rat model of Alzheimer's disease. Physiology and Behavior, 2016, 157, 55-62.	1.0	21
2197	Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain AÎ² Reduction in Rodents. ACS Medicinal Chemistry Letters, 2016, 7, 271-276.	1.3	35
2198	Designed Glycopeptidomimetics Disrupt Proteinâ€“Protein Interactions Mediating Amyloid Î²-Peptide Aggregation and Restore Neuroblastoma Cell Viability. Journal of Medicinal Chemistry, 2016, 59, 2025-2040.	2.9	37
2199	How to bake a brain: yeast as a model neuron. Current Genetics, 2016, 62, 347-370.	0.8	22
2200	Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease. Progress in Neurobiology, 2016, 144, 121-141.	2.8	238
2201	The new Î² amyloid-derived peptide AÎ²1â€“6A2V-TAT(D) prevents AÎ² oligomer formation and protects transgenic C. elegans from AÎ² toxicity. Neurobiology of Disease, 2016, 88, 75-84.	2.1	17
2202	BRICHOS binds to a designed amyloid-forming Î²-protein and reduces proteasomal inhibition and aggresome formation. Biochemical Journal, 2016, 473, 167-178.	1.7	17

#	Article	IF	Citations
2203	Stabilization of Î±-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity. Biochemistry, 2016, 55, 675-685.	1.2	30
2204	Study of a Bifunctional AÎ² Aggregation Inhibitor with the Abilities of Antiamyloid-Î² and Copper Chelation. Biomacromolecules, 2016, 17, 661-668.	2.6	37
2205	Effects of Charged Cholesterol Derivatives on AÎ²40 Amyloid Formation. Journal of Physical Chemistry B, 2016, 120, 59-68.	1.2	10
2206	A new procedure for amyloid Î² oligomers preparation enables the unambiguous testing of their effects on cytosolic and mitochondrial Ca 2+ entry and cell death in primary neurons. Neuroscience Letters, 2016, 612, 66-73.	1.0	12
2207	Temperature dependent rapid annealing effect induces amorphous aggregation of human serum albumin. International Journal of Biological Macromolecules, 2016, 82, 844-855.	3.6	18
2209	Simultaneous acquisition of infrared, fluorescence and light scattering spectra of proteins: direct evidence for pre-fibrillar species in amyloid fibril formation. Analyst, The, 2016, 141, 963-973.	1.7	7
2210	Characterization of AÎ² Monomers through the Convergence of Ensemble Properties among Simulations with Multiple Force Fields. Journal of Physical Chemistry B, 2016, 120, 259-277.	1.2	81
2211	BIIB042, a novel Î³-secretase modulator, reduces amyloidogenic AÎ² isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease. Neuropharmacology, 2016, 103, 57-68.	2.0	11
2212	Environmental enrichment as a method to improve cognitive function. What can we learn from animal models?. NeuroImage, 2016, 131, 42-47.	2.1	68
2213	Crystal Structures of IAPP Amyloidogenic Segments Reveal a Novel Packing Motif of Out-of-Register Beta Sheets. Journal of Physical Chemistry B, 2016, 120, 5810-5816.	1.2	61
2214	Stability analysis of the ODE model representation of amyloidogenic processing in Alzheimer's disease in the presence of SORLA. Molecular BioSystems, 2016, 12, 1468-1477.	2.9	3
2215	Dopamine agonists rescue AÎ²â€“induced LTP impairment byÂSrc-family tyrosine kinases. Neurobiology of Aging, 2016, 40, 98-102.	1.5	26
2216	Establishing the fluorescent amyloid ligand h-FTAA for studying human tissues with systemic and localized amyloid. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 98-108.	1.4	28
2217	The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease. Journal of Nutritional Biochemistry, 2016, 38, 1-11.	1.9	91
2218	Expedient Synthesis of Furo[2,3-d][1,3]thiazinamines and Pyrano[2,3-d][1,3]thiazinamines from Enones and Thiourea. Journal of Organic Chemistry, 2016, 81, 3386-3390.	1.7	4
2219	Molecular insights into cell toxicity of a novel familial amyloidogenic variant of Î²2â€microglobulin. Journal of Cellular and Molecular Medicine, 2016, 20, 1443-1456.	1.6	23
2220	Learning impairment by minimal cortical injury in a mouse model of Alzheimer×³s disease. Brain Research, 2016, 1637, 56-63.	1.1	5
2221	Conformational changes of AÎ² (1â€“42) monomers in different solvents. Journal of Molecular Graphics and Modelling, 2016, 65, 8-14.	1.3	14

#	Article	IF	Citations
2222	Conformational transition of AÎ² 42 inhibited by a mimetic peptide. A molecular modeling study using QM/MM calculations and QTAIM analysis. Computational and Theoretical Chemistry, 2016, 1080, 56-65.	1.1	23
2223	An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic AÎ²42 aggregates linked with Alzheimerâ€™s disease. Science Advances, 2016, 2, e1501244.	4.7	180
2224	The structure of chromophore-grafted amyloid-Î²_{12â€“28} dimers in the gas-phase: FRET-experiment guided modelling. Physical Chemistry Chemical Physics, 2016, 18, 9061-9069.	1.3	12
2225	Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmission. Physiological Reports, 2016, 4, e12665.	0.7	13
2226	Design and Optimization of Anti-amyloid Domain Antibodies Specific for Î²-Amyloid and Islet Amyloid Polypeptide. Journal of Biological Chemistry, 2016, 291, 2858-2873.	1.6	35
2227	Decoding DNA, RNA and peptides with quantum tunnelling. Nature Nanotechnology, 2016, 11, 117-126.	15.6	183
2228	Nano-biosensors to detect beta-amyloid for Alzheimer's disease management. Biosensors and Bioelectronics, 2016, 80, 273-287.	5.3	145
2229	Amyloid-Î²-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimerâ€™s Disease. Analytical Chemistry, 2016, 88, 2755-2762.	3.2	97
2230	Tau-directed approaches for the treatment of Alzheimerâ€™s disease: focus on leuco-methylthioninium. Expert Review of Neurotherapeutics, 2016, 16, 259-277.	1.4	35
2231	Polyoxometalate-based nanozyme: Design of a multifunctional enzyme for multi-faceted treatment of Alzheimerâ€™s disease. Nano Research, 2016, 9, 1079-1090.	5.8	96
2232	Synthesis of pyrimido[4,5- c]azepine- and pyrimido[4,5- c]oxepine-based Î³-secretase modulators. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1554-1557.	1.0	5
2233	Opposing Effects of Cucurbit[7]uril and 1,2,3,4,6-Penta-O-galloyl-Î²-<scp>d</scp>-glucopyranose on Amyloid Î²_{25â€“35} Assembly. ACS Chemical Neuroscience, 2016, 7, 218-226.	1.7	27
2234	A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins. ACS Combinatorial Science, 2016, 18, 144-153.	3.8	35
2235	Quantifying the Distribution of the Stoichiometric Composition of Anticancer Peptide Lycosin-I on the Lipid Membrane with Single Molecule Spectroscopy. Journal of Physical Chemistry B, 2016, 120, 3081-3088.	1.2	11
2236	Peripherally administered sera antibodies recognizing amyloid-Î² oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3Ã— Tg-AD mice. Vaccine, 2016, 34, 1758-1766.	1.7	11
2237	PP2A methylation controls sensitivity and resistance to Î²-amyloidâ€“induced cognitive and electrophysiological impairments. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3347-3352.	3.3	48
2238	Amyloid fibrillogenesis of lysozyme is suppressed by a food additive brilliant blue FCF. Colloids and Surfaces B: Biointerfaces, 2016, 142, 351-359.	2.5	20
2239	Cognitive benefits of memantine in Alzheimer's 5XFAD model mice decline during advanced disease stages. Pharmacology Biochemistry and Behavior, 2016, 144, 60-66.	1.3	25

#	Article	IF	Citations
2240	Therapeutic Potentials of Curcumin for Alzheimer Disease. , 2016, , .		13
2241	Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease. , 2016, , 77-111.		0
2242	Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer's disease brain, serum and cerebrospinal fluid towards potential biomarker discovery. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1716-1727.	1.1	68
2243	Structural insights into mechanisms for inhibiting amyloid Î²42 aggregation by non-catechol-type flavonoids. Bioorganic and Medicinal Chemistry, 2016, 24, 304-313.	1.4	47
2244	RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neuroscience and Biobehavioral Reviews, 2016, 62, 48-55.	2.9	119
2245	Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. Neurobiology of Disease, 2016, 87, 19-28.	2.1	54
2246	Cerebral Glucose Metabolism Assessment in Rat Models of Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 333-340.	0.9	19
2247	Surface plasmon resonance for the label-free detection of Alzheimerâ€™s Î²-amyloid peptide aggregation. Analytical and Bioanalytical Chemistry, 2016, 408, 849-854.	1.9	25
2248	Molecular dynamics simulations of biological membranes and membrane proteins using enhanced conformational sampling algorithms. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 1635-1651.	1.4	111
2249	Î²â€Amyloid pathogenesis: Chemical properties versus cellular levels. Alzheimer's and Dementia, 2016, 12, 184-194.	0.4	28
2250	Interplay between the hydrophobic effect and dipole interactions in peptide aggregation at interfaces. Physical Chemistry Chemical Physics, 2016, 18, 2449-2458.	1.3	16
2251	Glimepiride protects neurons against amyloid-Î²-induced synapse damage. Neuropharmacology, 2016, 101, 225-236.	2.0	37
2252	Alzheimer's peptide amyloid-Î², fragment 22â€“40, perturbs lipid dynamics. Soft Matter, 2016, 12, 1444-1451.	1.2	17
2253	Battling Alzheimerâ€™s Disease: Targeting SUMOylation-Mediated Pathways. Neurochemical Research, 2016, 41, 568-578.	1.6	24
2254	Drosophila melanogaster as a Model for Studies on the Early Stages of Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 227-239.	0.4	6
2255	A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid Î² peptide-mediated neuronal disorder. Applied Microbiology and Biotechnology, 2016, 100, 825-835.	1.7	34
2256	Why therapies for Alzheimerâ€™s disease do not work: Do we have consensus over the path to follow?. Ageing Research Reviews, 2016, 25, 70-84.	5.0	23
2257	The Effects of Early Life Lead Exposure on the Expression of Glycogen Synthase Kinase-3Î² and Insulin-like Growth Factor 1 Receptor in the Hippocampus of Mouse Pups. Biological Trace Element Research, 2016, 169, 114-120.	1.9	6

#	Article	IF	Citations
2258	Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimerâ€™s and Parkinsonâ€™s Diseases. Biosystems and Biorobotics, 2016, , 293-325.	0.2	2
2259	MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2016, 73, 217-236.	2.4	96
2261	Preclinical Evaluation of [18F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. Molecular Imaging and Biology, 2016, 18, 258-266.	1.3	29
2263	Microglia in Alzheimerâ€™s disease: A multifaceted relationship. Brain, Behavior, and Immunity, 2016, 55, 138-150.	2.0	98
2264	The Chemistry of Neurodegeneration: Kinetic Data and Their Implications. Molecular Neurobiology, 2016, 53, 3400-3415.	1.9	62
2265	Pathophysiological Links Among Hypertension and Alzheimerâ€™s Disease. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 3-7.	1.0	39
2266	Future Treatments of Memory Loss, Alzheimer's Disease, and Dementia. , 2016, , 187-199.		1
2267	Thiosemicarbazone modification of 3-acetyl coumarin inhibits AÎ² peptide aggregation and protect against AÎ²-induced cytotoxicity. European Journal of Medicinal Chemistry, 2016, 121, 803-809.	2.6	35
2268	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Progress in Neurobiology, 2017, 155, 171-193.	2.8	137
2269	Neuroprotective Effect of Fisetin Against Amyloid-Beta-Induced Cognitive/Synaptic Dysfunction, Neuroinflammation, and Neurodegeneration in Adult Mice. Molecular Neurobiology, 2017, 54, 2269-2285.	1.9	161
2270	Antidepressant-Like Effect of RoprenÂ® in Î²-Amyloid-(25â€“35) Rat Model of Alzheimerâ€™s Disease with Altered Levels of Androgens. Molecular Neurobiology, 2017, 54, 2611-2621.	1.9	9
2271	Back and forth in time: Directing age in iPSC-derived lineages. Brain Research, 2017, 1656, 14-26.	1.1	38
2272	Decreased peripheral brain-derived neurotrophic factor levels in Alzheimerâ€™s disease: a meta-analysis study (N=7277). Molecular Psychiatry, 2017, 22, 312-320.	4.1	109
2273	D-amino acid-containing supramolecular nanofibers for potential cancer therapeutics. Advanced Drug Delivery Reviews, 2017, 110-111, 102-111.	6.6	74
2274	Amyloidâ€Î² induces sleep fragmentation that is rescued by fatty acid binding proteins in Drosophila. Journal of Neuroscience Research, 2017, 95, 1548-1564.	1.3	28
2275	Vanillic acid attenuates AÎ²1-42-induced oxidative stress and cognitive impairment in mice. Scientific Reports, 2017, 7, 40753.	1.6	139
2276	Two decades of new drug discovery and development for Alzheimer's disease. RSC Advances, 2017, 7, 6046-6058.	1.7	60
2277	Bacoside-A, an Indian Traditional-Medicine Substance, Inhibits Î²-Amyloid Cytotoxicity, Fibrillation, and Membrane Interactions. ACS Chemical Neuroscience, 2017, 8, 884-891.	1.7	60

#	Article	IF	Citations
2278	Update on Alzheimer's Disease Therapy and Prevention Strategies. Annual Review of Medicine, 2017, 68, 413-430.	5.0	402
2279	Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an inÂvitro model of Alzheimer's disease. Neuropharmacology, 2017, 116, 82-97.	2.0	21
2280	Structural Studies of Amyloid Proteins at the Molecular Level. Annual Review of Biochemistry, 2017, 86, 69-95.	5.0	419
2281	Self-Assembly of Human Profilin-1 Detected by Carrâ€“Purcellâ€“Meiboomâ€“Gill Nuclear Magnetic Resonance (CPMG NMR) Spectroscopy. Biochemistry, 2017, 56, 692-703.	1.2	23
2282	Linking amyotrophic lateral sclerosis and spinal muscular atrophy through <scp>RNA</scp>â€transcriptome homeostasis: a genomics perspective. Journal of Neurochemistry, 2017, 141, 12-30.	2.1	25
2283	When proteostasis goes bad: Protein aggregation in the cell. IUBMB Life, 2017, 69, 49-54.	1.5	38
2284	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of Î²-Amyloid in an Animal Model of Alzheimerâ€™s Disease. Molecular Therapy, 2017, 25, 153-164.	3.7	13
2285	Real-Time Analysis of Binding Events between Different AÎ²_{1â€“42} Species and Human Lilrb2 by Dual Polarization Interferometry. Analytical Chemistry, 2017, 89, 2606-2612.	3.2	21
2286	Insights from molecular dynamics simulations for computational protein design. Molecular Systems Design and Engineering, 2017, 2, 9-33.	1.7	149
2287	Investigation of the Subcellular Neurotoxicity of Amyloidâ€Î² Using a Device Integrating Microfluidic Perfusion and Chemotactic Guidance. Advanced Healthcare Materials, 2017, 6, 1600895.	3.9	16
2288	The expression of insulin-like growth factor-1 in senior patients with diabetes and dementia. Experimental and Therapeutic Medicine, 2017, 13, 103-106.	0.8	3
2289	Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 130, 440-457.	2.6	67
2290	Mechanistic basis for the recognition of a misfolded protein by the molecular chaperone Hsp90. Nature Structural and Molecular Biology, 2017, 24, 407-413.	3.6	44
2291	The application of self-assembled nanostructures in peptide-based subunit vaccine development. European Polymer Journal, 2017, 93, 670-681.	2.6	57
2292	Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization. Scientific Reports, 2017, 7, 42880.	1.6	29
2293	<scp>PPARs</scp> in the central nervous system: roles in neurodegeneration and neuroinflammation. Biological Reviews, 2017, 92, 2046-2069.	4.7	80
2294	Disease-Modifying Effects of M₁ Muscarinic Acetylcholine Receptor Activation in an Alzheimerâ€™s Disease Mouse Model. ACS Chemical Neuroscience, 2017, 8, 1177-1187.	1.7	36
2295	Clearance of cerebral AÎ² in Alzheimerâ€™s disease: reassessing the role of microglia and monocytes. Cellular and Molecular Life Sciences, 2017, 74, 2167-2201.	2.4	199

#	Article	IF	Citations
2296	Î±-Helix Mimetics as Modulators of AÎ² Self-Assembly. Journal of the American Chemical Society, 2017, 139, 5744-5755.	6.6	73
2297	The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-Î², Amylin, and Tau Proteins. Journal of Alzheimer's Disease, 2017, 59, 421-432.	1.2	154
2298	Interaction of amyloid-Î² (AÎ²) oligomers with neurexin 2Î± and neuroligin 1 mediates synapse damage and memory loss in mice. Journal of Biological Chemistry, 2017, 292, 7327-7337.	1.6	67
2299	Multiply charged oligomer complexes composed of the amyloid-forming peptides NNQQNY, VQIVYK, and LYQLEN analyzed by collision-induced dissociation with electrospray ionization mass spectroscopy. International Journal of Mass Spectrometry, 2017, 415, 55-62.	0.7	4
2300	Low-temperature exothermic transitions in brain proteome of mice, effect of scopolamine. Thermochimica Acta, 2017, 650, 26-32.	1.2	19
2301	Analyzing Amyloid Beta Aggregates with a Combinatorial Fluorescent Molecular Sensor. Journal of the American Chemical Society, 2017, 139, 2136-2139.	6.6	115
2302	The Levinthal Problem in Amyloid Aggregation: Sampling of a Flat Reaction Space. Journal of Physical Chemistry B, 2017, 121, 1576-1586.	1.2	14
2303	The thermodynamics of protein aggregation reactions may underpin the enhanced metabolic efficiency associated with heterosis, some balancing selection, and the evolution of ploidy levels. Progress in Biophysics and Molecular Biology, 2017, 126, 1-21.	1.4	8
2304	Biological basis for amyloidogenesis in Alzheimerâ€™S disease. Biochemistry (Moscow), 2017, 82, 122-139.	0.7	25
2305	Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimerâ€™s disease. Science Advances, 2017, 3, e1601068.	4.7	45
2306	Lumbrokinase for degradation and reduction of amyloid fibrils associated with amyloidosis. Journal of Applied Biomedicine, 2017, 15, 96-104.	0.6	17
2307	Dual Electrophoresis Detection System for Rapid and Sensitive Immunoassays with Nanoparticle Signal Amplification. Scientific Reports, 2017, 7, 42562.	1.6	2
2308	Transcranial LED therapy on amyloid-Î² toxin 25â€“35 in the hippocampal region of rats. Lasers in Medical Science, 2017, 32, 749-756.	1.0	36
2309	Kinetics of Protein Aggregates Disposal by Aggrephagy. Methods in Enzymology, 2017, 588, 245-281.	0.4	25
2310	Synthetic toxic AÎ² 1â€“42 oligomers can assemble in different morphologies. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1168-1176.	1.1	19
2311	Amyloid-beta peptide decreases expression and function of glutamate transporters in nervous system cells. International Journal of Biochemistry and Cell Biology, 2017, 85, 75-84.	1.2	25
2312	Hematiteâ€Based Photoelectrode Materials for Photoelectrocatalytic Inhibition of Alzheimer's Î²â€Amyloid Selfâ€Assembly. Advanced Healthcare Materials, 2017, 6, 1601133.	3.9	11
2313	Understanding Alzheimer's disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: A chance for new biomarkers in neuroproteomics?. Journal of Proteomics, 2017, 161, 11-25.	1.2	23

#	Article	IF	Citations
2314	A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia. Behavioural Pharmacology, 2017, 28, 199-206.	0.8	0
2315	Multitarget trehalose-carnosine conjugates inhibit AÎ² aggregation, tune copper(II) activity and decrease acrolein toxicity. European Journal of Medicinal Chemistry, 2017, 135, 447-457.	2.6	32
2316	Intrahippocampal Pathways Involved in Learning/Memory Mechanisms are Affected by Intracerebral Infusions of Amyloid-Î²25-35 Peptide and Hydrated Fullerene C60 in Rats. Journal of Alzheimer's Disease, 2017, 58, 711-724.	1.2	15
2317	Alzheimerâ€™s Disease II. Topics in Medicinal Chemistry, 2017, , .	0.4	2
2318	Cellular Osmolytes. , 2017, , .		5
2319	Rapamycin suppresses AÎ² 25â€“35 - or LPS-induced neuronal inflammation via modulation of NF-ÎºB signaling. Neuroscience, 2017, 355, 188-199.	1.1	41
2320	Metaplasticity mechanisms restore plasticity and associativity in an animal model of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5527-5532.	3.3	48
2321	The effects of aging on Amyloid-Î²42-induced neurodegeneration and regeneration in adult zebrafish brain. Neurogenesis (Austin, Tex), 2017, 4, e1322666.	1.5	60
2322	<scp>TREM</scp>2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Reports, 2017, 18, 1186-1198.	2.0	240
2323	Role of Nutrition to Promote Healthy Brain Aging and Reduce Risk of Alzheimerâ€™s Disease. Current Nutrition Reports, 2017, 6, 63-71.	2.1	12
2324	Osmotin-loaded magnetic nanoparticles with electromagnetic guidance for the treatment of Alzheimer's disease. Nanoscale, 2017, 9, 10619-10632.	2.8	86
2325	The Exceptional Vulnerability of Humans to Alzheimerâ€™s Disease. Trends in Molecular Medicine, 2017, 23, 534-545.	3.5	74
2326	Identification of a novel PSEN1 mutation (Leu232Pro) in a Korean patient with early-onset Alzheimer's disease and a family history of dementia. Neurobiology of Aging, 2017, 56, 212.e11-212.e17.	1.5	14
2327	PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. Neurobiology of Aging, 2017, 55, 99-114.	1.5	34
2328	Inhibition of amyloid Î² aggregation and protective effect on SH-SY5Y cells by triterpenoid saponins from the cactus Polaskia chichipe. Bioorganic and Medicinal Chemistry, 2017, 25, 3377-3383.	1.4	16
2329	In silico studies of the early stages of aggregation of A $$eta _{42}$$ Î² 42 Âpeptides. Journal of Chemical Sciences, 2017, 129, 899-909.	0.7	5
2330	Spreading of Pathology in Alzheimerâ€™s Disease. Neurotoxicity Research, 2017, 32, 707-722.	1.3	13
2331	Tat-haFGF 14â€“154 Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice through the PI3K-CREB-IRE1Î±/XBP1 Pathway. Molecular Therapy - Nucleic Acids, 2017, 7, 439-452.	2.3	24

#	Article	IF	Citations
2332	Extracellular lowâ€n oligomers of tau cause selective synaptotoxicity without affecting cell viability. Alzheimer's and Dementia, 2017, 13, 1270-1291.	0.4	87
2333	Alzheimerâ€™s disease: How metal ions define Î²-amyloid function. Coordination Chemistry Reviews, 2017, 351, 127-159.	9.5	120
2334	(â^')-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimerâ€™s disease. NeuroReport, 2017, 28, 590-597.	0.6	51
2335	Protein Phosphorylation is a Key Mechanism in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 953-978.	1.2	57
2336	Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Proâ€Substituted Analogues. Chemistry - A European Journal, 2017, 23, 9618-9624.	1.7	23
2337	Clinical Implications of Osmolytes in Various Human Diseases. , 2017, , 161-193.		0
2338	Poly(trehalose) Nanoparticles Prevent Amyloid Aggregation and Suppress Polyglutamine Aggregation in a Huntingtonâ€™s Disease Model Mouse. ACS Applied Materials & Interfaces, 2017, 9, 24126-24139.	4.0	109
2339	Nano-assembly of amyloid Î² peptide: role of the hairpin fold. Scientific Reports, 2017, 7, 2344.	1.6	29
2340	Methods of probing the interactions between small molecules and disordered proteins. Cellular and Molecular Life Sciences, 2017, 74, 3225-3243.	2.4	56
2341	Selective targeting of primary and secondary nucleation pathways in AÎ²42 aggregation using a rational antibody scanning method. Science Advances, 2017, 3, e1700488.	4.7	116
2342	Inhibitors of Tau-Phosphorylating Kinases. Topics in Medicinal Chemistry, 2017, , 119-158.	0.4	1
2343	Î³-Secretase Modulators as AÎ²42-Lowering Pharmacological Agents to Treat Alzheimerâ€™s Disease. Topics in Medicinal Chemistry, 2017, , 87-118.	0.4	6
2344	Attenuation of Î²-Amyloid Toxicity In Vitro and In Vivo by Accelerated Aggregation. Neuroscience Bulletin, 2017, 33, 405-412.	1.5	12
2345	The impact of obesity on neurodegenerative diseases. Life Sciences, 2017, 182, 22-28.	2.0	114
2346	Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6444-6449.	3.3	60
2347	Self-assembling peptide and protein amyloids: from structure to tailored function in nanotechnology. Chemical Society Reviews, 2017, 46, 4661-4708.	18.7	670
2348	Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1604-1614.	1.4	52
2349	Influence of Hyperglycemic Conditions on Self-Association of the Alzheimerâ€™s Amyloid Î² (AÎ²_{1â€“42}) Peptide. ACS Omega, 2017, 2, 2134-2147.	1.6	15

#	Article	IF	Citations
2350	Aromatic-interaction-mediated inhibition of Î²-amyloid assembly structures and cytotoxicity. Journal of Peptide Science, 2017, 23, 679-684.	0.8	7
2351	Inhibition of AÎ² Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry. ACS Chemical Neuroscience, 2017, 8, 1767-1778.	1.7	72
2352	Antibodyâ€Mimetic Peptoid Nanosheet for Labelâ€Free Serumâ€Based Diagnosis of Alzheimer's Disease. Advanced Materials, 2017, 29, 1700057.	11.1	60
2353	Molybdenum Disulfide Nanoparticles as Multifunctional Inhibitors against Alzheimerâ€™s Disease. ACS Applied Materials & Interfaces, 2017, 9, 21116-21123.	4.0	100
2354	Lithium and memantine improve spatial memory impairment and neuroinflammation induced by Î²-amyloid 1-42 oligomers in rats. Neurobiology of Learning and Memory, 2017, 141, 84-92.	1.0	33
2355	Inclusion of lipopeptides into the DMPC lipid bilayers prevents AÎ² peptide insertion. Physical Chemistry Chemical Physics, 2017, 19, 10087-10098.	1.3	6
2356	GluA1 subunit ubiquitination mediates amyloid-Î²-induced loss of surface Î±-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Journal of Biological Chemistry, 2017, 292, 8186-8194.	1.6	53
2357	Recent Studies on Mechanisms of New Drug Candidates for Alzheimerâ€™s Disease Interacting with Amyloid-Î² Protofibrils Using Molecular Dynamics Simulations. Translational Medicine Research, 2017, , 135-151.	0.0	4
2358	Amyloidogenicity at a Distance: How Distal Protein Regions Modulate Aggregation in Disease. Journal of Molecular Biology, 2017, 429, 1289-1304.	2.0	8
2359	Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimerâ€™s disease. Pharmacological Research, 2017, 120, 68-87.	3.1	67
2360	Paradigm shift from diagnosing patients based on common symptoms to categorizing patients into subtypes with different pathogenic mechanisms to guide treatment for Alzheimerâ€™s disease. Journal of Biochemistry, 2017, 161, 463-470.	0.9	3
2361	Mechanical Deformation Mechanisms and Properties of Prion Fibrils Probed by Atomistic Simulations. Nanoscale Research Letters, 2017, 12, 228.	3.1	6
2362	Cellular levels of growth factor receptor bound protein 2 (Grb2) and cytoskeleton stability are correlated in a neurodegenerative scenario. DMM Disease Models and Mechanisms, 2017, 10, 655-669.	1.2	13
2363	Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 23-35.	1.2	23
2364	The molecular behavior of a single Î²â€amyloid inside a dipalmitoylphosphatidylcholine bilayer at three different temperatures: An atomistic simulation study: AÎ² interaction with DPPC: Atomistic simulation. Proteins: Structure, Function and Bioinformatics, 2017, 85, 1298-1310.	1.5	7
2365	Synthesis and Characterization of Hairpin Mimics that Modulate the Early Oligomerization and Fibrillization of Amyloid Î²â€Peptide. European Journal of Organic Chemistry, 2017, 2017, 2971-2980.	1.2	12
2366	Ion mobility-mass spectrometry and orthogonal gas-phase techniques to study amyloid formation and inhibition. Current Opinion in Structural Biology, 2017, 46, 7-15.	2.6	31
2367	Long non-coding RNAs in brain development, synaptic biology, and Alzheimerâ€™s disease. Brain Research Bulletin, 2017, 132, 160-169.	1.4	52

#	Article	IF	Citations
2368	Application of proteinous nanofibrils to culture retinal pigmented epithelium cells: A versatile biomaterial. Reactive and Functional Polymers, 2017, 115, 36-42.	2.0	1
2370	Preclinical to phase II amyloid beta (A_{Î²}) peptide modulators under investigation for Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2017, 26, 579-592.	1.9	23
2371	Stabilizing the monomeric amyloid-Î² peptide by tyrocidine A prevents and reverses amyloidogenesis without the accumulation of oligomers. Chemical Communications, 2017, 53, 3886-3889.	2.2	18
2372	Self-Assembly and Anti-Amyloid Cytotoxicity Activity of Amyloid beta Peptide Derivatives. Scientific Reports, 2017, 7, 43637.	1.6	47
2373	Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2017, 57, 557-573.	1.2	45
2374	RNAi of arcRNA hsrï‰ affects sub-cellular localization of Drosophila FUS to drive neurodiseases. Experimental Neurology, 2017, 292, 125-134.	2.0	41
2375	The Effects of Gene Mutations onÂDefaultÂMode Network inÂFamilialÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 56, 327-334.	1.2	8
2376	Structural and Mechanistic Insights into Development of Chemical Tools to Control Individual and Interâ€Related Pathological Features in Alzheimer's Disease. Chemistry - A European Journal, 2017, 23, 2706-2715.	1.7	25
2377	Systematic development of small molecules to inhibit specific microscopic steps of AÎ²42 aggregation in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E200-E208.	3.3	180
2378	Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities atÂSynapses of Alzheimerâ€™s disease Neurons. Journal of Alzheimer's Disease, 2017, 57, 975-999.	1.2	294
2379	Structural analysis of oligomeric and protofibrillar AÎ² amyloid pair structures considering F20L mutation effects using molecular dynamics simulations. Proteins: Structure, Function and Bioinformatics, 2017, 85, 580-592.	1.5	1
2380	Tautomeric Effect of Histidine on the Monomeric Structure of Amyloid Î²-Peptide(1â€“42). ACS Chemical Neuroscience, 2017, 8, 669-675.	1.7	35
2381	Synthetic Models of Quasi-Stable Amyloid Î²40 Oligomers with Significant Neurotoxicity. ACS Chemical Neuroscience, 2017, 8, 807-816.	1.7	28
2382	The function of NODâ€like receptors in central nervous system diseases. Journal of Neuroscience Research, 2017, 95, 1565-1573.	1.3	25
2383	Young microglia restore amyloid plaque clearance of aged microglia. EMBO Journal, 2017, 36, 583-603.	3.5	124
2384	The Amyloidâ€Î² Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions. Israel Journal of Chemistry, 2017, 57, 674-685.	1.0	21
2385	Using chiral peptide substitutions to probe the structure function relationship of a key residue of AÎ²42. Chirality, 2017, 29, 5-9.	1.3	6
2386	Development of [11C]/[3H]THK-5351 â€“ A potential novel carbon-11 tau imaging PET radioligand. Nuclear Medicine and Biology, 2017, 46, 50-53.	0.3	16

#	Article	IF	Citations
2387	Decreasing amyloid toxicity through an increased rate of aggregation. Physical Chemistry Chemical Physics, 2017, 19, 1458-1465.	1.3	22
2388	The synergistic effect between KLVFF and self-assembly chaperones on both disaggregation of beta-amyloid fibrils and reducing consequent toxicity. Chemical Communications, 2017, 53, 1289-1292.	2.2	34
2389	Increased susceptibility to AÎ² toxicity in neuronal cultures derived from familial Alzheimerâ€™s disease (PSEN1-A246E) induced pluripotent stem cells. Neuroscience Letters, 2017, 639, 74-81.	1.0	44
2390	Impact of enriched environment on production of tau, amyloid precursor protein and, amyloid-Î² peptide in high-fat and high-sucrose-fed rats. Acta Neuropsychiatrica, 2017, 29, 291-298.	1.0	17
2391	Facile three-dimensional nanoarchitecturing of double-bent gold strips on roll-to-roll nanoimprinted transparent nanogratings for flexible and scalable plasmonic sensors. Nanoscale, 2017, 9, 1398-1402.	2.8	39
2392	Ion Channel Formation by Amyloid-Î²42 Oligomers but Not Amyloid-Î²40 in Cellular Membranes. Journal of Biological Chemistry, 2017, 292, 1404-1413.	1.6	159
2393	Binding Sites for Amyloid-Î² Oligomers and Synaptic Toxicity. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024075.	2.9	76
2394	Structural Characteristics of Î±-Synuclein Oligomers. International Review of Cell and Molecular Biology, 2017, 329, 79-143.	1.6	95
2395	In vitro monitoring of amyloid Î²-peptide oligomerization by Electrospray differential mobility analysis: An alternative tool to evaluate Alzheimer's disease drug candidates. Talanta, 2017, 165, 84-91.	2.9	12
2396	Colorimetric sandwich immunosensor for AÎ²(1-42) based on dual antibody-modified gold nanoparticles. Sensors and Actuators B: Chemical, 2017, 243, 792-799.	4.0	64
2397	Shatavarin IV elicits lifespan extension and alleviates Parkinsonism inCaenorhabditis elegans. Free Radical Research, 2017, 51, 954-969.	1.5	29
2398	Oligomers at the Synapse: Synaptic Dysfunction and Neurodegeneration. , 2017, , 33-56.		0
2399	Alzheimerâ€™s disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-Î² peptide aggregation. Scientific Reports, 2017, 7, 14423.	1.6	81
2400	A Metalloporphyrin-Peptide Conjugate as an Effective Inhibitor of Amyloid-Î² Peptide Fibrillation and Cytotoxicity. ChemistrySelect, 2017, 2, 9122-9129.	0.7	15
2401	Fluoro-substituted cyanine for reliablein vivolabelling of amyloid-Î² oligomers and neuroprotection against amyloid-Î² induced toxicity. Chemical Science, 2017, 8, 8279-8284.	3.7	54
2402	The vascular facet of late-onset Alzheimer's disease: an essential factor in a complex multifactorial disorder. Current Opinion in Neurology, 2017, 30, 623-629.	1.8	14
2403	Brain Aging in the Dog. , 2017, , 93-102.		0
2404	Statistical Mechanics and Kinetics of Amyloid Fibrillation. World Scientific Lecture and Course Notes in Chemistry, 2017, , 113-186.	0.2	11

#	Article	IF	Citations
2405	Kinetic Studies on Protein Aggregation With and Without the Presence of Crowders. World Scientific Lecture and Course Notes in Chemistry, 2017, , 187-220.	0.2	4
2406	Chiral Inactivation: An Old Phenomenon with a New Twist. Chemistry - A European Journal, 2017, 23, 16920-16923.	1.7	16
2408	Genetic underpinnings in Alzheimerâ€™s disease â€“ a review. Reviews in the Neurosciences, 2017, 29, 21-38.	1.4	25
2409	The effect of Benzothiazoloneâ€2 on the expression of Metallothioneinâ€3 in modulating Alzheimer's disease. Brain and Behavior, 2017, 7, e00799.	1.0	11
2410	How accurate are your simulations? Effects of confined aqueous volume and AMBER FF99SB and CHARMM22/CMAP force field parameters on structural ensembles of intrinsically disordered proteins: Amyloid-Î²₄₂in water. Intrinsically Disordered Proteins, 2017, 5, e1377813.	1.9	37
2411	Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. Cytotherapy, 2017, 19, 1426-1437.	0.3	9
2412	Selenomethionine Attenuates the Amyloid-Î² Level by Both Inhibiting Amyloid-Î² Production and Modulating Autophagy in Neuron-2a/AÎ²PPswe Cells. Journal of Alzheimer's Disease, 2017, 59, 591-602.	1.2	21
2413	The current agonists and positive allosteric modulators of Î± 7 nAChR for CNS indications in clinical trials. Acta Pharmaceutica Sinica B, 2017, 7, 611-622.	5.7	87
2414	Comparing the Aggregation Free Energy Landscapes of Amyloid Beta(1â€“42) and Amyloid Beta(1â€“40). Journal of the American Chemical Society, 2017, 139, 16666-16676.	6.6	86
2415	Foldamer-Mediated Structural Rearrangement Attenuates AÎ² Oligomerization and Cytotoxicity. Journal of the American Chemical Society, 2017, 139, 17098-17108.	6.6	61
2416	A simplified and sensitive method to identify Alzheimerâ€™s disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs). Journal of Biochemistry, 2017, 162, 391-394.	0.9	15
2417	Gold Nanoparticles as a Probe for Amyloid-Î² Oligomer and Amyloid Formation. Journal of Physical Chemistry C, 2017, 121, 20007-20015.	1.5	51
2418	Sleep architecture and the risk of incident dementia in the community. Neurology, 2017, 89, 1244-1250.	1.5	174
2419	Peptidomimetics That Inhibit and Partially Reverse the Aggregation of AÎ²_{1â€“42}. Biochemistry, 2017, 56, 4840-4849.	1.2	15
2420	Dissecting Amyloid Beta Deposition Using Distinct Strains of the Neurotropic Parasite Toxoplasma gondii as a Novel Tool. ASN Neuro, 2017, 9, 175909141772491.	1.5	30
2421	Monomer-dependent secondary nucleation in amyloid formation. Biophysical Reviews, 2017, 9, 329-338.	1.5	112
2422	Computational integration of nanoscale physical biomarkers and cognitive assessments for Alzheimerâ€™s disease diagnosis and prognosis. Science Advances, 2017, 3, e1700669.	4.7	18
2423	Gene Therapy in the Nervous System: Failures and Successes. Advances in Experimental Medicine and Biology, 2017, 1007, 241-257.	0.8	6

#	Article	IF	Citations
2424	Emerging role of amyloid beta in stress response: Implication for depression and diabetes. European Journal of Pharmacology, 2017, 817, 22-29.	1.7	44
2425	Size-Dependent Conformational Features of AÎ²_{17â€“42} Protofilaments from Molecular Simulation Studies. Journal of Chemical Information and Modeling, 2017, 57, 2378-2392.	2.5	12
2426	Lessons learned from protein aggregation: toward technological and biomedical applications. Biophysical Reviews, 2017, 9, 501-515.	1.5	11
2427	Cholesterol Changes the Mechanisms of AÎ² Peptide Binding to the DMPC Bilayer. Journal of Chemical Information and Modeling, 2017, 57, 2554-2565.	2.5	22
2428	Perturbation of the F19-L34 Contact in Amyloid Î² (1-40) Fibrils Induces Only Local Structural Changes but Abolishes Cytotoxicity. Journal of Physical Chemistry Letters, 2017, 8, 4740-4745.	2.1	14
2429	Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation. ACS Chemical Neuroscience, 2017, 8, 2791-2808.	1.7	26
2430	Tuning the stereo-hindrance of a curcumin scaffold for the selective imaging of the soluble forms of amyloid beta species. Chemical Science, 2017, 8, 7710-7717.	3.7	69
2431	SEN1500, a novel oral amyloid-Î² aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimerâ€™s disease. Neuroscience Letters, 2017, 660, 96-102.	1.0	3
2432	Molecular Insights into Human Serum Albumin as a Receptor of Amyloid-Î² in the Extracellular Region. Journal of the American Chemical Society, 2017, 139, 15437-15445.	6.6	61
2433	A Toxic Conformer of AÎ²42 with a Turn at 22â€“23 is a Novel Therapeutic Target for Alzheimerâ€™s Disease. Scientific Reports, 2017, 7, 11811.	1.6	23
2434	Seed-induced acceleration of amyloid-Î² mediated neurotoxicity in vivo. Nature Communications, 2017, 8, 512.	5.8	57
2435	Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Science Translational Medicine, 2017, 9, .	5.8	44
2436	Aqueous RAFT Synthesis of Glycopolymers for Determination of Saccharide Structure and Concentration Effects on Amyloid Î² Aggregation. Biomacromolecules, 2017, 18, 3359-3366.	2.6	22
2437	In Situ Architecture and Cellular Interactions of PolyQ Inclusions. Cell, 2017, 171, 179-187.e10.	13.5	271
2438	Suppression of Oligomer Formation and Formation of Nonâ€Toxic Fibrils upon Addition of Mirrorâ€Image AÎ²42 to the Natural <scp>l</scp>â€Enantiomer. Angewandte Chemie - International Edition, 2017, 56, 11506-11510.	7.2	76
2439	Suppression of Oligomer Formation and Formation of Nonâ€Toxic Fibrils upon Addition of Mirrorâ€Image AÎ²42 to the Natural <scp>l</scp>â€Enantiomer. Angewandte Chemie, 2017, 129, 11664-11668.	1.6	15
2440	Role of miRNAs in development and disease: Lessons learnt from small organisms. Life Sciences, 2017, 185, 8-14.	2.0	72
2441	Self-Assembly and Associated Photophysics of Dendron-Appended Peptide-Ï€-Peptide Triblock Macromolecules. Macromolecules, 2017, 50, 5315-5322.	2.2	8

#	Article	IF	Citations
2442	Structural studies of amyloid-Î² peptides: Unlocking the mechanism of aggregation and the associated toxicity. Biochimie, 2017, 140, 176-192.	1.3	59
2443	Metabolite Clearance During Wakefulness and Sleep. Handbook of Experimental Pharmacology, 2017, 253, 385-423.	0.9	23
2444	Alzheimerâ€™s-Causing Mutations Shift AÎ² Length by Destabilizing Î³-Secretase-AÎ²n Interactions. Cell, 2017, 170, 443-456.e14.	13.5	199
2445	CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice. Neurological Research, 2017, 39, 885-894.	0.6	22
2446	Protein aggregation, cardiovascular diseases, and exercise training: Where do we stand?. Ageing Research Reviews, 2017, 40, 1-10.	5.0	42
2447	Oligomerization of the tetramerization domain of p53 probed by two- and three-color single-molecule FRET. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6812-E6821.	3.3	45
2448	Secretases-related miRNAs in Alzheimerâ€™s disease: new approach for biomarker discovery. Neurological Sciences, 2017, 38, 1921-1926.	0.9	12
2449	Aggregation and Fibril Structure of AÎ²_{M01â€“42} and AÎ²_{1â€“42}. Biochemistry, 2017, 56, 4850-4859.	1.2	19
2450	Microscopic and macroscopic models for the onset and progression of Alzheimer's disease. Journal of Physics A: Mathematical and Theoretical, 2017, 50, 414003.	0.7	13
2451	Resveratrol for Alzheimer's disease. Annals of the New York Academy of Sciences, 2017, 1403, 142-149.	1.8	198
2452	Filling the void: a role for exercise-induced BDNF and brain amyloid precursor protein processing. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 313, R585-R593.	0.9	25
2453	Plasma Membrane Protein Profiling in Betaâ€Amyloidâ€Treated Microglia Cell Line. Proteomics, 2017, 17, 1600439.	1.3	21
2454	Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state. Nature Communications, 2017, 8, 2081.	5.8	67
2455	Inhibiting the Ca 2+ Influx Induced by Human CSF. Cell Reports, 2017, 21, 3310-3316.	2.9	20
2456	Initial Structural Models of the AÎ²42 Dimer from Replica Exchange Molecular Dynamics Simulations. ACS Omega, 2017, 2, 7621-7636.	1.6	10
2457	Spatiotemporal Proteomic Profiling of Huntingtonâ€™s Disease Inclusions Reveals Widespread Loss of Protein Function. Cell Reports, 2017, 21, 2291-2303.	2.9	107
2458	Dissociation of haemolytic and oligomer-preventing activities of gramicidin S derivatives targeting the amyloid-Î² N-terminus. Chemical Communications, 2017, 53, 13340-13343.	2.2	7
2459	Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations. Cell, 2017, 171, 1001-1014.	13.5	39

#	Article	IF	Citations
2460	Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13018-13023.	3.3	170
2461	Coordination Chemistry of Bifunctional Chemical Agents Designed for Applications in ⁶⁴Cu PET Imaging for Alzheimerâ€™s Disease. Inorganic Chemistry, 2017, 56, 13801-13814.	1.9	42
2462	Using an NMR metabolomics approach to investigate the pathogenicity of amyloid-beta and alpha-synuclein. Metabolomics, 2017, 13, 151.	1.4	17
2463	Stabilizing amyloid-Î² peptide by the N-terminus capture is capable of preventing and eliminating amyloid-Î² oligomers. Chemical Communications, 2017, 53, 7673-7676.	2.2	10
2464	Amyloid plaques beyond AÎ²: a survey of the diverse modulators of amyloid aggregation. Biophysical Reviews, 2017, 9, 405-419.	1.5	74
2465	Glucose directs amyloid-beta into membrane-active oligomers. Physical Chemistry Chemical Physics, 2017, 19, 18036-18046.	1.3	21
2466	Ultrasensitive Measurement of Ca²⁺ Influx into Lipid Vesicles Induced by Protein Aggregates. Angewandte Chemie, 2017, 129, 7858-7862.	1.6	9
2467	Ultrasensitive Measurement of Ca²⁺ Influx into Lipid Vesicles Induced by Protein Aggregates. Angewandte Chemie - International Edition, 2017, 56, 7750-7754.	7.2	72
2468	Backbone Hydrogen Bond Strengths Can Vary Widely in Transmembrane Helices. Journal of the American Chemical Society, 2017, 139, 10742-10749.	6.6	36
2469	How Does the P7C3-Series of Neuroprotective Small Molecules Prevent Membrane Disruption?. Journal of Chemical Information and Modeling, 2017, 57, 2009-2019.	2.5	3
2470	Monomeric and fibrillar Î±-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of AÎ²42 aggregates. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8005-8010.	3.3	45
2471	Alzheimerâ€™s Disease: Insights from Genetic Mouse Models and Current Advances in Human IPSC-Derived Neurons. Advances in Neurobiology, 2017, 15, 3-29.	1.3	4
2472	Impact of a discordant helix on Î²-amyloid structure, aggregation ability and toxicity. European Biophysics Journal, 2017, 46, 681-687.	1.2	9
2473	Zn(II) - pramlintide: Stability, binding sites and unexpected aggregation. Journal of Inorganic Biochemistry, 2017, 174, 150-155.	1.5	20
2474	Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action. Neurochemistry International, 2017, 108, 481-493.	1.9	34
2475	Chronic cerebral hypoperfusion alters amyloid-Î² peptide pools leading to cerebral amyloid angiopathy, microinfarcts and haemorrhages in Tg-SwDI mice. Clinical Science, 2017, 131, 2109-2123.	1.8	27
2476	Transmission of pathogenic protein aggregates in Alzheimerâ€™s disease. Molecular Biology, 2017, 51, 368-371.	0.4	8
2477	A vaccine with AÎ² oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 41.	3.0	9

#	Article	IF	Citations
2478	Taxifolin inhibits amyloid-Î² oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy. Acta Neuropathologica Communications, 2017, 5, 26.	2.4	72
2479	Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease. Neuropharmacology, 2017, 123, 465-476.	2.0	81
2480	Regulation of 1, 4, 5-triphosphate receptor channel gating dynamics by mutant presenilin in Alzheimerâ€™s disease cells. Frontiers of Physics, 2017, 12, 1.	2.4	1
2481	Oligomer Formation and Crossâ€Seeding: The New Frontier. Israel Journal of Chemistry, 2017, 57, 665-673.	1.0	8
2482	Pittsburgh Compoundâ€B (PiB) binds amyloid Î²â€protein protofibrils. Journal of Neurochemistry, 2017, 140, 210-215.	2.1	33
2483	Sorting receptor SORLA: cellular mechanisms and implications for disease. Cellular and Molecular Life Sciences, 2017, 74, 1475-1483.	2.4	44
2484	Large Soluble Oligomers of Amyloid Î²-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. Journal of Neuroscience, 2017, 37, 152-163.	1.7	262
2485	Structural Characterization of Monomers and Oligomers of D-Amino Acid-Containing Peptides Using T-Wave Ion Mobility Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2017, 28, 110-118.	1.2	20
2486	Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition. Israel Journal of Chemistry, 2017, 57, 586-601.	1.0	25
2487	Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 607-619.	1.8	37
2488	eEF2K inhibition blocks AÎ²42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathologica, 2017, 133, 101-119.	3.9	48
2489	Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's AÎ² peptide. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 723-732.	1.7	47
2490	Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein. Molecular Psychiatry, 2017, 22, 981-989.	4.1	33
2491	Imaging Approaches to Cerebral Cortex Pathology. , 2017, , 57-80.		0
2492	Maternal separation exacerbates Alzheimerâ€™s disease-like behavioral and pathological changes in adult APPswe/PS1dE9 mice. Behavioural Brain Research, 2017, 318, 18-23.	1.2	24
2493	Analysis of anticoagulants for blood-based quantitation of amyloid Î² oligomers in the sFIDA assay. Biological Chemistry, 2017, 398, 465-475.	1.2	11
2494	Preparation of pure populations of covalently stabilized amyloid Î²-protein oligomers of specific sizes. Analytical Biochemistry, 2017, 518, 78-85.	1.1	26
2495	Structural and functional diversity among amyloid proteins: Agents of disease, building blocks of biology, and implications for molecular engineering. Biotechnology and Bioengineering, 2017, 114, 7-20.	1.7	27

#	Article	IF	Citations
2496	Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice. Journal of Neuroscience Research, 2017, 95, 992-999.	1.3	7
2497	Resveratrol ameliorates spatial learning memory impairment induced by AÎ² 1â€“42 in rats. Neuroscience, 2017, 344, 39-47.	1.1	82
2498	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progress in Biophysics and Molecular Biology, 2017, 123, 16-41.	1.4	64
2499	Antiamyloidogenic Activity of AÎ²42-Binding Peptoid in Modulating Amyloid Oligomerization. Small, 2017, 13, 1602857.	5.2	17
2500	Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia. Ageing Research Reviews, 2017, 34, 30-38.	5.0	74
2501	1,2,3,4,6-penta-O-galloyl-Î²-d-glucopyranose binds to the N-terminal metal binding region to inhibit amyloid Î²-protein oligomer and fibril formation. International Journal of Mass Spectrometry, 2017, 420, 24-34.	0.7	24
2502	Î²-Hairpin mimics containing a piperidineâ€“pyrrolidine scaffold modulate the Î²-amyloid aggregation process preserving the monomer species. Chemical Science, 2017, 8, 1295-1302.	3.7	39
2503	Docosahexaenoic acid: one molecule diverse functions. Critical Reviews in Biotechnology, 2017, 37, 579-597.	5.1	139
2504	Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: Is AÎ² a Crucial Factor in Both Pathologies?. Antioxidants and Redox Signaling, 2017, 26, 542-560.	2.5	46
2505	Decrease of high voltage Ca2+ currents in the dentate gyrus granule cells by entorhinal amyloidopathy is reversed by calcium channel blockade. European Journal of Pharmacology, 2017, 794, 154-161.	1.7	9
2506	Treadmill exercise decreases amyloid-Î² burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer's disease. Experimental Neurology, 2017, 288, 142-152.	2.0	115
2507	Flowâ€cytometric screening of aggregationâ€inhibitors using a fluorescenceâ€assisted intracellular method. Biotechnology Journal, 2017, 12, 1600364.	1.8	3
2508	Fluorescent peptide nanoparticles to monitor AÎ² oligomers. , 2017, , .		0
2509	Application of Nucleic Acid Aptamers in Polypeptides Researches. Chinese Journal of Analytical Chemistry, 2017, 45, 1795-1803.	0.9	1
2510	Suppression of Alzheimer's diseaseâ€related phenotypes by the heat shock protein 70 inducer, geranylgeranylacetone, in APP/PS1 transgenic mice via the ERK/p38 MAPK signaling pathway. Experimental and Therapeutic Medicine, 2017, 14, 5267-5274.	0.8	25
2511	Single-Molecule Analysis Methods Using Nanogap Electrodes and Their Application to DNA Sequencing Technologies. Bulletin of the Chemical Society of Japan, 2017, 90, 1189-1210.	2.0	18
2512	Structure-Property Relationship of Amyloidogenic Prion Nanofibrils. , 2017, , .		0
2513	Analysis for biological network properties of Alzheimer's disease associated gene set by enrichment and topological examinations. International Journal of Bioinformatics Research and Applications, 2017, 13, 214.	0.1	3

#	Article	IF	Citations
2514	Cholesterol and Fat Metabolism in Alzheimerâ€™s Disease. , 2017, , 161-193.		0
2515	Membrane-Accelerated Amyloid-Î² Aggregation and Formation of Cross-Î² Sheets. Membranes, 2017, 7, 49.	1.4	41
2516	BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimerâ€™s Disease Pathology. Molecules, 2017, 22, 1723.	1.7	89
2517	Amyloid Î² Hypothesis in the Development of Therapeutic Agents for Alzheimerâ€™s Disease. , 2017, , 109-143.		5
2518	Molecular Hybridization. , 2017, , 219-237.		5
2519	The Physiological and Pathological Implications of the Formation of Hydrogels, with a Specific Focus on Amyloid Polypeptides. Biomolecules, 2017, 7, 70.	1.8	7
2520	Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds. International Journal of Molecular Sciences, 2017, 18, 227.	1.8	24
2521	Amyloid Î² Modification: A Key to the Sporadic Alzheimer's Disease?. Frontiers in Genetics, 2017, 8, 58.	1.1	52
2522	Wnt/TLR Dialog in Neuroinflammation, Relevance in Alzheimerâ€™s Disease. Frontiers in Immunology, 2017, 8, 187.	2.2	39
2523	Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants. Frontiers in Aging Neuroscience, 2017, 9, 168.	1.7	176
2524	Decreased Complexity in Alzheimer's Disease: Resting-State fMRI Evidence of Brain Entropy Mapping. Frontiers in Aging Neuroscience, 2017, 9, 378.	1.7	99
2525	Analysis of Amyloid-Î² Pathology Spread in Mouse Models Suggests Spread Is Driven by Spatial Proximity, Not Connectivity. Frontiers in Neurology, 2017, 8, 653.	1.1	20
2526	Metal Dyshomeostasis and Their Pathological Role in Prion and Prion-Like Diseases: The Basis for a Nutritional Approach. Frontiers in Neuroscience, 2017, 11, 3.	1.4	44
2527	Osthole Stimulated Neural Stem Cells Differentiation into Neurons in an Alzheimer's Disease Cell Model via Upregulation of MicroRNA-9 and Rescued the Functional Impairment of Hippocampal Neurons in APP/PS1 Transgenic Mice. Frontiers in Neuroscience, 2017, 11, 340.	1.4	47
2528	G-Protein-Coupled Inwardly Rectifying Potassium (GIRK) Channel Activation by the p75 Neurotrophin Receptor Is Required for Amyloid Î² Toxicity. Frontiers in Neuroscience, 2017, 11, 455.	1.4	19
2529	The Endoplasmic Reticulum Unfolded Protein Response in Neurodegenerative Disorders and Its Potential Therapeutic Significance. Frontiers in Molecular Neuroscience, 2017, 10, 187.	1.4	138
2530	Markers of Alzheimerâ€™s Disease in Primary Visual Cortex in Normal Aging in Mice. BioMed Research International, 2017, 2017, 1-10.	0.9	7
2531	Early Contextual Fear Memory Deficits in a Double-Transgenic Amyloid-Î²Precursor Protein/Presenilin 2 Mouse Model of Alzheimerâ€™s Disease. International Journal of Alzheimer's Disease, 2017, 2017, 1-7.	1.1	5

#	Article	IF	Citations
2532	Pathological Role of Peptidyl-Prolyl Isomerase Pin1 in the Disruption of Synaptic Plasticity in Alzheimerâ€™s Disease. Neural Plasticity, 2017, 2017, 1-12.	1.0	28
2533	Antineuroinflammatory Effects of Modified Wu-Zi-Yan-Zong Prescription in Î²-Amyloid-Stimulated BV2 Microglia via the NF-Î°B and ERK/p38 MAPK Signaling Pathways. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-10.	0.5	10
2534	Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease. Theranostics, 2017, 7, 3933-3947.	4.6	27
2535	Study of structural stability and damaging effect on membrane for four AÎ²42 dimers. PLoS ONE, 2017, 12, e0179147.	1.1	4
2536	Assemblies of amyloid-Î²30â€“36 hexamer and its G33V/L34T mutants by replica-exchange molecular dynamics simulation. PLoS ONE, 2017, 12, e0188794.	1.1	13
2537	Neurochemical Aspects of Î²-Amyloid Cascade Hypothesis for Alzheimerâ€™s Disease. , 2017, , 1-46.		0
2538	TRPA1 channels promote astrocytic Ca2+ hyperactivity and synaptic dysfunction mediated by oligomeric forms of amyloid-Î² peptide. Molecular Neurodegeneration, 2017, 12, 53.	4.4	62
2539	Dynamic changes of oligomeric amyloid Î² levels in plasma induced by spiked synthetic AÎ²42. Alzheimer's Research and Therapy, 2017, 9, 86.	3.0	57
2540	A phase III randomized trial of gantenerumab in prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 95.	3.0	396
2541	Vitamin D Affects Neuronal Peptides in Neurodegenerative Disease: Differences of V-D2 and V-D3 for Affinity to Amyloid-Î² and Scrapie Prion Protein In Vitro. , 2017, , .		0
2542	Strategy to discover full-length amyloid-beta peptide ligands using high-efficiency microarray technology. Beilstein Journal of Nanotechnology, 2017, 8, 2446-2453.	1.5	2
2543	Neuroprotection by aripiprazole against Î²-amyloid-induced toxicity by P-CK2Î± activation via inhibition of GSK-3Î². Oncotarget, 2017, 8, 110380-110391.	0.8	9
2544	SUMOylation and calcium signalling: potential roles in the brain and beyond. Neuronal Signaling, 2017, 1, NS20160010.	1.7	6
2545	The Sea Urchin Embryo: A Model for Studying Molecular Mechanisms Involved in Human Diseases and for Testing Bioactive Compounds. , 0, , .		6
2546	Metal-Binding to Amyloid-Î² Peptide: Coordination, Aggregation, and Reactive Oxygen Species Production. , 2017, , 265-281.		12
2547	The emerging role of PET imaging in dementia. F1000Research, 2017, 6, 1830.	0.8	43
2548	Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimerâ€™s Disease. Molecules, 2017, 22, 1693.	1.7	26
2549	Effect of retinoid X receptor-Î± nuclear export inhibition on apoptosis of neurons in vivo and in vitro. Molecular Medicine Reports, 2017, 16, 2037-2044.	1.1	3

#	Article	IF	Citations
2550	Neuronal vs Glial Cell Contribution to Adenosine A 2A Receptor-Induced Neurodegeneration. , 2017, , 131-150.		0
2551	Early Presymptomatic Changes in the Proteome of Mitochondria-Associated Membrane in the APP/PS1 Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7839-7857.	1.9	55
2552	Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease. Neuropharmacology, 2018, 136, 223-242.	2.0	38
2553	<scp>NGF</scp> steers microglia toward a neuroprotective phenotype. Glia, 2018, 66, 1395-1416.	2.5	72
2554	Metal ions affect the formation and stability of amyloid Î² aggregates at multiple length scales. Physical Chemistry Chemical Physics, 2018, 20, 8951-8961.	1.3	39
2555	Peripheral post-ischemic vascular repair is impaired in a murine model of Alzheimerâ€™s disease. Angiogenesis, 2018, 21, 557-569.	3.7	5
2557	Semenâ€derived amyloidogenic peptidesâ€”Key players of HIV infection. Protein Science, 2018, 27, 1151-1165.	3.1	15
2558	Highly Disordered Amyloid-Î² Monomer Probed by Single-Molecule FRET and MD Simulation. Biophysical Journal, 2018, 114, 870-884.	0.2	88
2559	AÎ² dimers induce behavioral and neurochemical deficits of relevance to early Alzheimer's disease. Neurobiology of Aging, 2018, 69, 1-9.	1.5	14
2560	Biomolecular Corona Dictates AÎ² Fibrillation Process. ACS Chemical Neuroscience, 2018, 9, 1725-1734.	1.7	23
2561	Interactions between amyloid Î² peptide and lipid membranes. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1663-1669.	1.4	82
2562	Structure-activity relationship of clovamide and its related compounds for the inhibition of amyloid Î² aggregation. Bioorganic and Medicinal Chemistry, 2018, 26, 3202-3209.	1.4	23
2563	Neuroprotective Effects of Ferruginol, Jatrophone, and Junicedric Acid Against Amyloid-Î² Injury in Hippocampal Neurons. Journal of Alzheimer's Disease, 2018, 63, 705-723.	1.2	8
2564	Nobiletin Reduces Intracellular and Extracellular Î²-Amyloid in iPS Cell-Derived Alzheimerâ€™s Disease Model Neurons. Biological and Pharmaceutical Bulletin, 2018, 41, 451-457.	0.6	40
2565	Amyloid-Î² Peptide Interactions with Amphiphilic Surfactants: Electrostatic and Hydrophobic Effects. ACS Chemical Neuroscience, 2018, 9, 1680-1692.	1.7	51
2566	Heptamer Peptide Disassembles Native Amyloid in Human Plasma Through Heat Shock Protein 70. Rejuvenation Research, 2018, 21, 527-534.	0.9	5
2567	Substrate Insolubility Dictates Hsp104-Dependent Endoplasmic-Reticulum-Associated Degradation. Molecular Cell, 2018, 70, 242-253.e6.	4.5	27
2568	Synaptotoxic Signaling by Amyloid Beta Oligomers in Alzheimer's Disease Through Prion Protein and mGluR5. Advances in Pharmacology, 2018, 82, 293-323.	1.2	67

#	Article	IF	Citations
2569	No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. Biological Reviews, 2018, 93, 1518-1557.	4.7	92
2570	A spidroinâ€derived solubility tag enables controlled aggregation of a designed amyloid protein. FEBS Journal, 2018, 285, 1873-1885.	2.2	32
2571	Lipid nanocarriers loaded with natural compounds: Potential new therapies for age related neurodegenerative diseases?. Progress in Neurobiology, 2018, 168, 21-41.	2.8	27
2572	Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimerâ€™s Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. ACS Chemical Neuroscience, 2018, 9, 1802-1817.	1.7	60
2573	Peptidomimetic-Based Multidomain Targeting Offers Critical Evaluation of AÎ² Structure and Toxic Function. Journal of the American Chemical Society, 2018, 140, 6562-6574.	6.6	49
2574	Effects of Bioactive Components of Green Tea on Alzheimer's Disease. Studies in Natural Products Chemistry, 2018, 56, 151-172.	0.8	3
2575	Mechanistic analyses of the suppression of amyloid Î²42 aggregation by apomorphine. Bioorganic and Medicinal Chemistry, 2018, 26, 1538-1546.	1.4	18
2576	Competitive homo- and hetero- self-assembly of amyloid-Î² 1â€“42 and 1â€“40 in the early stage of fibrillation. International Journal of Mass Spectrometry, 2018, 428, 15-21.	0.7	10
2577	Aggregation-prone Regions in HYPK Help It to Form Sequestration Complex for Toxic Protein Aggregates. Journal of Molecular Biology, 2018, 430, 963-986.	2.0	17
2578	Shedding light on aberrant interactions â€“ a review of modern tools for studying protein aggregates. FEBS Journal, 2018, 285, 3604-3630.	2.2	10
2579	Molecular subtypes of Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 3269.	1.6	68
2580	Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks AÎ²â€“Fibrinogen Interaction and AÎ²-Induced Contact System Activation. Biochemistry, 2018, 57, 1399-1409.	1.2	12
2581	Mass and charge distributions of amyloid fibers involved in neurodegenerative diseases: mapping heterogeneity and polymorphism. Chemical Science, 2018, 9, 2791-2796.	3.7	26
2582	Amyloid-Î² oligomers synaptotoxicity: The emerging role of EphA4/c-Abl signaling in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1148-1159.	1.8	48
2583	Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death. Cell Death and Disease, 2018, 9, 166.	2.7	38
2584	Amyloids of multiple species: are they helpful in survival?. Biological Reviews, 2018, 93, 1363-1386.	4.7	11
2585	Amyloid Î²-targeted metal complexes for potential applications in Alzheimer's disease. Future Medicinal Chemistry, 2018, 10, 679-701.	1.1	45
2586	Single-molecule diffusometry reveals the nucleotide-dependent oligomerization pathways of Nicotiana tabacum Rubisco activase. Journal of Chemical Physics, 2018, 148, 123319.	1.2	25

#	Article	IF	Citations
2587	Assembly of Nanoconjugates as New Kind Inhibitor of the Aggregation of Amyloid Peptides Associated with Alzheimer's Disease. Particle and Particle Systems Characterization, 2018, 35, 1700384.	1.2	6
2588	New Technologies for Analysis of Extracellular Vesicles. Chemical Reviews, 2018, 118, 1917-1950.	23.0	1,041
2589	Critical aggregation concentration for the formation of early Amyloid-Î² (1â€“42) oligomers. Scientific Reports, 2018, 8, 1783.	1.6	111
2590	Lysosomal enzyme tripeptidyl peptidase 1 destabilizes fibrillar AÎ² by multiple endoproteolytic cleavages within the Î²-sheet domain. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1493-1498.	3.3	33
2592	Proteomic profile of 4-PBA treated human neuronal cells during ER stress. Molecular Omics, 2018, 14, 53-63.	1.4	33
2593	Intracellular Ca ²⁺ stores control in vivo neuronal hyperactivity in a mouse model of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1279-E1288.	3.3	97
2594	Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimerâ€™s disease mouse model 5xFAD. Scientific Reports, 2018, 8, 1550.	1.6	81
2595	Investigation of the interaction of amyloid Î² peptide (11â€“42) oligomers with a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membrane using molecular dynamics simulation. Physical Chemistry Chemical Physics, 2018, 20, 6817-6829.	1.3	27
2596	GABA-containing liposomes: neuroscience applications and translational perspectives for targeting neurological diseases. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 781-788.	1.7	18
2597	Ionic liquid based ultrasound assisted dispersive liquid-liquid micro-extraction for simultaneous determination of 15 neurotransmitters in rat brain, plasma and cell samples. Analytica Chimica Acta, 2018, 1005, 43-53.	2.6	39
2598	Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-Î² oligomers. Journal of Biological Chemistry, 2018, 293, 1957-1975.	1.6	146
2599	An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 420-437.	3.1	16
2600	Cinnamon, a promising prospect towards Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 241-258.	3.1	67
2601	Interaction of AÎ²_{1â€“42} peptide or their variant with model membrane of different composition probed by infrared nanospectroscopy. Nanoscale, 2018, 10, 936-940.	2.8	35
2602	Copper-assisted interaction between amyloid-Î² and prion: Ternary metal complexes with AÎ² N-terminus and octarepeat. Inorganica Chimica Acta, 2018, 472, 93-102.	1.2	6
2603	Intracellular Peptide Self-Assembly: A Biomimetic Approach for in Situ Nanodrug Preparation. Bioconjugate Chemistry, 2018, 29, 826-837.	1.8	37
2604	APBB2 is associated with amphetamine use and plasma beta-amyloids in patients receiving methadone maintenance treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 83, 92-98.	2.5	6
2605	NMR-driven identification of anti-amyloidogenic compounds in green and roasted coffee extracts. Food Chemistry, 2018, 252, 171-180.	4.2	47

#	Article	IF	Citations
2606	Amyloid Beta Peptide VHHQ, KLVFF, and IIGLMVGGVV Domains Involved in Fibrilization: AFM and Electrochemical Characterization. Analytical Chemistry, 2018, 90, 2285-2292.	3.2	32
2607	Trophic modulation of gamma oscillations: The key role of processing protease for Neuregulin-1 and BDNF precursors. Neurochemistry International, 2018, 119, 2-10.	1.9	12
2608	Liver X Receptor Agonist GW3965 Regulates Synaptic Function upon Amyloid Beta Exposure in Hippocampal Neurons. Neurotoxicity Research, 2018, 33, 569-579.	1.3	22
2609	Using Herpes Simplex Virus Type 1-Based Amplicon Vectors for Neuroscience Research and Gene Therapy of Neurologic Diseases. , 2018, , 445-477.		0
2610	Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its Î±-Helical Conformation, and Inhibits Î³-Secretase Nonselectively in Liposomes. ACS Chemical Neuroscience, 2018, 9, 1702-1713.	1.7	11
2611	Soluble AÎ²1â€“42 increases the heterogeneity in synaptic vesicle pool size among synapses by suppressing intersynaptic vesicle sharing. Molecular Brain, 2018, 11, 10.	1.3	5
2612	Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-Î²-induced pathology. Alzheimer's Research and Therapy, 2018, 10, 1.	3.0	120
2613	Change of Amyloid-Î² 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic NormalÂPressure Hydrocephalus. Journal of Alzheimer's Disease, 2018, 63, 989-1002.	1.2	19
2614	Modulation of the expression of genes related to the system of amyloid-beta metabolism in the brain as a novel mechanism of ceftriaxone neuroprotective properties. BMC Neuroscience, 2018, 19, 13.	0.8	25
2615	Well-Posedness of a Mathematical Model for Alzheimer's Disease. SIAM Journal on Mathematical Analysis, 2018, 50, 2362-2388.	0.9	9
2616	Structural characteristics and membrane interactions of tandem Î±-synuclein oligomers. Scientific Reports, 2018, 8, 6755.	1.6	23
2617	Surface Enhanced Raman Spectroscopy for Medical Diagnostics. , 2018, , 1-66.		6
2618	Interference of citrate-stabilized gold nanoparticles with Î²2-microglobulin oligomeric association. Chemical Communications, 2018, 54, 5422-5425.	2.2	11
2619	Supratherapeutic concentrations of cilostazol inhibits Î²-amyloid oligomerization in vitro. Neuroscience Letters, 2018, 677, 19-25.	1.0	12
2620	Discovery of tetrahydroindazoles as a novel class of potent and in vivo efficacious gamma secretase modulators. Bioorganic and Medicinal Chemistry, 2018, 26, 3227-3241.	1.4	8
2621	ABBY. Neurology, 2018, 90, e1889-e1897.	1.5	188
2622	The Gelsolin Pathogenic D187N Mutant Exhibits Altered Conformational Stability and Forms Amyloidogenic Oligomers. Biochemistry, 2018, 57, 2359-2372.	1.2	16
2623	Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2143-2153.	1.8	14

#	Article	IF	Citations
2624	A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. Nature Communications, 2018, 9, 1097.	5.8	251
2625	The Mitochondrial Permeability Transition Pore. , 2018, , 47-73.		3
2626	Role of ASIC1a in AÎ²-induced synaptic alterations in the hippocampus. Pharmacological Research, 2018, 131, 61-65.	3.1	20
2627	Distinct thermodynamic signatures of oligomer generation in the aggregation of the amyloid-Î² peptide. Nature Chemistry, 2018, 10, 523-531.	6.6	129
2628	Zinc ion rapidly induces toxic, off-pathway amyloid-Î² oligomers distinct from amyloid-Î² derived diffusible ligands in Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 4772.	1.6	104
2629	Looking at the Disordered Proteins through the Computational Microscope. ACS Central Science, 2018, 4, 534-542.	5.3	46
2630	Anti-AÎ² drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease. Analyst, The, 2018, 143, 2204-2212.	1.7	19
2631	Role of the cell membrane interface in modulating production and uptake of Alzheimer's beta amyloid protein. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1639-1651.	1.4	47
2632	Alzheimerâ€™s Disease, Oligomers, and Inflammation. Journal of Alzheimer's Disease, 2018, 62, 1261-1276.	1.2	141
2633	Analysis of Physicochemical Interaction of AÎ²₄₀ with a GM1 Ganglioside-Containing Lipid Membrane. Journal of Physical Chemistry B, 2018, 122, 3771-3781.	1.2	18
2634	Metal-involved theranostics: An emerging strategy for fighting Alzheimerâ€™s disease. Coordination Chemistry Reviews, 2018, 362, 72-84.	9.5	53
2635	Neuroprotective and Antiaging Essential Oils and Lipids in Plants. Reference Series in Phytochemistry, 2018, , 1-18.	0.2	3
2636	Mutations in the Î²-amyloid precursor protein in familial Alzheimerâ€™s disease increase AÎ² oligomer production in cellular models. Heliyon, 2018, 4, e00511.	1.4	10
2637	Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation. Human and Experimental Toxicology, 2018, 37, 399-411.	1.1	28
2638	In silico investigation on the inhibition of AÎ²₄₂ aggregation by AÎ²₄₀ peptide by potential of mean force study. Journal of Biomolecular Structure and Dynamics, 2018, 36, 741-752.	2.0	10
2639	Injected Amyloid Beta in the Olfactory Bulb Transfers to Other Brain Regions via Neural Connections in Mice. Molecular Neurobiology, 2018, 55, 1703-1713.	1.9	13
2640	AÎ² truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 208-225.	1.8	53
2641	The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. Neurobiology of Disease, 2018, 109, 178-190.	2.1	62

#	Article	IF	Citations
2642	Direct pharmacological Akt activation rescues Alzheimer's disease like memory impairments and aberrant synaptic plasticity. Neuropharmacology, 2018, 128, 282-292.	2.0	66
2643	Dendritic Polyglycerol Sulfates in the Prevention of Synaptic Loss and Mechanism of Action on Glia. ACS Chemical Neuroscience, 2018, 9, 260-271.	1.7	28
2644	A decay of the adaptive capacity of the unfolded protein response exacerbates Alzheimer's disease. Neurobiology of Aging, 2018, 63, 162-164.	1.5	15
2645	Modulation of Alzheimer's amyloid Î² peptide oligomerization and toxicity by extracellular Hsp70. Cell Stress and Chaperones, 2018, 23, 269-279.	1.2	33
2646	Interaction of polymers with amyloidogenic peptides. Polymer International, 2018, 67, 15-24.	1.6	5
2647	The effects of betulinic acid on neurobehavioral activity, electrophysiology and histological changes in an animal model of the Alzheimerâ€™s disease. Behavioural Brain Research, 2018, 337, 99-106.	1.2	34
2648	Capping effects on polymorphic AÎ² 16â€“21 amyloids depend on their size: A molecular dynamics simulation study. Biophysical Chemistry, 2018, 232, 1-11.	1.5	3
2649	Effects of Acetylcholine on Î²-Amyloid-Induced cPLA2 Activation in the TB Neuroectodermal Cell Line: Implications for the Pathogenesis of Alzheimerâ€™s Disease. Cellular and Molecular Neurobiology, 2018, 38, 817-826.	1.7	8
2650	Pharmacological activation of the Nrf2 pathway by 3H-1, 2-dithiole-3-thione is neuroprotective in a mouse model of Alzheimer disease. Behavioural Brain Research, 2018, 336, 219-226.	1.2	41
2651	Pharmacotherapeutic potential of ginger and its compounds in age-related neurological disorders. , 2018, 182, 56-69.		98
2652	Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced Î±-Synuclein Fibrillation and Cytotoxicity. ACS Chemical Neuroscience, 2018, 9, 230-240.	1.7	14
2653	Rational design of a â€œsense and treatâ€•system to target amyloid aggregates related to Alzheimerâ€™s disease. Nano Research, 2018, 11, 1987-1997.	5.8	21
2654	Protection against Î²â€amyloid neurotoxicity by a nonâ€toxic endogenous Nâ€terminal Î²â€amyloid fragment and its active hexapeptide core sequence. Journal of Neurochemistry, 2018, 144, 201-217.	2.1	23
2655	Calmodulinâ€like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease. Journal of Neurochemistry, 2018, 144, 218-233.	2.1	12
2656	Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease. Neuropeptides, 2018, 67, 79-86.	0.9	12
2657	Light-triggered dissociation of self-assembled Î²-amyloid aggregates into small, nontoxic fragments by ruthenium (II) complex. Acta Biomaterialia, 2018, 67, 147-155.	4.1	55
2658	In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome. Journal of Psychopharmacology, 2018, 32, 174-190.	2.0	5
2659	Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2018, 114, 93-102.	1.9	11

#	Article	IF	Citations
2660	Functional adlayers on Au electrodes: some recent applications in hydrogen evolution and oxygen reduction. Journal of Materials Chemistry A, 2018, 6, 1323-1339.	5.2	14
2661	Amyloid-Î² and tau complexity â€" towards improved biomarkers and targeted therapies. Nature Reviews Neurology, 2018, 14, 22-39.	4.9	303
2662	Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. Progress in Neurobiology, 2018, 162, 17-36.	2.8	34
2663	Synergistic Inhibitory Effect of GQDsâ€“Tramiprosate Covalent Binding on Amyloid Aggregation. ACS Chemical Neuroscience, 2018, 9, 817-823.	1.7	40
2664	The neuroprotective effects of Chinese bayberry leaves proanthocyanidins. Journal of Functional Foods, 2018, 40, 554-563.	1.6	15
2665	Somatostatin in Alzheimer's disease: A new Role for an Old Player. Prion, 2018, 12, 1-8.	0.9	54
2666	Total flavonoid extract from Dracoephalum moldavica L. attenuates Î²-amyloid-induced toxicity through anti-amyloidogenesic and neurotrophic pathways. Life Sciences, 2018, 193, 214-225.	2.0	25
2667	Exploration of ligand-induced protein conformational alteration, aggregate formation, and its inhibition: A biophysical insight. Preparative Biochemistry and Biotechnology, 2018, 48, 43-56.	1.0	9
2668	In silico ligandâ€based modeling of <scp>hBACE</scp>â€1 inhibitors. Chemical Biology and Drug Design, 2018, 91, 817-827.	1.5	3
2669	Combined determination of copper ions and Î²-amyloid peptide by a single ratiometric electrochemical biosensor. Analyst, The, 2018, 143, 323-331.	1.7	40
2670	Neurogenesis and morphological-neural alterations closely related to amyloid Î²-peptide (25â€“35)-induced memory impairment in male rats. Neuropeptides, 2018, 67, 9-19.	0.9	20
2671	Crosstalk between endoplasmic reticulum stress and brain inflammation in Alzheimer's disease. Neuropharmacology, 2018, 136, 350-360.	2.0	61
2672	To What Extent Are the Terminal Stages of Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome, and Multiple Organ Dysfunction Syndrome Actually Driven by a Prion/Amyloid Form of Fibrin?. Seminars in Thrombosis and Hemostasis, 2018, 44, 224-238.	1.5	45
2673	Curcumin-loaded chitosanâ€“bovine serum albumin nanoparticles potentially enhanced AÎ² 42 phagocytosis and modulated macrophage polarization in Alzheimerâ€™s disease. Nanoscale Research Letters, 2018, 13, 330.	3.1	55
2674	ALZHEIMERâ€™S DISEASE THERAPEUTIC APPROACHES. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 17.	0.3	2
2675	Molecular rotors report on changes in live cell plasma membrane microviscosity upon interaction with beta-amyloid aggregates. Soft Matter, 2018, 14, 9466-9474.	1.2	30
2676	Alzheimer's amyloid-beta intermediates generated using polymer-nanodiscs. Chemical Communications, 2018, 54, 12883-12886.	2.2	69
2677	The Alzheimer's disease amyloid-Î² peptide affects the size-dynamics of raft-mimicking Lo domains in GM1-containing lipid bilayers. Soft Matter, 2018, 14, 9609-9618.	1.2	18

#	Article	IF	Citations
2678	ANTI-ALZHEIMER ACTIVITY OF TACRINE LOADED METHOXYPOLY (ETHYLENE GLYCOL) POLY (CAPROLACTONE) NANOPARTICLES. Asian Journal of Pharmaceutical and Clinical Research, 0, 11, .	0.3	0
2679	Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2018, 26, 6115-6127.	1.4	12
2680	The Role of Long Noncoding RNAs in Diabetic Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2018, 7, 461.	1.0	8
2681	VGF nerve growth factor inducible is involved in retinal ganglion cells death induced by optic nerve crush. Scientific Reports, 2018, 8, 16443.	1.6	16
2682	Structural Optimization of Foldamer-Dendrimer Conjugates as Multivalent Agents against the Toxic Effects of Amyloid Beta Oligomers. Molecules, 2018, 23, 2523.	1.7	11
2683	Amyloids Are Novel Cell-Adhesive Matrices. Advances in Experimental Medicine and Biology, 2018, 1112, 79-97.	0.8	6
2684	Small-molecule induction of AÎ²-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes. PLoS ONE, 2018, 13, e0209150.	1.1	53
2685	The Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 396.	1.7	38
2686	Jowiseungchungtang Inhibits Amyloid-Î² Aggregation and Amyloid-Î²-Mediated Pathology in 5XFAD Mice. International Journal of Molecular Sciences, 2018, 19, 4026.	1.8	9
2687	Transgenic Mouse Models as Tools for Understanding How Increased Cognitive and Physical Stimulation Can Improve Cognition in Alzheimerâ€™s Disease. Brain Plasticity, 2018, 4, 127-150.	1.9	20
2688	New Therapeutic Drugs from Bioactive Natural Molecules: The Role of Gut Microbiota Metabolism in Neurodegenerative Diseases. Current Drug Metabolism, 2018, 19, 478-489.	0.7	26
2689	Liposome delivery systems for the treatment of Alzheimer’s disease. International Journal of Nanomedicine, 2018, Volume 13, 8507-8522.	3.3	127
2690	Derivation of cutoffs for the Elecsys^{Â®} amyloid Î² (1â€“42) assay in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 698-705.	1.2	50
2691	Discovery and Chemical Development of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimerâ€™s Disease. ACS Symposium Series, 2018, , 53-89.	0.5	0
2692	Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders. Medicines (Basel, Switzerland), 2018, 5, 126.	0.7	62
2693	Third generation antibody discovery methods:in silicorational design. Chemical Society Reviews, 2018, 47, 9137-9157.	18.7	94
2694	Measurement of plasma amyloid-Î² precursor protein APP770 concentration in healthy young volunteers: Preliminary study of APP770 as a potential biomarker for Alzheimer's disease diagnosis. . Journal of Allied Health Sciences, 2018, 9, 6-11.	0.0	0
2695	Distinct functional roles of Vps41-mediated neuroprotection in Alzheimerâ€™s and Parkinsonâ€™s disease models of neurodegeneration. Human Molecular Genetics, 2018, 27, 4176-4193.	1.4	16

#	Article	IF	Citations
2697	Î±1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid Î²1â€“42-stimulated murine astrocytes. Journal of Neuroinflammation, 2018, 15, 282.	3.1	53
2698	d-Amino Acid Pseudopeptides as Potential Amyloid-Beta Aggregation Inhibitors. Molecules, 2018, 23, 2387.	1.7	9
2699	Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?. Neurotherapeutics, 2018, 15, 1032-1035.	2.1	8
2700	Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Expert Opinion on Therapeutic Targets, 2018, 22, 833-848.	1.5	83
2701	Reappraisal of AÎ²40 and AÎ²42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 66, 219-227.	1.2	9
2702	SAR by kinetics for drug discovery in protein misfolding diseases. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10245-10250.	3.3	54
2703	Comparative synaptosome imaging: a semi-quantitative method to obtain copy numbers for synaptic and neuronal proteins. Scientific Reports, 2018, 8, 14838.	1.6	13
2704	Hydrophobic Modification of Carboxyl-Terminated Polyamidoamine Dendrimer Surface Creates a Potent Inhibitor of Amyloid-Î² Fibrillation. Langmuir, 2018, 34, 14419-14427.	1.6	14
2705	Amyloid-peptide Î² 42 Enhances the Oligomerization and Neurotoxicity of apoE4: The C-terminal Residues Leu279, Lys282 and Gln284 Modulate the Structural and Functional Properties of apoE4. Neuroscience, 2018, 394, 144-155.	1.1	7
2706	Î²-Amyloid Accumulation Slows Earlier than Expected in Preclinical Alzheimer's Disease Patients. Journal of Neuroscience, 2018, 38, 9123-9125.	1.7	6
2707	Enriched Environment Significantly Reduced Senile Plaques in a Transgenic Mice Model of Alzheimerâ€™s Disease, Improving Memory. Frontiers in Aging Neuroscience, 2018, 10, 288.	1.7	22
2708	Modifying Rap1-signalling by targeting Pde6Î´ is neuroprotective in models of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2018, 13, 50.	4.4	9
2709	Porphyrinic Metalâ€“Organic Framework PCN-224 Nanoparticles for Near-Infrared-Induced Attenuation of Aggregation and Neurotoxicity of Alzheimerâ€™s Amyloid-Î² Peptide. ACS Applied Materials & Interfaces, 2018, 10, 36615-36621.	4.0	107
2710	Molecular Determinants of AÎ²₄₂ Adsorption to Amyloid Fibril Surfaces. Journal of Physical Chemistry Letters, 2018, 9, 6437-6443.	2.1	19
2711	Insulin Resistance in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 830.	1.4	147
2712	An oligomer-specific antibody improved motor function and attenuated neuropathology in the SOD1-G93A transgenic mouse model of ALS. International Immunopharmacology, 2018, 65, 413-421.	1.7	16
2713	Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the bloodâ€“brain barrier. Fluids and Barriers of the CNS, 2018, 15, 30.	2.4	142
2714	Amyloid Fibril Design: Limiting Structural Polymorphism in Alzheimerâ€™s AÎ² Protofilaments. Journal of Physical Chemistry B, 2018, 122, 11535-11545.	1.2	7

#	Article	IF	Citations
2715	Î±1-Antitrypsin Deficiency. , 2018, , 960-970.e3.		0
2716	Dephosphorylated rather than hyperphosphorylated Tau triggers a pro-inflammatory profile in microglia through the p38 MAPK pathway. Experimental Neurology, 2018, 310, 14-21.	2.0	39
2717	TOM1 Regulates Neuronal Accumulation of Amyloid-Î² Oligomers by FcÎ³RIIb2 Variant in Alzheimer's Disease. Journal of Neuroscience, 2018, 38, 9001-9018.	1.7	21
2718	Nanoporeâ€Based, Rapid Characterization of Individual Amyloid Particles in Solution: Concepts, Challenges, and Prospects. Small, 2018, 14, e1802412.	5.2	53
2719	A standard model of Alzheimerâ€™s disease?. Prion, 2018, 12, 261-265.	0.9	20
2720	Targeting NLRP3 Inflammasome in the Treatment of CNS Diseases. Frontiers in Molecular Neuroscience, 2018, 11, 320.	1.4	87
2721	Effects of Tea Catechins on Alzheimerâ€™s Disease: Recent Updates and Perspectives. Molecules, 2018, 23, 2357.	1.7	71
2722	Etersalate prevents the formations of 6AÎ²16-22 oligomer: An in silico study. PLoS ONE, 2018, 13, e0204026.	1.1	11
2723	An AÎ²42 variant that inhibits intra- and extracellular amyloid aggregation and enhances cell viability. Biochemical Journal, 2018, 475, 3087-3103.	1.7	13
2724	Green synthesis of silver nanoparticles, its characterization, and chaperone-like activity in the aggregation inhibition of Î±-chymotrypsinogen A. International Journal of Biological Macromolecules, 2018, 120, 2381-2389.	3.6	14
2725	Lipid Extraction by Î±-Synuclein Generates Semi-Transmembrane Defects and Lipoprotein Nanoparticles. ACS Omega, 2018, 3, 9586-9597.	1.6	20
2726	Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition. Frontiers in Molecular Neuroscience, 2018, 11, 302.	1.4	33
2727	Peroxisome proliferatorâ€activated receptor alpha accelerates neuronal differentiation and this might involve the mitogenâ€activated protein kinase pathway. International Journal of Developmental Neuroscience, 2018, 71, 46-51.	0.7	5
2728	Manganese causes neurotoxic iron accumulation via translational repression of amyloid precursor protein and Hâ€Ferritin. Journal of Neurochemistry, 2018, 147, 831-848.	2.1	52
2729	Dihydrochalcone molecules destabilize Alzheimer's amyloid-Î² protofibrils through binding to the protofibril cavity. Physical Chemistry Chemical Physics, 2018, 20, 17208-17217.	1.3	32
2730	Fabrication of thioflavinâ€<scp>T</scp>â€modified nanopillared <scp>SERS</scp> substrates for ultrasensitive betaâ€amyloid peptide detection. Journal of Raman Spectroscopy, 2018, 49, 1247-1256.	1.2	21
2731	Insights into Stabilizing Forces in Amyloid Fibrils of Differing Sizes from Polarizable Molecular Dynamics Simulations. Journal of Molecular Biology, 2018, 430, 3819-3834.	2.0	26
2732	Structure-activity relationships of Î²-hairpin mimics as modulators of amyloid Î²-peptide aggregation. European Journal of Medicinal Chemistry, 2018, 154, 280-293.	2.6	15

#	Article	IF	Citations
2733	Lengthâ€Dependent Manifestation of Vibration Modes Regulates a Specific Intermediate Morphology of AÎ²17â€42 in Different Environments. ChemPhysChem, 2018, 19, 1643-1654.	1.0	1
2734	Role of the carboxy groups of triterpenoids in their inhibition of the nucleation of amyloid Î²42 required for forming toxic oligomers. Chemical Communications, 2018, 54, 6272-6275.	2.2	27
2735	Hetero-assembly of a dual Î²-amyloid variant peptide system. Chemical Communications, 2018, 54, 6380-6383.	2.2	10
2736	Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2018, 9, 2588-2598.	1.7	17
2737	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals AÎ² Aggregation Dependent Anionic Lipid Accumulations and Metabolism. Analytical Chemistry, 2018, 90, 8130-8138.	3.2	39
2738	An Efficient Method for the Expression and Purification of AÎ²(M1â€“42). Biochemistry, 2018, 57, 3861-3866.	1.2	19
2739	Dynamical crossover of water confined within the amphiphilic nanocores of aggregated amyloid Î² peptides. Physical Chemistry Chemical Physics, 2018, 20, 14835-14845.	1.3	13
2740	Human Cord Blood Serum-Derived APP Î±-Secretase Cleavage Activity is Mediated by C1 Complement. Cell Transplantation, 2018, 27, 666-676.	1.2	3
2741	Superâ€resolution Imaging of Amyloid Structures over Extended Times by Using Transient Binding of Single Thioflavinâ€...T Molecules. ChemBioChem, 2018, 19, 1944-1948.	1.3	43
2742	3D Culture Method for Alzheimer's Disease Modeling Reveals Interleukin-4 Rescues AÎ²42-Induced Loss of Human Neural Stem Cell Plasticity. Developmental Cell, 2018, 46, 85-101.e8.	3.1	118
2743	Alzheimerâ€™s Disease Model System Using Drosophila. Advances in Experimental Medicine and Biology, 2018, 1076, 25-40.	0.8	33
2744	Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 563-585.	1.2	32
2745	The role of phenolic OH groups of flavonoid compounds with H-bond formation ability to suppress amyloid mature fibrils by destabilizing Î²-sheet conformation of monomeric AÎ²17-42. PLoS ONE, 2018, 13, e0199541.	1.1	27
2746	Chiral modulation of amyloid beta fibrillation and cytotoxicity by enantiomeric carbon dots. Chemical Communications, 2018, 54, 7762-7765.	2.2	95
2747	Selenium-enriched yeast inhibited Î²-amyloid production and modulated autophagy in a triple transgenic mouse model of Alzheimer's disease. Metallomics, 2018, 10, 1107-1115.	1.0	26
2748	Calcium signaling in Alzheimer's disease & therapies. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 1745-1760.	1.9	155
2749	A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. International Journal of Nanomedicine, 2018, Volume 13, 843-856.	3.3	60
2750	Age-dependent Disturbances of Neuronal and Glial Protein Expression Profiles in Areas of Secondary Neurodegeneration Post-stroke. Neuroscience, 2018, 393, 185-195.	1.1	16

#	Article	IF	Citations
2751	Chronic Lyme Disease: A Working Case Definition. American Journal of Infectious Diseases, 2018, 14, 1-44.	0.1	23
2752	A novel repetitive mild traumatic brain injury mouse model for chronic traumatic encephalopathy research. Journal of Neuroscience Methods, 2018, 308, 162-172.	1.3	22
2753	Betaine reduces Î²-amyloid-induced paralysis through activation of cystathionine-Î²-synthase in an Alzheimer model of Caenorhabditis elegans. Genes and Nutrition, 2018, 13, 21.	1.2	15
2754	Exploring the potential of marine microbes in clinical management of Alzheimer's disease: A road map for bioprospecting and identifying promising isolates. Life Sciences, 2018, 208, 149-160.	2.0	6
2755	Comprehensive Characterization of the Pyroglutamate Amyloid-Î² Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. Journal of Alzheimer's Disease, 2018, 63, 115-130.	1.2	10
2756	Research Progress in the Pathogenesis of Alzheimer's Disease. Chinese Medical Journal, 2018, 131, 1618-1624.	0.9	76
2757	Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells. ChemBioChem, 2018, 19, 2033-2038.	1.3	52
2758	Remarkably Efficient Bloodâ€“Brain Barrier Crossing Polyfluoreneâ€“Chitosan Nanoparticle Selectively Tweaks Amyloid Oligomer in Cerebrospinal Fluid and AÎ²1â€“40. ACS Omega, 2018, 3, 8059-8066.	1.6	19
2759	The amyloid hypothesis on trial. Nature, 2018, 559, S4-S7.	13.7	286
2760	A peptideâ€“WS₂ nanosheet based biosensing platform for determination of Î²-secretase and screening of its inhibitors. Analyst, The, 2018, 143, 4585-4591.	1.7	24
2761	Stabilization of a Membrane-Associated Amyloid-Î² Oligomer for Its Validation in Alzheimer's Disease. Frontiers in Molecular Biosciences, 2018, 5, 38.	1.6	11
2762	Use of Peptides for the Management of Alzheimerâ€™s Disease: Diagnosis and Inhibition. Frontiers in Aging Neuroscience, 2018, 10, 21.	1.7	79
2763	Dissecting Endoplasmic Reticulum Unfolded Protein Response (UPRER) in Managing Clandestine Modus Operandi of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 30.	1.7	29
2764	Recent Advances: Decoding Alzheimerâ€™s Disease With Stem Cells. Frontiers in Aging Neuroscience, 2018, 10, 77.	1.7	26
2765	Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 100.	1.7	20
2766	Stabilization and Characterization of Cytotoxic AÎ²₄₀ Oligomers Isolated from an Aggregation Reaction in the Presence of Zinc Ions. ACS Chemical Neuroscience, 2018, 9, 2959-2971.	1.7	42
2767	Rac1 activation links tau hyperphosphorylation and AÎ² dysmetabolism in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 61.	2.4	49
2768	Secondary nucleation in amyloid formation. Chemical Communications, 2018, 54, 8667-8684.	2.2	323

#	Article	IF	Citations
2769	Calprotectin influences the aggregation of metal-free and metal-bound amyloid-Î² by direct interaction. Metallomics, 2018, 10, 1116-1127.	1.0	10
2770	Insights into the Molecular Mechanisms of Alzheimerâ€™s and Parkinsonâ€™s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology. International Journal of Molecular Sciences, 2018, 19, 336.	1.8	51
2771	Aptamers Selected for Recognizing Amyloid Î²-Proteinâ€"A Case for Cautious Optimism. International Journal of Molecular Sciences, 2018, 19, 668.	1.8	14
2772	A Rationally Designed Hsp70 Variant Rescues the Aggregation-Associated Toxicity of Human IAPP in Cultured Pancreatic Islet Î²-Cells. International Journal of Molecular Sciences, 2018, 19, 1443.	1.8	14
2773	Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases. International Journal of Molecular Sciences, 2018, 19, 1637.	1.8	151
2774	A Systematic Review of Antiamyloidogenic and Metal-Chelating Peptoids: Two Structural Motifs for the Treatment of Alzheimerâ€™s Disease. Molecules, 2018, 23, 296.	1.7	12
2775	Small Molecules: Therapeutic Application in Neuropsychiatric and Neurodegenerative Disorders. Molecules, 2018, 23, 411.	1.7	17
2776	Multifunctionalized Reduced Graphene Oxide Biosensors for Simultaneous Monitoring of Structural Changes in Amyloid-Î² 40. Sensors, 2018, 18, 1738.	2.1	12
2777	A discrete mathematical model for the aggregation of Î²-Amyloid. PLoS ONE, 2018, 13, e0196402.	1.1	24
2778	Inhibition of PAI (Plasminogen Activator Inhibitor)-1 Improves Brain Collateral Perfusion and Injury After Acute Ischemic Stroke in Aged Hypertensive Rats. Stroke, 2018, 49, 1969-1976.	1.0	37
2779	Detection and characterization at nM concentration of oligomers formed by hIAPP, AÎ²(1â€“40) and their equimolar mixture using SERS and MD simulations. Physical Chemistry Chemical Physics, 2018, 20, 20588-20596.	1.3	22
2780	Untangling the Tauopathy for Alzheimerâ€™s disease and parkinsonism. Journal of Biomedical Science, 2018, 25, 54.	2.6	37
2781	Heat Shock Proteins and Autophagy Pathways in Neuroprotection: From Molecular Bases to Pharmacological Interventions. International Journal of Molecular Sciences, 2018, 19, 325.	1.8	68
2782	Highâ€density lipoprotein mimetic peptide 4F mitigates amyloidâ€Îâ€induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia. Journal of Neurochemistry, 2018, 147, 647-662.	2.1	31
2783	A novel AÎ² epitope vaccine based on bacterium-like particle against Alzheimerâ€™s disease. Molecular Immunology, 2018, 101, 259-267.	1.0	7
2784	In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed forÂthe Treatment of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 64, 859-873.	1.2	10
2785	Mechanisms of Pathology-Induced Neural Stem Cell Plasticity and Neural Regeneration in Adult Zebrafish Brain. Current Pathobiology Reports, 2018, 6, 71-77.	1.6	32
2786	Rational Design of Novel 1,3-Oxazine Based Î²-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust AÎ² Reduction in the Brain. Journal of Medicinal Chemistry, 2018, 61, 5122-5137.	2.9	29

#	Article	IF	Citations
2787	Sex-Dependent Differences in Spontaneous Autoimmunity in Adult 3xTg-AD Mice. Journal of Alzheimer's Disease, 2018, 63, 1191-1205.	1.2	18
2788	An arabinogalactan from fruits of Lycium barbarum L. inhibits production and aggregation of AÎ²42. Carbohydrate Polymers, 2018, 195, 643-651.	5.1	52
2789	Binding of Cytotoxic AÎ²25â€“35 Peptide to the Dimyristoylphosphatidylcholine Lipid Bilayer. Journal of Chemical Information and Modeling, 2018, 58, 1053-1065.	2.5	28
2790	Femtosecond X-ray coherent diffraction of aligned amyloid fibrils on low background graphene. Nature Communications, 2018, 9, 1836.	5.8	34
2791	ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and AÎ² production independently of their cholesterol efflux capacity. Biochemical Journal, 2018, 475, 1839-1859.	1.7	19
2792	Heat shock promotes inclusion body formation of mutant huntingtin (mHtt) and alleviates mHtt-induced transcription factor dysfunction. Journal of Biological Chemistry, 2018, 293, 15581-15593.	1.6	18
2793	Designing of Selective Î³-Secretase Inhibitory Benzenesulfonamides through Comparative In Vitro and In Silico Analysis. Current Drug Discovery Technologies, 2018, 15, 65-77.	0.6	4
2794	A pectin from fruits of Lycium barbarum L. decreases Î²-amyloid peptide production through modulating APP processing. Carbohydrate Polymers, 2018, 201, 65-74.	5.1	32
2795	Are N- and C-terminally truncated AÎ² species key pathological triggers in Alzheimer's disease?. Journal of Biological Chemistry, 2018, 293, 15419-15428.	1.6	84
2796	Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimerâ€™s disease. Translational Psychiatry, 2018, 8, 153.	2.4	64
2797	Understanding the microscopic origin behind heterogeneous properties of water confined in and around AÎ²17â€“42 protofilaments. Journal of Chemical Physics, 2018, 149, 065101.	1.2	7
2798	Application of nanodiagnostics and nanotherapy to CNS diseases. Nanomedicine, 2018, 13, 2341-2371.	1.7	37
2799	Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and crossâ€seeding behavior. Protein Science, 2018, 27, 1901-1909.	3.1	88
2800	Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntingtonâ€™s Disease. , 2018, , 207-228.		0
2801	Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathologica, 2018, 136, 69-87.	3.9	23
2802	Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating <scp>d</scp>-Peptides in the Interaction with Amyloid-Beta Monomers. ACS Chemical Neuroscience, 2018, 9, 2679-2688.	1.7	12
2803	Metal Binding to Amyloid-Î²_{1â€“42}: A Ligand Field Molecular Dynamics Study. ACS Chemical Neuroscience, 2018, 9, 2795-2806.	1.7	19
2804	On the role of sidechain size and charge in the aggregation of A Î² 42 with familial mutations. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5849-E5858.	3.3	98

#	Article	IF	Citations
2805	Design of novel amyloid Î² aggregation inhibitors using QSAR, pharmacophore modeling, molecular docking and ADME prediction. In Silico Pharmacology, 2018, 6, 12.	1.8	24
2806	Beneficial Effects of Sideritis scardica and Cichorium spinosum against Amyloidogenic Pathway and Tau Misprocessing in Alzheimerâ€™s Disease Neuronal Cell Culture Models. Journal of Alzheimer's Disease, 2018, 64, 787-800.	1.2	12
2807	Prion-like mechanisms in Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 303-319.	1.0	42
2808	Preparation of Pure Populations of Amyloid Î²-Protein Oligomers of Defined Size. Methods in Molecular Biology, 2018, 1779, 3-12.	0.4	6
2809	Neurotoxic Ca2+ Signaling Induced by Amyloidâ€“Î² Oligomers in Aged Hippocampal Neurons In Vitro. Methods in Molecular Biology, 2018, 1779, 341-354.	0.4	6
2810	Cholesterol catalyses AÎ²42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. Nature Chemistry, 2018, 10, 673-683.	6.6	186
2811	Distinct disruptions in Land's cycle remodeling of glycerophosphocholines in murine cortex mark symptomatic onset and progression in two Alzheimer's disease mouse models. Journal of Neurochemistry, 2019, 149, 499-517.	2.1	23
2812	Agingâ€•and vascularâ€•related pathologies. Microcirculation, 2019, 26, e12463.	1.0	22
2813	Plasmalogens Inhibit Endocytosis of Toll-like Receptor 4 to Attenuate the Inflammatory Signal in Microglial Cells. Molecular Neurobiology, 2019, 56, 3404-3419.	1.9	29
2814	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chemical Reviews, 2019, 119, 1221-1322.	23.0	360
2815	<scp>MGCD</scp>0103, a selective histone deacetylase inhibitor, coameliorates oligomeric AÎ²_{25â€“35}â€•induced anxiety and cognitive deficits in a mouse model. CNS Neuroscience and Therapeutics, 2019, 25, 175-186.	1.9	15
2816	AÎ² Oligomer Elimination Restores Cognition in Transgenic Alzheimerâ€™s Mice with Full-blown Pathology. Molecular Neurobiology, 2019, 56, 2211-2223.	1.9	29
2817	Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers. International Journal of Molecular Sciences, 2019, 20, 3810.	1.8	108
2818	A pathogenic PSEN1 Trp165Cys mutation associated with early-onset Alzheimerâ€™s disease. BMC Neurology, 2019, 19, 188.	0.8	13
2819	Cytotoxic species in amyloid-associated diseases: Oligomers or mature fibrils. Advances in Protein Chemistry and Structural Biology, 2019, 118, 333-369.	1.0	26
2820	Shaping the Nrf2-ARE-related pathways in Alzheimerâ€™s and Parkinsonâ€™s diseases. Ageing Research Reviews, 2019, 54, 100942.	5.0	163
2821	Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. CNS Drugs, 2019, 33, 883-904.	2.7	23
2822	Aldosterone, STX and amyloid-Î²1-42 peptides modulate GPER (GPR30) signalling in an embryonic mouse hippocampal cell line (mHippoE-18). Molecular and Cellular Endocrinology, 2019, 496, 110537.	1.6	7

#	Article	IF	Citations
2823	Can We Use 2,3,5-Triphenyltetrazolium Chloride-Stained Brain Slices for Other Purposes? The Application of Western Blotting. Frontiers in Molecular Neuroscience, 2019, 12, 181.	1.4	23
2824	Observation of Î²-Amyloid Peptide Oligomerization by Pressure-Jump NMR Spectroscopy. Journal of the American Chemical Society, 2019, 141, 13762-13766.	6.6	36
2825	Molecular Marker and Therapeutic Regimen for Neurodegenerative Diseases. , 2019, , 13-41.		0
2826	Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimerâ€™s Disease and Multiple Sclerosis. Frontiers in Cellular Neuroscience, 2019, 13, 355.	1.8	77
2827	Ghrelin in Alzheimerâ€™s disease: Pathologic roles and therapeutic implications. Ageing Research Reviews, 2019, 55, 100945.	5.0	34
2828	The First Generation of iPSC Line from a Korean Alzheimer's Disease Patient Carrying APP-V715M Mutation Exhibits a Distinct Mitochondrial Dysfunction. Experimental Neurobiology, 2019, 28, 329-336.	0.7	6
2829	Enhancement of the Anti-Aggregation Activity of a Molecular Chaperone Using a Rationally Designed Post-Translational Modification. ACS Central Science, 2019, 5, 1417-1424.	5.3	18
2830	Trapping and Characterization of Nontoxic AÎ²42 Aggregation Intermediates. ACS Chemical Neuroscience, 2019, 10, 3880-3887.	1.7	25
2831	Inhibition of Histone Methyltransferases EHMT1/2 Reverses Amyloid-Î²-Induced Loss of AMPAR Currents in Human Stem Cell-Derived Cortical Neurons. Journal of Alzheimer's Disease, 2019, 70, 1175-1185.	1.2	14
2832	Application of artificial neural network model in diagnosis of Alzheimerâ€™s disease. BMC Neurology, 2019, 19, 154.	0.8	23
2833	Copper imbalance in Alzheimerâ€™s disease: Convergence of the chemistry and the clinic. Coordination Chemistry Reviews, 2019, 397, 168-187.	9.5	65
2834	Inhibition of AÎ²_{1â€“42} Fibrillation by Chaperonins: Human Hsp60 Is a Stronger Inhibitor than Its Bacterial Homologue GroEL. ACS Chemical Neuroscience, 2019, 10, 3565-3574.	1.7	16
2835	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimerâ€™s disease pathogenesis. Nature Neuroscience, 2019, 22, 1258-1268.	7.1	48
2836	A simple approach to quantitative determination of soluble amyloid-Î² peptides using a ratiometric fluorescence probe. Biosensors and Bioelectronics, 2019, 142, 111518.	5.3	19
2837	Characterizing the inhibition of Î±â€synuclein oligomerization by a pharmacological chaperone that prevents prion formation by the protein PrP. Protein Science, 2019, 28, 1690-1702.	3.1	9
2838	Protein NMR: Boundless opportunities. Journal of Magnetic Resonance, 2019, 306, 187-191.	1.2	33
2839	Cellular Prion Protein as a Receptor of Toxic Amyloid-Î²42 Oligomers Is Important for Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2019, 13, 339.	1.8	46
2840	Dual strategy for reduced signalâ€suppression effects in matrixâ€assisted laser desorption/ionization mass spectrometry imaging. Rapid Communications in Mass Spectrometry, 2019, 33, 1711-1721.	0.7	5

#	Article	IF	Citations
2841	Fluorescence Detection and Dissociation of Amyloidâ€Î² Species for the Treatment of Alzheimer's Disease. Advanced Therapeutics, 2019, 2, 1900054.	1.6	19
2842	ERÎ² promotes AÎ² degradation via the modulation of autophagy. Cell Death and Disease, 2019, 10, 565.	2.7	51
2843	Doxycycline for Alzheimerâ€™s Disease: Fighting Î²-Amyloid Oligomers and Neuroinflammation. Frontiers in Pharmacology, 2019, 10, 738.	1.6	58
2844	Structure and Physicochemical Properties of the AÎ²42 Tetramer: Multiscale Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2019, 123, 7253-7269.	1.2	25
2846	Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains. Biochemistry, 2019, 58, 3155-3168.	1.2	20
2847	Mechanistic insight into E22Q-mutation-induced antiparallel-to-parallel Î²-sheet transition of AÎ²_{16â^22}fibrils: an all-atom simulation study. Physical Chemistry Chemical Physics, 2019, 21, 15686-15694.	1.3	18
2848	Poster Viewing Sessions PB01-B01 to PB03-V09. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 167-523.	2.4	7
2849	His6, His13, and His14 residues in AÎ² 1â€“40 peptide significantly and specifically affect oligomeric equilibria. Scientific Reports, 2019, 9, 9449.	1.6	10
2851	A simplified and sensitive immunoprecipitation mass spectrometry protocol for the analysis of amyloid-beta peptides in brain tissue. Clinical Mass Spectrometry, 2019, 14, 83-88.	1.9	3
2852	Modulation of Proteome Profile in AÎ²PP/PS1 Mice Hippocampus, Medial Prefrontal Cortex, and Striatum by Palm Oil Derived Tocotrienol-Rich Fraction. Journal of Alzheimer's Disease, 2019, 72, 229-246.	1.2	12
2853	Effects of Cu(II) on the aggregation of amyloid-Î². Journal of Biological Inorganic Chemistry, 2019, 24, 1197-1215.	1.1	30
2854	Inhibitory Effects of Essential Oil Extracts From Panax Plants Against Î²-Secretase, Cholinesterase, and Amyloid Aggregation. Natural Product Communications, 2019, 14, 1934578X1988154.	0.2	7
2855	Curcumin, Hormesis and the Nervous System. Nutrients, 2019, 11, 2417.	1.7	89
2856	Biological and Bio-inspired Nanomaterials. Advances in Experimental Medicine and Biology, 2019, , .	0.8	8
2857	N , N â€²-Diacetyl- p -phenylenediamine restores microglial phagocytosis and improves cognitive defects in Alzheimerâ€™s disease transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23426-23436.	3.3	34
2858	Interrogating Amyloid Aggregates using Fluorescent Probes. Chemical Reviews, 2019, 119, 11819-11856.	23.0	184
2859	Mixed Carboxyl and Hydrophobic Dendrimer Surface Inhibits Amyloid-Î² Fibrillation: New Insight from the Generation Number Effect. Langmuir, 2019, 35, 14681-14687.	1.6	14
2860	Evaluating the Combined Cognitive Enhancement Effect of Brassica Juncea and Cynadon Dactylon Extract in Scopolamine Induced Amnesia Zebrafish Model. Toxicology and Environmental Health Sciences, 2019, 11, 190-196.	1.1	3

#	Article	IF	Citations
2861	Kinetic Transition in Amyloid Assembly as a Screening Assay for Oligomer-Selective Dyes. Biomolecules, 2019, 9, 539.	1.8	12
2862	Intra- and extracellular Î²-amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus. Scientific Reports, 2019, 9, 15936.	1.6	12
2863	SERF engages in a fuzzy complex that accelerates primary nucleation of amyloid proteins. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23040-23049.	3.3	25
2864	Plant sphingolipids promote extracellular vesicle release and alleviate amyloid-Î² pathologies in a mouse model of Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 16827.	1.6	29
2865	The Tripeptide RER Mimics Secreted Amyloid Precursor Protein-Alpha in Upregulating LTP. Frontiers in Cellular Neuroscience, 2019, 13, 459.	1.8	2
2866	A Human Embryonic Stem Cell Model of AÎ²-Dependent Chronic Progressive Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 1007.	1.4	6
2867	Cryo-EM structure and polymorphism of AÎ² amyloid fibrils purified from Alzheimerâ€™s brain tissue. Nature Communications, 2019, 10, 4760.	5.8	411
2868	Cell size effects in the molecular dynamics of the intrinsically disordered AÎ² peptide. Journal of Chemical Physics, 2019, 151, 085101.	1.2	17
2869	Aggregation dynamics of charged peptides in water: Effect of salt concentration. Journal of Chemical Physics, 2019, 151, 074901.	1.2	7
2870	Encephalopathy induced by Alzheimer brain inoculation in a non-human primate. Acta Neuropathologica Communications, 2019, 7, 126.	2.4	33
2871	Neurosteroids as regulators of neuroinflammation. Frontiers in Neuroendocrinology, 2019, 55, 100788.	2.5	133
2872	Autophagy alleviates the decrease in proliferation of amyloid Î²1â€‘42â€‘treated bone marrow mesenchymal stem cells via the AKT/mTOR signaling pathway. Molecular Medicine Reports, 2019, 19, 4091-4100.	1.1	9
2873	aFGF Promotes Neurite Growth by Regulating GSK3Î²-CRMP2 Signaling Pathway in Cortical Neurons Damaged by Amyloid-Î². Journal of Alzheimer's Disease, 2019, 72, 97-109.	1.2	5
2874	Long-Term Dabigatran Treatment Delays Alzheimerâ€™s Disease Pathogenesis in the TgCRND8ÂMouse Model. Journal of the American College of Cardiology, 2019, 74, 1910-1923.	1.2	61
2875	A catalytic antioxidant for limiting amyloid-beta peptide aggregation and reactive oxygen species generation. Chemical Science, 2019, 10, 1634-1643.	3.7	44
2876	Disclosing the Template-Induced Misfolding Mechanism of Tau Protein by Studying the Dissociation of the Boundary Chain from the Formed Tau Fibril Based on a Steered Molecular Dynamics Simulation. ACS Chemical Neuroscience, 2019, 10, 1854-1865.	1.7	14
2877	Photoactive chlorin e6 is a multifunctional modulator of amyloid-Î² aggregation and toxicity via specific interactions with its histidine residues. Chemical Science, 2019, 10, 208-217.	3.7	25
2878	Conformationâ€specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen. Journal of Cellular and Molecular Medicine, 2019, 23, 2103-2114.	1.6	11

#	Article	IF	Citations
2879	Black Phosphorus Nanomaterials Regulate the Aggregation of Amyloidâ€Î²2. ChemNanoMat, 2019, 5, 606-611.	1.5	17
2880	Neuroprotective and Antiaging Essential Oils and Lipids in Plants. Reference Series in Phytochemistry, 2019, , 587-604.	0.2	2
2881	Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Neuroscience, 2019, 12, 25.	1.4	459
2882	Seeding and Cross-Seeding Aggregations of AÎ²₄₀ and Its N-Terminal-Truncated Peptide AÎ²_{11â€“40}. Langmuir, 2019, 35, 2821-2831.	1.6	13
2883	Biological activity of peptides purified from fish skin hydrolysates. Fisheries and Aquatic Sciences, 2019, 22, .	0.3	75
2884	Phytoâ€Tacrine Hybrids as Promising Drugs to Treat Alzheimer's Disease. ChemistrySelect, 2019, 4, 5776-5790.	0.7	5
2885	Melatonin in Alzheimerâ€™s Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimerâ€™s Neuropathology. Molecular Neurobiology, 2019, 56, 8255-8276.	1.9	103
2886	Molecular insights into the surface-catalyzed secondary nucleation of amyloid-Î² ₄₀ (AÎ²) Tj ETQq1 1 0.784314 rgBT /Ove	4.7	54
2887	Design, synthesis, and evaluation of a water soluble C5-monoketone type curcumin analogue as a potent amyloid Î² aggregation inhibitor. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2157-2161.	1.0	26
2888	Chemokines in Alzheimerâ€™s Disease: New Insights Into Prokineticins, Chemokine-Like Proteins. Frontiers in Pharmacology, 2019, 10, 622.	1.6	44
2889	Developments with multi-target drugs for Alzheimerâ€™s disease: an overview of the current discovery approaches. Expert Opinion on Drug Discovery, 2019, 14, 879-891.	2.5	60
2890	The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases. Frontiers in Molecular Neuroscience, 2019, 12, 121.	1.4	61
2892	Bioactive Lipids and the Gut-Brain Axis: Diet as a Modulator of Bioactivity and Diversity of Lipids in the Brain. Advances in Experimental Medicine and Biology, 2019, 1127, 147-168.	0.8	1
2893	Interactions between BIM Protein and Beta-Amyloid May Reveal a Crucial Missing Link between Alzheimerâ€™s Disease and Neuronal Cell Death. ACS Chemical Neuroscience, 2019, 10, 3555-3564.	1.7	21
2894	Naphthalene-triazolopyrimidine hybrid compounds as potential multifunctional anti-Alzheimerâ€™s agents. Bioorganic and Medicinal Chemistry, 2019, 27, 3156-3166.	1.4	16
2895	Visual discrimination impairment after experimental stroke is associated with disturbances in the polarization of the astrocytic aquaporin-4 and increased accumulation of neurotoxic proteins. Experimental Neurology, 2019, 318, 232-243.	2.0	18
2896	An App knock-in mouse inducing the formation of a toxic conformer of AÎ² as a model for evaluating only oligomer-induced cognitive decline in Alzheimer's disease. Biochemical and Biophysical Research Communications, 2019, 515, 462-467.	1.0	14
2897	Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid Î²42 Anti-Aggregation Properties. Molecules, 2019, 24, 2125.	1.7	24

#	Article	IF	Citations
2898	The effects of bioactive components from the rhizome of Salvia miltiorrhiza (Danshen) on the characteristics of Alzheimerâ€™s disease. Chinese Medicine, 2019, 14, 19.	1.6	27
2899	Novel Therapeutic Potentials of Taxifolin for Amyloid-Î²-associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives. International Journal of Molecular Sciences, 2019, 20, 2139.	1.8	30
2900	Evaluating the effect of aminoglycosides on the interaction between bovine serum albumins by atomic force microscopy. International Journal of Biological Macromolecules, 2019, 134, 28-35.	3.6	8
2901	Molecular dynamics simulations reveal the mechanism of graphene oxide nanosheet inhibition of AÎ²_{1â€“42} peptide aggregation. Physical Chemistry Chemical Physics, 2019, 21, 10981-10991.	1.3	48
2902	Nitrite reductase activity of heme and copper bound AÎ² peptides. Dalton Transactions, 2019, 48, 7451-7461.	1.6	10
2903	De novo aggregation of Alzheimerâ€™s AÎ²25-35 peptides in a lipid bilayer. Scientific Reports, 2019, 9, 7161.	1.6	21
2904	Neuroimaging and Molecular Biomarkers for Dementia. Neuroscience and Behavioral Physiology, 2019, 49, 406-412.	0.2	0
2905	Blood amyloid-Î² oligomerization associated with neurodegeneration of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 40.	3.0	38
2906	Exploring Amyloid-Î² Dimer Structure Using Molecular Dynamics Simulations. Journal of Physical Chemistry A, 2019, 123, 4658-4670.	1.1	13
2907	Different protonated states at the C-terminal of the amyloid-Î² peptide modulate the stability of S-shaped protofibril. Journal of Chemical Physics, 2019, 150, 185102.	1.2	3
2908	Effects of Metal Ions on AÎ²₄₂ Peptide Conformations from Molecular Simulation Studies. Journal of Chemical Information and Modeling, 2019, 59, 2879-2893.	2.5	15
2909	Steady, Symmetric, and Reversible Growth and Dissolution of Individual Amyloid-Î² Fibrils. ACS Chemical Neuroscience, 2019, 10, 2967-2976.	1.7	16
2910	Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimerâ€™s Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARÎ³) Agonist. Molecular Neurobiology, 2019, 56, 7267-7283.	1.9	25
2911	A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 175, 2-19.	2.6	53
2912	A review on shared clinical and molecular mechanisms between bipolar disorder and frontotemporal dementia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 93, 269-283.	2.5	19
2913	X-ray Absorption Spectroscopy Investigations of Copper(II) Coordination in the Human Amyloid Î² Peptide. Inorganic Chemistry, 2019, 58, 6294-6311.	1.9	30
2914	Fluorescent 1,4-Naphthoquinones To Visualize Diffuse and Dense-Core Amyloid Plaques in APP/PS1 Transgenic Mouse Brains. ACS Chemical Neuroscience, 2019, 10, 3031-3044.	1.7	14
2915	Fluorescence Chemicals To Detect Insoluble and Soluble Amyloid-Î² Aggregates. ACS Chemical Neuroscience, 2019, 10, 2647-2657.	1.7	39

#	Article	IF	Citations
2916	Î±-Sheet secondary structure in amyloid Î²-peptide drives aggregation and toxicity in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8895-8900.	3.3	118
2917	Structure of proteins: Evolution with unsolved mysteries. Progress in Biophysics and Molecular Biology, 2019, 149, 160-172.	1.4	8
2918	Phosphorylation mapping of Laminin Î²1-chain: Kinases in association with active sites. Journal of Biosciences, 2019, 44, 1.	0.5	1
2919	Use of a Stereochemical Strategy To Probe the Mechanism of Phenol-Soluble Modulin Î±3 Toxicity. Journal of the American Chemical Society, 2019, 141, 7660-7664.	6.6	32
2920	Conformational Change of Amyloid-Î² 40 in Association with Binding to GM1-Glycan Cluster. Scientific Reports, 2019, 9, 6853.	1.6	33
2921	Distinct Binding Dynamics, Sites and Interactions of Fullerene and Fullerenols with Amyloid-Î² Peptides Revealed by Molecular Dynamics Simulations. International Journal of Molecular Sciences, 2019, 20, 2048.	1.8	28
2922	The Potential Role of Curcumin in Treatment and Prevention for Neurological Disorders. , 2019, , 85-103.		2
2923	Usefulness of Curcumin Analogs for the Diagnosis and Treatment of Alzheimer Disease. , 2019, , 231-245.		0
2924	Curcumin Impact on Multiple Sclerosis. , 2019, , 365-380.		7
2925	Methionine Oxidation Changes the Mechanism of AÎ² Peptide Binding to the DMPC Bilayer. Scientific Reports, 2019, 9, 5947.	1.6	13
2926	Insight into the internal structure of amyloid-Î² oligomers by isotope-edited Fourier transform infrared spectroscopy. Physical Chemistry Chemical Physics, 2019, 21, 8587-8597.	1.3	22
2927	Rapid Fragmentation during Seeded Lysozyme Aggregation Revealed at the Single Molecule Level. Analytical Chemistry, 2019, 91, 6880-6886.	3.2	7
2928	Neuroimaging and Neurolaw: Drawing the Future of Aging. Frontiers in Endocrinology, 2019, 10, 217.	1.5	5
2929	Structure-Based Peptide Inhibitor Design of Amyloid-Î² Aggregation. Frontiers in Molecular Neuroscience, 2019, 12, 54.	1.4	58
2930	Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from Boesenbergia rotunda. Nutrients, 2019, 11, 662.	1.7	32
2931	Extending Lifespan of Alzheimerâ€™s Mode Nematode CL4176 Using a Novel Bifunctional Peptide with Inhibition of Î²-Amyloid Aggregation and Anti-oxidation. Chemical Research in Chinese Universities, 2019, 35, 245-250.	1.3	0
2932	Monitoring amyloid-Î² proteins aggregation based on label-free aptasensor. Sensors and Actuators B: Chemical, 2019, 288, 535-542.	4.0	56
2933	What Is the â€œRelevantâ€•Amyloid Î²42 Concentration?. ChemBioChem, 2019, 20, 1725-1726.	1.3	20

#	Article	IF	Citations
2934	Direct observation of prion protein oligomer formation reveals an aggregation mechanism with multiple conformationally distinct species. Chemical Science, 2019, 10, 4588-4597.	3.7	22
2935	Matter over mind: Liquid phase separation and neurodegeneration. Journal of Biological Chemistry, 2019, 294, 7160-7168.	1.6	176
2936	Effects of concentration of amyloid Î² (AÎ²) on viability of cultured retinal pigment epithelial cells. BMC Ophthalmology, 2019, 19, 70.	0.6	20
2937	Antiamyloid activity of functionalized cerium oxide nanoparticle on lysozyme fibrillation: Spectroscopic and microscopic investigation. Materialia, 2019, 6, 100285.	1.3	11
2938	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Journal of Controlled Release, 2019, 301, 62-75.	4.8	207
2939	A small molecule Nec-1 directly induces amyloid clearance in the brains of aged APP/PS1 mice. Scientific Reports, 2019, 9, 4183.	1.6	27
2940	A Practical Review of Proteasome Pharmacology. Pharmacological Reviews, 2019, 71, 170-197.	7.1	245
2941	Reactive Amphiphilic Conjugated Polymers for Inhibiting Amyloid Î² Assembly. Angewandte Chemie, 2019, 131, 6049-6054.	1.6	16
2942	A Novel PEGylated Block Copolymer in New Age Therapeutics for Alzheimerâ€™s Disease. Molecular Neurobiology, 2019, 56, 6551-6565.	1.9	16
2943	Modulation of protein oligomerization: An overview. Progress in Biophysics and Molecular Biology, 2019, 149, 99-113.	1.4	24
2944	Beyond the sleep-amyloid interactions in Alzheimerâ€™s disease pathogenesis. Journal of Neurophysiology, 2019, 122, 1-4.	0.9	21
2945	Chiral Effect at Nano-Bio Interface: A Model of Chiral Gold Nanoparticle on Amylin Fibrillation. Nanomaterials, 2019, 9, 412.	1.9	17
2946	Protein Solubility Predictions Using the CamSol Method in the Study of Protein Homeostasis. Cold Spring Harbor Perspectives in Biology, 2019, 11, a033845.	2.3	42
2947	The Crocus sativus Compounds trans-Crocin 4 and trans-Crocetin Modulate the Amyloidogenic Pathway and Tau Misprocessing in Alzheimer Disease Neuronal Cell Culture Models. Frontiers in Neuroscience, 2019, 13, 249.	1.4	42
2948	Conductance Changes in Bovine Serum Albumin Caused by Drug-Binding Triggered Structural Transitions. Materials, 2019, 12, 1022.	1.3	15
2949	Influence of crowding and surfaces on protein amyloidogenesis: A thermo-kinetic perspective. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 941-953.	1.1	10
2950	Transition Metal Ion Interactions with Disordered Amyloid-Î² Peptides in the Pathogenesis of Alzheimerâ€™s Disease: Insights from Computational Chemistry Studies. Journal of Chemical Information and Modeling, 2019, 59, 1782-1805.	2.5	46
2951	Ephrin-B2 inhibits AÎ²25-35-induced apoptosis by alleviating endoplasmic reticulum stress and promoting autophagy in HT22 cells. Neuroscience Letters, 2019, 704, 50-56.	1.0	12

#	Article	IF	Citations
2952	Jia-Wei-Kai-Xin-San, an Herbal Medicine Formula, Ameliorates Cognitive Deficits via Modulating Metabolism of Beta Amyloid Protein and Neurotrophic Factors in Hippocampus of AÎ²1-42 Induced Cognitive Deficit Mice. Frontiers in Pharmacology, 2019, 10, 258.	1.6	9
2953	Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe/PS1dE9 mice. Neuropharmacology, 2019, 150, 175-183.	2.0	30
2954	Late Effects. , 2019, , 496-554.		0
2955	Large fatty acid-derived AÎ²42 oligomers form ring-like assemblies. Journal of Chemical Physics, 2019, 150, 075101.	1.2	9
2956	Intrinsic origin of amyloid aggregation: Behavior of histidine (ÎµÎµÎµ) and (ÎÎÎ) tautomer homodimers of AÎ² (1â€“40). Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 795-801.	1.1	27
2957	A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimerâ€™s disease. Neuroscience Letters, 2019, 701, 125-131.	1.0	43
2958	In vivo localization of human acetylcholinesterase-derived species in a Î²-sheet conformation at the core of senile plaques in Alzheimer's disease. Journal of Biological Chemistry, 2019, 294, 6253-6272.	1.6	19
2959	Reactive Amphiphilic Conjugated Polymers for Inhibiting Amyloid Î² Assembly. Angewandte Chemie - International Edition, 2019, 58, 5988-5993.	7.2	60
2960	Nanoparticle formulations in the diagnosis and therapy of Alzheimer's disease. International Journal of Biological Macromolecules, 2019, 130, 515-526.	3.6	104
2961	Solvent Composition Effects on the Structural Properties of the AÎ²42 Monomer from the 3D-RISM-KH Molecular Theory of Solvation. Journal of Physical Chemistry B, 2019, 123, 2491-2506.	1.2	6
2962	Studies of the Anti-amnesic Effects and Mechanisms of Single and Combined Use of Donepezil and Ginkgo Ketoester Tablet on Scopolamine-Induced Memory Impairment in Mice. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-16.	1.9	19
2963	Secreted APP Modulates Synaptic Activity: A Novel Target for Therapeutic Intervention?. Neuron, 2019, 101, 557-559.	3.8	14
2964	Pinus halepensis essential oil attenuates the toxic Alzheimerâ€™s amyloid beta (1-42)-induced memory impairment and oxidative stress in the rat hippocampus. Biomedicine and Pharmacotherapy, 2019, 112, 108673.	2.5	63
2965	Filamentous Aggregates Are Fragmented by the Proteasome Holoenzyme. Cell Reports, 2019, 26, 2140-2149.e3.	2.9	43
2966	The Role of Apolipoprotein E Isoforms in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 68, 459-471.	1.2	21
2967	Alzheimerâ€™s-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26230-26238.	3.3	46
2969	Current state of research on nonâ€human primate models of Alzheimerâ€™s disease. Animal Models and Experimental Medicine, 2019, 2, 227-238.	1.3	29
2970	An Integrated View on Vascular Dysfunction in Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2019, 19, 109-127.	0.8	62

#	Article	IF	Citations
2971	Different aspects of Alzheimerâ€™s disease-related amyloid Î²-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathologica Communications, 2019, 7, 178.	2.4	29
2972	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1140.	1.1	46
2973	Membrane domain modulation of AÎ²_{1â€“42} oligomer interactions with supported lipid bilayers: an atomic force microscopy investigation. Nanoscale, 2019, 11, 20857-20867.	2.8	34
2974	c-Abl Deficiency Provides Synaptic Resiliency Against AÎ²-Oligomers. Frontiers in Cellular Neuroscience, 2019, 13, 526.	1.8	10
2975	Effects of the H6R and D7H Mutations on the Heparin-Dependent Modulation of Zinc-Induced Aggregation of Amyloid Î². Molecular Biology, 2019, 53, 922-928.	0.4	1
2976	Multifunctional hybrid sulfonamides as novel therapeutic agents for Alzheimerâ€™s disease. Future Medicinal Chemistry, 2019, 11, 3161-3178.	1.1	25
2977	Do Cholesterol and Sphingomyelin Change the Mechanism of AÎ²_{25â€“35} Peptide Binding to Zwitterionic Bilayer?. Journal of Chemical Information and Modeling, 2019, 59, 5207-5217.	2.5	7
2978	Kinetic Control of Parallel versus Antiparallel Amyloid Aggregation via Shape of the Growing Aggregate. Scientific Reports, 2019, 9, 15987.	1.6	4
2979	Mitochondrial Cholesterol in Alzheimer's Disease and Niemannâ€“Pick Type C Disease. Frontiers in Neurology, 2019, 10, 1168.	1.1	37
2980	Puerariae Radix Prevents Anxiety and Cognitive Deficits in Mice Under Oligomeric AÎ²-Induced Stress. The American Journal of Chinese Medicine, 2019, 47, 1459-1481.	1.5	17
2981	Modification of AÎ² Peptide Aggregation via Covalent Binding of a Series of Ru(III) Complexes. Frontiers in Chemistry, 2019, 7, 838.	1.8	16
2982	Effect of Riluzole, a Glutamate Release Inhibitor, on Synaptic Plasticity in the Intrahippocampal AÎ² Rat Model of Alzheimerâ€™s Disease. Neurophysiology, 2019, 51, 266-271.	0.2	0
2983	Brain Microbiota in Huntingtonâ€™s Disease Patients. Frontiers in Microbiology, 2019, 10, 2622.	1.5	24
2984	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric AÎ². Alzheimer's Research and Therapy, 2019, 11, 97.	3.0	22
2985	Gantenerumab reduces amyloid-Î² plaques in patients with prodromal to moderate Alzheimerâ€™s disease: a PET substudy interim analysis. Alzheimer's Research and Therapy, 2019, 11, 101.	3.0	131
2986	Tracking amyloid oligomerization with monomer resolution using a 13-amino acid peptide with a backbone-fixed spin label. Physical Chemistry Chemical Physics, 2019, 21, 25187-25195.	1.3	4
2987	Role of repulsive forces on self-assembly behavior of amyloid<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" overflow="scroll" id="d1e748" altimg="si46.gif"><mml:mi>Î²</mml:mi></mml:math>-peptide (1-40): Molecular dynamics simulation approach. Physica A: Statistical Mechanics and Its Applications, 2019, 513, 524-535.	1.2	7
2988	Application of molecular framework-based data-mining method in the search for beta-secretase 1 inhibitors through drug repurposing. Journal of Biomolecular Structure and Dynamics, 2019, 37, 3674-3685.	2.0	13

#	Article	IF	Citations
2989	Diverse antithetical effects of the bio-compatible Ag-NPs on the hen egg lysozyme amyloid aggregation: from an efficient inhibitor to obscure inducer. Journal of the Iranian Chemical Society, 2019, 16, 33-44.	1.2	4
2990	Alzheimerâ€™s Disease Clinical Trials: Moving Toward Successful Prevention. CNS Drugs, 2019, 33, 99-106.	2.7	33
2991	Effects of a Hydrophilic/Hydrophobic Interface on Amyloid-Î² Peptides Studied by Molecular Dynamics Simulations and NMR Experiments. Journal of Physical Chemistry B, 2019, 123, 160-169.	1.2	36
2992	Differential accumulation of Tau phosphorylated at residues Thr231, Ser262 and Thr205 in hippocampal interneurons and its modulation by Tau mutations (VLW) and amyloid-Î² peptide. Neurobiology of Disease, 2019, 125, 232-244.	2.1	17
2993	Exosomes: The next generation of endogenous nanomaterials for advanced drug delivery and therapy. Acta Biomaterialia, 2019, 86, 1-14.	4.1	275
2994	Effect of Familial Mutations on the Interconversion of Î±-Helix to Î²-Sheet Structures in an Amyloid-Forming Peptide: Insight from Umbrella Sampling Simulations. ACS Chemical Neuroscience, 2019, 10, 1347-1354.	1.7	16
2995	Potential Application of Prunus armeniaca L. and P. domestica L. Leaf Essential Oils as Antioxidant and of Cholinesterases Inhibitors. Antioxidants, 2019, 8, 2.	2.2	20
2996	Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 429-440.	0.4	69
2997	Norepinephrine Inhibits Alzheimerâ€™s Amyloid-Î² Peptide Aggregation and Destabilizes Amyloid-Î² Protofibrils: A Molecular Dynamics Simulation Study. ACS Chemical Neuroscience, 2019, 10, 1585-1594.	1.7	83
2998	Vascular Risk and Î²â€Amyloid Are Synergistically Associated with Cortical Tau. Annals of Neurology, 2019, 85, 272-279.	2.8	75
2999	Single Posttranslational Modifications in the Central Repeat Domains of Tau4 Impact its Aggregation and Tubulin Binding. Angewandte Chemie, 2019, 131, 1630-1634.	1.6	11
3000	Deceleration of the neurodegenerative phenotype in pyroglutamate-AÎ² accumulating transgenic mice by oral treatment with the AÎ² oligomer eliminating compound RD2. Neurobiology of Disease, 2019, 124, 36-45.	2.1	13
3001	Amyloid-ÃŸ promotes neurotoxicity by Cdk5-induced p53 stabilization. Neuropharmacology, 2019, 146, 19-27.	2.0	40
3002	Systems biology and gene networks in Alzheimerâ€™s disease. Neuroscience and Biobehavioral Reviews, 2019, 96, 31-44.	2.9	17
3003	Recognition of the amyloid precursor protein by human Î³-secretase. Science, 2019, 363, .	6.0	229
3004	A Fluorogenic AggTag Method Based on Haloâ€•and SNAPâ€Tags to Simultaneously Detect Aggregation of Two Proteins in Live Cells. ChemBioChem, 2019, 20, 1078-1087.	1.3	45
3005	Sleepâ€“wake regulation and the hallmarks of the pathogenesis of Alzheimerâ€™s disease. Sleep, 2019, 42, .	0.6	42
3006	Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease. Brain Research Bulletin, 2019, 146, 171-184.	1.4	70

#	Article	IF	Citations
3007	Alkali ion influence on structure and stability of fibrillar amyloid-Î² oligomers. Journal of Molecular Modeling, 2019, 25, 37.	0.8	14
3008	Neuroprotective efficacy of thymoquinone against amyloid beta-induced neurotoxicity in human induced pluripotent stem cell-derived cholinergic neurons. Biochemistry and Biophysics Reports, 2019, 17, 122-126.	0.7	20
3009	Obstructive sleep apnea may induce orexinergic system and cerebral Î²-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?. Sleep Medicine, 2019, 56, 171-176.	0.8	53
3010	Combined treatment with the phenolics (â^')-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. Journal of Biological Chemistry, 2019, 294, 2714-5444.	1.6	78
3011	Trodusquemine enhances AÎ²42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes. Nature Communications, 2019, 10, 225.	5.8	111
3012	Porins and Amyloids are Coded by Similar Sequence Motifs. Proteomics, 2019, 19, 1800075.	1.3	5
3013	Essential Oils as Treatment Strategy for AlzheimerÊ¼s Disease: Current and Future Perspectives. Planta Medica, 2019, 85, 239-248.	0.7	56
3014	Tacrine hybrids as multi-target-directed ligands in Alzheimerâ€™s disease: influence of chemical structures on biological activities. Chemical Papers, 2019, 73, 269-289.	1.0	44
3015	Brain Development Measured With MRI in Children With Down Syndrome Correlates With Blood Biochemical Biomarkers. Pediatric Neurology, 2019, 92, 43-47.	1.0	1
3016	Amyloid-Î² and Parkinsonâ€™s disease. Journal of Neurology, 2019, 266, 2605-2619.	1.8	79
3017	Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's Î²-amyloid self-assembly. Biomaterials, 2019, 190-191, 121-132.	5.7	62
3018	Pseudoginsenosideâ€F11 alleviates oligomeric Î²â€amyloidâ€induced endosomeâ€lysosome defects in microglia. Traffic, 2019, 20, 61-70.	1.3	20
3019	Interaction between mesenchymal stromal cellâ€derived extracellular vesicles and immune cells by distinct protein content. Journal of Cellular Physiology, 2019, 234, 8249-8258.	2.0	112
3020	Chirality Dependence of Amyloidâ€...Î² Cellular Uptake and a New Mechanistic Perspective. ChemBioChem, 2019, 20, 1023-1026.	1.3	29
3021	Single Posttranslational Modifications in the Central Repeat Domains of Tau4 Impact its Aggregation and Tubulin Binding. Angewandte Chemie - International Edition, 2019, 58, 1616-1620.	7.2	38
3022	Nurr1 (NR4A2) regulates Alzheimerâ€™s diseaseâ€related pathogenesis and cognitive function in the 5XFAD mouse model. Aging Cell, 2019, 18, e12866.	3.0	72
3023	Underappreciated Roles of the Translocase of the Outer and Inner Mitochondrial Membrane Protein Complexes in Human Disease. DNA and Cell Biology, 2019, 38, 23-40.	0.9	21
3024	Synthesis, molecular modeling and BACE-1 inhibitory study of tetrahydrobenzo[b] pyran derivatives. Bioorganic Chemistry, 2019, 84, 202-210.	2.0	22

#	Article	IF	Citations
3025	Could Alzheimerâ€™s Disease Originate in the Periphery and If So How So?. Molecular Neurobiology, 2019, 56, 406-434.	1.9	71
3026	New substituted aminopyrimidine derivatives as BACE1 inhibitors: in silico design, synthesis and biological assays. Journal of Biomolecular Structure and Dynamics, 2019, 37, 229-246.	2.0	7
3027	Metformin as a protective agent against natural or chemical toxicities: a comprehensive review on drug repositioning. Journal of Endocrinological Investigation, 2020, 43, 1-19.	1.8	6
3028	The Amyloid Phenomenon and Its Significance in Biology and Medicine. Cold Spring Harbor Perspectives in Biology, 2020, 12, a033878.	2.3	111
3029	New diagnostic method for Alzheimerâ€™s disease based on the toxic conformation theory of amyloid Î². Bioscience, Biotechnology and Biochemistry, 2020, 84, 1-16.	0.6	32
3030	Discovery of AM-6494: A Potent and Orally Efficacious Î²-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2. Journal of Medicinal Chemistry, 2020, 63, 2263-2281.	2.9	25
3031	Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimerâ€™s Disease. Journal of Pharmaceutical Sciences, 2020, 109, 68-73.	1.6	25
3032	Andrographolide Reduces Neuroinflammation and Oxidative Stress in Aged Octodon degus. Molecular Neurobiology, 2020, 57, 1131-1145.	1.9	30
3033	The Role of Secretase Pathway in Long-term Brain Inflammation and Cognitive Impairment in an Animal Model of Severe Sepsis. Molecular Neurobiology, 2020, 57, 1159-1169.	1.9	15
3034	ATR-IR and EPR spectroscopy for detecting the alterations in cortical synaptosomes induced by aluminium stress. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 228, 117535.	2.0	8
3035	Amyloid structures: much more than just a cross-Î² fold. Current Opinion in Structural Biology, 2020, 60, 7-16.	2.6	150
3036	A Î²-sheet-targeted theranostic agent for diagnosing and preventing aggregation of pathogenic peptides in Alzheimerâ€™s disease. Science China Chemistry, 2020, 63, 73-82.	4.2	23
3037	Telmisartan ameliorates AÎ² oligomer-induced inflammation via PPARÎ³/PTEN pathway in BV2 microglial cells. Biochemical Pharmacology, 2020, 171, 113674.	2.0	27
3038	Mercury and Alzheimerâ€™s Disease: Hg(II) Ions Display Specific Binding to the Amyloid-Î² Peptide and Hinder Its Fibrillization. Biomolecules, 2020, 10, 44.	1.8	26
3039	Flavonoidâ€Derived Human Phenylâ€Îµâ€Valerolactone Metabolites Selectively Detoxify Amyloidâ€Î² Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. Molecular Nutrition and Food Research, 2020, 64, e1900890.	1.5	24
3040	Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimerâ€™s disease course. Alzheimer's Research and Therapy, 2020, 12, 5.	3.0	39
3041	Proteomic and Unbiased Post-Translational Modification Profiling of Amyloid Plaques and Surrounding Tissue in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 393-411.	1.2	9
3042	Highly specific detection of AÎ² oligomers in early Alzheimer's disease by a near-infrared fluorescent probe with a â€œV-shapedâ€•spatial conformation. Chemical Communications, 2020, 56, 583-586.	2.2	34

#	Article	IF	Citations
3043	Effect of aggregated AÎ²Âprotofilaments on intermolecular vibrational spectrum of confined water. Journal of Chemical Sciences, 2020, 132, 1.	0.7	2
3044	Novel properties and applications of chiral inorganic nanostructures. Nano Today, 2020, 30, 100824.	6.2	61
3045	Reelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy. Progress in Neurobiology, 2020, 186, 101743.	2.8	26
3046	A Focused Chiral Mutant Library of the Amyloid Î² 42 Central Electrostatic Cluster as a Tool To Stabilize Aggregation Intermediates. Journal of Organic Chemistry, 2020, 85, 1385-1391.	1.7	19
3047	Preferential Recruitment of Conformationally Distinct Amyloid-Î² Oligomers by the Intrinsically Disordered Region of the Human Prion Protein. ACS Chemical Neuroscience, 2020, 11, 86-98.	1.7	16
3048	Mammalian phospholipase D: Function, and therapeutics. Progress in Lipid Research, 2020, 78, 101018.	5.3	48
3049	Inactivation of GAP-43 due to the depletion of cellular calcium by the Pb and amyloid peptide induced toxicity: An in vitro approach. Chemico-Biological Interactions, 2020, 316, 108927.	1.7	15
3050	Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome after rmTBI. Molecular Therapy, 2020, 28, 503-522.	3.7	121
3051	Interactions between Soluble Species of Î²-Amyloid and Î±-Synuclein Promote Oligomerization while Inhibiting Fibrillization. Biochemistry, 2020, 59, 425-435.	1.2	20
3052	Peripheral Blood-Derived Microglia-Like Cells Decrease Amyloid-Î² Burden and Ameliorate Cognitive Impairment in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 413-429.	1.2	10
3053	Spectroscopic investigation on alteration of dynamic properties of lipid membrane in presence of Gamma-Aminobutyric Acid (GABA). Journal of Molecular Liquids, 2020, 297, 111877.	2.3	12
3054	Implicit Micelle Model for Membrane Proteins Using Superellipsoid Approximation. Journal of Chemical Theory and Computation, 2020, 16, 711-724.	2.3	10
3055	Catalytic antibody (catabody) platform for age-associated amyloid disease: From Heisenbergâ€™s uncertainty principle to the verge of medical interventions. Mechanisms of Ageing and Development, 2020, 185, 111188.	2.2	2
3056	Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease. Brain, 2020, 143, 336-358.	3.7	52
3057	Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints. Bioorganic and Medicinal Chemistry, 2020, 28, 115194.	1.4	12
3058	Multifaceted Influences of Melaninâ€Like Particles on Amyloidâ€beta Aggregation. Chemistry - an Asian Journal, 2020, 15, 91-97.	1.7	4
3059	Combining Chalcones with Donepezil to Inhibit Both Cholinesterases and AÎ² Fibril Assembly. Molecules, 2020, 25, 77.	1.7	8
3060	ALS-Related Mutant SOD1 Aggregates Interfere with Mitophagy by Sequestering the Autophagy Receptor Optineurin. International Journal of Molecular Sciences, 2020, 21, 7525.	1.8	24

#	Article	IF	Citations
3061	Surface plasmon resonance biosensors for detection of Alzheimer's biomarkers; an effective step in early and accurate diagnosis. Biosensors and Bioelectronics, 2020, 167, 112511.	5.3	58
3062	Investigating the Structure of Neurotoxic Protein Aggregates Inside Cells. Trends in Cell Biology, 2020, 30, 951-966.	3.6	24
3063	Environment and Gene Association With Obesity and Their Impact on Neurodegenerative and Neurodevelopmental Diseases. Frontiers in Neuroscience, 2020, 14, 863.	1.4	61
3064	Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease. Neurochemistry International, 2020, 141, 104881.	1.9	17
3065	Amitriptyline interferes with autophagy-mediated clearance of protein aggregates via inhibiting autophagosome maturation in neuronal cells. Cell Death and Disease, 2020, 11, 874.	2.7	9
3066	Rapid Structural, Kinetic, and Immunochemical Analysis of Alpha-Synuclein Oligomers in Solution. Nano Letters, 2020, 20, 8163-8169.	4.5	24
3067	Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimerâ€™s Disease. Neuron, 2020, 108, 801-821.	3.8	132
3068	RP1, a RAGE antagonist peptide, can improve memory impairment and reduce AÎ² plaque load in the APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology, 2020, 180, 108304.	2.0	18
3069	EphA4 regulates AÎ² production via BACE1 expression in neurons. FASEB Journal, 2020, 34, 16383-16396.	0.2	8
3070	Amyloid-Î² peptides slightly affect lifespan or antimicrobial peptide gene expression in Drosophila melanogaster. BMC Genetics, 2020, 21, 65.	2.7	2
3071	Retinal Levels of Amyloid Beta Correlate with Cerebral Levels of Amyloid Beta in Young APPswe/PS1dE9 Transgenic Mice before Onset of Alzheimerâ€™s Disease. Behavioural Neurology, 2020, 2020, 1-8.	1.1	11
3072	Blood-Brain Barrier Permeable Chitosan Oligosaccharides Interfere with Î²-Amyloid Aggregation and Alleviate Î²-Amyloid Protein Mediated Neurotoxicity and Neuroinflammation in a Dose- and Degree of Polymerization-Dependent Manner. Marine Drugs, 2020, 18, 488.	2.2	25
3073	Bridging the Gap Between Fluid Biomarkers for Alzheimerâ€™s Disease, Model Systems, and Patients. Frontiers in Aging Neuroscience, 2020, 12, 272.	1.7	17
3074	The Effects of Resveratrol, Caffeine, Î²â€Carotene, and Epigallocatechin Gallate (EGCG) on Amyloidâ€Î²25--35 Aggregation in Synthetic Brain Membranes. Molecular Nutrition and Food Research, 2020, 64, e2000632.	1.5	8
3075	Nitrogenâ€Doped Carbonized Polymer Dots: A Potent Scavenger and Detector Targeting Alzheimer's Î²â€Amyloid Plaques. Small, 2020, 16, e2002804.	5.2	46
3076	The amyloid cascade hypothesis and Alzheimerâ€™s disease: A mathematical model. European Journal of Applied Mathematics, 2021, 32, 749-768.	1.4	10
3077	Phosphorylation Promotes AÎ²25â€“35 Peptide Aggregation within the DMPC Bilayer. ACS Chemical Neuroscience, 2020, 11, 3430-3441.	1.7	8
3078	Photostimulation of Extravasation of Beta-Amyloid through the Model of Blood-Brain Barrier. Electronics (Switzerland), 2020, 9, 1056.	1.8	15

#	Article	IF	Citations
3079	Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis. Drugs in R and D, 2020, 20, 197-207.	1.1	29
3080	Amyloid Evolution: Antiparallel Replaced by Parallel. Biophysical Journal, 2020, 118, 2526-2536.	0.2	28
3081	Meta-Analysis of the Alzheimerâ€™s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908.	2.9	199
3082	Paired Helical Filament-Forming Region of Tau (297â€“391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells. Journal of Molecular Biology, 2020, 432, 4891-4907.	2.0	15
3083	Passive immunotherapies targeting AÎ² and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010.	2.1	81
3084	Analyzing microglial-associated AÎ² in Alzheimerâ€™s disease transgenic mice with a novel mid-domain AÎ²-antibody. Scientific Reports, 2020, 10, 10590.	1.6	3
3085	Clustering of human prion protein and Î±-synuclein oligomers requires the prion protein N-terminus. Communications Biology, 2020, 3, 365.	2.0	26
3086	Molecular simulations of amyloid beta assemblies. Advances in Physics: X, 2020, 5, 1770627.	1.5	16
3087	Extracellular Vesicles in Alzheimerâ€™s and Parkinsonâ€™s Disease: Small Entities with Large Consequences. Cells, 2020, 9, 2485.	1.8	36
3088	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	1.8	23
3089	Critical Review of the Alzheimerâ€™s Disease Non-Transgenic Models: Can They Contribute to Disease Treatment?. Journal of Alzheimer's Disease, 2021, 82, S227-S250.	1.2	6
3090	TDP-43 interacts with amyloid-Î², inhibits fibrillization, and worsens pathology in a model of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 5950.	5.8	45
3091	Neuroprotective Effects of Curcumin and Vitamin D3 on Scopolamine-Induced Learning-Impaired Rat Model of Alzheimerâ€™s Disease. , 0, , .		2
3092	MIRRAGGE â€“ Minimum Information Required for Reproducible AGGregation Experiments. Frontiers in Molecular Neuroscience, 2020, 13, 582488.	1.4	19
3093	Design of a multivalent bifunctional chelator for diagnostic ⁶⁴ Cu PET imaging in Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30928-30933.	3.3	25
3094	Edge Strand Dissociation and Conformational Changes in Transthyretin under Amyloidogenic Conditions. Biophysical Journal, 2020, 119, 1995-2009.	0.2	12
3095	Designed Metal-ATCUN Derivatives: Redox- and Non-redox-Based Applications Relevant for Chemistry, Biology, and Medicine. IScience, 2020, 23, 101792.	1.9	30
3096	HSF1 physically neutralizes amyloid oligomers to empower overgrowth and bestow neuroprotection. Science Advances, 2020, 6, .	4.7	13

#	Article	IF	Citations
3097	Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers. International Journal of Molecular Sciences, 2020, 21, 8920.	1.8	8
3098	The Role of Mitochondrial Calcium Homeostasis in Alzheimerâ€™s and Related Diseases. International Journal of Molecular Sciences, 2020, 21, 9153.	1.8	54
3099	Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target. Frontiers in Neurology, 2020, 11, 590754.	1.1	32
3100	Alpha-Synucleinâ€"Nanoparticle Interactions: Understanding, Controlling and Exploiting Conformational Plasticity. Molecules, 2020, 25, 5625.	1.7	15
3101	Tandem-Homodimer of a Î²-Sheet-Forming Short Peptide Inhibits Random-to-Î² Structural Transition of Its Original Monomer. Processes, 2020, 8, 1421.	1.3	2
3102	Aryldiazoquinoline based multifunctional small molecules for modulating AÎ²₄₂aggregation and cholinesterase activity related to Alzheimer's disease. RSC Advances, 2020, 10, 28827-28837.	1.7	8
3103	Effects of Stereochemistry and Hydrogen Bonding on Glycopolymerâ€"Amyloid-Î² Interactions. Biomacromolecules, 2020, 21, 4280-4293.	2.6	12
3104	LMDS-1, a potential TrkB receptor agonist provides a safe and neurotrophic effect for early-phase Alzheimerâ€™s disease. Psychopharmacology, 2020, 237, 3173-3190.	1.5	11
3105	Direct measurement of lipid membrane disruption connects kinetics and toxicity of AÎ²42 aggregation. Nature Structural and Molecular Biology, 2020, 27, 886-891.	3.6	38
3106	Design, Synthesis and Biological Evaluation of Novel Triazole N-acylhydrazone Hybrids for Alzheimerâ€™s Disease. Molecules, 2020, 25, 3165.	1.7	14
3107	Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimerâ€™s disease. Journal of Neuroinflammation, 2020, 17, 218.	3.1	16
3108	Effects of IL-34 on Macrophage Immunological Profile in Response to Alzheimer's-Related AÎ²42 Assemblies. Frontiers in Immunology, 2020, 11, 1449.	2.2	15
3109	Reduction of advanced tau-mediated memory deficits by the MAP kinase p38Î³. Acta Neuropathologica, 2020, 140, 279-294.	3.9	24
3110	Phosphorylated AÎ² peptides in human Down syndrome brain and different Alzheimerâ€™s-like mouse models. Acta Neuropathologica Communications, 2020, 8, 118.	2.4	14
3111	Effects of rosmarinic acid on nervous system disorders: an updated review. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1779-1795.	1.4	53
3112	The existence of AÎ² strains and their potential for driving phenotypic heterogeneity in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
3113	Alzheimer's disease in the gutâ€"Major changes in the gut of 5xFAD model mice with ApoA1 as potential key player. FASEB Journal, 2020, 34, 11883-11899.	0.2	18
3114	Amentoflavone: A Bifunctional Metal Chelator that Controls the Formation of Neurotoxic Soluble AÎ²₄₂ Oligomers. ACS Chemical Neuroscience, 2020, 11, 2741-2752.	1.7	25

#	Article	IF	Citations
3115	Amyloid Beta Secreted during Consolidation Prevents Memory Malleability. Current Biology, 2020, 30, 1934-1940.e4.	1.8	13
3116	Noncanonical function of an autophagy protein prevents spontaneous Alzheimerâ€™s disease. Science Advances, 2020, 6, eabb9036.	4.7	62
3117	Evidence for aggregation-independent, PrP ^C -mediated AÎ² cellular internalization. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28625-28631.	3.3	26
3118	Simulations on the dual effects of flavonoids as suppressors of AÎ²42 fibrillogenesis and destabilizers of mature fibrils. Scientific Reports, 2020, 10, 16636.	1.6	7
3119	Hyaluronan-carnosine conjugates inhibit AÎ² aggregation and toxicity. Scientific Reports, 2020, 10, 15998.	1.6	17
3120	On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications. Frontiers in Immunology, 2020, 11, 571083.	2.2	22
3121	The Dynamism of Intrinsically Disordered Proteins: Binding-Induced Folding, Amyloid Formation, and Phase Separation. Journal of Physical Chemistry B, 2020, 124, 11541-11560.	1.2	31
3122	Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-Î² Cascade in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 7443.	1.8	33
3123	Liposomes Decorated with 2-(4â€²-Aminophenyl)benzothiazole Effectively Inhibit AÎ²_{1â€“42} Fibril Formation and Exhibit in Vitro Brain-Targeting Potential. Biomacromolecules, 2020, 21, 4685-4698.	2.6	10
3124	Co-treatment of AMPA endocytosis inhibitor and GluN2B antagonist facilitate consolidation and retrieval of memory impaired by Î² amyloid peptide. International Journal of Neuroscience, 2020, , 1-10.	0.8	4
3125	Altered Expression of Glial Gap Junction Proteins Cx43, Cx30, and Cx47 in the 5XFAD Model of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 582934.	1.4	22
3126	<scp>AP</scp> â€2 reduces amyloidogenesis by promoting <scp>BACE</scp> 1 trafficking and degradation in neurons. EMBO Reports, 2020, 21, e47954.	2.0	36
3127	Detection of Amyloid Î² Oligomers with RNA Aptamers in App^{NL-G-F/NL-G-F} Mice: A Model of Arctic Alzheimerâ€™s Disease. ACS Omega, 2020, 5, 21531-21537.	1.6	15
3128	New prenylated flavonoid and neuroprotective compounds from Tephrosia purpurea subsp. dunensis. Natural Product Research, 2020, 35, 1-9.	1.0	4
3129	Both Amyloid-Î² Peptide and Tau Protein Are Affected by an Anti-Amyloid-Î² Antibody Fragment in Elderly 3xTg-AD Mice. International Journal of Molecular Sciences, 2020, 21, 6630.	1.8	10
3130	A rationally designed bicyclic peptide remodels AÎ²42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimerâ€™s disease. Scientific Reports, 2020, 10, 15280.	1.6	15
3131	Synaptic Organizers in Alzheimerâ€™s Disease: A Classification Based on Amyloid-Î² Sensitivity. Frontiers in Cellular Neuroscience, 2020, 14, 281.	1.8	10
3132	Role of Microglia in Modulating Adult Neurogenesis in Health and Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 6875.	1.8	21

#	Article	IF	Citations
3133	Evaluation of the neuroprotective effect of taurine in Alzheimerâ€™s disease using functional molecular imaging. Scientific Reports, 2020, 10, 15551.	1.6	23
3134	NMR Relaxation of Nuclei of Buffer as a Probe for Monitoring Protein Solutions Including Aggregation Processes. Applied Magnetic Resonance, 2020, 51, 1653-1668.	0.6	1
3135	Tetrapeptide Ac-HAEE-NH2 Protects Î±4Î²2 nAChR from Inhibition by AÎ². International Journal of Molecular Sciences, 2020, 21, 6272.	1.8	9
3136	Frondoside A Attenuates Amyloid-Î² Proteotoxicity in Transgenic Caenorhabditis elegans by Suppressing Its Formation. Frontiers in Pharmacology, 2020, 11, 553579.	1.6	17
3137	Fluorescence-Labeled Amyloid Beta Monomer: A Molecular Dynamical Study. Molecules, 2020, 25, 3524.	1.7	3
3138	Dynamic Blood Concentrations of AÎ²1â€“40 and AÎ²1â€“42 in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 768.	1.8	14
3139	Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimerâ€™s disease mutations but not by inhibition of BACE1. Molecular Neurodegeneration, 2020, 15, 53.	4.4	44
3140	The coarse-grained plaque: a divergent AÎ² plaque-type in early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2020, 140, 811-830.	3.9	45
3141	Invasive and non-invasive therapies for Alzheimerâ€™s disease and other amyloidosis. Biophysical Reviews, 2020, 12, 1175-1186.	1.5	11
3142	Gallic acid is a dual Î±/Î²-secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice. Journal of Biological Chemistry, 2020, 295, 16251-16266.	1.6	49
3143	Regulation of NRF1, a master transcription factor of proteasome genes: implications for cancer and neurodegeneration. Molecular Biology of the Cell, 2020, 31, 2158-2163.	0.9	20
3144	Experimentally Consistent Simulation of AÎ²_{21â€“30} Peptides with a Minimal NMR Bias. Journal of Physical Chemistry B, 2020, 124, 8266-8277.	1.2	2
3145	Neurodegenerative Diseases: Potential Effect of Glutathione. , 2020, , .		4
3146	AggFluor: Fluorogenic Toolbox Enables Direct Visualization of the Multi-Step Protein Aggregation Process in Live Cells. Journal of the American Chemical Society, 2020, 142, 17515-17523.	6.6	90
3147	Somatostatin, an In Vivo Binder to AÎ² Oligomers, Binds to Î²PFO_{AÎ²(1â€“42)} Tetramers. ACS Chemical Neuroscience, 2020, 11, 3358-3365.	1.7	7
3148	Synthetic and Biophysical Studies on the Toxic Conformer in Amyloid Î² with the E22Î” Mutation in Alzheimer Pathology. ACS Chemical Neuroscience, 2020, 11, 3017-3024.	1.7	2
3149	Role of EGFR in the Nervous System. Cells, 2020, 9, 1887.	1.8	88
3150	Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism. Communications Biology, 2020, 3, 435.	2.0	44

#	Article	IF	Citations
3151	The retinal toxicity profile towards assemblies of Amyloid-Î² indicate the predominant pathophysiological activity of oligomeric species. Scientific Reports, 2020, 10, 20954.	1.6	11
3152	Label-free vibrational imaging of different AÎ² plaque types in Alzheimerâ€™s disease reveals sequential events in plaque development. Acta Neuropathologica Communications, 2020, 8, 222.	2.4	40
3153	Signaling Functions of Intramembrane Aspartyl-Proteases. Frontiers in Cardiovascular Medicine, 2020, 7, 591787.	1.1	13
3154	Evaluating the Effects of Grain of Isogenic Wheat Lines Differing in the Content of Anthocyanins in Mouse Models of Neurodegenerative Disorders. Nutrients, 2020, 12, 3877.	1.7	27
3155	An insight into the in vivo imaging potential of curcumin analogues as fluorescence probes. Asian Journal of Pharmaceutical Sciences, 2021, 16, 419-431.	4.3	16
3156	Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimerâ€™s disease. Science Advances, 2020, 6, .	4.7	52
3157	Functional module detection through integration of single-cell RNA sequencing data with proteinâ€“protein interaction networks. BMC Genomics, 2020, 21, 756.	1.2	13
3158	Target Enzymes Considered for the Treatment of Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. BioMed Research International, 2020, 2020, 1-14.	0.9	10
3159	Small-molecule sequestration of amyloid-Î² as a drug discovery strategy for Alzheimerâ€™s disease. Science Advances, 2020, 6, .	4.7	95
3160	Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2146.	5.8	219
3161	Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimerâ€™s Disease. Molecular Neurobiology, 2020, 57, 2902-2919.	1.9	101
3162	Development of novel N-(6-methanesulfonyl-benzothiazol-2-yl)-3-(4-substituted-piperazin-1-yl)-propionamides with cholinesterase inhibition, anti-Î²-amyloid aggregation, neuroprotection and cognition enhancing properties for the therapy of Alzheimer's disease. RSC Advances, 2020, 10, 17602-17619.	1.7	14
3163	The monomers, oligomers, and fibrils of amyloid-Î² inhibit the activity of mitoBKCa channels by a membrane-mediated mechanism. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183337.	1.4	22
3164	Complementary Role of Co- and Post-Translational Events in De Novo Protein Biogenesis. Journal of Physical Chemistry B, 2020, 124, 6488-6507.	1.2	13
3165	Golgi-Cox impregnation combined with fluorescence staining of amyloid plaques reveals local spine loss in an Alzheimer mouse model. Journal of Neuroscience Methods, 2020, 341, 108797.	1.3	12
3166	Visual and Quantitative Evaluation of Amyloid Brain PET Image Synthesis with Generative Adversarial Network. Applied Sciences (Switzerland), 2020, 10, 2628.	1.3	16
3167	Neuroligin-1 is altered in the hippocampus of Alzheimerâ€™s disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers. Scientific Reports, 2020, 10, 6956.	1.6	23
3168	Nrf2 Ablation Promotes Alzheimerâ€™s Disease-Like Pathology in APP/PS1 Transgenic Mice: The Role of Neuroinflammation and Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-13.	1.9	55

#	Article	IF	Citations
3169	Insulin resistance and Alzheimerâ€™s disease. , 2020, , 249-292.		1
3170	Oligomeric Cucurbituril Complexes: from Peculiar Assemblies to Emerging Applications. Angewandte Chemie - International Edition, 2020, 59, 21280-21292.	7.2	58
3171	Oligomeric Cucurbituril Complexes: from Peculiar Assemblies to Emerging Applications. Angewandte Chemie, 2020, 132, 21464-21476.	1.6	7
3172	Impact of A2V Mutation and Histidine Tautomerism on AÎ²42 Monomer Structures from Atomistic Simulations. Journal of Chemical Information and Modeling, 2020, 60, 3587-3592.	2.5	18
3173	Biophysical studies of protein misfolding and aggregation inin vivomodels of Alzheimer's and Parkinson's diseases. Quarterly Reviews of Biophysics, 2020, 53, e22.	2.4	13
3174	Nâ€terminal heterogeneity of parenchymal and vascular amyloidâ€Îβ deposits in Alzheimerâ€™s disease. Neuropathology and Applied Neurobiology, 2020, 46, 673-685.	1.8	20
3175	Rational design of a conformation-specific antibody for the quantification of AÎ² oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13509-13518.	3.3	61
3176	Piezoelectric materials for ultrasound-driven dissociation of Alzheimer's Î²-amyloid aggregate structure. Biomaterials, 2020, 255, 120165.	5.7	47
3177	Dimerization of AÎ²40 inside dipalmitoylphosphatidylcholine bilayer and its effect on bilayer integrity: Atomistic simulation at three temperatures. Proteins: Structure, Function and Bioinformatics, 2020, 88, 1540-1552.	1.5	8
3178	Fluorogenic detection of protein aggregates in live cells using the AggTag method. Methods in Enzymology, 2020, 639, 1-22.	0.4	9
3179	Cu(II) disrupts autophagy-mediated lysosomal degradation of oligomeric AÎ² in microglia via mTOR-TFEB pathway. Toxicology and Applied Pharmacology, 2020, 401, 115090.	1.3	9
3180	Commentary: Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk. Frontiers in Aging Neuroscience, 2020, 12, 127.	1.7	1
3181	Nanoliposomes as a Therapeutic Tool for Alzheimerâ€™s Disease. Frontiers in Synaptic Neuroscience, 2020, 12, 20.	1.3	24
3182	Expedition into Taurine Biology: Structural Insights and Therapeutic Perspective of Taurine in Neurodegenerative Diseases. Biomolecules, 2020, 10, 863.	1.8	18
3183	Unraveling the Role of Inwardly Rectifying Potassium Channels in the Hippocampus of an AÎ²(1â€“42)-Infused Rat Model of Alzheimerâ€™s Disease. Biomedicines, 2020, 8, 58.	1.4	8
3184	Three Popular Force Fields Predict Consensus Mechanism of Amyloid Î² Peptide Binding to the Dimyristoylglycerophosphocholine Bilayer. Journal of Chemical Information and Modeling, 2020, 60, 2282-2293.	2.5	11
3185	TV 3326 for Alzheimerâ€™s dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimerâ€™s-like neuropathology. Journal of Pharmacy and Pharmacology, 2020, 72, 1001-1012.	1.2	33
3186	Effect of Alzheimerâ€™s Disease Causative and Protective Mutations on the Hydration Environment of Amyloid-Î². Journal of Physical Chemistry B, 2020, 124, 2311-2322.	1.2	5

#	Article	IF	Citations
3187	AÎ²42 Double Mutant Inhibits AÎ²42-Induced Plasma and Mitochondrial Membrane Disruption in Artificial Membranes, Isolated Organs, and Intact Cells. ACS Chemical Neuroscience, 2020, 11, 1027-1037.	1.7	23
3188	The Influence of Pathogenic Mutations in Î±-Synuclein on Biophysical and Structural Characteristics of Amyloid Fibrils. ACS Nano, 2020, 14, 5213-5222.	7.3	58
3189	NRBP1-Containing CRL2/CRL4A Regulates Amyloid Î² Production by Targeting BRI2 and BRI3 for Degradation. Cell Reports, 2020, 30, 3478-3491.e6.	2.9	20
3190	An RNA aptamer with potent affinity for a toxic dimer of amyloid Î²42 has potential utility for histochemical studies of Alzheimer's disease. Journal of Biological Chemistry, 2020, 295, 4870-4880.	1.6	18
3191	Breviscapine exerts neuroprotective effects through multiple mechanisms in APP/PS1 transgenic mice. Molecular and Cellular Biochemistry, 2020, 468, 1-11.	1.4	14
3192	Computational studies of protein aggregation mediated by amyloid: Fibril elongation and secondary nucleation. Progress in Molecular Biology and Translational Science, 2020, 170, 461-504.	0.9	12
3193	A computational tool (H-MAGMA) for improved prediction of brain-disorder risk genes by incorporating brain chromatin interaction profiles. Nature Neuroscience, 2020, 23, 583-593.	7.1	194
3194	Heat-induced degradation of fibrils: Exponential vs logistic kinetics. Journal of Chemical Physics, 2020, 152, 115101.	1.2	6
3195	Antioxidant Berberine-Derivative Inhibits Multifaceted Amyloid Toxicity. IScience, 2020, 23, 101005.	1.9	63
3196	Dynamics of oligomer and amyloid fibril formation by yeast prion Sup35 observed by high-speed atomic force microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7831-7836.	3.3	36
3197	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memoryâ€Impairing Antiâ€Parallel AÎ² Dimers. Angewandte Chemie - International Edition, 2020, 59, 11491-11500.	7.2	15
3198	Soluble Assemblies in the Fibrillation Pathway of Prion-Inspired Artificial Functional Amyloids are Highly Cytotoxic. Biomacromolecules, 2020, 21, 2334-2345.	2.6	10
3199	Microfluidic Shrinking Droplet Concentrator for Analyte Detection and Phase Separation of Protein Solutions. Analytical Chemistry, 2020, 92, 5803-5812.	3.2	38
3200	Destruction of ERP responses to deviance in an auditory oddball paradigm in amyloid infusion mice with memory deficits. PLoS ONE, 2020, 15, e0230277.	1.1	8
3201	Activation of cannabinoid receptor 2 protects rat hippocampal neurons against AÎ²-induced neuronal toxicity. Neuroscience Letters, 2020, 735, 135207.	1.0	24
3202	Application of electrochemical method to a comparative study of spontaneous aggregation of amyloid-Î² isoforms. Journal of Electroanalytical Chemistry, 2020, 861, 113938.	1.9	7
3203	Alzheimerâ€™s Disease: The Link Between Amyloid-Î² and Neurovascular Dysfunction. Journal of Alzheimer's Disease, 2020, 76, 1179-1198.	1.2	76
3204	Pathogenic PSEN1 Thr119Ile Mutation in Two Korean Patients with Early-Onset Alzheimerâ€™s Disease. Diagnostics, 2020, 10, 405.	1.3	2

#	Article	IF	Citations
3205	Recombinant Bri3 BRICHOS domain is a molecular chaperone with effect against amyloid formation and non-fibrillar protein aggregation. Scientific Reports, 2020, 10, 9817.	1.6	16
3206	Rationally Designed Antibodies as Research Tools to Study the Structureâ€“Toxicity Relationship of Amyloid-Î² Oligomers. International Journal of Molecular Sciences, 2020, 21, 4542.	1.8	12
3207	Age-Specific Retinal and Cerebral Immunodetection of Amyloid-Î² Plaques and Oligomers in a Rodent Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 1135-1150.	1.2	26
3208	Small molecule-mediated co-assembly of amyloid-Î² oligomers reduces neurotoxicity through promoting non-fibrillar aggregation. Chemical Science, 2020, 11, 7158-7169.	3.7	27
3209	Synthetic and biochemical studies on the effect of persulfidation on disulfide dimer models of amyloid Î²42 at position 35 in Alzheimer's etiology. RSC Advances, 2020, 10, 19506-19512.	1.7	3
3210	Potential Bidirectional Relationship Between Periodontitis and Alzheimerâ€™s Disease. Frontiers in Physiology, 2020, 11, 683.	1.3	49
3211	Amyloid-Î², tau, and the cholinergic system in Alzheimerâ€™s disease: seeking direction in a tangle of clues. Reviews in the Neurosciences, 2020, 31, 391-413.	1.4	56
3212	Genetic Dissection of Alzheimerâ€™s Disease Using Drosophila Models. International Journal of Molecular Sciences, 2020, 21, 884.	1.8	27
3213	Neuroprotective Effect of New Nanochelating-Based Nano Complex, ALZc3, Against AÎ² (1â€“42)-Induced Toxicity in Rat: a Comparison with Memantine. Pharmaceutical Research, 2020, 37, 48.	1.7	8
3214	Prion protein â€” mediator of toxicity in multiple proteinopathies. Nature Reviews Neurology, 2020, 16, 187-188.	4.9	4
3215	Enhanced self-assembly of the 7â€“12 sequence of amyloid-Î² peptide by tyrosine bromination. Supramolecular Chemistry, 2020, 32, 247-255.	1.5	8
3216	Defective Mitochondrial Pyruvate Flux Affects Cell Bioenergetics in Alzheimerâ€™s Disease-Related Models. Cell Reports, 2020, 30, 2332-2348.e10.	2.9	67
3217	Hypoxia-Induced Degenerative Protein Modifications Associated with Aging and Age-Associated Disorders. , 2020, 11, 341.		28
3218	Sclerotiorin Stabilizes the Assembly of Nonfibrillar Abeta42 Oligomers with Low Toxicity, Seeding Activity, and Beta-sheet Content. Journal of Molecular Biology, 2020, 432, 2080-2098.	2.0	12
3219	Computer simulations of proteinâ€“membrane systems. Progress in Molecular Biology and Translational Science, 2020, 170, 273-403.	0.9	31
3220	Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. Neurobiology of Disease, 2020, 139, 104823.	2.1	20
3221	FMN reduces Amyloid-Î² toxicity in yeast by regulating redox status and cellular metabolism. Nature Communications, 2020, 11, 867.	5.8	50
3222	Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 16.	3.0	31

#	Article	IF	Citations
3223	High-yield Production of Amyloid-Î² Peptide Enabled by a Customized Spider Silk Domain. Scientific Reports, 2020, 10, 235.	1.6	45
3224	Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the AÎ²42:AÎ²40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model. Journal of Neuroscience, 2020, 40, 1956-1974.	1.7	114
3225	Sodium Butyrate Reduces Brain Amyloid-Î² Levels and Improves Cognitive Memory Performance in an Alzheimerâ€™s Disease Transgenic Mouse Model at an Early Disease Stage. Journal of Alzheimer's Disease, 2020, 74, 91-99.	1.2	65
3226	Dietary Lactoferrin Supplementation Prevents Memory Impairment and Reduces Amyloid-Î² Generation in J20 Mice. Journal of Alzheimer's Disease, 2020, 74, 245-259.	1.2	24
3227	Molecular dynamics simulations of copper binding to amyloid-Î² Glu22 mutants. Heliyon, 2020, 6, e03071.	1.4	8
3228	Osmolytes: A Possible Therapeutic Molecule for Ameliorating the Neurodegeneration Caused by Protein Misfolding and Aggregation. Biomolecules, 2020, 10, 132.	1.8	29
3229	6â€´-Feruloylspinosin alleviated beta-amyloid induced toxicity by promoting mitophagy in Caenorhabditis elegans (GMC101) and PC12 cells. Science of the Total Environment, 2020, 715, 136953.	3.9	31
3230	Misfolded amyloid-Î²-42 impairs the endosomalâ€“lysosomal pathway. Cellular and Molecular Life Sciences, 2020, 77, 5031-5043.	2.4	36
3231	Amyloid assembly is dominated by misregistered kinetic traps on an unbiased energy landscape. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10322-10328.	3.3	47
3232	Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases. Frontiers in Physiology, 2020, 11, 361.	1.3	24
3233	Assessing Reproducibility in Amyloid Î² Research: Impact of AÎ² Sources on Experimental Outcomes. ChemBioChem, 2020, 21, 2425-2430.	1.3	8
3234	Molecular insights into the inhibitory mechanisms of gallate moiety on the AÎ²1â€“40 amyloid aggregation: A molecular dynamics simulation study. International Journal of Biological Macromolecules, 2020, 156, 40-50.	3.6	13
3235	Revisiting thioflavin T (ThT) fluorescence as a marker of protein fibrillation â€“ The prominent role of electrostatic interactions. Journal of Colloid and Interface Science, 2020, 573, 87-95.	5.0	46
3236	Metal ion coordination delays amyloid-Î² peptide self-assembly by forming an aggregationâ€“inert complex. Journal of Biological Chemistry, 2020, 295, 7224-7234.	1.6	26
3237	Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimerâ€™s Disease in Health Screening Population. Diagnostics, 2020, 10, 237.	1.3	9
3238	Substrate recruitment by Î³-secretase. Seminars in Cell and Developmental Biology, 2020, 105, 54-63.	2.3	13
3239	Medroxyprogesterone Acetate Impairs Amyloid Beta Degradation in a Matrix Metalloproteinase-9 Dependent Manner. Frontiers in Aging Neuroscience, 2020, 12, 92.	1.7	13
3240	Hippocampal Deficits in Amyloid-Î²-Related Rodent Models of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 266.	1.4	44

#	Article	IF	Citations
3241	miR-16-5p is upregulated by amyloid Î² deposition in Alzheimer's disease models and induces neuronal cell apoptosis through direct targeting and suppression of BCL-2. Experimental Gerontology, 2020, 136, 110954.	1.2	31
3242	Role of Cholesterol on Binding of Amyloid Fibrils to Lipid Bilayers. Journal of Physical Chemistry B, 2020, 124, 3036-3042.	1.2	21
3243	Discovery of Chemicals to Either Clear or Indicate Amyloid Aggregates by Targeting Memoryâ€Impairing Antiâ€Parallel AÎ² Dimers. Angewandte Chemie, 2020, 132, 11588-11597.	1.6	3
3244	A Multifunctional Chemical Agent as an Attenuator of Amyloid Burden and Neuroinflammation in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2020, 11, 1471-1481.	1.7	25
3245	Synthetic biology based construction of biological activity-related library of fungal decalin-containing diterpenoid pyrones. Nature Communications, 2020, 11, 1830.	5.8	64
3246	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms. International Journal of Neuroscience, 2021, 131, 800-809.	0.8	14
3247	Isolation of infectious, non-fibrillar and oligomeric prions from a genetic prion disease. Brain, 2020, 143, 1512-1524.	3.7	21
3248	Identification of calcium and integrinâ€binding protein 1 as a novel regulator of production of amyloid Î² peptide using CRISPR/Cas9â€based screening system. FASEB Journal, 2020, 34, 7661-7674.	0.2	14
3249	Bioactive Polyphenols and Neuromodulation: Molecular Mechanisms in Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 2564.	1.8	63
3250	Anti-aging Klotho Protects SH-SY5Y Cells Against Amyloid Î²1â€“42 Neurotoxicity: Involvement of Wnt1/pCREB/Nrf2/HO-1 Signaling. Journal of Molecular Neuroscience, 2021, 71, 19-27.	1.1	15
3251	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. Medicinal Research Reviews, 2021, 41, 2689-2745.	5.0	26
3252	The Ups and Downs of BACE1: Walking a Fine Line between Neurocognitive and Other Psychiatric Symptoms of Alzheimerâ€™s Disease. Neuroscientist, 2021, 27, 222-234.	2.6	4
3253	Is there a link between inorganic polyphosphate (polyP), mitochondria, and neurodegeneration?. Pharmacological Research, 2021, 163, 105211.	3.1	20
3254	Mechanisms of neuronal survival safeguarded by endocytosis and autophagy. Journal of Neurochemistry, 2021, 157, 263-296.	2.1	25
3255	Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimerâ€™s disease diagnosis and progression monitoring. Chemical Engineering Journal, 2021, 405, 126733.	6.6	13
3256	NMR-based Lavado cocoa chemical characterization and comparison with fermented cocoa varieties: Insights on cocoaâ€™s anti-amyloidogenic activity. Food Chemistry, 2021, 341, 128249.	4.2	15
3257	Overexpression of protein kinase MÎ¶ in the hippocampus mitigates Alzheimerâ€™s disease-related cognitive deficit in rats. Brain Research Bulletin, 2021, 166, 64-72.	1.4	5
3258	Synthesis and in vitro carbonic anhydrases and acetylcholinesterase inhibitory activities of novel imidazolinoneâ€based benzenesulfonamides. Archiv Der Pharmazie, 2021, 354, e2000375.	2.1	32

#	Article	IF	Citations
3259	The impact of the microbiota-gut-brain axis on Alzheimerâ€™s disease pathophysiology. Pharmacological Research, 2021, 164, 105314.	3.1	144
3260	Tau-related white-matter alterations along spatially selective pathways. NeuroImage, 2021, 226, 117560.	2.1	30
3261	Design, synthesis, and biological activity of novel semicarbazones as potent Ryanodine receptor1 inhibitors of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2021, 29, 115891.	1.4	9
3262	Orally Administered Benzofuran Derivative Disaggregated AÎ² Plaques and Oligomers in the Brain of 5XFAD Alzheimer Transgenic Mouse. ACS Chemical Neuroscience, 2021, 12, 99-108.	1.7	5
3263	The interaction of insoluble Amyloidâ€Îβ with soluble Amyloidâ€Îβ dimers decreases Amyloidâ€Îβ plaque numbers. Neuropathology and Applied Neurobiology, 2021, 47, 603-610.	1.8	3
3264	(m)RVD-hemopressin (Îα) and (m)VD-hemopressin (Îα) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice. Peptides, 2021, 136, 170442.	1.2	3
3265	Conjugation of tacrine with genipin derivative not only enhances effects on AChE but also leads to autophagy against Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2021, 211, 113067.	2.6	5
3266	Length-Dependent Distinct Cytotoxic Effect of Amyloid Fibrils beyond Optical Diffraction Limit Revealed by Nanoscopic Imaging. ACS Nano, 2021, 15, 934-943.	7.3	22
3267	The pro-apoptotic domain of BIM protein forms toxic amyloid fibrils. Cellular and Molecular Life Sciences, 2021, 78, 2145-2155.	2.4	7
3268	A peptide fraction of Olive Flounder (Paralichthys olivaceus) Skin Hydrolysate Inhibits Amyloid-Îβ Generation in SH-SY5Y Cells via Suppression of BACE1 Expression. International Journal of Peptide Research and Therapeutics, 2021, 27, 627-639.	0.9	1
3269	Early life stress amplifies fear responses and hippocampal synaptic potentiation in the APPswe/PS1dE9 Alzheimer mouse model. Neuroscience, 2021, 454, 151-161.	1.1	8
3270	Identifying the key residues instrumental in imparting stability to amyloid beta protofibrils â€“ a comparative study using MD simulations of 17â€“42 residues. Journal of Biomolecular Structure and Dynamics, 2021, 39, 431-456.	2.0	9
3271	Functionalized Upconversion Nanoparticles for Disassembly of Îβâ€˜Amyloid Aggregation with Near-Infrared Excitation. Acta Chimica Sinica, 2021, 79, 1049.	0.5	3
3272	Use of saffron as a functional food and saffron nutraceuticals. , 2021, , 241-273.		2
3273	Magnolia officinalis Rehder & E.H.Wilson. , 2021, , 359-371.		0
3275	Mutant VAPB: Culprit or Innocent Bystander of Amyotrophic Lateral Sclerosis?. Contact (Thousand) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	8
3276	Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated AÎ² Species in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2020, 13, 619639.	1.4	7
3277	Effects of Ions and Small Compounds on the Structure of AÎ²42 Monomers. Journal of Physical Chemistry B, 2021, 125, 1085-1097.	1.2	3

#	Article	IF	Citations
3278	Preparation of Amyloid Fibrils Using Recombinant Technology. Methods in Molecular Biology, 2021, 2347, 113-121.	0.4	0
3279	Plasmonic nanoparticle amyloid corona for screening AÎ² oligomeric aggregate-degrading drugs. Nature Communications, 2021, 12, 639.	5.8	17
3280	AÎ² misfolding in blood plasma measured by immunoâ€infraredâ€sensor as an ageâ€independent risk marker of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12151.	1.2	2
3281	Review of the current state of protein aggregation inhibition from a materials chemistry perspective: special focus on polymeric materials. Materials Advances, 2021, 2, 1139-1176.	2.6	83
3282	The F19W mutation reduces the binding affinity of the transmembrane AÎ²11â€“40 trimer to the membrane bilayer. RSC Advances, 2021, 11, 2664-2676.	1.7	2
3283	Effects of clovamide and its related compounds on the aggregations of amyloid polypeptides. Journal of Natural Medicines, 2021, 75, 299-307.	1.1	8
3284	Glia-Like Cells from Human Mesenchymal Stem Cells Protect Neural Stem Cells in anIn VitroModel of Alzheimer's Disease by Reducing NLRP-3 Inflammasome. Dementia and Neurocognitive Disorders, 2021, 20, 1.	0.4	2
3285	Nanotechnology Therapy for Alzheimerâ€²s Disease Memory Impairment Attenuation. International Journal of Molecular Sciences, 2021, 22, 1102.	1.8	4
3286	Attack of the Oligomers â€“ Alpha-synuclein amyloid oligomers and their pathogenic roles. , 2021, , 129-158.		0
3287	Physical properties, classification, synthesis, and functionalization of magnetic nanomaterials. , 2021, , 3-21.		1
3288	Modeling Brain Pathology of <scp>Niemannâ€Pick</scp> Disease Type C Using Patientâ€Derived Neurons. Movement Disorders, 2021, 36, 1022-1027.	2.2	4
3289	The C99 domain of the amyloid precursor protein resides in the disordered membrane phase. Journal of Biological Chemistry, 2021, 296, 100652.	1.6	9
3290	Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties. RSC Medicinal Chemistry, 2021, 12, 1154-1163.	1.7	11
3291	Biophysical characteristics of lipidâ€induced AÎ² oligomers correlate to distinctive phenotypes in transgenic mice. FASEB Journal, 2021, 35, e21318.	0.2	12
3292	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. , 2021, , 291-310.		0
3293	Somatostatin Ameliorates Î²-Amyloid-Induced Cytotoxicity via the Regulation of CRMP2 Phosphorylation and Calcium Homeostasis in SH-SY5Y Cells. Biomedicines, 2021, 9, 27.	1.4	5
3294	Soluble Î²-amyloid impaired the GABA inhibition by mediating KCC2 in early APP/PS1 mice. BioScience Trends, 2021, 15, 330-340.	1.1	7
3295	A continuous-time mathematical model and discrete approximations for the aggregation of Î²-Amyloid. Journal of Biological Dynamics, 2021, 15, 109-136.	0.8	5

#	Article	IF	Citations
3296	The amyloidâ€“melanin connection: a cross sectional study on primary cutaneous Macular Amyloidosis. Pigment International, 2021, 8, 95.	0.1	0
3297	Kir Channel Molecular Physiology, Pharmacology, and Therapeutic Implications. Handbook of Experimental Pharmacology, 2021, 267, 277-356.	0.9	21
3298	Sequence-dependent aggregation-prone conformations of islet amyloid polypeptide. Physical Chemistry Chemical Physics, 2021, 23, 22532-22542.	1.3	5
3299	Targeting the APP-Mint2 Proteinâ€“Protein Interaction with a Peptide-Based Inhibitor Reduces Amyloid-Î² Formation. Journal of the American Chemical Society, 2021, 143, 891-901.	6.6	15
3300	Modification of amyloid-beta peptide aggregation via photoactivation of strained Ru(<scp>ii</scp>) polypyridyl complexes. Chemical Science, 2021, 12, 7510-7520.	3.7	15
3301	Infrared nanospectroscopy reveals the molecular interaction fingerprint of an aggregation inhibitor with single AÎ²42 oligomers. Nature Communications, 2021, 12, 688.	5.8	52
3302	Development of molecular tools for diagnosis of Alzheimerâ€™s disease that are based on detection of amyloidogenic proteins. Prion, 2021, 15, 56-69.	0.9	12
3303	Rationally Designed Bicyclic Peptides Prevent the Conversion of AÎ²42 Assemblies Into Fibrillar Structures. Frontiers in Neuroscience, 2021, 15, 623097.	1.4	6
3304	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nature Reviews Chemistry, 2021, 5, 277-294.	13.8	56
3305	Mitochondrial ubiquitin ligase alleviates Alzheimerâ€™s disease pathology via blocking the toxic amyloid-Î² oligomer generation. Communications Biology, 2021, 4, 192.	2.0	19
3306	Association of SHANK Family with Neuropsychiatric Disorders: An Update on Genetic and Animal Model Discoveries. Cellular and Molecular Neurobiology, 2022, 42, 1623-1643.	1.7	7
3307	Serotonin and Melatonin Show Different Modes of Action on AÎ²₄₂ Protofibril Destabilization. ACS Chemical Neuroscience, 2021, 12, 799-809.	1.7	24
3308	Peptidomimetic-Based Vesicles Inhibit Amyloid-Î² Fibrillation and Attenuate Cytotoxicity. Journal of the American Chemical Society, 2021, 143, 3086-3093.	6.6	32
3309	Gastrodin as a multi-target protective compound reverses learning memory deficits and AD-like pathology in APP/PS1 transgenic mice. Journal of Functional Foods, 2021, 77, 104324.	1.6	9
3310	Neuroprotective potential of Malva neglecta is mediated via down-regulation of cholinesterase and modulation of oxidative stress markers. Metabolic Brain Disease, 2021, 36, 889-900.	1.4	33
3311	Effect of Lauric Acid on the Stability of AÎ²₄₂ Oligomers. ACS Omega, 2021, 6, 5795-5804.	1.6	3
3312	Prebiotic Lactulose Ameliorates the Cognitive Deficit in Alzheimerâ€™s Disease Mouse Model through Macroautophagy and Chaperone-Mediated Autophagy Pathways. Journal of Agricultural and Food Chemistry, 2021, 69, 2422-2437.	2.4	37
3313	Cytoprotective Potential of Fucoxanthin in Oxidative Stress-Induced Age-Related Macular Degeneration and Retinal Pigment Epithelial Cell Senescence In Vivo and In Vitro. Marine Drugs, 2021, 19, 114.	2.2	20

#	Article	IF	Citations
3314	MicroRNAs as Candidate Biomarkers for Alzheimerâ€™s Disease. Non-coding RNA, 2021, 7, 8.	1.3	10
3315	CART mitigates oxidative stress and DNA damage in memory deficits of APP/PS1 mice via upregulating Î²â€˜amyloid metabolismâ€˜associated enzymes. Molecular Medicine Reports, 2021, 23, .	1.1	14
3316	Exploring Charged Polymeric Cyclodextrins for Biomedical Applications. Molecules, 2021, 26, 1724.	1.7	6
3317	A reactionâ€“diffusion model of spatial propagation of A$$eta $$ oligomers in early stage Alzheimerâ€™s disease. Journal of Mathematical Biology, 2021, 82, 39.	0.8	7
3319	Ibrutinib modulates AÎ²/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease. Aging Cell, 2021, 20, e13332.	3.0	29
3320	Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: Pathological mechanisms and therapeutic outlooks. European Journal of Pharmacology, 2021, 895, 173873.	1.7	24
3321	Neuroprotective effects of carbenoxolone against amyloid-beta 1â€“42 oligomer-induced neuroinflammation and cognitive decline in rats. NeuroToxicology, 2021, 83, 89-105.	1.4	6
3322	Anomaly Analysis of Alzheimerâ€™s Disease in PET Images Using an Unsupervised Adversarial Deep Learning Model. Applied Sciences (Switzerland), 2021, 11, 2187.	1.3	12
3323	Aggregation of AÎ²40/42 chains in the presence of cyclic neuropeptides investigated by molecular dynamics simulations. PLoS Computational Biology, 2021, 17, e1008771.	1.5	5
3324	Azobioisosteres of Curcumin with Pronounced Activity against Amyloid Aggregation, Intracellular Oxidative Stress, and Neuroinflammation. Chemistry - A European Journal, 2021, 27, 6015-6027.	1.7	4
3325	Chemical Aspects of Human and Environmental Overload with Fluorine. Chemical Reviews, 2021, 121, 4678-4742.	23.0	202
3326	Probing the Structure of Toxic Amyloid-Î² Oligomers with Electron Spin Resonance and Molecular Modeling. ACS Chemical Neuroscience, 2021, 12, 1150-1161.	1.7	9
3327	Hydration Thermodynamics of Familial Parkinsonâ€™s Disease-Linked Mutants of Î±-Synuclein. Journal of Chemical Information and Modeling, 2021, 61, 1850-1858.	2.5	8
3328	A Skate Skin Hydrolysate Restores Cognitive Function in 5XFAD Alzheimer Disease Mice Model by Suppressing Amyloid-Î² Accumulation via Upregulation of ERK-CREB. International Journal of Peptide Research and Therapeutics, 2021, 27, 1419-1428.	0.9	0
3329	Rosmarinic acid and ursolic acid alleviate deficits in cognition, synaptic regulation and adult hippocampal neurogenesis in an AÎ²1-42-induced mouse model of Alzheimer's disease. Phytomedicine, 2021, 83, 153490.	2.3	44
3330	Exploring How Low Oxygen Post Conditioning Improves Stroke-Induced Cognitive Impairment: A Consideration of Amyloid-Beta Loading and Other Mechanisms. Frontiers in Neurology, 2021, 12, 585189.	1.1	6
3331	An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimerâ€™s Disease. Cells, 2021, 10, 546.	1.8	11
3332	Liver X Receptor Activation with an Intranasal Polymer Therapeutic Prevents Cognitive Decline without Altering Lipid Levels. ACS Nano, 2021, 15, 4678-4687.	7.3	17

#	Article	IF	Citations
3333	More than motor impairment: A spatiotemporal analysis of cognitive impairment and associated neuropathological changes following cortical photothrombotic stroke. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2439-2455.	2.4	21
3334	Anti-tuberculotic thionamide antibiotics show antioxidative and neuronal cytoprotective nature by inhibiting amyloid formation in human insulin and amyloid Î²-42. Journal of Molecular Liquids, 2021, 326, 115396.	2.3	6
3335	GDE2-RECK controls ADAM10 Î±-secretaseâ€“mediated cleavage of amyloid precursor protein. Science Translational Medicine, 2021, 13, .	5.8	12
3336	Simultaneous Quantification of Four Marker Compounds in Bauhinia coccinea Extract and Their Potential Inhibitory Effects on Alzheimerâ€™s Disease Biomarkers. Plants, 2021, 10, 702.	1.6	2
3337	Inhibitory mechanism of an antifungal drug, caspofungin against amyloid Î² peptide aggregation: Repurposing via neuroinformatics and an experimental approach. Molecular and Cellular Neurosciences, 2021, 112, 103612.	1.0	3
3338	Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease. Clinical Nuclear Medicine, 2021, 46, 527-531.	0.7	6
3339	Recent advances in pre-clinical diagnosis of Alzheimerâ€™s disease. Metabolic Brain Disease, 2021, , 1.	1.4	3
3340	Curcumin and Homotaurine Suppress Amyloid-Î²_{25â€“35} Aggregation in Synthetic Brain Membranes. ACS Chemical Neuroscience, 2021, 12, 1395-1405.	1.7	10
3341	An excellent electrochemical aptasensor for amyloid-Î² oligomers based on a triple-helix aptamer switch via target-triggered signal transduction DNA displacement events. Analytical and Bioanalytical Chemistry, 2021, 413, 3707-3716.	1.9	15
3342	Surgery Performed Under Propofol Anesthesia Induces Cognitive Impairment and Amyloid Pathology in ApoE4 Knock-In Mouse Model. Frontiers in Aging Neuroscience, 2021, 13, 658860.	1.7	16
3343	Beneficial Effects of Cyclic Ether 2-Butoxytetrahydrofuran from Sea Cucumber Holothuria scabra against AÎ² Aggregate Toxicity in Transgenic Caenorhabditis elegans and Potential Chemical Interaction. Molecules, 2021, 26, 2195.	1.7	9
3344	DNAJB chaperones suppress destabilised protein aggregation via a region distinct from that used to inhibit amyloidogenesis. Journal of Cell Science, 2021, 134, .	1.2	12
3345	Downregulation of ATP6V1A Involved in Alzheimerâ€™s Disease via Synaptic Vesicle Cycle, Phagosome, and Oxidative Phosphorylation. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15.	1.9	16
3346	Identification of highest neurotoxic amyloid-Î² plaque type showing reduced contact with astrocytes. Biochemical and Biophysical Research Communications, 2021, 549, 67-74.	1.0	4
3347	Generation of a humanized AÎ² expressing mouse demonstrating aspects of Alzheimerâ€™s disease-like pathology. Nature Communications, 2021, 12, 2421.	5.8	53
3349	Neuroprotective Efficacy of Co-Encapsulated Rosiglitazone and Vorinostat Nanoparticle on Streptozotocin Induced Mice Model of Alzheimer Disease. ACS Chemical Neuroscience, 2021, 12, 1528-1541.	1.7	19
3350	Astrocytes and Adenosine A2A Receptors: Active Players in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 666710.	1.4	19
3351	Alzheimer disease. Nature Reviews Disease Primers, 2021, 7, 33.	18.1	784

#	Article	IF	Citations
3353	Understanding amphisomes. Biochemical Journal, 2021, 478, 1959-1976.	1.7	57
3354	Amyloidâ€beta is present in human lymph nodes and greatly enriched in those of the cervical region. Alzheimer's and Dementia, 2022, 18, 205-210.	0.4	18
3355	Polyphenol-Peptide Interactions in Mitigation of Alzheimerâ€™s Disease: Role of Biosurface-Induced Aggregation. Journal of Alzheimer's Disease, 2021, 81, 33-55.	1.2	4
3356	Insights into Î²-amyloid transition prevention by cucurbit[7]uril from molecular modeling. Journal of Biomolecular Structure and Dynamics, 2022, 40, 9602-9612.	2.0	3
3357	Effect of packing density of lipid vesicles on the AÎ²42 fibril polymorphism. Chemistry and Physics of Lipids, 2021, 236, 105073.	1.5	7
3358	Exploring the Impact of Glyoxal Glycation on Î²-Amyloid Peptide (AÎ²) Aggregation in Alzheimerâ€™s Disease. Journal of Physical Chemistry B, 2021, 125, 5559-5571.	1.2	6
3359	Alpha lipoic acid ameliorates scopolamine induced memory deficit and neurodegeneration in the cerebello-hippocampal cortex. Metabolic Brain Disease, 2021, 36, 1729-1745.	1.4	9
3360	Calcium Dyshomeostasis in Alzheimerâ€™s Disease Pathogenesis. International Journal of Molecular Sciences, 2021, 22, 4914.	1.8	76
3361	The Cryo-EM Effect: Structural Biology of Neurodegenerative Disease Aggregates. Journal of Neuropathology and Experimental Neurology, 2021, 80, 514-529.	0.9	11
3362	Binding Mechanisms of Amyloid-like Peptides to Lipid Bilayers and Effects of Divalent Cations. ACS Chemical Neuroscience, 2021, 12, 2027-2035.	1.7	19
3363	Brain Targeting and AÎ² Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice. ACS Chemical Neuroscience, 2021, 12, 2110-2121.	1.7	15
3364	Axonal generation of amyloid-Î² from palmitoylated APP in mitochondria-associated endoplasmic reticulum membranes. Cell Reports, 2021, 35, 109134.	2.9	29
3365	Cooperative inhibition of SNARE-mediated vesicle fusion by Î±-synuclein monomers and oligomers. Scientific Reports, 2021, 11, 10955.	1.6	20
3366	Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals. Nuclear Medicine and Biology, 2021, 96-97, 112-147.	0.3	6
3367	VEGF counteracts amyloid-Î²-induced synaptic dysfunction. Cell Reports, 2021, 35, 109121.	2.9	19
3368	Effects of vanillic acid on AÎ²1-40-induced oxidative stress and learning and memory deficit in male rats. Brain Research Bulletin, 2021, 170, 264-273.	1.4	41
3369	Rapid Conversion of Amyloid-Beta 1-40 Oligomers to Mature Fibrils through a Self-Catalytic Bimolecular Process. International Journal of Molecular Sciences, 2021, 22, 6370.	1.8	8
3370	Chirality Effects in Peptide Assembly Structures. Frontiers in Bioengineering and Biotechnology, 2021, 9, 703004.	2.0	23

#	Article	IF	Citations
3371	Single molecule imaging of protein aggregation in Dementia: Methods, insights and prospects. Neurobiology of Disease, 2021, 153, 105327.	2.1	2
3372	A screened PirB antagonist peptide antagonizes AÎ²42-mediated inhibition of neurite outgrowth in vitro. Applied Microbiology and Biotechnology, 2021, 105, 4649-4662.	1.7	6
3376	Utilizing magnetic resonance techniques to study membrane interactions of amyloid peptides. Biochemical Society Transactions, 2021, 49, 1457-1465.	1.6	5
3377	UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation. Nature Communications, 2021, 12, 3291.	5.8	30
3378	An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?. International Journal of Molecular Sciences, 2021, 22, 5991.	1.8	28
3379	Microglia show differential transcriptomic response to AÎ² peptide aggregates ex vivo and in vivo. Life Science Alliance, 2021, 4, e202101108.	1.3	17
3380	A multimethod approach for analyzing FapC fibrillation and determining mass per length. Biophysical Journal, 2021, 120, 2262-2275.	0.2	10
3381	A Novel Cu(II)-Binding Peptide Identified by Phage Display Inhibits Cu2+-Mediated AÎ² Aggregation. International Journal of Molecular Sciences, 2021, 22, 6842.	1.8	14
3382	Nanomechanical Stability of AÎ² Tetramers and Fibril-like Structures: Molecular Dynamics Simulations. Journal of Physical Chemistry B, 2021, 125, 7628-7637.	1.2	9
3383	Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2021, 219, 113441.	2.6	20
3384	Plasma amyloid-Î² oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	3.0	19
3385	Refining the amyloid Î² peptide and oligomer fingerprint ambiguities in Alzheimerâ€™s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
3387	Overexpression of LIMK1 in hippocampal excitatory neurons improves synaptic plasticity and social recognition memory in APP/PS1 mice. Molecular Brain, 2021, 14, 121.	1.3	7
3388	PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) ameliorate learning and memory deficit in a rat model of Alzheimerâ€™s disease: Potential participation of STIMs. NeuroToxicology, 2021, 85, 145-159.	1.4	18
3389	Insulin Resistance Exacerbates Alzheimer Disease via Multiple Mechanisms. Frontiers in Neuroscience, 2021, 15, 687157.	1.4	40
3390	Effects of the Hydrophilic N-Terminal Region on AÎ²-Mediated Membrane Disruption. Journal of Physical Chemistry B, 2021, 125, 7671-7678.	1.2	1
3391	Nanomaterials for Modulating the Aggregation of Î²-Amyloid Peptides. Molecules, 2021, 26, 4301.	1.7	17
3392	A highâ€fat diet exacerbates the Alzheimer's disease pathology in the hippocampus of the App^{NLâ^'F/NLâ^'F} knockâ€in mouse model. Aging Cell, 2021, 20, e13429.	3.0	19

#	Article	IF	Citations
3393	Chiral LVFFARK enantioselectively inhibits amyloid-Î² protein fibrillogenesis. Chinese Journal of Chemical Engineering, 2022, 48, 227-235.	1.7	2
3394	Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, Behavior, and Immunity, 2022, 99, 363-382.	2.0	8
3395	Exogenous misfolded protein oligomers can cross the intestinal barrier and cause a disease phenotype in C. elegans. Scientific Reports, 2021, 11, 14391.	1.6	6
3396	Role of the English (H6R) Mutation on the Structural Properties of AÎ²40 and AÎ²42 Owing to the Histidine Tautomeric Effect. ACS Chemical Neuroscience, 2021, 12, 2705-2711.	1.7	2
3397	Inhibition of aggregation of amyloid-Î² through covalent modification with benzylpenicillin; potential relevance to Alzheimer's disease. Biochemistry and Biophysics Reports, 2021, 26, 100943.	0.7	3
3398	Development of liquid crystal biosensor for the detection of amyloid beta-42 levels associated with Alzheimer's disease. Journal of Bioscience and Bioengineering, 2021, 132, 88-94.	1.1	10
3399	Multifunctional nanorods based on self-assembly of biomimetic apolipoprotein E peptide for the treatment of Alzheimer's disease. Journal of Controlled Release, 2021, 335, 637-649.	4.8	14
3400	Sequence Determinants of the Aggregation of Proteins Within Condensates Generated by Liquid-liquid Phase Separation. Journal of Molecular Biology, 2022, 434, 167201.	2.0	62
3401	Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimerâ€™s Disease. ACS Medicinal Chemistry Letters, 2021, 12, 1389-1395.	1.3	19
3402	Reference interval and the role of plasma oligomeric beta amyloid in screening of risk groups for cognitive dysfunction at health checkups. Journal of Clinical Laboratory Analysis, 2021, 35, e23933.	0.9	3
3403	Quantum dots as a theranostic approach in Alzheimer's disease: a systematic review. Nanomedicine, 2021, 16, 1595-1611.	1.7	23
3404	Met35 Oxidation Hinders AÎ²25-35 Peptide Aggregation within the Dimyristoylphosphatidylcholine Bilayer. ACS Chemical Neuroscience, 2021, 12, 3225-3236.	1.7	7
3406	Differential interaction with <scp>TREM2</scp> modulates microglial uptake of modified AÎ² species. Glia, 2021, 69, 2917-2932.	2.5	9
3407	The amyloid-inhibiting NCAM-PrP peptide targets AÎ² peptide aggregation in membrane-mimetic environments. IScience, 2021, 24, 102852.	1.9	15
3408	Focused ultrasound with anti-pGlu3 AÎ² enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. Journal of Controlled Release, 2021, 336, 443-456.	4.8	21
3409	N-Acetylcysteine prevents amyloid-Î² secretion in neurons derived from human pluripotent stem cells with trisomy 21. Scientific Reports, 2021, 11, 17377.	1.6	3
3410	Exercise hormone irisin is a critical regulator of cognitive function. Nature Metabolism, 2021, 3, 1058-1070.	5.1	134
3411	AÎ² misfolding in blood plasma is inversely associated with body mass index even in middle adulthood. Alzheimer's Research and Therapy, 2021, 13, 145.	3.0	3

#	Article	IF	Citations
3412	Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis. Communications Biology, 2021, 4, 961.	2.0	2
3413	Engineering Amyloid Aggregation as a New Way to Eliminate Cancer Stem Cells by the Disruption of Iron Homeostasis. Nano Letters, 2021, 21, 7379-7387.	4.5	7
3414	Amyloid-Î² (1-42) peptide induces rapid NMDA receptor-dependent alterations at glutamatergic synapses in the entorhinal cortex. Neurobiology of Aging, 2021, 105, 296-309.	1.5	6
3416	Receptor tyrosine kinase ROR1 ameliorates AÎ²1â€“42 induced cytoskeletal instability and is regulated by the miR146a-NEAT1 nexus in Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 19254.	1.6	6
3417	Comparative Review of Microglia and Monocytes in CNS Phagocytosis. Cells, 2021, 10, 2555.	1.8	16
3418	Synthetic amyloid-Î² oligomers drive early pathological progression of Alzheimerâ€™s disease in nonhuman primates. IScience, 2021, 24, 103207.	1.9	9
3419	Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer's disease. Ageing Research Reviews, 2021, 70, 101417.	5.0	43
3420	O-alkylated quercetins with selective acetylcholinesterase and Î²-secretase inhibitions from Melicope glabra leaves, and their flavonols profile by LC-ESI-Q-TOF/MS. Journal of Functional Foods, 2021, 84, 104602.	1.6	6
3421	Molecular Insights into the Inhibitory Effect of GV971 Components Derived from Marine Acidic Oligosaccharides against the Conformational Transition of AÎ²42 Monomers. ACS Chemical Neuroscience, 2021, 12, 3772-3784.	1.7	4
3422	Neuronal Deposition of Amyloid-Î² Oligomers and Hyperphosphorylated Tau Is Closely Connected with Cognitive Dysfunction in Aged Dogs. Journal of Alzheimer's Disease Reports, 2021, 5, 749-760.	1.2	4
3423	Curcumin Complex Analogues as Near-Infrared Fluorescent Probes for Monitoring all AÎ² Species in the Early Alzheimerâ€™s Disease Model. ACS Chemical Neuroscience, 2021, 12, 3683-3689.	1.7	13
3424	A Super-Resolved View of the Alzheimerâ€™s Disease-Related Amyloidogenic Pathway in Hippocampal Neurons. Journal of Alzheimer's Disease, 2021, 83, 833-852.	1.2	5
3425	Romidepsin and metformin nanomaterials delivery on streptozocin for the treatment of Alzheimer's disease in animal model. Biomedicine and Pharmacotherapy, 2021, 141, 111864.	2.5	10
3426	Î²-Amyloid fibrils catalyze neurotransmitter degradation. Chem Catalysis, 2021, 1, 908-922.	2.9	24
3427	AbsoluRATE: An in-silico method to predict the aggregation kinetics of native proteins. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2021, 1869, 140682.	1.1	8
3428	Rhein Relieves Oxidative Stress in an AÎ²1-42 Oligomer-Burdened Neuron Model by Activating the SIRT1/PGC-1Î±-Regulated Mitochondrial Biogenesis. Frontiers in Pharmacology, 2021, 12, 746711.	1.6	18
3429	Neuroprotective Effects of Ceftriaxone Involve the Reduction of AÎ² Burden and Neuroinflammatory Response in a Mouse Model of Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 736786.	1.4	14
3430	Enzymatically Forming Intranuclear Peptide Assemblies for Selectively Killing Human Induced Pluripotent Stem Cells. Journal of the American Chemical Society, 2021, 143, 15852-15862.	6.6	49

#	Article	IF	Citations
3431	Direct visualization and profiling of protein misfolding and aggregation in live cells. Current Opinion in Chemical Biology, 2021, 64, 116-123.	2.8	8
3432	Understanding and controlling amyloid aggregation with chirality. Current Opinion in Chemical Biology, 2021, 64, 1-9.	2.8	18
3433	Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 222, 113565.	2.6	10
3434	Functional bioprobe for responsive imaging and inhibition of amyloid-Î² oligomer based on curcuminoid scaffold. Journal of Luminescence, 2021, 238, 118218.	1.5	8
3435	Alzheimer's disease: Is there a role for galectins?. European Journal of Pharmacology, 2021, 909, 174437.	1.7	6
3436	Can platelet activation result in increased plasma AÎ² levels and contribute to the pathogenesis of Alzheimerâ€™s disease?. Ageing Research Reviews, 2021, 71, 101420.	5.0	15
3437	Internet-like brain hierarchical network model: Alzheimer's disease study as an example. Computer Methods and Programs in Biomedicine, 2021, 211, 106393.	2.6	2
3438	Principles of brain aging: Status and challenges of modeling human molecular changes in mice. Ageing Research Reviews, 2021, 72, 101465.	5.0	7
3439	Neurodegeneration & imperfect ageing: Technological limitations and challenges?. Mechanisms of Ageing and Development, 2021, 200, 111574.	2.2	2
3440	Mimosine functionalized gold nanoparticles (Mimo-AuNPs) suppress Î²-amyloid aggregation and neuronal toxicity. Bioactive Materials, 2021, 6, 4491-4505.	8.6	19
3441	Contributions of the neurological examination to the diagnosis of dementia in Down syndrome. , 2022, , 251-272.		0
3442	Multifunctional peptide-assembled micelles for simultaneously reducing amyloid-Î² and reactive oxygen species. Chemical Science, 2021, 12, 6449-6457.	3.7	15
3443	Analysis and Numerical Simulations of a Reaction-Diffusion Model with Fixed Active Bodies. SIAM Journal on Applied Mathematics, 2021, 81, 1339-1360.	0.8	0
3444	Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimerâ€™s disease-associated markers in 3xTg-AD mice. Alzheimer's Research and Therapy, 2021, 13, 30.	3.0	7
3445	A conformation-specific antibody against oligomeric Î²-amyloid restores neuronal integrity in a mouse model of Alzheimer's disease. Journal of Biological Chemistry, 2021, 296, 100241.	1.6	4
3446	Poria cocos could ameliorate cognitive dysfunction in <scp>APP</scp>/<scp>PS1</scp> mice by restoring imbalance of AÎ² production and clearance and gut microbiota dysbiosis. Phytotherapy Research, 2021, 35, 2678-2690.	2.8	14
3447	A dopamine metabolite stabilizes neurotoxic amyloid-Î² oligomers. Communications Biology, 2021, 4, 19.	2.0	25
3448	Design, synthesis and comparison of water-soluble phthalocyanine/porphyrin analogues and their inhibition effects on AÎ²₄₂ fibrillization. Inorganic Chemistry Frontiers, 2021, 8, 3501-3513.	3.0	6

#	Article	IF	Citations
3449	Detection of retinal and blood AÎ² oligomers with nanobodies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12193.	1.2	16
3451	Are Amyloids Infectious?. , 2009, , 171-180.		2
3452	Heat Shock Proteins at the Synapse: Implications for Functional Protection of the Nervous System. , 2008, , 239-254.		8
3453	Prion Protein Misfolding at the Synapse. , 2011, , 289-312.		1
3454	The Structure of Intrinsically Disordered Peptides Implicated in Amyloid Diseases: Insights from Fully Atomistic Simulations. Biological and Medical Physics Series, 2012, , 215-227.	0.3	8
3455	Disease Influence on BBB Transport in Neurodegenerative Disorders. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 591-634.	0.2	3
3456	NGF and BDNF Gene Therapy for Alzheimerâ€™s Disease. , 2016, , 33-64.		4
3457	Caenorhabditis elegans as a Model Organism for Dementia. Neuromethods, 2011, , 241-253.	0.2	1
3458	Establishing the Links Between AÎ² Aggregation and Cytotoxicity In Vitro Using Biophysical Approaches. Methods in Molecular Biology, 2012, 849, 227-243.	0.4	1
3459	Study of Neurotoxic Intracellular Calcium Signalling Triggered by Amyloids. Methods in Molecular Biology, 2012, 849, 289-302.	0.4	11
3460	Study Protein Folding and Aggregation Using Nonnatural Amino Acid p-Cyanophenylalanine as a Sensitive Optical Probe. Methods in Molecular Biology, 2013, 1081, 77-89.	0.4	4
3461	Amyloid Oligomers, Protofibrils and Fibrils. Sub-Cellular Biochemistry, 2019, 93, 471-503.	1.0	13
3462	Implications of Heparan Sulfate and Heparanase in Amyloid Diseases. Advances in Experimental Medicine and Biology, 2020, 1221, 631-645.	0.8	9
3463	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
3465	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. Current Clinical Pathology, 2015, , 9-29.	0.0	3
3466	SH3 Domains as Suitable Models to Study Amyloid Aggregation. , 2015, , 1-15.		1
3467	Why Alzheimerâ€™s is a Disease of Memory: Synaptic Targeting by Pathogenic AÎ² Oligomers (ADDLs). Research and Perspectives in Alzheimer's Disease, 2008, , 103-132.	0.1	4
3468	Is Alzheimerâ€™s a Disorder of Ageing and Why Donâ€™t Mice get it? The Centrality of Insulin Signalling to Alzheimerâ€™s Disease Pathology. Research and Perspectives in Alzheimer's Disease, 2010, , 129-152.	0.1	3

#	Article	IF	Citations
3469	Drug Development for Neurodegenerative Diseases. , 2015, , 183-216.		5
3470	Overview of Fibrillar and Oligomeric Assemblies of Amyloidogenic Proteins. , 2012, , 1-36.		3
3471	Role of Prion Protein Oligomers in the Pathogenesis of Transmissible Spongiform Encephalopathies. , 2012, , 319-335.		6
3472	Protein Misfolding and Toxicity in Dialysis-Related Amyloidosis. , 2012, , 377-405.		2
3473	Preparation and Structural Characterization of Pre-fibrillar Assemblies of Amyloidogenic Proteins. , 2012, , 61-102.		1
3474	Taurine-Carbohydrate Derivative Stimulates Fibrillogenesis of Amyloid-Î² and Reduce Alzheimer-Like Behaviors. Advances in Experimental Medicine and Biology, 2017, 975 Pt 1, 225-232.	0.8	3
3475	Secondary Metabolites from Rosemary (Rosmarinus officinalis L.): Structure, Biochemistry and Therapeutic Implications Against Neurodegenerative Diseases. , 2019, , 1-24.		8
3476	Protein Microgels from Amyloid Fibril Networks. Advances in Experimental Medicine and Biology, 2019, 1174, 223-263.	0.8	10
3477	Protein Nanofibrils as Storage Forms of Peptide Drugs and Hormones. Advances in Experimental Medicine and Biology, 2019, 1174, 265-290.	0.8	18
3478	The Central Nervous System. , 2010, , 1279-1344.		67
3479	Dimerization and Structural Stability of Amyloid Precursor Proteins Affected by the Membrane Microenvironments. Journal of Chemical Information and Modeling, 2017, 57, 1375-1387.	2.5	23
3480	Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting AÎ²₄₂ Protofibril. ACS Chemical Neuroscience, 2020, 11, 1841-1851.	1.7	73
3481	Scara1 deficiency impairs clearance of soluble amyloid-Î² by mononuclear phagocytes and accelerates Alzheimerâ€™s-like disease progression. Nature Communications, 2013, 4, 2030.	5.8	162
3482	Screening of small molecules using the inhibition of oligomer formation in Î±-synuclein aggregation as a selection parameter. Communications Chemistry, 2020, 3, .	2.0	27
3483	Multi-target-directed phenolâ€“triazole ligands as therapeutic agents for Alzheimer's disease. Chemical Science, 2017, 8, 5636-5643.	3.7	79
3484	Membrane affinity of individual toxic protein oligomers determined at the single-molecule level. Physical Chemistry Chemical Physics, 2020, 22, 14613-14620.	1.3	8
3485	Module 12: Signalling Defects and Disease. Cell Signalling Biology, 2014, 6, csb0001012.	1.0	10
3486	The role of fibril structure and surface hydrophobicity in secondary nucleation of amyloid fibrils. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25272-25283.	3.3	58

#	Article	IF	Citations
3487	Nanoelectrical characterization of individual exosomes secreted by AÎ²42-ingested cells using electrostatic force microscopy. Nanotechnology, 2021, 32, 025705.	1.3	7
3488	14 Amyloid Imaging and (What is â€œNormalâ€?) Aging. , 2009, , 191-244.		2
3499	Activation of CaMKIV by soluble amyloid-Î² _{1â€“42} impedes trafficking of axonal vesicles and impairs activity-dependent synaptogenesis. Science Signaling, 2017, 10, .	1.6	30
3500	Development of an Immunoassay for the Detection of Amyloid Beta 1-42 and Its Application in Urine Samples. Journal of Immunology Research, 2020, 2020, 1-9.	0.9	6
3501	Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. Journal of Clinical Investigation, 2008, 118, 2796-2807.	3.9	192
3502	A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. Journal of Clinical Investigation, 2009, 119, 1382-1395.	3.9	238
3503	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimerâ€™s diseaseâ€“associated AÎ² oligomers. Journal of Clinical Investigation, 2012, 122, 1339-1353.	3.9	697
3504	FcÎ³RIIb mediates amyloid-Î² neurotoxicity and memory impairment in Alzheimerâ€™s disease. Journal of Clinical Investigation, 2013, 123, 2791-2802.	3.9	105
3505	Protective effects of Huang-Lian-Jie-Du-Tang against AÎ²25â€“35-induced memory deficits and oxidative stress in rats. Journal of International Medical Research, 2020, 48, 030006051989385.	0.4	7
3506	Soluble amyloid beta levels are elevated in the white matter of AlzheimerÂ¿s patients, independent of cortical plaque severity. Acta Neuropathologica Communications, 2014, 2, 83.	2.4	33
3508	Non-ionotropic signaling by the NMDA receptor: controversy and opportunity. F1000Research, 2016, 5, 1010.	0.8	23
3509	Mitochondrial Complex I Inhibition Accelerates Amyloid Toxicity. Development & Reproduction, 2017, 21, 417-424.	0.1	13
3510	Misfolded Proteins in Neurodegenerative Dementias: Molecular Mechanisms. Dementia and Neurocognitive Disorders, 2012, 11, 38.	0.4	2
3511	Is the Conformational Ensemble of Alzheimerâ€™s AÎ²10-40 Peptide Force Field Dependent?. PLoS Computational Biology, 2017, 13, e1005314.	1.5	22
3512	A Drosophila Model of ALS: Human ALS-Associated Mutation in VAP33A Suggests a Dominant Negative Mechanism. PLoS ONE, 2008, 3, e2334.	1.1	109
3513	Mitochondrial Ca2+ Overload Underlies AÎ² Oligomers Neurotoxicity Providing an Unexpected Mechanism of Neuroprotection by NSAIDs. PLoS ONE, 2008, 3, e2718.	1.1	183
3514	Mechanisms of Hybrid Oligomer Formation in the Pathogenesis of Combined Alzheimer's and Parkinson's Diseases. PLoS ONE, 2008, 3, e3135.	1.1	233
3515	RNA Aptamers Generated against Oligomeric AÎ²40 Recognize Common Amyloid Aptatopes with Low Specificity but High Sensitivity. PLoS ONE, 2009, 4, e7694.	1.1	52

#	Article	IF	Citations
3516	How Cholesterol Constrains Glycolipid Conformation for Optimal Recognition of Alzheimer's Î² Amyloid Peptide (AÎ²1-40). PLoS ONE, 2010, 5, e9079.	1.1	101
3517	Regulation of Amyloid Precursor Protein Processing by the Beclin 1 Complex. PLoS ONE, 2010, 5, e11102.	1.1	175
3518	Amyloid-Î² Triggers the Release of Neuronal Hexokinase 1 from Mitochondria. PLoS ONE, 2010, 5, e15230.	1.1	86
3519	AÎ²40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease. PLoS ONE, 2010, 5, e15725.	1.1	96
3520	Calcium Ions Promote Formation of Amyloid Î²-Peptide (1â€“40) Oligomers Causally Implicated in Neuronal Toxicity of Alzheimer's Disease. PLoS ONE, 2011, 6, e18250.	1.1	103
3521	A Cyclic Undecamer Peptide Mimics a Turn in Folded Alzheimer Amyloid Î² and Elicits Antibodies against Oligomeric and Fibrillar Amyloid and Plaques. PLoS ONE, 2011, 6, e19110.	1.1	13
3522	Non-Conjugated Small Molecule FRET for Differentiating Monomers from Higher Molecular Weight Amyloid Beta Species. PLoS ONE, 2011, 6, e19362.	1.1	41
3523	PrPSc-Specific Antibodies with the Ability to Immunodetect Prion Oligomers. PLoS ONE, 2011, 6, e19998.	1.1	21
3524	Selenomethionine Incorporation into Amyloid Sequences Regulates Fibrillogenesis and Toxicity. PLoS ONE, 2011, 6, e27999.	1.1	17
3525	The Orthologue of SjÃ¶gren's Syndrome Nuclear Autoantigen 1 (SSNA1) in Trypanosoma brucei Is an Immunogenic Self-Assembling Molecule. PLoS ONE, 2012, 7, e31842.	1.1	13
3526	Excitability and Synaptic Alterations in the Cerebellum of APP/PS1 Mice. PLoS ONE, 2012, 7, e34726.	1.1	36
3527	The Role of Activity in Synaptic Degeneration in a Protein Misfolding Disease, Prion Disease. PLoS ONE, 2012, 7, e41182.	1.1	21
3528	Isoflurane Exposure during Mid-Adulthood Attenuates Age-Related Spatial Memory Impairment in APP/PS1 Transgenic Mice. PLoS ONE, 2012, 7, e50172.	1.1	24
3529	Alzheimer's Disease Related Markers, Cellular Toxicity and Behavioral Deficits Induced Six Weeks after Oligomeric Amyloid-Î² Peptide Injection in Rats. PLoS ONE, 2013, 8, e53117.	1.1	96
3530	Sirtuin1: A Promising Serum Protein Marker for Early Detection of Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e61560.	1.1	127
3531	NMDA-Receptor Activation but Not Ion Flux Is Required for Amyloid-Beta Induced Synaptic Depression. PLoS ONE, 2013, 8, e65350.	1.1	56
3532	Neurotoxicity of Prion Peptides Mimicking the Central Domain of the Cellular Prion Protein. PLoS ONE, 2013, 8, e70881.	1.1	20
3533	The Non-Structural NS1 Protein Unique to Respiratory Syncytial Virus: A Two-State Folding Monomer in Quasi-Equilibrium with a Stable Spherical Oligomer. PLoS ONE, 2013, 8, e74338.	1.1	18

#	Article	IF	Citations
3534	Development of a New DNA Vaccine for Alzheimer Disease Targeting a Wide Range of AÎ² Species and Amyloidogenic Peptides. PLoS ONE, 2013, 8, e75203.	1.1	25
3535	Suppression of Alzheimerâ€™s Disease-Related Phenotypes by Geranylgeranylacetone in Mice. PLoS ONE, 2013, 8, e76306.	1.1	35
3536	Aminostyrylbenzofuran Directly Reduces Oligomeric Amyloid-Î² and Reverses Cognitive Deficits in Alzheimer Transgenic Mice. PLoS ONE, 2014, 9, e95733.	1.1	12
3537	Aggregation of AÃŸ(25-35) on DOPC and DOPC/DHA Bilayers: An Atomic Force Microscopy Study. PLoS ONE, 2014, 9, e115780.	1.1	19
3538	Characterization of a Novel Mouse Model of Alzheimerâ€™s Diseaseâ€”Amyloid Pathology and Unique Î²-Amyloid Oligomer Profile. PLoS ONE, 2015, 10, e0126317.	1.1	23
3539	Endocytosed Î²2-Microglobulin Amyloid Fibrils Induce Necrosis and Apoptosis of Rabbit Synovial Fibroblasts by Disrupting Endosomal/Lysosomal Membranes: A Novel Mechanism on the Cytotoxicity of Amyloid Fibrils. PLoS ONE, 2015, 10, e0139330.	1.1	25
3540	Unique Properties of the Rabbit Prion Protein Oligomer. PLoS ONE, 2016, 11, e0160874.	1.1	4
3541	Palmitoylated APP Forms Dimers, Cleaved by BACE1. PLoS ONE, 2016, 11, e0166400.	1.1	23
3542	Concurrent Treatment with Taxifolin and Cilostazol on the Lowering of Î²-Amyloid Accumulation and Neurotoxicity via the Suppression of P-JAK2/P-STAT3/NF-ÎºB/BACE1 Signaling Pathways. PLoS ONE, 2016, 11, e0168286.	1.1	48
3543	MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors. PLoS ONE, 2017, 12, e0181799.	1.1	29
3544	Low-dose proton radiation effects in a transgenic mouse model of Alzheimerâ€™s disease â€“ Implications for space travel. PLoS ONE, 2017, 12, e0186168.	1.1	31
3545	Excessive aggregation of membrane proteins in the Martini model. PLoS ONE, 2017, 12, e0187936.	1.1	147
3546	Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimerâ€™s Disease. , 2015, 6, 400.		31
3547	Platelet-generated amyloid beta peptides in Alzheimer's disease and glaucoma. Histology and Histopathology, 2019, 34, 843-856.	0.5	28
3548	Electrophysiological Characterization of Networks and Single Cells in the Hippocampal Region of a Transgenic Rat Model of Alzheimerâ€™s Disease. ENeuro, 2019, 6, ENEURO.0448-17.2019.	0.9	18
3549	Large Soluble Oligomers of Amyloid Î²-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. Journal of Neuroscience, 2017, 37, 152-163.	1.7	19
3550	Î³â€Secretase cleavage of the Alzheimer risk factor <scp>TREM</scp> 2 is determined by its intrinsic structural dynamics. EMBO Journal, 2020, 39, e104247.	3.5	16
3551	The diphenylpyrazole compound anle138b blocks AÎ² channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine, 2018, 10, 32-47.	3.3	63

#	Article	IF	Citations
3552	THE ROLE OF BETA-AMYLOID IN NORM AND AT ALZHEIMER`S DISEASE. Fiziolohichnyi Zhurnal (Kiev,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	3
3553	Classification of ¹⁸F-Florbetaben Amyloid Brain PET Image using PCA-SVM. Biomedical Science Letters, 2019, 25, 99-106.	0.0	5
3556	Molecular dynamic of the complexes of (RADA)4 - the self-organizing ionic peptides. Mathematical Biology and Bioinformatics, 2011, 6, 92-101.	0.1	5
3557	Protein Folding, Misfolding, Aggregation And Amyloid Formation: Mechanisms of AÎ² Oligomer Mediated Toxicities. Journal of Biochemistry and Molecular Biology Research, 2015, 1, 36-45.	0.3	3
3558	AÎ² Plaques. Free Neuropathology, 2020, 1, .	2.4	21
3560	Phosphorylation of amyloid beta (AÎ²) peptides â€“ A trigger for formation of toxic aggregates in Alzheimer's disease. Aging, 2011, 3, 803-812.	1.4	142
3561	Activation of Î±7 nAChR by PNU-282987 improves synaptic and cognitive functions through restoring the expression of synaptic-associated proteins and the CaM-CaMKII-CREB signaling pathway. Aging, 2020, 12, 543-570.	1.4	27
3562	Riluzole: a therapeutic strategy in Alzheimerâ€™s disease by targeting the WNT/Î²-catenin pathway. Aging, 2020, 12, 3095-3113.	1.4	29
3563	Î³-Secretase regulates the Î±-secretase cleavage of the Alzheimerâ€™s disease, amyloid precursor protein. Matters, 0, , .	1.0	2
3564	Disrupting Self-Assembly and Toxicity of Amyloidogenic Protein Oligomers by “ Molecular Tweezers” - from the Test Tube to Animal Models. Current Pharmaceutical Design, 2014, 20, 2469-2483.	0.9	40
3565	The Effects of Soluble A.β Oligomers on Neurodegeneration in Alzheimer's Disease. Current Pharmaceutical Design, 2014, 20, 2506-2519.	0.9	30
3566	Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimerâ€™s Disease. Current Pharmaceutical Design, 2013, 19, 6635-6646.	0.9	34
3567	The Potential Effect of Fluorinated Compounds in the Treatment of Alzheimerâ€™s Disease. Current Pharmaceutical Design, 2015, 21, 5725-5735.	0.9	7
3568	The Main Targets Involved in Neuroprotection for the Treatment of Alzheimerâ€™s Disease and Parkinson Disease. Current Pharmaceutical Design, 2020, 26, 509-516.	0.9	9
3569	The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimerâ€™s Disease. Current Pharmaceutical Design, 2020, 26, 1345-1355.	0.9	3
3570	Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins. Current Organic Chemistry, 2013, 17, 580-593.	0.9	25
3571	Pathogenesis of Abeta Oligomers in Synaptic Failure. Current Alzheimer Research, 2013, 10, 316-323.	0.7	77
3572	Therapeutic Strategies Targeting Amyloid-Î² in Alzheimerâ€™s Disease. Current Alzheimer Research, 2019, 16, 418-452.	0.7	88

#	Article	IF	Citations
3573	Strategies Targeting Soluble Î²-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimerâ€™s Disease. Current Alzheimer Research, 2020, 16, 1132-1142.	0.7	5
3574	Mechanistic Modeling of Soluble AÎ² Dynamics and Target Engagement in the Brain by Anti-AÎ² mAbs in Alzheimerâ€™s Disease. Current Alzheimer Research, 2020, 17, 393-406.	0.7	6
3575	Targeting Pathological Amyloid Aggregates with Conformation-Sensitive Antibodies. Current Alzheimer Research, 2020, 17, 722-734.	0.7	12
3576	Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases. Current Topics in Medicinal Chemistry, 2013, 13, 2484-2490.	1.0	5
3577	Small Molecule Natural Products and Alzheimerâ€™s Disease. Current Topics in Medicinal Chemistry, 2019, 19, 187-204.	1.0	23
3578	Protein-Protein Interactions and Aggregation Inhibitors in Alzheimerâ€™s Disease. Current Topics in Medicinal Chemistry, 2019, 19, 501-533.	1.0	21
3579	Evidence Linking Protein Misfolding to Quality Control in Progressive Neurodegenerative Diseases. Current Topics in Medicinal Chemistry, 2020, 20, 2025-2043.	1.0	18
3580	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy. Current Neuropharmacology, 2013, 11, 491-498.	1.4	53
3581	Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimerâ€™s Disease. Current Neuropharmacology, 2014, 12, 2-36.	1.4	163
3582	Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. Current Neuropharmacology, 2019, 17, 563-579.	1.4	48
3583	Hepatocyte Growth Factor (HGF): Neurotrophic Functions and Therapeutic Implications for Neuronal Injury/Diseases. Current Signal Transduction Therapy, 2011, 6, 156-167.	0.3	22
3584	Cross Currents in Protein Misfolding Disorders: Interactions and Therapy. CNS and Neurological Disorders - Drug Targets, 2009, 8, 363-371.	0.8	61
3585	Protein Misfolding and Aggregation in Alzheimerâ€™s Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1280-1293.	0.8	138
3586	MicroRNA Landscape in Alzheimer’s Disease. CNS and Neurological Disorders - Drug Targets, 2015, 14, 168-175.	0.8	22
3587	The MMP-2/TIMP-2 System in Alzheimer Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 402-416.	0.8	14
3588	A Sensitive AÎ² Oligomerization Assay for Identification of Small Molecule Inhibitors. Open Biotechnology Journal, 2009, 3, 108-116.	0.6	5
3589	Insights into the Structure of Amyloid Fibrils. The Open Biology Journal, 2009, 2, 185-192.	0.5	13
3590	Current Strategies of Therapy in Alzheimer`s Disease. The Open Neuropsychopharmacology Journal, 2008, 1, 19-23.	0.3	3

#	Article	IF	Citations
3591	Methods for Studying and Structureâ€“Function Relationships of Non-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders. , 2014, , 291-374.		1
3592	Targeting of the Prion Protein to the Cytosol: Mechanisms and Consequences.. , 2010, , .		15
3594	Autophagy in neuroprotection and neurodegeneration: a question of balance. Future Neurology, 2008, 3, 309-323.	0.9	155
3595	Neuronal AÎ²42 is enriched in small vesicles at the presynaptic side of synapses. Life Science Alliance, 2018, 1, e201800028.	1.3	46
3596	Dementias Caused by Persistent Pathogens and the Protective Role of HLA Against them. Journal of Neurology and Neuromedicine, 2020, 5, 1-11.	0.9	2
3597	Tenuifolin Attenuates Amyloid-Î²42-Induced Neuroinflammation in Microglia Through the NF-ÎºB Signaling Pathway. Journal of Alzheimer's Disease, 2020, 76, 195-205.	1.2	20
3598	Age-Related Changes of Hippocampal Synaptic Plasticity in AÎ²PP-Null Mice are Restored by NGF Through p75NTR. Journal of Alzheimer's Disease, 2012, 33, 265-272.	1.2	11
3599	Oxidatively Modified Proteins: Cause and Control of Diseases. Applied Sciences (Switzerland), 2020, 10, 6419.	1.3	12
3600	Intracellular Calcium Dysregulation by the Alzheimerâ€™s Disease-Linked Protein Presenilin 2. International Journal of Molecular Sciences, 2020, 21, 770.	1.8	42
3601	Extracellular Amyloid Deposits in Alzheimerâ€™s and Creutzfeldtâ€“Jakob Disease: Similar Behavior of Different Proteins?. International Journal of Molecular Sciences, 2021, 22, 7.	1.8	15
3602	Zn2+ Interaction with Amyloid-Î²: Affinity and Speciation. Molecules, 2019, 24, 2796.	1.7	13
3603	Alzheimerâ€™s Disease: Current Status of Etiopathogenesis and Therapeutic Strategies. Pakistan Journal of Biological Sciences, 2011, 14, 257-272.	0.2	27
3604	Novel insights into the function of the conserved domain of the CAP superfamily of proteins. AIMS Biophysics, 2016, 3, 232-246.	0.3	13
3606	Î²-Amyloid precursor protein (APP) and the human diseases. AIMS Neuroscience, 2019, 6, 273-281.	1.0	28
3608	Metabolic alteration of neuroactive steroids and protective effect of progesterone in Alzheimer's disease-like rats. Neural Regeneration Research, 2013, 8, 2800-10.	1.6	27
3609	Inhibitory Activity of Hispidin Derivatives Isolated from Inonotus obliquus on Amyloid Î² Aggregation. Heterocycles, 2017, 94, 1280.	0.4	7
3610	Plant-Derived Compounds and Their Potential Role in Drug Development. International Journal of Biomedical and Clinical Engineering, 2018, 7, 53-66.	0.2	1
3611	Amyloid Beta Annular Protofibrils in Cell Processes and Synapses Accumulate with Aging and Alzheimer-Associated Genetic Modification. International Journal of Alzheimer's Disease, 2009, 2009, 1-7.	1.1	18

#	Article	IF	Citations
3612	Low-Intensity Light Therapy (1068 nm) Protects CAD Neuroblastoma Cells from ÃŽÂ²-Amyloid-Mediated Cell Death. Biology and Medicine (Aligarh), 2014, 01, .	0.3	3
3613	Newly Designed Magnetic and Non-Magnetic Nanoparticles for Potential Diagnostics and Therapy of Alzheimer?s Disease. Journal of Biotechnology & Biomaterials, 2013, 03, .	0.3	6
3614	Melatonin: Therapeutic Intervention in Mild Cognitive Impairment and Alzheimer Disease. Journal of Neurology & Neurophysiology, 2013, 04, .	0.1	8
3615	FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimerâ€™s Disease. Advances in Molecular Imaging, 2014, 04, 15-26.	0.3	31
3616	Selective manipulation of aging: a novel strategy for the treatment of neurodegenerative disorders. Swiss Medical Weekly, 2014, 144, w13917.	0.8	11
3617	Gains and losses on the road to understanding Alzheimerâ€™s disease. Swiss Medical Weekly, 2015, 145, w14233.	0.8	6
3618	It All Starts at the Ends: Multifaceted Involvement of C- and N-Terminally Modified Cholinesterases in Alzheimerâ€™s Disease. Rambam Maimonides Medical Journal, 2010, 1, e0014.	0.4	9
3619	Amyloid pore-channel hypothesis: effect of ethanol on aggregation state using frog oocytes for an Alzheimer's disease study. BMB Reports, 2015, 48, 13-18.	1.1	16
3620	Cerebrospinal fluid and blood biomarkers in Alzheimerâ€™s disease. World Journal of Psychiatry, 2011, 1, 8.	1.3	34
3621	Pin1 Protects Against Alzheimer's Disease: One Goal, Multiple Mechanisms. , 0, , .		2
3622	Control of the structural landscape and neuronal proteotoxicity of mutant Huntingtin by domains flanking the polyQ tract. ELife, 2016, 5, .	2.8	62
3623	Fibrillar AÎ² triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. ELife, 2020, 9, .	2.8	80
3624	Surfactant protein C peptides with salt-bridges (â€œion-locksâ€) promote high surfactant activities by mimicking theÎ±-helix and membrane topography of the native protein. PeerJ, 2014, 2, e485.	0.9	17
3625	Implantable Systems for Continuous Liquorpheresis and CSF Replacement. Cureus, 2017, 9, e1022.	0.2	9
3626	Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimerâ€™s Disease Pathogenesis. Molecular Biology, 2021, 55, 670-682.	0.4	10
3627	Cognitive Disorders and Oxidative Stress Status Attenuated by Chrysophyllum Perpulchrum Extract in Alzheimer- like Rat Model of Intracerebroventricular AÎ²1-40 injection. Biomedical and Pharmacology Journal, 2021, 14, 1175-1187.	0.2	0
3628	Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapy for Alzheimerâ€™s Disease: Progress and Opportunity. Membranes, 2021, 11, 796.	1.4	11
3629	The Hsp70â€“Hsp90 go-between Hop/Stip1/Sti1 is a proteostatic switch and may be a drug target in cancer and neurodegeneration. Cellular and Molecular Life Sciences, 2021, 78, 7257-7273.	2.4	26

#	Article	IF	Citations
3630	Finite-time stability and optimal control of a stochastic reaction-diffusion model for Alzheimerâ€™s disease with impulse and time-varying delay. Applied Mathematical Modelling, 2022, 102, 511-539.	2.2	12
3631	The Structure and Functions of PRMT5 in Human Diseases. Life, 2021, 11, 1074.	1.1	27
3632	Interactions of the AÎ²(1â€“42) Peptide with Boron Nitride Nanoparticles of Varying Curvature in an Aqueous Medium: Different Pathways to Inhibit Î²-Sheet Formation. Journal of Physical Chemistry B, 2021, 125, 11159-11178.	1.2	8
3633	Protein Misfolding, a Common Mechanism in the Pathogenesis of Neurodegenerative Diseases. , 2008, , 285-304.		0
3634	AÎ²-Induced Toxicity Mediated by Caspase Cleavage of the Amyloid Precursor Protein (APP). Research and Perspectives in Alzheimer's Disease, 2008, , 145-155.	0.1	0
3635	Small-molecule aggregation inhibitors reduce excess amyloid in a trisomy 16 mouse cortical cell line. Biological Research, 2008, 41, .	1.5	2
3636	La maladie dâ€™Alzheimer : des lÃ©sions cÃ©rÃ©brales aux perspectives thÃ©rapeutiques. Bulletin De L'Academie Nationale De Medecine, 2008, 192, 363-380.	0.0	6
3637	Alternative pathways for production of Î²-amyloid peptides of Alzheimer's disease. Biological Chemistry, 2008, .	1.2	1
3638	Intramembrane Proteolysis by Î³-Secretase and Signal Peptide Peptidases. Research and Perspectives in Alzheimer's Disease, 2009, , 11-26.	0.1	0
3639	Alzheimerâ€™s Disease: Neurodegeneration. , 2009, , 275-281.		0
3640	Proteases In Î’-Amyloid Metabolism: Potential Therapeutic Targets Against Alzheimerâ€˜S Disease. , 2009, , 385-402.		0
3641	Prion protein. The AFCS-nature Molecule Pages, 0, , .	0.2	3
3643	Introduction to Part V. , 2009, , 393-394.		0
3644	Pathogenesis of Systemic Amyloidoses. , 2010, , 49-64.		0
3646	Neurochemical Aspects of Neurodegenerative Diseases. , 2010, , 249-324.		0
3647	One-Compound-Multi-Targets at Amyloid Î² Cascade Offered By Bis(7)-Cognitin, a Novel Anti-Alzheimerâ€™s Dimer. , 2010, , 165-183.		0
3648	3, 4-Dihydroxyphenylacetic Acid (DOPAC) Impairs Î±-Synuclein Interaction with Lipids. The Open Proteomics Journal, 2010, 3, 1-7.	0.4	1
3649	VAPB Aggregates and Neurodegeneration. , 2011, , 215-231.		0

#	Article	IF	Citations
3651	Future treatments of memory loss. , 2011, , 199-213.		0
3652	Demenzen. , 2011, , 925-953.		0
3653	Pathophysiology of Late Onset Alzheimer Disease. , 0, , .		0
3654	Role of Central Insulin-Like Growth Factor-1 Receptor Signalling in Ageing and Endocrine Regulation. , 0, , .		0
3655	Effect of cadmium ions on amyloid beta peptide 1-42 channel activity. Journal of Environmental Chemistry and Ecotoxicology, 2011, 3, .	0.2	0
3656	Diagnosis of Dementia Using Nuclear Medicine Imaging Modalities. , 0, , .		0
3657	Structure-Toxicity Relationships of Amyloid Peptide Oligomers. , 0, , .		1
3659	Oligomers of Î±-Synuclein in the Pathogenesis of Parkinsonâ€™s Disease. , 2012, , 189-216.		0
3661	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. , 2012, , 9-29.		0
3662	Alzheimer-Demenz und weitere neurodegenerative Erkrankungen. , 2012, , 267-279.		0
3664	Proteomics Analysis of Kinetically Stable Proteins. , 0, , .		0
3665	The Amyloid _-Protein and Alzheimer's Disease. Frontiers in Neuroscience, 2012, , 1-85.	0.0	0
3666	New Small Molecule Drug Discovery for Alzheimer's Disease. Frontiers in Neuroscience, 2012, , 163-210.	0.0	0
3667	The Current Status of Alzheimer's Disease Treatment. Frontiers in Neuroscience, 2012, , 117-161.	0.0	0
3669	Biofunctional peptide design. Amino Acids, Peptides and Proteins, 2013, , 79-121.	0.7	0
3670	Post Operative Effects: Anesthesia. Journal of Anesthesia & Clinical Research, 2013, 04, .	0.1	1
3671	Amyloid-Î² Transmissibility. Research and Perspectives in Alzheimer's Disease, 2013, , 71-86.	0.1	0
3672	Brain Hypometabolism, Oxidative Stress, Maternal Transmission, and Risk of Late-Onset Alzheimerâ€™s Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 137-157.	0.4	0

#	Article	IF	Citations
3673	Herpes Simplex Virus 1 (HSV-1)-Based Vectors. Neuromethods, 2014, , 51-93.	0.2	0
3676	Update on the Free Radical Theory of Aging â€“ The Role of Oxidative Stress in Age-Related Hearing Loss. , 2014, , 3581-3598.		1
3677	Lessons from In Vivo Imaging. , 2014, , 81-114.		0
3678	Quinolinate and Related Excitotoxins: Mechanisms of Neurotoxicity and Disease Relevance. , 2014, , 1543-1565.		0
3679	Correspondence amongst the PENO Test Battery Cognitive Results and Hippocampal Lesions in Alzheimerâ€™s Disease. Advances in Aging Research, 2014, 03, 239-251.	0.3	0
3680	Structure and Function of Stefin B Oligomers â€“ Important Role in Amyloidogenesis. , 0, , .		0
3681	A Mini Review on AÎ² Oligomers and its Pathogencity. Journal of the Chosun Natural Science, 2014, 7, 79-86.	0.0	0
3682	Brain Aging as a Cause of Alzheimerâ€™s Disease. , 2015, , 305-318.		0
3683	Verhaltens- und Neurogenetik. , 2015, , 667-735.		0
3684	Effects of Long Term Consumption of High Calorie Diet on Neurological Disorders. , 2015, , 245-275.		0
3685	Protein Misfolding and Amyloid Formation in Alzheimerâ€™s Disease. , 2015, , 119-135.		0
3686	Thermodynamics and Kinetics of Amyloid Aggregation from Atomistic Simulations. , 2015, , 29-45.		0
3687	Age-Related Hearing Loss: Mitochondrial Biochemical Pathways and Molecular Targets. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 273-288.	0.4	1
3688	Semaphorins and Neurodegenerative Disorders. , 2015, , 189-205.		0
3689	Gene Therapy for Alzheimerâ€™s Disease. , 2015, , 1217-1232.		0
3690	The effect of treadmill exercise on neuroinflammation and neuronal cell death in intracerebroventricular streptozotocin-induced cognitive impairment in rats. Korean Journal of Sport Science, 2015, 26, 50-60.	0.0	0
3691	New Frontiers in Alzheimer's Disease Diagnosis. , 0, , .		0
3692	Intraneuronal Amyloid and Cognitive Impairment. , 2016, , 133-137.		0

#	Article	IF	Citations
3693	Liver Disease in Î±1-Antitrypsin Deficiency. Respiratory Medicine, 2016, , 111-140.	0.1	0
3694	Immunotherapy and Vaccines. , 2016, , 441-464.		0
3696	Bio-Targets for Polyionic Glucan Derivatives and Their Nano- Therapeutic Systems. , 2016, , 487-513.		0
3698	Small Molecule-Assisted PET: Approaches to Imaging of Conformational Diseases of the Brain. World Journal of Neuroscience, 2017, 07, 106-139.	0.1	1
3699	Antioxidants and Their Mechanisms of Action. , 2017, , 561-584.		1
3700	The Increase of the Pro-inflammatory Double Negative (IgDâ^'CD27â^') B Cell Subset Is Related to the Severity of Alzheimerâ€™s Disease. , 2018, , 1-13.		0
3701	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		0
3703	Solving the Puzzle of Neurodegeneration. , 2018, , 1-22.		2
3704	Cellular and Molecular Signalling Mechanisms in Neuronal Injury and Neurodegeneration. SSRN Electronic Journal, 0, , .	0.4	0
3712	The Increase of the Pro-inflammatory Double Negative (IgDâ^'CD27â^') B Cell Subset Is Related to the Severity of Alzheimerâ€™s Disease. , 2019, , 2305-2317.		0
3713	Studies toward Identifying the Pharmacophore of L-755,807 for Amyloid-Î² Aggregation Inhibitory Activity. Heterocycles, 2019, 98, 1769.	0.4	1
3718	Something Old, Something New and Something Used in Alzheimer's; the Idea of Pore, Ethanol and the Use of Oocytes to Understand the Disease. Current Chemical Biology, 2019, 13, 105-109.	0.2	1
3722	Influencia de la enfermedad de Alzheimer en los sistemas de neurotransmisiÃ³n sinÃ¡ptica. Revista Medica Sinergia, 2020, 5, e442.	0.0	1
3725	The Î²-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2020, 19, 184-194.	0.8	5
3726	Evaluation of Amyloid Polypeptide Aggregation Inhibition and Disaggregation Activity of A-Type Procyanidins. Pharmaceuticals, 2021, 14, 1118.	1.7	7
3727	Gene Therapy Strategy for Alzheimerâ€™s and Parkinsonâ€™s Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells. International Journal of Molecular Sciences, 2021, 22, 11550.	1.8	10
3729	Alzheimerâ€™s disease and Down syndrome. , 2020, , 283-297.		0
3731	The effects of lead exposure on the expression of IGF1R, IGFBP3, AÎ²40, and AÎ²42 in PC12 cells. Journal of Trace Elements in Medicine and Biology, 2022, 69, 126877.	1.5	2

#	Article	IF	Citations
3732	Excess activity of 3-hydroxykynurenine, quinolinic acid, and other toxic tryptophan metabolites in neurogenerative diseases and other protein misfolding diseases. , 2022, , 115-130.		0
3733	Tau and its interactions with other proteins in neurodegenerative diseases. , 2020, , 447-462.		1
3734	AÎ²42-Î±7-like nicotinic acetylcholine receptors and Alzheimerâ€™s disease. , 2020, , 457-471.		0
3735	Regulation of liquidâ€“liquid phase separation with focus on post-translational modifications. Chemical Communications, 2021, 57, 13275-13287.	2.2	49
3736	APP palmitoylation is involved in the increase in AÎ²1-42 induced by aluminum. Brain Research, 2021, 1774, 147709.	1.1	2
3737	Model Identifies Genetic Predisposition of Alzheimerâ€™s Disease as Key Decider in Cell Susceptibility to Stress. International Journal of Molecular Sciences, 2021, 22, 12001.	1.8	1
3739	Dendritic Organelles for Postsynaptic Trafficking. , 2008, , 205-249.		1
3740	Mechanistic Links Between Aging and Aggregation-Mediated Proteotoxicity: Role of HSF-1 and DAF-16. , 2008, , 337-348.		0
3741	Neurobiologie psychischer StÃ¶rungen. , 2008, , 233-340.		0
3743	Life inter vivos: modeling regeneration in the relation between bodies and biomaterials. BioSocieties, 0, , 1.	0.8	0
3744	Potential of sugi wood diterpenes as an Alzheimer's disease preventive and therapeutic drug by the Î²-amyloid toxicity reduction effect. Journal of Wood Science, 2020, 66, .	0.9	1
3745	Promising molecular targets for pharmacological therapy of neurodegenerative pathologies. Acta Naturae, 2020, 12, 60-80.	1.7	3
3756	Alzheimer's disease: diverse aspects of mitochondrial malfunctioning. International Journal of Clinical and Experimental Pathology, 2010, 3, 570-81.	0.5	75
3758	Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 114-21.	0.4	29
3759	Cyclic peptidomimetic lead compounds to reduce neurotoxicity and associated oxidative stress in Alzheimer's disease. International Journal of Biomedical Science, 2010, 6, 216-24.	0.5	0
3760	Construction of human Fab library and screening of a single-domain antibody of amyloid-beta 42 oligomers. Neural Regeneration Research, 2013, 8, 3107-15.	1.6	5
3764	Neural stem/progenitor cells in Alzheimer's disease. Yale Journal of Biology and Medicine, 2016, 89, 23-35.	0.2	47
3765	Prion neurotoxicity: insights from prion protein mutants. Current Issues in Molecular Biology, 2010, 12, 51-61.	1.0	51

#	Article	IF	Citations
3766	A genetically immortalized human stem cell line: a promising new tool for Alzheimer's disease therapy. EXCLI Journal, 2015, 14, 1135-14.	0.5	2
3768	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. Colombia Medica, 2016, 47, 203-212.	0.7	21
3769	Calcium Channel Blockade Ameliorates Endoplasmic Reticulum Stress in the Hippocampus Induced by Amyloidopathy in the Entorhinal Cortex. Iranian Journal of Pharmaceutical Research, 2019, 18, 1466-1476.	0.3	2
3770	Environmental factors modulating protein conformations and their role in protein aggregation diseases. Toxicology, 2022, 465, 153049.	2.0	13
3771	Ethanol Alleviates Amyloid-Î²-Induced Toxicity in an Alzheimerâ€™s Disease Model of Caenorhabiditis elegans. Frontiers in Aging Neuroscience, 2021, 13, 762659.	1.7	6
3772	Single-Molecule Localization Microscopy of 3D Orientation and Anisotropic Wobble Using a Polarized Vortex Point Spread Function. Journal of Physical Chemistry B, 2021, 125, 12718-12729.	1.2	26
3773	Advances in Proteasome Enhancement by Small Molecules. Biomolecules, 2021, 11, 1789.	1.8	13
3774	Positron Emission Tomography in Animal Models of Alzheimerâ€™s Disease Amyloidosis: Translational Implications. Pharmaceuticals, 2021, 14, 1179.	1.7	13
3775	Myelinosome Organelles in the Retina of R6/1 Huntington Disease (HD) Mice: Ubiquitous Distribution and Possible Role in Disease Spreading. International Journal of Molecular Sciences, 2021, 22, 12771.	1.8	4
3776	The Interplay of the Unfolded Protein Response in Neurodegenerative Diseases: A Therapeutic Role of Curcumin. Frontiers in Aging Neuroscience, 2021, 13, 767493.	1.7	12
3777	Bcl-2-Homology-Only Proapoptotic Peptides Modulate Î²-Amyloid Aggregation and Toxicity. ACS Chemical Neuroscience, 2021, 12, 4554-4563.	1.7	1
3778	Accurate Description of Proteinâ€“Protein Recognition and Protein Aggregation with the Implicit-Solvent-Based PACSAB Protein Model. Polymers, 2021, 13, 4172.	2.0	1
3779	Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimerâ€™s Disease and Related Dementias. Methods in Molecular Biology, 2022, 2383, 447-457.	0.4	0
3780	Magnetic Resonance Imaging in Animal Models of Alzheimerâ€™s Disease Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 12768.	1.8	18
3781	Proteotoxicity and Autophagy in Neurodegenerative and Cardiovascular Diseases. , 2022, , 219-237.		0
3782	Role of Receptors in Relation to Plaques and Tangles in Alzheimerâ€™s Disease Pathology. International Journal of Molecular Sciences, 2021, 22, 12987.	1.8	12
3783	Discovery of a novel pseudo Î²-hairpin structure of N-truncated amyloid-Î² for use as a vaccine against Alzheimerâ€™s disease. Molecular Psychiatry, 2021, , .	4.1	11
3784	Oligomeric AÎ²25â€“35 induces the tyrosine phosphorylation of PSD-95 by SrcPTKs in rat hippocampal CA1 subfield. International Journal of Neuroscience, 2023, 133, 888-895.	0.8	1

#	Article	IF	Citations
3785	Biological and methodological complexities of betaâ€amyloid peptide: Implications for Alzheimerâ€™s disease research. Journal of Neurochemistry, 2022, 160, 434-453.	2.1	12
3786	Bio-nano Interface and Its Potential Application in Alzheimerâ€™s Disease. , 2022, , 209-224.		2
3787	Circulatory GSK-3Î²: Blood-Based Biomarker and Therapeutic Target for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 85, 249-260.	1.2	5
3788	Pyroptosis: A New Insight Into Eye Disease Therapy. Frontiers in Pharmacology, 2021, 12, 797110.	1.6	23
3789	Liposomes: An Emerging Carrier for Brain Targetting and Delivery. SSRN Electronic Journal, 0, , .	0.4	0
3790	Ginsenoside F1 Protects the Brain against Amyloid Beta-Induced Toxicity by Regulating IDE and NEP. Life, 2022, 12, 58.	1.1	14
3791	Plant-Derived Compounds and Their Potential Role in Drug Development. , 2022, , 502-517.		0
3792	Crosslinked zwitterionic polymeric ionic liquid-functionalized nitinol wires for fiber-in-tube solid-phase microextraction and UHPLC-MS/MS as an amyloid beta peptide binding protein assay in biological fluids. Analytica Chimica Acta, 2022, 1193, 339394.	2.6	10
3793	The molecular mechanism, targets, and novel molecules in the treatment of Alzheimerâ€™s disease. Bioorganic Chemistry, 2022, 119, 105562.	2.0	26
3794	Role of Chain Extension in the Ability of Peptide Oligomers to Damage the Lipid Membrane Studied by the <scp>l</scp>- to <scp>d</scp>-Amino Acid Substitutions of hIAPP_{18â€“27}. Journal of Physical Chemistry B, 2020, 124, 10147-10156.	1.2	0
3795	Synapses, Microglia, and Lipids in Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2021, 15, 778822.	1.4	10
3796	Visualizing the Multistep Process of Protein Aggregation in Live Cells. Accounts of Chemical Research, 2022, 55, 381-390.	7.6	26
3797	Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies. Alzheimer's Research and Therapy, 2022, 14, 16.	3.0	5
3798	Effects of Î±-Lipoic Acid on Phagocytosis of Oligomeric Beta-Amyloid1â€“42 in BV-2 Mouse Microglial Cells. Frontiers in Aging Neuroscience, 2021, 13, 788723.	1.7	2
3799	Regulation of neuronal autophagy and the implications in neurodegenerative diseases. Neurobiology of Disease, 2022, 162, 105582.	2.1	23
3800	Administration of mucuna beans (Mucuna pruriences (L.) DC. var. utilis) improves cognition and neuropathology of 3â€‰Ã—â€‰Tg-AD mice. Scientific Reports, 2022, 12, 996.	1.6	4
3801	Congenital cataract-causing mutation Î²B1-L116P is prone to amyloid fibrils aggregation and protease degradation with low structural stability. International Journal of Biological Macromolecules, 2022, 195, 475-482.	3.6	6
3802	The amyloid-Î²1â€“42-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution. Journal of Biological Chemistry, 2022, 298, 101483.	1.6	1

#	Article	IF	Citations
3803	The role of membranes in function and dysfunction of intrinsically disordered amyloidogenic proteins. Advances in Protein Chemistry and Structural Biology, 2022, 128, 397-434.	1.0	1
3804	Multifocal Cerebral Microinfarcts Modulate Early Alzheimerâ€™s Disease Pathology in a Sex-Dependent Manner. Frontiers in Immunology, 2021, 12, 813536.	2.2	15
3805	A molecular view of human amyloid-Î² folds. Science, 2022, 375, 147-148.	6.0	7
3806	A Disulfide-Stabilized AÎ² that Forms Dimers but Does Not Form Fibrils. Biochemistry, 2022, 61, 252-264.	1.2	4
3807	Integrated Stress Response in Neuronal Pathology and in Health. Biochemistry (Moscow), 2022, 87, S111-S127.	0.7	2
3808	Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia. Frontiers in Aging Neuroscience, 2021, 13, 751897.	1.7	12
3809	Atomic view of an amyloid dodecamer exhibiting selective cellular toxic vulnerability in acute brain slices. Protein Science, 2021, , .	3.1	8
3810	Herbal Mixture of Carthamus tinctorius L. Seed and Taraxacum coreanum Attenuates Amyloid Beta-Induced Cognitive Dysfunction In Vivo. Foods, 2022, 11, 142.	1.9	3
3811	Nanoparticles in Combating Neuronal Dysregulated Signaling Pathways: Recent Approaches to the Nanoformulations of Phytochemicals and Synthetic Drugs Against Neurodegenerative Diseases. International Journal of Nanomedicine, 2022, Volume 17, 299-331.	3.3	17
3812	Revisiting APP secretases: an overview on the holistic effects of retinoic acid receptor stimulation in APP processing. Cellular and Molecular Life Sciences, 2022, 79, 101.	2.4	7
3813	Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases. Journal of Biological Chemistry, 2022, 298, 101478.	1.6	12
3814	Molecular insights into the primary nucleation of polymorphic amyloid Î² dimers in <scp>DOPC</scp> lipid bilayer membrane. Protein Science, 2022, 31, .	3.1	17
3815	Anti-Amyloidogenic and Fibril-Disaggregating Potency of the Levodopa-Functionalized Gold Nanoroses as Exemplified in a Diphenylalanine-Based Amyloid Model. Bioconjugate Chemistry, 2022, 33, 397-410.	1.8	5
3816	Siteâ€Directed Chemical Modification of Amyloid by Polyoxometalates for Inhibition of Protein Misfolding and Aggregation. Angewandte Chemie - International Edition, 2022, 61, .	7.2	26
3817	Selective neurodegeneration of the hippocampus caused by chronic cerebral hypoperfusion: F-18 FDG PET study in rats. PLoS ONE, 2022, 17, e0262224.	1.1	4
3818	Siteâ€Directed Chemical Modification of Amyloid by Polyoxometalates for Inhibition of Protein Misfolding and Aggregation. Angewandte Chemie, 2022, 134, .	1.6	4
3819	Strategic Design of Amyloid-Î² Species Fluorescent Probes for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2022, 13, 540-551.	1.7	23
3820	Î±-synuclein-assisted oligomerization of Î²-amyloid (1â€“42). Archives of Biochemistry and Biophysics, 2022, 717, 109120.	1.4	10

#	Article	IF	Citations
3821	Progress in Nanomaterials-based Electrochemical Biosensors for Beta-amyloid Peptides as the Biomarkers of Alzheimer's Disease. International Journal of Electrochemical Science, 0, , ArticleID:220342.	0.5	0
3822	Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimerâ€™s disease: an overview of pre-clinical studies focused on Î²-amyloid peptide. Food Science and Human Wellness, 2022, 11, 483-493.	2.2	29
3823	The gut metabolite, trimethylamine N-oxide inhibits protein folding by affecting cisâ€“trans isomerization and induces cell cycle arrest. Cellular and Molecular Life Sciences, 2022, 79, 12.	2.4	4
3824	A Review of the Current Mammalian Models of Alzheimerâ€™s Disease and Challenges That Need to Be Overcome. International Journal of Molecular Sciences, 2021, 22, 13168.	1.8	31
3825	Phosphorylation mapping of Laminin Î²1-chain: Kinases in association with active sites. Journal of Biosciences, 2019, 44, .	0.5	0
3826	Engineering of donor-acceptor-donor curcumin analogues as near-infrared fluorescent probes for in vivo imaging of amyloid-Î² species. Theranostics, 2022, 12, 3178-3195.	4.6	16
3827	Molecular dynamics simulations of amyloid-Î² peptides in heterogeneous environments. Biophysics and Physicobiology, 2022, 19, n/a.	0.5	3
3828	Computational Identification and Design of Complementary Î²-Strand Sequences. Methods in Molecular Biology, 2022, 2405, 83-94.	0.4	1
3829	Protective effects of Populus tomentiglandulosa against cognitive impairment by regulating oxidative stress in an amyloid beta_{25â€“35}-induced Alzheimer's disease mouse model. Nutrition Research and Practice, 2022, 16, 173.	0.7	2
3830	All-Atom Molecular Dynamics Simulation Methods for the Aggregation of Protein and Peptides: Replica Exchange/Permutation and Nonequilibrium Simulations. Methods in Molecular Biology, 2022, 2340, 197-220.	0.4	5
3831	Characterization of Amyloidogenic Peptide Aggregability in Helical Subspace. Methods in Molecular Biology, 2022, 2340, 401-448.	0.4	3
3832	Inhibition of Amyloid Î² Aggregation by p-Terphenyl Derivatives Isolated from Boletopsis leucomelas. Heterocycles, 2022, 104, 925.	0.4	3
3833	Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 805063.	1.7	2
3834	Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. International Journal of Molecular Sciences, 2022, 23, 2011.	1.8	22
3835	Clearâ€headed into old age: Resilience and resistance against brain agingâ€”A <scp>PET</scp> imaging perspective. Journal of Neurochemistry, 2023, 164, 325-345.	2.1	3
3836	Alzheimer's disease amyloid-Î² pathology in the lens of the eye. Experimental Eye Research, 2022, 221, 108974.	1.2	5
3837	Advances in stem cell therapy in Alzheimerâ€™s disease: a comprehensive clinical trial review. Stem Cell Investigation, 2022, 9, 2-2.	1.3	8
3838	TAR DNAâ€binding protein 43 oligomers in physiology and pathology. IUBMB Life, 2022, 74, 794-811.	1.5	10

#	Article	IF	Citations
3839	Alzheimerâ€™s Disease: An Update and Insights Into Pathophysiology. Frontiers in Aging Neuroscience, 2022, 14, 742408.	1.7	65
3840	Relationship between Plasma Level of Beta-amyloid, Alpha-synuclein, and Tau Protein with Cognitive Impairment in Parkinson Disease. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 663-667.	0.1	2
3841	Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice. International Journal of Molecular Sciences, 2022, 23, 2757.	1.8	10
3842	Chronic PPARÎ³ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition. Frontiers in Aging Neuroscience, 2022, 14, 854031.	1.7	5
3843	Novel Amylin Analogues Reduce Amyloid-Î² Cross-Seeding Aggregation and Neurotoxicity. Journal of Alzheimer's Disease, 2022, , 1-18.	1.2	2
3844	Endogenous Human Proteins Interfering with Amyloid Formation. Biomolecules, 2022, 12, 446.	1.8	9
3845	Lipid Homeostasis and Its Links With Protein Misfolding Diseases. Frontiers in Molecular Neuroscience, 2022, 15, 829291.	1.4	11
3846	Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimerâ€™s Disease Neuropathology. Journal of Alzheimer's Disease, 2022, 87, 51-81.	1.2	14
3847	Effect of Sirtuin-1 and Wnt/Î²-Catenin Signaling Pathway in Rat Model of Spinal Cord Injury. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-7.	0.7	5
3848	The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity. EMBO Molecular Medicine, 2022, 14, e13952.	3.3	16
3849	Admixture Mapping of Alzheimerâ€™s disease in Caribbean Hispanics identifies a new locus on 22q13.1. Molecular Psychiatry, 2022, 27, 2813-2820.	4.1	12
3850	Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action. Biomedicine and Pharmacotherapy, 2022, 149, 112877.	2.5	54
3851	The prion protein and its ligands: Insights into structure-function relationships. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119240.	1.9	10
3852	Telomerase reverse transcriptase preserves neuron survival and cognition in Alzheimerâ€™s disease models. Nature Aging, 2021, 1, 1162-1174.	5.3	24
3853	Connecting the dots: The boons and banes of network modeling. Patterns, 2021, 2, 100374.	3.1	3
3854	Aberrant role of pyruvate kinase M2 in the regulation of gamma-secretase and memory deficits in Alzheimerâ€™s disease. Cell Reports, 2021, 37, 110102.	2.9	19
3855	Lack of p62 Impairs Glycogen Aggregation and Exacerbates Pathology in a Mouse Model of Myoclonic Epilepsy of Lafora. Molecular Neurobiology, 2022, 59, 1214-1229.	1.9	4
3856	Amyloid-like aggregating proteins cause lysosomal defects in neurons via gain-of-function toxicity. Life Science Alliance, 2022, 5, e202101185.	1.3	13

#	Article	IF	Citations
3857	Examining the Ensembles of Amyloid-Î² Monomer Variants and Their Propensities to Form Fibers Using an Energy Landscape Visualization Method. Journal of Physical Chemistry B, 2022, 126, 93-99.	1.2	17
3858	Habituation of Somatosensory Evoked Potentials in Patients with Alzheimerâ€™s Disease and Those with Vascular Dementia. Medicina (Lithuania), 2021, 57, 1364.	0.8	0
3859	Nanocomposites Facilitate the Removal of AÎ² Fibrils for Neuroprotection. Chemical Research in Chinese Universities, 0, , 1.	1.3	1
3861	EDEM1 Regulates Amyloid Precursor Protein (APP) Metabolism and Amyloid-Î² Production. International Journal of Molecular Sciences, 2022, 23, 117.	1.8	7
3863	Evidence for a Strong Relationship between the Cytotoxicity and Intracellular Location of Î²-Amyloid. Life, 2022, 12, 577.	1.1	3
3864	Molecular Dynamics Simulation Studies on the Aggregation of Amyloid-Î² Peptides and Their Disaggregation by Ultrasonic Wave and Infrared Laser Irradiation. Molecules, 2022, 27, 2483.	1.7	8
3865	AN ENANTIOMERIC FRAGMENT PAIR (EFP) APPROACH FOR THE STUDY OF CELLULAR UPTAKE OF INTRINSICALLY DISORDERED PROTEINS. ChemBioChem, 2022, , .	1.3	0
3866	Exploiting Focused Ultrasound to Aid Intranasal Drug Delivery for Brain Therapy. Frontiers in Pharmacology, 2022, 13, 786475.	1.6	3
3867	A nearâ€infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 456-466.	0.4	8
3914	Stress and Neurodegeneration: Adding Insult to Injury?. , 0, , 297-316.		0
3919	Inhibition of aluminum chloride-induced amyloid AÎ² peptide accumulation and brain neurodegeneration by flower decoction.. Iranian Journal of Basic Medical Sciences, 2021, 24, 1437-1445.	1.0	1
3921	Two statins and cromolyn as possible drugs against the cytotoxicity of AÎ²(31â€“35) and AÎ²(25â€“35) peptides: a comparative study by advanced computer simulation methods. RSC Advances, 2022, 12, 13352-13366.	1.7	1
3922	Phosphorylation of covalent organic framework nanospheres for inhibition of amyloid-Î² peptide fibrillation. Chemical Science, 2022, 13, 5902-5912.	3.7	7
3923	Multifunctional Anti-Alzheimerâ€™s Disease Effects of Natural Xanthone Derivatives: A Primary Structure-Activity Evaluation. Frontiers in Chemistry, 2022, 10, .	1.8	6
3924	Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAÎ²): A Plasma-Based Biomarker Differentiates Alzheimerâ€™s Disease from Other Etiologies of Dementia. International Journal of Alzheimer's Disease, 2022, 2022, 1-6.	1.1	3
3925	Biological basis and psychiatric symptoms in frontotemporal dementia. Psychiatry and Clinical Neurosciences, 2022, 76, 351-360.	1.0	5
3926	Cucurbit[7]uril Inhibits IAPP Aggregation by Targeting Nâ€terminus Hot Segments and Attenuates Cytotoxicity. Chemistry - A European Journal, 2022, , .	1.7	2
3927	Phosphoâ€specific plasma pâ€tau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 734-746.	1.7	11

#	Article	IF	Citations
3928	Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome. Nutrients, 2022, 14, 2039.	1.7	5
3929	Constructing conformational library for amyloid-Î²42 dimers as the smallest toxic oligomers using two CHARMM force fields. Journal of Molecular Graphics and Modelling, 2022, 115, 108207.	1.3	5
3930	Amyloid-Î² Oligomers: Multiple Moving Targets. Biophysica, 2022, 2, 91-110.	0.6	17
3931	Amyloid Beta Oligomers-Induced Ca2+ Entry Pathways: Role of Neuronal Networks, NMDA Receptors and Amyloid Channel Formation. Biomedicines, 2022, 10, 1153.	1.4	7
3932	On Computing Equilibrium Binding Constants for Proteinâ€“Protein Association in Membranes. Journal of Chemical Theory and Computation, 2022, 18, 3961-3971.	2.3	8
3933	Construction of Self-Assembling Lipopeptide-Based Benign Nanovesicles to Prevent Amyloid Fibril Formation and Reduce Cytotoxicity of GxxxGxxxGxxxG Motif. Bioconjugate Chemistry, 2022, 33, 1201-1209.	1.8	1
3935	Microparticle immunocapture assay for quantitation of protein multimer amount and size. Cell Reports Methods, 2022, 2, 100214.	1.4	2
3936	Novel Stilbene-Nitroxyl Hybrid Compounds Display Discrete Modulation of Amyloid Beta Toxicity and Structure. Frontiers in Chemistry, 2022, 10, .	1.8	1
3937	Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's diseases. Heliyon, 2022, 8, e09575.	1.4	8
3938	Quantitative detection of Î±-Synuclein and Tau oligomers and other aggregates by digital single particle counting. Npj Parkinson's Disease, 2022, 8, .	2.5	13
3939	Universal protein misfolding intermediates can bypass the proteostasis network and remain soluble and less functional. Nature Communications, 2022, 13, .	5.8	24
3940	N-terminally truncated AÎ²4-x proteoforms and their relevance for Alzheimerâ€™s pathophysiology. Translational Neurodegeneration, 2022, 11, .	3.6	7
3941	Combined induction of mTOR-dependent and mTOR-independent pathways of autophagy activation as an experimental therapy for Alzheimer's disease-like pathology in a mouse model. Pharmacology Biochemistry and Behavior, 2022, 217, 173406.	1.3	10
3943	Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers. Chemical Science, 2022, 13, 8526-8535.	3.7	8
3944	The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders. Advances in Protein Chemistry and Structural Biology, 2022, , 49-87.	1.0	7
3945	Monosialotetrahexosylganglioside Promotes Early AÎ²42 Oligomer Formation and Maintenance. ACS Chemical Neuroscience, 2022, 13, 1979-1991.	1.7	6
3947	Therapeutic nanotechnologies for Alzheimerâ€™s disease: A critical analysis of recent trends and findings. Advanced Drug Delivery Reviews, 2022, 187, 114397.	6.6	11
3948	Sub-5 nm nanogap electrodes towards single-molecular biosensing. Biosensors and Bioelectronics, 2022, 213, 114486.	5.3	8

#	Article	IF	Citations
3949	Mechanistic Models of Protein Aggregation Across Length-Scales and Time-Scales: From the Test Tube to Neurodegenerative Disease. Frontiers in Neuroscience, 0, 16, .	1.4	8
3950	Polyrhachis vicina Roger Alleviates Memory Impairment in a Rat Model of Alzheimerâ€™s Disease Through the EGR1/BACE1/APP Axis. ACS Chemical Neuroscience, 2022, 13, 1857-1867.	1.7	3
3951	Shati/Nat8l Overexpression Improves Cognitive Decline by Upregulating Neuronal Trophic Factor in Alzheimerâ€™s Disease Model Mice. Neurochemical Research, 2022, 47, 2805-2814.	1.6	2
3953	NMR-Driven Identification of Cinnamon Bud and Bark Components With Anti-AÎ² Activity. Frontiers in Chemistry, 0, 10, .	1.8	6
3955	Increased Acetylcholine Levels and Other Brain Effects in 5XFAD Mice after Treatment with 8,14-Dihydroxy Metabolite of Efavirenz. International Journal of Molecular Sciences, 2022, 23, 7669.	1.8	3
3956	Exploring Heterogeneous Dynamical Environment around an Ensemble of AÎ²₄₂ Peptide Monomer Conformations. Journal of Chemical Information and Modeling, 2022, 62, 3453-3462.	2.5	4
3957	Modulation of MAPK- and PI3/AKT-Dependent Autophagy Signaling by Stavudine (D4T) in PBMC of Alzheimerâ€™s Disease Patients. Cells, 2022, 11, 2180.	1.8	11
3958	WNT/Î²-catenin Pathway: a Possible Link Between Hypertension and Alzheimerâ€™s Disease. Current Hypertension Reports, 2022, 24, 465-475.	1.5	5
3959	Sphingosine 1â€phosphate attenuates neuronal dysfunction induced by amyloidâ€Î² oligomers through endocytic internalization of <scp>NMDA</scp> receptors. FEBS Journal, 2023, 290, 112-133.	2.2	4
3960	Mathematical model of Alzheimerâ€™s disease with prion proteins interactions and treatment. Applied Mathematics and Computation, 2022, 433, 127377.	1.4	4
3961	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. PLoS Biology, 2022, 20, e3001694.	2.6	67
3962	Development of Î²-sheet structure in AÎ² aggregation intermediates diminishes exposed hydrophobic surface area and enhances proinflammatory activity. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2022, 1870, 140817.	1.1	1
3963	Clusterin Binding Modulates the Aggregation and Neurotoxicity of Amyloid-Î²(1â€“42). Molecular Neurobiology, 2022, 59, 6228-6244.	1.9	3
3964	Pleiotropic roles of evolutionarily conserved signaling intermediate in toll pathway (ECSIT) in pathophysiology. Journal of Cellular Physiology, 0, , .	2.0	1
3965	Synaptic Disruption by Soluble Oligomers in Patients with Alzheimerâ€™s and Parkinsonâ€™s Disease. Biomedicines, 2022, 10, 1743.	1.4	6
3966	Î²-secretase inhibition prevents structural spine plasticity deficits in AppNL-G-F mice. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
3967	Adsorption free energy predicts amyloid protein nucleation rates. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	7
3968	Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2022, 23, 9583.	1.8	11

#	Article	IF	Citations
3969	AÎ²₄₂ oligomers can seed the fibrillization of AÎ²₄₀ peptides. Journal of the Chinese Chemical Society, 2022, 69, 1318-1325.	0.8	2
3971	Protein Aggregation in Neurodegenerative Diseases. , 2022, , 26-58.		0
3972	Alzheimerâ€™s Disease: Molecular Biology, Pathophysiology and Biomarkers. , 2022, , 88-98.		0
3973	Synergistic effects of epigallocatechin gallate and l-theanine in nerve repair and regeneration by anti-amyloid damage, promoting metabolism, and nourishing nerve cells. Frontiers in Nutrition, 0, 9, .	1.6	3
3974	An in vitro workflow of neuron-laden agarose-laminin hydrogel for studying small molecule-induced amyloidogenic condition. PLoS ONE, 2022, 17, e0273458.	1.1	1
3975	Task-dependent learning and memory deficits in the TgF344-AD rat model of Alzheimerâ€™s disease: three key timepoints through middle-age in females. Scientific Reports, 2022, 12, .	1.6	8
3976	Oligomeropathies, inflammation and prion protein binding. Frontiers in Neuroscience, 0, 16, .	1.4	3
3977	Anti-Alzheimer's disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes. Biomedicine and Pharmacotherapy, 2022, 154, 113576.	2.5	12
3978	Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2022, 71, 116952.	1.4	4
3980	SORLA mediates endocytic uptake of proIAPP and protects against islet amyloid deposition. Molecular Metabolism, 2022, 65, 101585.	3.0	3
3981	Discovery of potent and selective dual cholinesterases and Î²-secretase inhibitors in pomegranate as a treatment for Alzheimerâ€™s disease. Bioorganic Chemistry, 2022, 129, 106137.	2.0	5
3982	NMR-based Ligandâ€“Receptor Interaction Studies under Conventional and Unconventional Conditions. New Developments in NMR, 2022, , 142-178.	0.1	2
3983	PEDF-Derived Peptide Protects Against Amyloid-Î² Toxicity in vitro and Prevents Retinal Dysfunction in Rats. SSRN Electronic Journal, 0, , .	0.4	0
3985	The destructive mechanism of AÎ²_{1â€“42} protofibrils by norepinephrine revealed via molecular dynamics simulations. Physical Chemistry Chemical Physics, 2022, 24, 19827-19836.	1.3	6
3986	Cysteine-based protein folding modulators for trapping intermediates and misfolded forms. RSC Advances, 2022, 12, 26658-26664.	1.7	5
3987	Protein Synthesis/Degradation: Protein Degradation â€“ Pathological Aspects â€“ Alpha-1-Antitrypsin Deficiency: A Misfolded Secretory Glycoprotein Damages the Liver by Proteotoxicity and its Reduced Secretion Predisposes to Emphysematous Lung Disease Because of Protease-Inhibitor Imbalance. , 2022, , .		0
3988	Basics of amyloid Î²-protein in Alzheimerâ€™s disease. , 2022, , 73-89.		0
3989	Characterization of Apathy-Like Behaviors in the 5xFAD Mouse Model of Alzheimer's Disease. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
3990	Cognitive therapy for brain diseases using artificial intelligence models. , 2023, , 185-207.		1
3991	Based on molecular structures: Amyloid-Î² generation, clearance, toxicity and therapeutic strategies. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	6
3992	Misfolded protein oligomers induce an increase of intracellular Ca2+ causing an escalation of reactive oxidative species. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	13
3993	Nuclear Pore Dysfunction in Neurodegeneration. Neurotherapeutics, 2022, 19, 1050-1060.	2.1	11
3994	Error-prone protein synthesis recapitulates early symptoms of Alzheimer disease in aging mice. Cell Reports, 2022, 40, 111433.	2.9	14
3995	Amyloid Polypeptide Disaggregation Activity of Passion Fruit Seed-Derived Polyphenol Compounds. Natural Product Communications, 2022, 17, 1934578X2210927.	0.2	0
3996	Mechanisms of prion-induced toxicity. Cell and Tissue Research, 2023, 392, 81-96.	1.5	9
3998	Novel bis-ureido-substituted sulfaguanidines and sulfisoxazoles as carbonic anhydrase and acetylcholinesterase inhibitors. Molecular Diversity, 2023, 27, 1735-1749.	2.1	25
4000	The role of microRNAs in neurodegenerative diseases: a review. Cell Biology and Toxicology, 2023, 39, 53-83.	2.4	20
4001	Inhibiting amyloid beta (1â€“42) peptide-induced mitochondrial dysfunction prevents the degradation of synaptic proteins in the entorhinal cortex. Frontiers in Aging Neuroscience, 0, 14, .	1.7	7
4002	Protective effect of Lactococcus laudensis and Pediococcus parvulus against neuropathy due to amyloid-beta in Caenorhabditis elegans. Biomedicine and Pharmacotherapy, 2022, 155, 113769.	2.5	1
4003	Cascade primer exchange reaction-based amplification strategy for sensitive and portable detection of amyloid Î² oligomer using personal glucose meters. Analytica Chimica Acta, 2022, 1232, 340440.	2.6	3
4004	Role of phosphatidylserine in amyloid-beta oligomerization at asymmetric phospholipid bilayers. Physical Chemistry Chemical Physics, 2023, 25, 7648-7661.	1.3	4
4005	Amphiphilic stilbene derivatives attenuate the neurotoxicity of soluble AÎ²₄₂ oligomers by controlling their interactions with cell membranes. Chemical Science, 2022, 13, 12818-12830.	3.7	5
4007	Preparation and Fractionation of Heterogeneous AÎ²42 Oligomers with Different Aggregation Properties. Methods in Molecular Biology, 2023, , 29-39.	0.4	0
4008	Exercise Training Prevents the Loss of Wall Thickness and Lowers Expression of Alzheimerâ€™s Related Proteins in 3xTg Mouse Jejunum. International Journal of Environmental Research and Public Health, 2022, 19, 14164.	1.2	0
4009	Amyloid beta and its naturally occurring N-terminal variants are potent activators of human and mouse formyl peptide receptor 1. Journal of Biological Chemistry, 2022, 298, 102642.	1.6	4
4010	AÎ² Deposits in the Neocortex of Adult and Infant Hypoxic Brains, Including in Cases of COVID-19. Journal of Neuropathology and Experimental Neurology, 2022, 81, 988-995.	0.9	7

#	Article	IF	Citations
4011	Catalytic Antibodies: Design, Expression, and Their Applications in Medicine. Applied Biochemistry and Biotechnology, 0, , .	1.4	5
4012	Carnosic Acid Attenuates AÎ²Os-Induced Apoptosis and Synaptic Impairment via Regulating NMDAR2B and Its Downstream Cascades in SH-SY5Y Cells. Molecular Neurobiology, 2023, 60, 133-144.	1.9	9
4013	Alzheimerâ€™s Disease: From Immune Homeostasis to Neuroinflammatory Condition. International Journal of Molecular Sciences, 2022, 23, 13008.	1.8	13
4014	The Potential Neuroprotective Effects of Extracts from Oat Seedlings against Alzheimerâ€™s Disease. Nutrients, 2022, 14, 4103.	1.7	4
4015	Tibolone Improves Memory and Decreases the Content of Amyloid-Î² Peptides and Tau Protein in the Hippocampus of a Murine Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 90, 1437-1447.	1.2	1
4016	Structural Determinant of Î²-Amyloid Formation: From Transmembrane Protein Dimerization to Î²-Amyloid Aggregates. Biomedicines, 2022, 10, 2753.	1.4	8
4017	Formation of toxic oligomers of polyQ-expanded Huntingtin by prion-mediated cross-seeding. Molecular Cell, 2022, 82, 4290-4306.e11.	4.5	7
4018	AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimerâ€™s and Parkinsonâ€™s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery. International Journal of Molecular Sciences, 2022, 23, 13383.	1.8	6
4019	Poly(I:C) promotes neurotoxic amyloid Î² accumulation through reduced degradation by decreasing neprilysin protein levels in astrocytes. Journal of Neurochemistry, 2022, 163, 517-530.	2.1	0
4020	Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status. Alzheimer's Research and Therapy, 2022, 14, .	3.0	7
4021	The central role of tau in Alzheimerâ€™s disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Research Bulletin, 2022, 190, 204-217.	1.4	22
4022	Near-Infrared Photooxygenation Theranostics Used for the Specific Mapping and Modulating of Amyloid-Î² Aggregation. Analytical Chemistry, 2022, 94, 15902-15907.	3.2	10
4023	Small-molecule drugs development for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6
4024	Inhibition of Amyloid Protein Aggregation Using Selected Peptidomimetics. ChemMedChem, 2023, 18, .	1.6	3
4025	Treatment of Alzheimer's disease with small-molecule photosensitizers. Chinese Chemical Letters, 2023, 34, 107966.	4.8	2
4026	Marine Natural Products from the Russian Pacific as Sources of Drugs for Neurodegenerative Diseases. Marine Drugs, 2022, 20, 708.	2.2	8
4027	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimerâ€™s Disease and Identifying Promising Drug Targets. Biomolecules, 2022, 12, 1676.	1.8	24
4028	Molecular Structure of Cu(II)-Bound Amyloid-Î² Monomer Implicated in Inhibition of Peptide Self-Assembly in Alzheimerâ€™s Disease. Jacs Au, 2022, 2, 2571-2584.	3.6	20

#	Article	IF	Citations
4029	Neuroprotective effect of Bis(Indolyl)phenylmethane in Alzheimerâ€™s disease rat model through inhibition of hen Lysozyme amyloid fibril-induced neurotoxicity. Journal of the Iranian Chemical Society, 0, , .	1.2	0
4030	Alzheimerâ€™s Disease: Treatment Strategies and Their Limitations. International Journal of Molecular Sciences, 2022, 23, 13954.	1.8	66
4031	Destruction of Lysozyme Amyloid Fibrils Induced by Magnetoferritin and Reconstructed Ferritin. International Journal of Molecular Sciences, 2022, 23, 13926.	1.8	2
4032	The protective effects of Esculentoside A through AMPK in the triple transgenic mouse model of Alzheimer's disease. Phytomedicine, 2022, , 154555.	2.3	2
4033	A study from structural insight to the antiamyloidogenic and antioxidant activities of flavonoids: scaffold for future therapeutics of Alzheimerâ€™s disease. Medicinal Chemistry Research, 2023, 32, 15-31.	1.1	2
4034	Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of Î±-Synuclein Aggregates. Molecular Pharmaceutics, 2023, 20, 183-193.	2.3	13
4035	Computational investigation of conformational fluctuations of AÎ²42 monomers in aqueous ionic liquid mixtures. Journal of Molecular Liquids, 2022, 368, 120779.	2.3	2
4036	Structural properties of AÎ² (1â€“40) peptide in protonation stage of one, two, and three: New insights from the histidine protonation behaviors. International Journal of Biological Macromolecules, 2022, 223, 1556-1561.	3.6	6
4037	RNA methyltransferase NSun2 deficiency promotes neurodegeneration through epitranscriptomic regulation of tau phosphorylation. Acta Neuropathologica, 2023, 145, 29-48.	3.9	4
4038	NIR-excited upconversion nanoparticles used for targeted inhibition of AÎ²42 monomers and disassembly of AÎ²42 fibrils. Journal of Materials Chemistry B, 0, , .	2.9	2
4039	A cationic amphiphilic peptide chaperone rescues AÎ²₄₂ aggregation and cytotoxicity. RSC Medicinal Chemistry, 2023, 14, 332-340.	1.7	1
4040	Metal-organic frameworks: A promising option for the diagnosis and treatment of Alzheimer's disease. Journal of Controlled Release, 2023, 353, 1-29.	4.8	13
4041	Current understanding of metal-dependent amyloid-Î² aggregation and toxicity. RSC Chemical Biology, 2023, 4, 121-131.	2.0	7
4042	Major depression and the biological hallmarks of aging. Ageing Research Reviews, 2023, 83, 101805.	5.0	13
4043	A Review of the Recent Advances in Alzheimerâ€™s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. Diagnostics, 2022, 12, 2975.	1.3	5
4044	The role of Î±-sheet structure in amyloidogenesis: characterization and implications. Open Biology, 2022, 12, .	1.5	3
4046	In Silico Studies to Predict the Role of Solvent in Guiding the Conformations of Intrinsically Disordered Peptides and Their Aggregated Protofilaments. ACS Omega, 2022, 7, 43337-43345.	1.6	0
4047	Enhanced activity of Alzheimer disease-associated variant of protein kinase CÎ± drives cognitive decline in a mouse model. Nature Communications, 2022, 13, .	5.8	9

#	Article	IF	Citations
4048	Early diagnosis and treatment of Alzheimerâ€™s disease by targeting toxic soluble AÎ² oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	18
4049	Role of Hydrophobicity at the N-Terminal Region of AÎ²42 in Secondary Nucleation. ACS Chemical Neuroscience, 2022, 13, 3477-3487.	1.7	1
4050	Lecanemab in Early Alzheimerâ€™s Disease. New England Journal of Medicine, 2023, 388, 9-21.	13.9	1,109
4052	Guanosine Prevents Spatial Memory Impairment and Hippocampal Damage Following Amyloid-Î²1â€“42 Administration in Mice. Metabolites, 2022, 12, 1207.	1.3	6
4053	Amyloid-Î² (25â€“35) induces the morphological alteration of dendritic spines and decreases NR2B and PSD-95 expression in the hippocampus. Neuroscience Letters, 2023, 795, 137030.	1.0	0
4054	Perphenazineâ€“Macrocycle Conjugates Rapidly Sequester the AÎ²42 Monomer and Prevent Formation of Toxic Oligomers and Amyloid. ACS Chemical Neuroscience, 2023, 14, 87-98.	1.7	1
4055	LOTUS suppresses amyloid Î²-induced dendritic spine elimination through the blockade of amyloid Î² binding to PirB. Molecular Medicine, 2022, 28, .	1.9	3
4056	Effects of multi-mode physical stimulation on APP/PS1 Alzheimer's disease model mice. Heliyon, 2022, 8, e12366.	1.4	1
4057	Putative Structures of Membrane-Embedded Amyloid Î² Oligomers. ACS Chemical Neuroscience, 2023, 14, 99-110.	1.7	7
4058	A dualâ€functional BODIPYâ€based molecular rotor probe reveals different viscosity of protein aggregates in live cells. Aggregate, 2023, 4, .	5.2	20
4059	Methylene Blue Delivery Mediated by Focused Ultrasound-Induced Bloodâ€“Brain Barrier Disruption Reduces Neural Damage and Amyloid-Beta Plaques by AQP-4 Upregulation. Biomedicines, 2022, 10, 3191.	1.4	3
4060	De Novo Transmembrane Aggregation of AÎ²10â€“40 Peptides in an Anionic Lipid Bilayer. Journal of Chemical Information and Modeling, 2022, 62, 6228-6241.	2.5	0
4061	Six-dimensional single-molecule imaging with isotropic resolution using a multi-view reflector microscope. Nature Photonics, 2023, 17, 179-186.	15.6	13
4062	The cellular model for Alzheimer's disease research: PC12 cells. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	14
4063	Prion Protein Complex with mGluR5 Mediates Amyloid-ÃŸ Synaptic Loss in Alzheimerâ€™s Disease. , 2023, , 467-481.		0
4064	Identification of novel regulators involved in AD pathogenesis using the CRISPR-Cas9 system. Folia Pharmacologica Japonica, 2023, 158, 21-25.	0.1	0
4065	New Insights into the Structural and Binding Properties on AÎ² Mature Fibrils Due to Histidine Protonation Behaviors. ACS Chemical Neuroscience, 2023, 14, 218-225.	1.7	4
4066	The interactions of amyloid Î² aggregates with phospholipid membranes and the implications for neurodegeneration. Biochemical Society Transactions, 2023, 51, 147-159.	1.6	5

#	Article	IF	Citations
4067	The Anaesthetics Isoflurane and Xenon Reverse the Synaptotoxic Effects of AÎ²1â€“42 on Megf10-Dependent Astrocytic Synapse Elimination and Spine Density in Ex Vivo Hippocampal Brain Slices. International Journal of Molecular Sciences, 2023, 24, 912.	1.8	5
4068	AÎ²42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimerâ€™s disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .	3.0	3
4069	Short Peptoid Evolved from the Key Hydrophobic Stretch of Amyloid-Î²42 Peptide Serves as a Potent Therapeutic Lead of Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2023, 14, 246-260.	1.7	3
4070	Lysine Acetylation Changes the Mechanism of AÎ²25â€“35 Peptide Binding and Dimerization in the DMPC Bilayer. ACS Chemical Neuroscience, 2023, 14, 494-505.	1.7	0
4071	Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases. Computational and Structural Biotechnology Journal, 2023, 21, 1189-1204.	1.9	4
4072	GxxxG Motif Stabilize Ion-Channel like Pores through CÎ±â€•HÂ·Â·Â·O Interaction in AÎ² (1-40). International Journal of Molecular Sciences, 2023, 24, 2192.	1.8	3
4073	Potential Protective Function of AÎ²₄₂ Monomer on Tauopathies. Journal of the American Society for Mass Spectrometry, 2023, 34, 472-483.	1.2	1
4074	Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimerâ€™s Disease. Brain Sciences, 2023, 13, 213.	1.1	4
4075	Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 57-71.	1.0	6
4076	Molecular Mechanisms of Amyloid-Î² Self-Assembly Seeded by In Vivo-Derived Fibrils and Inhibitory Effects of the BRICHOS Chaperone. ACS Chemical Neuroscience, 0, , .	1.7	2
4077	The pathomimetic oAÎ²25â€“35 model of Alzheimer's disease: Potential for screening of new therapeutic agents. , 2023, 245, 108398.		6
4078	Exploring the aggregation of amyloid-Î² 42 through Monte Carlo simulations. Biophysical Chemistry, 2023, 297, 107011.	1.5	3
4079	Control of mitochondria-associated endoplasmic reticulum membranes by protein S-palmitoylation: Novel therapeutic targets for neurodegenerative diseases. Ageing Research Reviews, 2023, 87, 101920.	5.0	6
4080	Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimerâ€™s Disease from 2004 to 2022. Dementia and Geriatric Cognitive Disorders, 2023, 52, 47-73.	0.7	10
4082	Combinations of Vitamin A and Vitamin E Metabolites Confer Resilience against Amyloid-Î² Aggregation. ACS Chemical Neuroscience, 2023, 14, 657-666.	1.7	0
4083	Therapeutically important bioactive compounds of the genusPolygonum L. and their possible interventions in clinical medicine. Journal of Pharmacy and Pharmacology, 2023, 75, 301-327.	1.2	2
4084	Protein Misfolding and Aggregation in Proteinopathies: Causes, Mechanism and Cellular Response. Diseases (Basel, Switzerland), 2023, 11, 30.	1.0	9
4085	Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils. Frontiers in Molecular Biosciences, 0, 10, .	1.6	6

#	Article	IF	Citations
4086	Stability of the AÎ²42 Peptide in Mixed Solutions of Denaturants and Proline. Journal of Physical Chemistry B, 2023, 127, 1572-1585.	1.2	0
4087	Using Optogenetics to Model Cellular Effects of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2023, 24, 4300.	1.8	1
4088	Peptide Selfâ€Assembly into Amyloid Fibrils at Hard and Soft Interfacesâ€”From Corona Formation to Membrane Activity. Macromolecular Bioscience, 2023, 23, .	2.1	4
4089	Copper homeostasis and the ubiquitin proteasome system. Metallomics, 2023, 15, .	1.0	3
4090	Residue-specific binding of Ni(II) ions influences the structure and aggregation of amyloid beta (AÎ²) peptides. Scientific Reports, 2023, 13, .	1.6	5
4091	Liposomal Drug Delivery System as An Emerging Technique for Treatment Of Neurodegenerative Diseases. Current Nanomedicine, 2023, 13, .	0.2	0
4092	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie, 2023, 135, .	1.6	0
4093	Imaging Amyloidâ€Î² Membrane Interactions: Ionâ€Channel Pores and Lipidâ€Bilayer Permeability in Alzheimer's Disease. Angewandte Chemie - International Edition, 2023, 62, .	7.2	9
4094	Î²-Carotene, a Potent Amyloid Aggregation Inhibitor, Promotes Disordered AÎ² Fibrillar Structure. International Journal of Molecular Sciences, 2023, 24, 5175.	1.8	1
4095	Alleviating the unwanted effects of oxidative stress on AÎ² clearance: a review of related concepts and strategies for the development of computational modelling. Translational Neurodegeneration, 2023, 12, .	3.6	2
4096	The effect of cerium dioxide nanoparticles on the viability of hippocampal neurons in Alzheimerâ€™s disease modeling. Frontiers in Cellular Neuroscience, 0, 17, .	1.8	0
4097	Amyloid inhibition by molecular chaperones in vitro can be translated to Alzheimer's pathology in vivo. RSC Medicinal Chemistry, 2023, 14, 848-857.	1.7	10
4098	An In Situ Study on Nanozyme Performance to Optimize Nanozyme-Strip for AÎ² Detection. Sensors, 2023, 23, 3414.	2.1	1
4099	Variation in Group Composition Alters an Early-Stage Social Phenotype in hAPP-Transgenic J20 Mice. Journal of Alzheimer's Disease, 2023, , 1-14.	1.2	0
4101	A new class of monoclonal AÎ² antibodies selectively targets and triggers deposition of AÎ² protofibrils. Journal of Neurochemistry, 2023, 165, 860-873.	2.1	2
4102	Molecular mechanisms of neuroprotective offerings by rosmarinic acid against neurodegenerative and other CNS pathologies. Phytotherapy Research, 2023, 37, 2119-2143.	2.8	5
4103	Investigation of Cyclo-Z Therapeutic Effect on Insulin Pathway in Alzheimer's Rat Model: Biochemical and Electrophysiological Parameters. Molecular Neurobiology, 2023, 60, 4030-4048.	1.9	1
4104	Rapid, scalable assay of amylin-Î² amyloid co-aggregation in brain tissue and blood. Journal of Biological Chemistry, 2023, 299, 104682.	1.6	3

#	Article	IF	Citations
4105	Cascade autohydrolysis of Alzheimer's AÎ² peptides. Chemical Science, 2023, 14, 4986-4996.	3.7	1
4106	Design, Synthesis and Evaluation of Catechol-Based Amyloid Beta Aggregation Inhibitors. Heterocycles, 2023, 106, 797.	0.4	1
4123	High-Throughput Searches for Natural Products as Aggregation Modulators of Amyloidogenic Proteins. , 2023, , 313-332.		0
4126	Amyloid formation as a protein phase transition. Nature Reviews Physics, 2023, 5, 379-397.	11.9	22
4142	Gene Expression Profiling and Bioinformatics Analysis in Neurodegenerative Diseases. , 2023, , 967-1002.		0
4182	Molecular Investigation of Proteinâ€“Protein Interaction Candidates Related to the Mammalian Brain. , 2023, , 81-107.		0
4193	EPR Studies of Chaperone Interactions and Dynamics. , 2023, , 242-277.		0
4198	Umbilical Cord-Derived Cells: Applications in Neurological Disorders. , 2023, , .		0
4215	Flavonoid-Based Derivatives for Modulating Various Targets of Alzheimerâ€™s Disease. , 2023, , 267-315.		0
4224	Liquidâ€“liquid phase separation in Alzheimerâ€™s disease. Journal of Molecular Medicine, 2024, 102, 167-181.	1.7	0
4231	Neuroprotective actions of hydroxytyrosol. , 2024, , 1587-1607.		0
4238	Enzymatic and synthetic regulation of polypeptide folding. Chemical Science, 2024, 15, 2282-2299.	3.7	0
4250	Curcuma longa: A Natural Ally in Alzheimerâ€™s Disease Management. , 2023, , 177-191.		0
4252	Alzheimerâ€™s disease: Systematic review of recent substantial therapeutic targets. AIP Conference Proceedings, 2024, , .	0.3	0